Department of Vermont Health Access
Pharmacy Benefit Management Program

VERMONT
PREFERRED DRUG LIST
and
DRUGS REQUIRING PRIOR AUTHORIZATION

Clinical Criteria Manual

August 19, 2014

Preferred Drug List and Drugs Requiring Prior Authorization

> The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include:
>
> > "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives"
>
> From Act 127 passed in 2002

The following pages contain:

- The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories.
- The therapeutic classes of drugs which have Clinical Criteria for Prior Authorization may or may not be subject to a preferred agent.
- Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters.

Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non-preferred agents have been included and are listed in the right-hand columns. Any drug not listed as preferred in any of the included categories requires Prior Authorization.

1. *THERAPEUTIC CLASS CRITERIA*

Acne Medications:
Oral 6
Topical-Anti-infectives 8
Topical-Retinoids 10
Topical-Rosacea 11
ADHD and Narcolepsy/Cataplexy Medications:
Short/Intermediate-Acting MPH 12
Long-Acting MPH 12
Short/Intermediate-Acting Amphetamines 12
Long-Acting Amphetamines 12
Non-Stimulant Products 14
Xyrem 15
Alpha$_1$-Proteinase Inhibitors 18
Alzheimer's Medications:
Cholinesterase Inhib/NMDA Receptor Antagonists 19
Analgesics:
Cox-2 Inhibitors and NSAIDs 21
Miscellaneous: Transdermal Patch 25
Opioids-Short Acting 26
Opioids-Long Acting 29
Long Acting Opioids - P. A. Request Form 34
Anemia Medications 35
Ankylosing Spondylitis-Injectables 37
Anti-anxiety: Anxiolytics 39
Anticoagulants 41
Anticonvulsants 43
Anti-depressants:
Miscellaneous 47
SNRIs 49
SSRIs 52
Tricyclics & MAOIs 54
Anti-diabetics:
Insulin 56
Oral 57
Peptide Hormones 61
Antidiarrheals: HIV/AIDS 62
Anti-emetics:
5-HT$_3$ Antagonists 63
Miscellaneous (Pregnancy) 65
NK1 Antagonists 66
THC Derivatives 67
Anti-hypertensives:
ACE Inhibitors & ACEI Combinations 68
ARBs & ARB Combinations 69
Beta-Blockers 72
Calcium Channel Blockers 74
Central Alpha Agonists 76
Ganglionic Blockers 78
Renin Inhibitors 79
Anti-infectives:
Antibiotics: Cephalosporins -1st, 2nd and 3rd Gen. 80
Antibiotics: Ketolides 82
Antibiotics: Macrolides 83
Antibiotics: Oxazolidinones 85
Antibiotics: Penicillins (Oral) 86
Antibiotics: Quinolones 87
Antibiotics: Rifamycins 88
Antibiotics: Vancomycin 90
Anti-fungal: Allylamines 91
Anti-fungal: Azoles 93
Antimalarials: Quinine 96
Antivirals: Herpes (Oral) 97
Antivirals: Influenza Medications 98
Antivirals: Influenza Vaccines 100
Anti-migraine: Triptans 102
Anti-Obesity 105
Anti-psychotics:
Atypicals & Combinations-CHILDREN 106
Antipsychotic Medications (Pediatric) PA Form 112
Atypicals & Combinations-ADULTS 113
Typicals 120
Bone Resorption Inhibitors 121
Bone Resorption Inhibitors Injectable – P.A. Form 125
Botulinum Toxins 126
BPH Agents 128
Cardiac Glycosides 130
Chemical Dependency 131
Buprenorphine - P. A. Request Form 133
Vivitrol - P. A. Request Form 134
Compounded Products 135
Constipation: Chronic, IBS-C or Opioid Induced 136
Contraceptives: Vaginal Ring 138
Coronary Vasodilators/Antianginals:
Oral and Topical 139
Corticosteroids: Oral 141
Cough and Cold Preparations 142
Cystic Fibrosis: Medications 143
Specialty Pharmacy Order Form 145
Dermatological Agents:
Actinic Keratosis Therapy 146
Antibiotics: Topical 148
Antifungals: Onychomycosis 149
Antifungals: Topical 150
Antivirals: Topical 152
Corticosteroids 153
Genital Wart Therapy 155
Immunomodulators 156
Scabicides and Pediculicides 157
Desmopressin: Intranasal/Oral 158
Diabetic Testing Supplies 159
Epinephrine: Autoinjector 160

Continued on next page

Estrogens: Vaginal 161
Fibromyalgia Agents 162
Gastrointestinals:
Crohn's Disease-Injectables 163
H. Pylori Combination Therapy 165
H2-blockers 166
Inflammatory Bowel Agents (Oral/Rectal) 167
Prokinetic Agents 169
Proton Pump Inhibitors 170
Ulcerative Colitis-Injectables 172
Gaucher Disease Medications 173
Gout Agents: Xanthine Oxidase Inhibitors 174
Growth Stimulating Agents 176
Growth Stimulating Agents - P.A./Order Form 178
Hemophilia Factors:
Specialty Pharmacy Order Form 179
Hepatitis C Medications 180
Hepatitis C Medications PA/Order Form 182
Hepatitis C Supplemental Clinical Form 183
Hereditary Angioedema Medications 184
Interleukin (IL)-1 Receptor Blockers 185
Lipotropics:
Bile Acid Sequestrants 187
Fibric Acid Derivatives 188
Homozygous Familial Hypercholesterolemia (HoFH) Agents 190
Nicotinic Acid Derivatives 191
Statins 192
Miscellaneous/Combinations 194
Management of Mental Health Medications 196
Miscellaneous
Benlysta® 197
Carbaglu® 198
Elaprase® (Hunter's Syndrome Injectable) 199
Gattex® 200
Glycopyrrolate 201
Korlym® 202
Makena® 203
Nuedexta® 204
Otrexup® 205
Samsca® (for Hyponatremia) 206
Signifor® 207
Solesta® 208
Soliris® 209
Somatuline® (Acromegaly Injectable) 210
Tranexamic Acid 211
Xenazine® (Huntington's Disease with Chorea) 212
Mood Stabilizers 213
Mucosal Coating Agents 214
Multiple Sclerosis Medications 215
Oral Specialty Pharmacy Order Form 217
Injectables Specialty Pharmacy Order Form 218
Nutritionals, enteral 219
Nutritionals, enteral - P.A. Request Form 220
Oncology: Oral (Selected Agents):
Specialty Pharmacy Order Form 221
Ophthalmics:
Antibiotics 222
Antihistamines 224
Corticosteroids: Topical 225
Cystaran® 226
Dry Eye Syndrome 227
Glaucoma Agents/Miotics 228
Mast Cell Stabilizers 231
NSAIDs 232
Otic: Anti-infectives 233
Over-the-Counter (OTC) Medications 235
Pancreatic Enzyme Products 236
Parkinson's Medications 237
Phosphodiesterase-4 Inhibitors 239
Phosphodiesterase-5 Inhibitors 240
Platelet Inhibitors 242
Post Herpetic Neuralgia Agents 243
Psoriasis Injectables 244
Psoriasis Non-biologics 247
Pulmonary:
Anticholinergics, Inhaled 249
Antihistamines: Intranasal 250
Antihistamines-1st Generation. 251
Antihistamines-2nd Generation. 252
Beta-Adrenergic Agents 254
Corticosteroids: Inhaled 256
Corticosteroids: Intranasal 258
Leukotriene Modifiers 259
Synagis® 260
Synagis® - P. A./Order Form 261
Xolair® 262
Xolair® - P.A. Request Form 263
Pulmonary Arterial HypertensionMedications 264
Renal Disease: Phosphate Binders 266
Restless Leg Syndrome Medications 267
Rheumatoid, Juvenile and Psoriatic Arthritis Medications 268
Saliva Stimulants 273
Sedative/Hypnotics:
Benzodiazepine 274
Non-Benzodiazepine, Non-Barbiturate 275
Skeletal Muscle Relaxants: Oral
Musculoskeletal Agents 277
Antispasticity Agents 277
Smoking Cessation Therapies 279
Testosterone: Topical 281

Continued on next page

Thrombopoietin Receptor Agonists 282
Urinary Antispasmodics..... 283
Vaginal: Anti-infectives..... 285
Vitamins: Prenatal Vitamins..... 286

2. PRIOR AUTHORIZATION REQUEST & SPECIALTY PHARMACY ORDER FORMS

Antipsychotic Medications (Pediatric) 289
Bone Resorption Inhibitors Injectable..... 290
Buprenorphine..... 291
Cimzia® 292
Cystic Fibrosis Inhaled..... 293
Enbrel® 294
General 295
General SPECIALTY..... 296
Growth Stimulating Agents..... 297
Hemophilia Factors 298
Hepatitis C Medications PA/Order Form..... 299
Hepatitis C – Supplemental Clinical Form..... 300
Humira®..... 301
Kineret® 302
Long-Acting Opioids..... 303
Multiple Sclerosis Orals 304
Multiple Sclerosis Self Injectables 305
Nutritionals..... 306
Oncology: Oral..... 307
Quetiapine 308
Remicade®..... 309
Simponi® 310
Stelara®..... 311
Synagis® 312
Vivitrol® 313
Xeljanz®..... 314
Xolair®..... 315

Acne Drugs: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name minocycline products:

- The patient has had a documented side effect, allergy, or treatment failure with generic minocycline. If a product has an AB rated generic, the trial must be the generic formulation.

Brand name doxycycline products (see below for Oracea® and Vibramycin® Suspension):

- The patient has had a documented side effect, allergy, or treatment failure with generic doxycycline. If a product has an AB rated generic, the trial must be the generic formulation.

Oracea®:

- The patient has a diagnosis of Rosacea.

AND

- The patient has had a documented side effect, allergy, or treatment failure with doxycycline, minocycline, and tetracycline.

Vibramycin® Suspension, Syrup:

- The patient has a medical necessity for a liquid dosage form.

Brand name erythromcyin products:

- The patient has had a documented side effector treatment failure with one preferred erythromycin product.

Brand name tetracycline products:

- The patient has had a documented side effect, allergy, or treatment failure with generic tetracycline. If a product has an AB rated generic, the trial must be the generic formulation.

LIMITATIONS:

Minocycline SR products and doxycycline SR and DR products (brand and generic) not covered. Adoxa® Pak and doxycycline monohydrate Pak specialty packaging dosage form not covered. Adoxa® 150mg cap and doxycycline monohydrate 150 mg cap (brand and generic) not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DOXYCYCLINE† 20mg, 50mg, 75mg, 100mg, tab, cap	Adoxa®* (doxycycline monohydrate) 50 mg, 75 mg, 100 mg tab Monodox®* (doxycycline monohydrate) 50 mg, 100 mg cap Oracea® (doxycycline monohydrate) 40 mg cap Periostat®* (doxycycline hyclate) 20 mg Vibramycin®* (doxycycline hyclate) 50 mg, 100 mg cap Vibramycin® (doxycycline hyclate) suspension Vibramycin® (doxycycline calcium) syrup Vibratab®* (doxycycline hyclate) 100 mg tab All other brands
E.E.S®† (erythromycin ethylsuccinate) ERY-TAB® (erythromycin base, delayed release) ERYTHROMYCIN BASE† ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S®, Eryped®)	Eryped®* (erythromycin ethylsuccinate) Erythrocin (erythromycin stearate) PCE Dispertab® (erythromycin base) All other brands
MINOCYCLINE† 50 mg, 75 mg, 100 mg	Minocin®* (minocycline) 50 mg, 75 mg, 100 mg cap Dynacin®* (minocycline) 50 mg, 75 mg, 100 mg cap/tab All other brands
TETRACYCLINE† 250 mg, 500 mg cap	All brands
ISOTRETINOIN† 10 mg, 20 mg, 40 mg cap (AMNESTEEM, CLARAVIS,MYORISAN, SOTRET)	Absorica® (isotretinoin) capsules All other brands

Acne Drugs: Topical-Anti-infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name single ingredient products:

- The patient has had a documented side effect, allergy, or treatment failure with a preferred generic benzoyl peroxide, clindamycin, erythromycin, and sodium sulfacetamide (from within the same sub-category). (If a product has an AB rated generic, there must have been a trial of the generic.)

Brand name combination products:

- The patient has had a documented side effect, allergy, or treatment failure with generic erythromycin/benzoyl peroxide and sodium sulfacetamide/sulfur. (If a product has an AB rated generic, one trial must be the generic.)

AND

- The patient has had a documented side effect or treatment failure on combination therapy with the separate generic ingredients of the requested combination product, if applicable.

Azelex®

- The diagnosis or indication is acne.

AND

- The patient has had a documented side effect, allergy, or treatment failure with two generic topical anti-infective agents (benzoyl peroxide, clindamycin, erythromycin, erythromycin/benzoyl peroxide, sodium sulfacetamide, sodium sulfacetamide/sulfur etc).

LIMITATIONS:

Kits with non-drug products are not covered.
Benzoyl Peroxide Aerosol (Foam) Benzefoam® and Riax® Foam not covered. Other topical generic benzoyl peroxide preparations preferred.
Clindamycin Aerosol (Foam) and Evoclin® not covered. Other topical generic clindamycin preparations preferred.
Sodium sulfacetamine/Sulfur Aerosol (Foam), Rosula® and Clarifoam® not covered. Other topical generic sodium sulfacetamide/sulfur preparations preferred.
Epiduo® (adapalene/benzoyl peroxide) combination not covered. Agents may be prescribed separately**.**
SE BPO® (benzoyl peroxide) foaming cloths dosage form not covered. Other topical generic benzoyl peroxide preparations preferred.
Prascion FC® and Plexion® (sodium sulfacetamide/sulfur) pads/cloths dosage form not covered. Other topical generic sodium sulfacetamide/sulfur preparations preferred.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical Anti-Infectives

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
BENZOYL PEROXIDE PRODUCTS	
BENZOYL PEROXIDE† 4%, 5%, 8%, 10% *G*, *2.5%, 4%, 5%, 7%, 8%, 10% W*; 3.5%, 5.5%, 8.5% *C*; 3%, 4%, 5%, 6%, 8%, 9%, *L*; 3%, 6%, 9% *P* BENZOYL PEROXIDE 2.5 % Gel	Benzac AC® 2.5%, 5%, 10% *G*, *W* Benzashave® 5%, 10% *C* Benzoyl peroxide® 10% L Brevoxyl® 4%, 8% W; 4%, 8%G; 4%, 8% *L* Clinac BPO® 7% *G* Desquam-E/X® 2.5%, 5%, 10% G; 5%, 10% *W* Inova 4% *P* Panoxyl/AQ 2.5%, 5%, 10% *G*; 5%, 10% *B* Pacnex HP/LP 4.25%, 7% *P* Triaz® 3%, 6%, 9% *G*; 3%, 6%, 9% *P* Zaclir®* 8% *L* All other brands
CLINDAMYCIN PRODUCTS	
CLINDAMYCIN 1% *S, G, L, P* †	Cleocin-T®* (clindamycin 2% *G*) Clindagel® (clindamycin 1% *G*) All other brands
ERYTHROMYCIN PRODUCTS	
ERYTHROMYCIN 2% *S, G, P* †	Akne-Mycin® (erythromycin 2% *O*) Erygel®* (erythromycin 2% *G*) All other brands
SODIUM SULFACETAMIDE PRODUCTS	
SODIUM SULFACETAMIDE 10% *L* †	Klaron®* (sodium sulfacetamide 10% *L*) All other brands
COMBINATION PRODUCTS	
ERYTHROMYCIN / BENZOYL PEROXIDE†	Benzaclin® (clindamycin/benzoyl peroxide) DUAC® (clindamycin/benzoyl peroxide) gel, kit Benzamycin®* (erythromycin/benzoyl peroxide) Sulfoxyl (erythromycin/benzoyl peroxide) Z-Clinz® (clindamycin/benzoyl peroxide kit) All other brands
SODIUM SULFACETAMIDE / SULFUR *L* † SODIUM SULFACETAMIDE / SULFUR *W* †	Avar® (sodium sulfacetamide/sulfur *G*) Avar-E LS® (sulfacetamide/sulfur *C)* Avar LS® (sulfacetamide/sulfur *W)* Plexion® / Sumaxin TS® (sulfacetamide/sulfur *S,C,L*) Rosac®* (sulfacetamide/sulfur *W*) Rosula®* (sulfacetamide/sulfur *W*) Sulfacet-R®* (sodium sulfacetamide/sulfur *L*) All other brands Zoderm® (urea/benzoyl peroxide) cream, gel
OTHER	
	Azelex® (azelaic acid 20% *C*) Aczone® (dapsone 5% G) All other brands any topical anti-infective acne medication

C=cream, E=emulsion, G=gel, L=lotion, O=ointment, P=pads, S=solution, W=wash, B=bar

Note: Please refer to "Acne Drugs: Topical - Retinoids" for Epiduo®Gel

Acne Drugs: Topical - Retinoids

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name tretinoin products and generic tretinoin microsphere:

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.

AND

- The patient has had a documented side effect, allergy, or treatment failure with a preferred generic topical tretinoin product. If a product has an AB rated generic, the trial must be the generic formulation.

Differin (brand) and adapalene (generic):

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.

AND

- The patient has had a documented side effect, allergy, or treatment failure with a preferred generic topical tretinoin product.

AND

- If the request is for the brand product, the patient has had a documented intolerance to a generic adapalene product.

Tretinoin (age <10 or >34):

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.

LIMITATIONS:

Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).
Epiduo Gel, Ziana – These combinations not covered, individual components may be prescribed separately.
Fabior® (tazarotene) Foam not covered. Tazorac® cream and gel preferred.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical - Retinoids

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
TRETINOIN† *(specific criteria required for ages <10 or >34)* 0.025%, 0.05%, 0.1% *C*; 0.01%, 0.025% *G* AVITA® (tretinoin)	All brand tretinoin products (Atralin® 0.05% *G*, Retin-A®*, Retin-A Micro® 0.1%, 0.04%, Tretin-X® etc.) Tretinoin microsphere† (compare to Retin-A Micro®) 0.1%, 0.04% adapalene† (compare to Differin®) 0.1% C, *G* Differin® (adapalene) 0.1% *C, G, L; 0.3% G*
TAZORAC® (tazarotene) 0.05%, 0.1% *C, G*	Avage® (tazarotene) ♣ Renova® (tretinoin) ♣ Solage® (tretinoin/mequinol) ♣ Tri-Luma® (tretinoin/hydroquinone/fluocinolone) ♣ ♣ *Not indicated for acne. Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).*

C=cream, G=gel

Acne Drugs: Topical - Rosacea

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name metronidazole products, metronidazole 1% gel (generic) and Finacea:

- The diagnosis or indication is rosacea.

AND

- The patient has had a documented side effect, allergy or treatment failure with a preferred generic topical metronidazole product. If a product has an AB rated generic, there must have also been a trial of the generic formulation.

LIMITATIONS:

The use of Mirvaso® (brimonidine topical gel) for treating skin redness is considered cosmetic. Medications used for cosmetic purposes are excluded from coverage. Mirvaso® topical gel has not been shown to improve any other symptom of rosacea (e.g. pustules, papules, flushing, etc.) or to alter the course of the disease.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical – Rosacea

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
METRONIDAZOLE† 0.75% *C, G, L*	All brand metronidazole products (MetroCream®* 0.75% *C*, Metrogel®* 0.75% *G*, Metrogel® 1% *G*, MetroLotion®* 0.75% *L*, Noritate® 1% *C*, Rozex® 0.75% *G* etc.) Metronidazole† 1% G Finacea® (azelaic acid) 15% *G*

C=cream, G=gel, L=lotion

ADHD and Narcolepsy/Cataplexy Medications

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*♠; 1 year for other indications
Xyrem: 6 months

CRITERIA FOR APPROVAL:

STIMULANTS

Dexmethylphenidate and Focalin®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient is also on Focalin XR and the prescriber is adding a shorter acting dosage form.

OR

- The patient has had a documented side-effect, allergy, or treatment failure on Methylin® or methylphenidate.

AND

- In addition, for approval of brand name Focalin®, the patient must have had a documented intolerance to generic dexmethylphenidate.

Metadate CD®, Ritalin LA®, methylphenidate CR, Methylphenidate SR 24 HR

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side-effect, allergy, or treatment failure on Focalin XR® or Methylphenidate SA OSM.

AND

- For approval of generic methylphenidate CR or methylphenidate SR 24 HR, the patient must have had a documented intolerance to the brand equivalent.

Concerta

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has had a documented intolerance to generic Methylphenidate SA OSM.

Ritalin® and Ritalin SR®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has had a documented intolerance to the preferred equivalent. For Ritalin SR® these are Methylin® ER, Metadate ER® or methylphenidate SR. For Ritalin these are Methylin® or methylphenidate.

Adderall® and Dexedrine CR®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has had a documented intolerance to the preferred generic equivalent.

Methamphetamine and Desoxyn®

- Given the high abuse potential of methamphetamine and Desoxyn®, the patient must have a diagnosis of ADD, ADHD or narcolepsy and have failed all preferred treatment alternatives. In addition, for approval of brand name Desoxyn®, the patient must have had a documented intolerance to generic methamphetamine.

Amphetamine/dextroamphetamine SR 24 HR (generic), dexmethylphenidate SR 24 HR IR/ER, 50:50% (generic)

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient must have a documented intolerance to the brand name equivalent.

Procentra®, dextroamphetamine oral solution

- The patient has a medical necessity for an oral liquid dosage form (eg. swallowing disorder).

AND

- If the request is for Procentra®, the patient has a documented intolerance to the generic equivalent.

Zenzedi® 2.5 mg or 7.5 mg tablets

- The prescriber provides clinical rationale explaining why other generic dextroamphetamine oral tablets products are not suitable alternatives.

Nuvigil®

Narcolepsy, excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment):

- The patient is > 17 years old.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history**).**

Nuvigil® **will not be approved** for sleepiness associated with shift work sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or **for ADHD (**for any age patient**).**

Provigil®, Modafinil

Narcolepsy, Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment), fatigue associated with multiple sclerosis, fatigue associated with the treatment of depression or schizophrenia:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history).

AND

- And if the request is for modafinil, the patient has a documented intolerance to brand Provigil.

ADHD age >12:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants or the patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety, substance abuse) to *one* long-acting CNS stimulant.

AND

- The patient has had a documented side-effect, allergy, or treatment failure to Strattera®.

AND

- And if the request is for modafinil, the patient has a documented intolerance to brand Provigil.

Provigil® /Modafinil **will not be approved** for sleepiness associated with shift work sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or **for ADHD in children age ≤12.**

CNS stimulants for beneficiaries age < 3

- The prescriber must provide a clinically valid reason for the use of the requested medication in a patient < 3 years of age.

NON-STIMULANTS

Intuniv®

- The patient has a diagnosis of ADD or ADHD.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphen idate SA OSM, Vyvanse® and Daytrana®)

OR

- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphenidate SA OSM, Vyvanse® and Daytrana®)

OR

- There is a question of substance abuse with the patient or family of the patient.

OR

- The family will choose to decline therapy if a stimulant must be trialed.

OR

- The patient has been trialed on immediate release guanfacine with good response but needs a dosage form with extended duration of therapy.

Kapvay®, Clonidine ER

- The patient has a diagnosis of ADD or ADHD.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphen idate SA OSM, Vyvanse® and Daytrana®)

OR

- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphen idate SA OSM, Vyvanse® and Daytrana®)

OR

- There is a question of substance abuse with the patient or family of the patient.

AND

- The patient has been trialed on clonidine IR with at least a partial response but needs an extended duration formulation to maximize the clinical benefit.

AND

- For approval of generic clonidine ER, the patient must have had a documented intolerance to the brand equivalent.

Strattera®

- The patient has a diagnosis of ADD or ADHD.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphenidate SA OSM, Vyvanse® and Daytrana®)

OR

- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD®, Ritalin LA®, Focalin XR®, Adderall XR®, Methylphenidate SA OSM, Vyvanse® and Daytrana®)

OR

- There is a question of substance abuse with the patient or family of the patient.

OR

- The family will choose to decline therapy if a stimulant must be trialed.

OR

- The patient's need for drug therapy is primarily in early AM and evenings in the home environment.

DEPRESSANTS

Xyrem®

- The patient has a diagnosis of narcolepsy with cataplexy.

AND

- The patient will not be using alcohol or receiving central nervous system (CNS) depressant drugs.

AND

- The patient has a documented side effect, allergy, treatment failure, or contraindication to at least TWO agents from the following classes; selective serotonin inhibitor (SSRIs), venlafaxine or tricyclic antidepressant (e.g. protriptyline, clomipramine).

OR

- The patient has a diagnosis of narcolepsy with Excessive Daytime Sleepiness (EDS).

AND

- The patient will not be using alcohol or receiving central nervous system (CNS) depressant drugs.

AND

- The patient has a documented side effect, allergy, treatment failure, or contraindication to both of ONE preferred sympathomimetic CNS stimulant (e.g. amphetamine, methylphenidate) **and** Provigil.

LIMITATIONS:

Kapvay dose pak not covered – prescribe multiple strengths individually.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

ADHD and Narcolepsy/Cataplexy Medications

Length of Authorization: Duration of need for mental health indications; 1 year for other indications, 6 months for Xyrem*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
STIMULANTS	
Short/Intermediate-Acting Methylphenidate Preps METADATE ER® (compare to Ritalin® SR) METHYLIN® (compare to Ritalin®) METHYLIN® ER (compare to Ritalin® SR) METHYLPHENIDATE † (compare to Ritalin®) METHYLPHENIDATE SR † (compare to Ritalin® SR)	Dexmethylphenidate † (compare to Focalin®) Focalin® (dexmethylphenidate) Ritalin®* (methylphenidate) Ritalin SR®* (methylphenidate SR)
Long-Acting Methylphenidate Preps **Oral** FOCALIN XR® (dexmethylphenidate SR 24 HR IR/ER, 50:50%) METHYLPHENIDATE SA OSM IR/ER, 22:78%† (compare to Concerta®) **Oral Suspension** QUILLIVANT XR® (methylphenidate IR/ER, 20:80%) *QL = 12 ml/day* **Transdermal Patch** DAYTRANA® (methylphenidate patch) (*QL = 1 patch/day)*	Concerta® (methylphenidate SA OSM IR/ER, 22:78%) dexmethylphenidate SR 24 HR IR/ER, 50:50% † (compare to Focalin XR®) Metadate CD® (methylphenidate CR, IR/ER, 30:70%) methylphenidate CR, IR/ER, 30:70% † (compare to Metadate CD®) Methylphenidate SR 24 HR, IR/ER, 50:50% † (compare to Ritalin LA®) Ritalin LA® (methylphenidate SR 24 HR, IR/ER, 50:50%)
Short/Intermediate-Acting Amphetamine Preps AMPHETAMINE/DETROAMPHETAMINE† (compare to Adderall®) DEXTROAMPHETAMINE IR† (Zenzedi 5 or 10 mg, previously Dexedrine®)	Adderall®* (amphetamine/detroamphetamine) Desoxyn® (methamphetamine) dextroamphetamine Sulfate† 1 mg/ml oral solution Methamphetamine † (compare to Desoxyn®) Procentra® (dextroamphetamine sulfate) 1 mg/ml oral solution Zenzedi® (dextroamphetamine IR) 2.5 mg, 7.5 mg tablets Amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50%† (compare to Adderall XR®) Dexedrine CR®* (dextroamphetamine 24 hr SR)
Long-Acting Amphetamine Preps ADDERALL XR® (amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50%) DEXTROAMPHETAMINE 24 hr SR† (compare to Dexedrine CR®) VYVANSE® (lisdexamfetamine) *(QL = 1 capsule/day)* ***CNS stimulants*** *(all forms short- & long-acting): PA for beneficiaries < **3** yrs*	
Table continued on next page	*Table continued on next page*

Stimulants – Miscellaneous	
	Modafinil (compare to Provigil®) **(not approvable for ADHD in children age ≤12)** ***(Max days supply = 30 days)*** *Qty limit: 100 mg = 1.5 tablets/day* *200 mg = 2 tablets/day* *Maximum Daily Dose = 400 mg* Nuvigil® (armodafinil) *Qty limit: 50 mg = 2 tablets/day* *150 mg/200 mg/250 mg = 1 tablet/day* Provigil® (modafinil) **(not approvable for ADHD in children age ≤12)** ***(Max days supply = 30 days)*** *Qty limit: 100 mg = 1.5 tablets/day* *200 mg = 2 tablets/day* *Maximum Daily Dose = 400 mg*
NON-STIMULANTS	Clonidine extended release † (compare to Kapvay®) *Qty limit = 4 tablets/day* Intuniv® (guanfacine extended release) Tablet *Qty limit = 1 tablet/day* Kapvay® (clonidine extended release) Tablet *Qty limit = 4 tablets/day* Strattera® (atomoxetine) *Qty limit:10, 18, 25 and 40 mg = 2 capsules/day* *60, 80 and 100 mg = 1 capsule/day* *FDA maximum recommended dose = 100 mg/day*
DEPRESSANTS **All require PA.**	Xyrem® (sodium oxybate) oral solution *Qty limit = 540 ml/30 days*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.
♠ For generic product when brand name product preferred, length of authorization is 1 year.

Alpha$_1$-Proteinase Inhibitors

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

The indication for use is treatment of alpha$_1$-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met:

- Patient's alpha$_1$-antitrypsin (AAT) concentration < 80 milligrams per deciliter (mg/dl) [or <11 micromolar (µM)]

AND

- Patient has obstructive lung disease as defined by a forced expiratory volume in one second (FEV_1) of 30 – 65 % of predicted or a rapid decline in lung function defined as a change in FEV_1 of > 120 mL/year.

AND

- Medication is being administered intravenously (inhalation administration will not be approved).

AND

- Patient is a non-smoker.

OR

- Patient meets above criteria except lung function has deteriorated beneath above limits while on therapy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.
- ✓ All requests for alpha$_1$-proteinase inhibitors (whether billed through the pharmacy or medical benefit (J0256 – all except Glassia® or J0257 - Glassia®)) require Prior Authorization through the Catamaran Clinical Call Center.

Alpha$_1$-Proteinase Inhibitors

Length of Authorization: 6 months

NO PA REQUIRED	PA REQUIRED
All products require PA.	Aralast NP® Glassia® Prolastin® Prolastin-C® Zemaira® ****Maximum days supply per fill for all drugs is 14 days****

Alzheimer's: Cholinesterase Inhibitors/NMDA Receptor Antagonists

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Galantamine Tablet, Galantamine ER Capsule, Razadyne Tablet, Razadyne ER Capsule:

- The diagnosis or indication for the requested medication is Alzheimer's disease.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient had a documented side effect, allergy or treatment failure to donepezil and Exelon.

AND

- If the product has an AB rated generic, the patient has a documented intolerance to the generic.

Aricept:

- The diagnosis or indication for the requested medication is Alzheimer's disease.

AND

- The patient has a documented intolerance to the generic product.

Galantamine Oral Solution, Razadyne Oral Solution:

- The diagnosis or indication for the requested medication is Alzheimer's disease.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient had a documented side effect, allergy or treatment failure to Exelon Oral Solution.

AND

- If the product has an AB rated generic, the patient has a documented intolerance to the generic.

Aricept ODT, donepezil ODT:

- The diagnosis or indication for the requested medication is Alzheimer's disease.

AND

- Medical necessity for a specialty dosage form has been provided.

AND

- If the request is for donepezil ODT, the patient has a documented intolerance to the brand product.

Rivastigmine Oral Capsule:

- The diagnosis or indication for the requested medication is Alzheimer's disease.

AND

- The patient has a documented intolerance to the brand Exelon product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Alzheimer's: Cholinesterase Inhibitors/NMDA Receptor Antagonists

Length of Authorization: 1 year

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CHOLINESTERASE INHIBITORS DONEPEZIL† (compare to Aricept®) tablet *(QL = 1 tablet/day)* EXELON® (rivastigmine) Capsule *(QL = 2 capsules/day)*	Aricept®* (donepezil) Tablet *(QL = 1 tablet/day)* galantamine† tablet § (compare to Razadyne®) galantamine ER† capsule § (compare to Razadyne ER®) Razadyne® (galantamine) Tablet Razadyne ER® (galantamine) Capsule rivastigmine† (compare to Exelon®) capsule *(QL = 2 capsules/day)* Aricept® ODT (donepezil) *(QL = 1 tablet/day)* donepezil ODT† (compare to Aricept® ODT) *(QL = 1 tablet/day)*
EXELON® (rivastigmine) Oral Solution	galantamine† (compare to Razadyne®) Oral Solution Razadyne® (galantamine) Oral Solution
EXELON® (rivastigmine transdermal) Patch *(QL = 1 patch/day)*	
NMDA RECEPTOR ANTAGONIST NAMENDA® (memantine) Tablet NAMENDA® XR (memantine ER) Oral Capsule *(QL = 1 capsule/day)* NAMENDA® (memantine) Oral Solution	

Analgesics: COX IIs and NSAIDs

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Arthrotec, diclofenac/misoprostol, Duexis:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS.

OR

- The patient is not a candidate for therapy with a preferred generic NSAID mono-therapy due to one of the following:
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

AND

- The patient is unable to take the individual components separately.

AND

- If the request is for brand Arthrotec, the patient has a documented intolerance to the generic equivalent.

Cambia:

- The drug is being prescribed for treatment of acute migraine attacks.

AND

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS, one of which must be generic diclofenac.

OR

- The drug is being prescribed for treatment of acute migraine attacks.

AND

- The patient has a requirement for an oral liquid dosage form (i.e. swallowing disorder, inability to take oral medications)

AND

- The patient has had a documented side-effect or treatment failure with the generic ibuprofen suspension **and** the generic naproxen suspension.

Celebrex:

- The patient does not have a history of a sulfonamide allergy.

AND

- The patient has had a documented side effect, allergy, or treatment failure to two or more preferred generic NSAIDS.

OR

- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an anticoagulant (warfarin or heparin)
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

Flector Patch, Pennsaid, Diclofenac 1.5% Topical Solution:

- The diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions.

AND

- The patient has had a documented side-effect or inadequate response to Voltaren gel.

AND

- The patient has had a documented side effect or treatment failure with at least two preferred generic NSAIDS.

OR

- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

OR

- The patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medications).

AND

- For approval of Pennsaid 1.5%, the patient has had a documented intolerance to the generic equivalent.

Sprix:

- The indication or diagnosis is moderate to moderately severe pain.

AND

- The patient has had a documented inadequate response or intolerance to generic ketorolac tablets.

OR

- The patient has a documented medical necessity for the specialty dosage form (i.e inability to take medication orally (NPO)).

Voltaren Gel:

- The diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions.

AND

- The patient has had a documented side effect or treatment failure with at least two preferred generic NSAIDS.

OR

- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

OR

- The patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medications).

Vimovo:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS.

OR

- The patient is not a candidate for therapy with a preferred generic NSAID mono-therapy due to one of the following:
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

AND

- The patient is unable to take naproxen and a preferred proton pump inhibitor, separately.

Zipsor, Zorvolex:

- The patient has had a documented intolerance to diclofenac tablets.

AND

- The patient has had a documented side effect, allergy, or treatment failure to four or more preferred generic NSAIDS.

All other PA requiring NSAIDs:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS. (If a product has an AB rated generic, one trial must be the generic.)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Consider selectivity for cyclooxygenase-2 of the available nonsteroidal anti-inflammatory agents.
In order of most to least selective for COX-2: (preferred agents bold)

Diclofenac (Voltaren®) > Mefenamic acid (Ponstel®) > **Meloxicam** (Mobic®) > **Celecoxib** (Celebrex®) = **Etodolac** (Lodine®) > **Nambumetone** (Relafen®) > **Piroxicam** (Feldene®) > **Ketorolac** (Toradol®) > **Ibuprofen** (Motrin®, Advil®) > **Indomethacin** (Indocin®) > **Naproxen** (Naprosyn®, Aleve®) > **Oxaprozin** (Daypro®) > **Aspirin** > **Tolmetin** (Tolectin®) > **Fenoprofen** (Nalfon®) > **Ketoprofen** (Orudis®) > **Flurbiprofen** (Ansaid®)[1]

[1] Feldman, McMahon in Ann Intern Med. 2000:132:134-143, Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity?

Analgesics: COX IIs AND NSAIDs

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

NSAIDs

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL **SINGLE AGENT** DICLOFENAC POTASSIUM† (compare to Cataflam®) DICLOFENAC SODIUM† (compare to Voltaren®) DIFLUNISAL† (formerly Dolobid®) ETODOLAC† (formerly Lodine®) FLURBIPROFEN† (formerly Ansaid®) IBUPROFEN† (compare to Motrin®) INDOMETHACIN† (formerlyIndocin®, Indocin SR®) KETOPROFEN† KETOPROFEN ER† KETOROLAC† (formerly Toradol®) *(QL = 20 doses/5 day supply every 90 days)* MECLOFENAMATE SODIUM† (formerly Meclomen®) MELOXICAM† **tabs** (compare to Mobic®) NABUMETONE† (formerly Relafen®) NAPROXEN† (compare to Naprosyn®) NAPROXEN ENTERIC COATED† (compare to EC-Naprosyn®) NAPROXEN SODIUM† (compare to Anaprox®, Anaprox DS®) OXAPROZIN† (compare to Daypro®) PIROXICAM† (compare to Feldene®) SULINDAC† (compare to Clinoril®) TOLMETIN SODIUM† (formerly Tolectin®)	Anaprox®* (naproxen sodium) Anaprox DS®* (naproxen sodium) Cambia® (diclofenac potassium) packet for oral solution *(QL = 9 packets/month))* Cataflam®* (diclofenac potassium) Clinoril®* (sulindac) Daypro®* (oxaprozin) EC-Naprosyn®* (naproxen sodium enteric coated) Feldene®* (piroxicam) Fenoprofen 600 mg tablets Indocin® (indomethacin) susp Indocin SR®* (indomethacin) caps mefenamic acid† capsules (compare to Ponstel®) meloxicam suspension Mobic® (meloxicam) suspension Mobic®* (meloxicam) tablets Motrin®* (ibuprofen) Nalfon® (fenoprofen) 200 & 400 mg capsules Naprelan® (naproxen sodium CR) Naprosyn®* (naproxen soiun) Ponstel® (mefenamic acid) Voltaren®* (dicofenac sodium) Voltaren XR®* (diclofenac sodium SR) Zipsor® (diclofenac potassium) Zorvolex® (diclofenac) Capsules *(QL = 3 capsules/day)*
INJECTABLE KETOROLAC † Injection (formerly Toradol®) *(QL = 1 dose per fill)*	
NASAL SPRAY **All products require PA.**	Sprix® (ketorolac) Nasal Spray *(QL = 5 bottles/5 days – once every 90 days)*
TOPICAL/TRANSDERMAL **All products require PA.**	diclofenac† (compare to Pennsaid®) 1.5 % Topical Solution Flector® (diclofenac) 1.3 % Patch *(QL = 2 patches/day)* Pennsaid® (diclofenac) 1.5 % or 2% Topical Solution Voltaren® (diclofenac) 1 % Gel
NSAID/ANTI-ULCER **All products require PA.**	Arthrotec® (diclofenac sodium w/misoprostol) diclofenac sodium w/misoprostol† (compare to Arthrotec®) Duexis® (ibuprofen/famotidine) *(QL = 3 tablets/day)* Vimovo® (naproxen/esomeprazole) *(QL = 2 tablets/day)*

COX II Inhibitors

PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Celebrex® (celecoxib) (Quantity limit all strengths = 2 capsules/day)

Note: Please refer to "Dermatologicals: Actinic Keratosis Therapy" for Solaraze®

Analgesics: Miscellaneous: Transdermal Patch

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

LIDODERM®, LIDOCAINE PATCH

- The diagnosis or indication is neuropathic pain/post-herpetic neuralgia.
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica
  OR
- The patient has a medical necessity for a transdermal formulation (ex. dysphagia, inability to take oral medications)
  AND
- If the request is for generic lidocaine patch, the patient has had a documented intolerance to the brand product.

QUTENZA®

- The diagnosis or indication is post-herpetic neuralgia.
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lidoderm
  OR
- The patient has a medical necessity for a transdermal formulation (ex. dysphagia, inability to take oral medications)
  AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lidoderm

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Analgesics: Miscellaneous: Transdermal Patch *Length of Authorization: 6 months*	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Lidocaine 5% patch† (compare to Lidoderm®) *Quantity Limit = 3 patches/day* Lidoderm® Patch (lidocaine 5 %) *Quantity Limit = 3 patches/day* Qutenza® Patch (capsaicin 8 %) *Quantity Limit =4 patches/90 days*

Note: Please refer to "Analgesics: Long Acting Narcotics" for Duragesic® and fentanyl patch
Please refer to "Analgesics: COX IIs and NSAIDs" for Flector® patch

Analgesics: Opioids: Short Acting

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 6 months

CRITERIA FOR APPROVAL:

Butorphanol Nasal Spray

- The member has had a documented side effect, allergy, treatment failure, or contraindication to codeine, hydrocodone, morphine, and oxycodone (all 4 generic entities) as single or combination products.

OR

- The member is unable to use tablet or liquid formulations.

Abstral®, Actiq®, fentanyl transmucosal, Fentora®, Lazanda®, Subsys®

- Indication of cancer breakthrough pain (**no** approval for acute pain or postoperative pain)

AND

- Documentation that the patient is opioid tolerant (oral morphine ≥ 60 mg/day, transdermal fentanyl 25 mcg/hr, oral oxycodone ≥ 30 mg/day, oral hydromorphone ≥ 8 mg/day or an equianalgesic dose of another opioid for ≥ 1 week)

AND

- The member is on a long-acting opioid formulation

AND

- Patient is 18 years of age or older OR patient is 16 years of age or older (Actiq® and generic only)

AND

- The prescriber is registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program (https://www.tirfremsaccess.com/TirfUI/rems/home.action)

AND

- The member has had a documented treatment failure with or intolerance to 2 of the following 3 immediate –release breakthrough pain treatment options: morphine, hydromorphone or oxycodone.

OR

- The member is unable to use tablet or liquid formulations.

AND

- If the request is for brand name Actiq®, the member has a documented intolerance to generic fentanyl transmucosal.

Dilaudid®-5 Oral Solution, Hydromorphone Oral Solution

- The member has had a documented side effect, allergy or treatment failure with oxycodone oral solution and morphine oral solution.

OR

- The member has been started and stabilized on another dosage form of hydromorphone.

AND

- The member has a medical necessity for a liquid dosage form.

AND

- If the request is for the branded product, the patient has a documented intolerance to the generic product.

Nucynta®, Opana®, Oxymorphone

- The member has had a documented side effect, allergy, or treatment failure to at least two of the following 3 immediate release generic short acting narcotic analgesics – morphine, hydromorphone or oxycodone.

AND

- If the request is for brand name Opana®, the member has a documented intolerance to generic oxymorphone.

Oxycodone (generic) Capsules

- The member has a documented intolerance to generic oxycodone tablets.

Oxecta:

- The prescriber provides a clinically valid rationale why the generic immediate-release oxycodone cannot be used.

AND

- The member has had a documented side effect, allergy, or treatment failure to at least TWO other preferred short acting narcotic analgesics.

- **Note:** A history of substance abuse does not warrant approval of Oxecta® (oxycodone IR) since a clear advantage of this product over preferred short-acting opioids in this population has not been established.

Ultram®, Ultracet®

- The member has a documented intolerance to the generic formulation.

Rybix ODT®

- The member has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder)

Xartemis XR®

- The diagnosis is acute pain.

AND

- The member has had a documented side effect, allergy, or treatment failure to at least two short acting opioids not requiring prior approval, one of which is oxycodone w/ acetaminophen.

AND

- In addition, the prescriber must provide a compelling clinical reason why an extended release product is required for the treatment of acute pain.

Other Short-acting Opioids

- The member has had a documented side effect, allergy, or treatment failure to at least two medications not requiring prior approval. (If a product has an AB rated generic, one trial must be the generic.)

LIMITATIONS:

Acetaminophen containing products: Daily doses that result in > 4 grams of acetaminophen/day will reject for Prior Authorization.

Meperidine 75 mg/ml injection no longer available – 25 mg/ml, 50 mg/ml and 100 mg/ml available. Brand name Demerol 75 mg/ml and 100 mg/2 ml not covered – no generic equivalents.

A history of substance abuse does not warrant approval of Oxecta® (oxycodone IR) since a clear advantage of this product over preferred short-acting opioids in this population has not been established.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on the **General Prior Authorization Request Form.**

Analgesics: Opioids: Short Acting

Length of Authorization: initial approval 3 months, subsequent approval up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (NO PA REQUIRED)	PA REQUIRED
ACETAMINOPHEN W/CODEINE† (compare to Tylenol w/codeine®)	Abstral® (fentanyl) Sublingual Tablets
ACETAMINOPHEN W/HYDROCODONE† (compare to Vicodin®, Lorcet®, Maxidone®, Norco®, Zamicet®, Zydone®) *(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day; 10/325 = 185 ml/day)*	Acetaminophen w/codeine: *all branded products*
ACETAMINOPHEN W/OXYCODONE† (compare to Percocet®) *(QL 10/650 = 6 tablets/day)*	Acetaminophen w/hydrocodone: *all branded products* *(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)*
ASPIRIN W/CODEINE†	Acetaminophen w/hydrocodone (compare to Xodol®) *(QL=13 tablets/day)*
ASPIRIN W/OXYCODONE† (compare to Percodan®)	Acetaminophen w/oxycodone: *all branded products* *(QL 10/650 = 6 tablets/day)*
BUTALBITAL COMPOUND W/ CODEINE† (compare to Fiorinal® w/codeine)	Actiq® (fentanyl citrate transmucosal)
CODEINE SULFATE†	Anexsia®* (acetaminophen w/hydrocodone)
DIHYDROCODEINE COMPOUND† (compare to Synalgos-DC®)	Butorphanol Nasal Spray† (Qty Limit = 2 bottles/month)
ENDOCET® (oxycodone w/ acetaminophen)	Capital® w/codeine* (acetaminophen w/codeine)
ENDODAN® (oxycodone w/ aspirin)	Cocet®/ Cocet Plus® (acetaminophen w/codeine) *(QL 30/650 or 60/650 = 6 tablets/day)*
FIORTAL W/ CODEINE #3® (butalbital w/ codeine)	Combunox®* (oxycodone w/ ibuprofen)
HYDROCODONE† (plain, w/acetaminophen or w/ibuprofen) (some excpetions apply)	Dazidox®* (oxycodone)
HYDROMORPHONE† (compare to Dilaudid®)	Demerol* (meperidine)
MEPERIDINE† (compare to Demerol®) (Maximum 30 tabs or 5 day supply)	Dilaudid®*(hydromorphone)
MORPHINE SULFATE†	Dilaudid-5®(hydromorphone) oral solution
MORPHINE SULFATE SOLN† (compare to Roxanol®)	fentanyl citrate transmucosal† (compare to Actiq®)
OXYCODONE† (plain, w/acetaminophen or w/ibuprofen)	Fentora® (fentanyl citrate buccal tablets)
PENTAZOCINE† (compare to Talwin®)	Fioricet® w/codeine*(butalbital/acetaminophen/caffeine/codeine)
ROXICET® (oxycodone w/ acetaminophen)	Hydromorphone† oral solution (compare to Dilaudid-5®)
ROXICODONE INTENSOL® (oxycodone)	Ibudone®* (hydrocodone w/ ibuprofen)
ROXICODONE® (oxycodone HCL)	Lazanda® (fentanyl) Nasal Spray
TRAMADOL† (compare to Ultram®) *(Qty Limit = 8 tablets/day)*	Liquicet® (hydrocodone w/ acetaminophen)
TRAMADOL/APAP† (compare to Ultracet®) *(Qty Limit = 8 tablets/day)*	Lorcet®* (also HD, PLUS) (hydrocodone w/ acetaminophen)
	Lortab®*(hydrocodone w/ acetaminophen)
	Magnacet® (oxycodone w/ acetaminophen)
	Maxidone®*(hydrocodone w/ acetaminophen)
	Meperidine† (Qty > 30 tabs or 5 day supply)
	Norco®*(hydrocodone w/ acetaminophen)
	Nucynta® (tapentadol)
	Opana® (oxymorphone)
	Oxecta® (oxycodone IR) Tablets
	Oxycodone† (plain) capsules
	Oxyfast®*(oxycodone)
	OxyIR®*(oxycodone)
Note: Acetaminophen containing products: (Preferred and PA Required)	Oxymorphone† (compare to Opana®)
Maximum daily dose acetaminophen = 4 grams	Panlor DC® (acetaminophen/caffeine/dihydrocodeine)
	Pentazocine w/acetaminophen†
	Pentazocine w/naloxone†
	Percocet®*(oxycodone w/ acetaminophen)
	Percodan®* (oxycodone w/aspirin)
	Reprexain®* (hydrocodone w/ ibuprofen)
	Roxanol®*(morphine sulfate)
	Rybix® ODT (tramadol ODT) *(Qty Limit = 8 tablets/day)*
	Subsys® (fentanyl) Sublingual Spray
	Synalgos DC®*(dihydrocodeine compound)
	Talwin®* (pentazocine) and branded combinations
	Trezix® (acetaminophen/caffeine/dihydrocodeine)
	Tylenol® #3*,#4*(acetaminophen w/codeine)
	Tylox®*(oxycodone w/ acetaminophen)
	Ultracet® (tramadol w/ acetaminophen) *(Qty Limit = 8 tablets/day)*
	Ultram®* (tramadol) *(Qty Limit = 8 tablets/day)*
	Vicodin®*(hydrocodone w/acetaminophen)
	Vicoprofen®*(hydrocodone w/ ibuprofen)
	Xartemis XR® (oxycodone w/acetamimophen) *(Qty Limit = 4 tablets/day)*
	Xodol® (hydrocodone w/acetaminophen)
	Xolox® (oxycodone w/ acetaminophen)
	Zamicet®*/ Zydone®* (hydrocodone w/ acetaminophen)

Analgesics: Opioids: Long Acting

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 6 months

PHARMACOLOGY/INDICATION:

Long acting opioids are potent medications. They are indicated for the management severe pain in adults - severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

CLINICAL CONSIDERATIONS:

- Long acting opioid dosage forms are intended for use in opioid tolerant patients only. These tablet/capsule/topical medication strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.
- Long acting opioids should be prescribed for patients with a diagnosis or condition that requires a continuous, around-the-clock analgesic.
- Long acting opioids should be reserved for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- Long acting opioids are NOT intended for use as a 'prn' analgesic.
- Long acting opioids are NOT indicated for pain in the immediate post-operative period (the first 12-24 hours following surgery) or if the pain is mild, or not expected to persist for an extended period of time.
- Long acting opioids are not intended to be used in a dosage frequency other than FDA approved regimens.
- Patients should not be using other extended release opioids prescribed by another physician.
- Prescribers should consult the VPMS (Vermont Prescription Monitoring System) to review a patient's Schedule II – IV medication use before prescribing long acting opioids

CRITERIA FOR APPROVAL:

Transdermal:

Brand Duragesic Fentanyl Patches

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

AND

- The patient has had a documented intolerance to generic fentanyl patches.

Butrans Transdermal System

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

AND

- The patient has had a documented side effect, allergy, or treatment failure to morphine sulfate CR 12 hr tablet (generic) AND generic fentanyl patch.

OR

- The prescriber provides compelling clinical information for case specific discussion with DVHA Medical Director who will determine PA decision.

Oral:

Methadone Tablet

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy)

AND

- The patient has been started and stabilized on the requested medication.

OR

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy)

AND

- The patient has had a documented side effect, allergy, or treatment failure to morphine sulfate CR 12 hr tablets.

AND

- The initial methadone daily dose does not exceed 30 mg.

AND

- For approval of brand Dolophine tablets, the patient must have a documented intolerance to the equivalent generic tablet.

Methadone Liquid

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy)

AND

- The patient has been started and stabilized on the requested oral liquid medication.

OR

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy)

AND

- The initial methadone daily dose does not exceed 30 mg.

AND

- The patient must have a medical necessity for an oral liquid (i.e. swallowing disorder, inability to take oral medications).

Conzip®, Tramadol ER biphasic-release Capsule, Tramadol ER biphasic-release Tablet, Tramadol ER/SR, Ultram ER®

- The member has had a documented treatment failure to a preferred short-acting tramadol product. In addition, for approval of tramadol ER biphasic-release capsule or tablet or Ultram ER®, the patient must have a documented intolerance to generic tramadol ER/SR.

Oral Non-Preferred (except methadone and tramadol containing products):

- The patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

AND

- The patient has had a documented side effect, allergy, or treatment failure to morphine sulfate CR 12 hr tablet (generic) **AND** generic fentanyl patch. (If a product has an AB rated generic, there must have been a trial of the generic) **Note:** A history of substance abuse does not warrant approval of Opana ER® (crush resistant) since a clear advantage of this product over preferred long-acting opioids in this population has not been established.

LIMITATIONS:

(1) Methadone 40 mg dispersible tablet not approved for retail dispensing. Methadone 2 mg/ml oral solution not covered – use 1 mg/ml generic oral solution.

(2) Opana ER (crush resistant): A history of substance abuse does not warrant approval of Opana ER® (crush resistant) since a clear advantage of this product over preferred long-acting opioids in this population has not been established.

DOCUMENTATION:

✓ Please complete and submit the **Long Acting Opioids Prior Authorization Request Form**.

Analgesics: Opioids: Long Acting

Length of Authorization: initial approval 3 months, subsequent approval up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (NO PA REQUIRED)	PA REQUIRED
TRANSDERMAL	
Buprenorphine **All products require PA.**	Butrans (buphrenorphine) Transdermal System *(QL = 2 patches/14 days)(Maximum 14 day fill)*
Fentanyl Fentanyl Patch† (compare to Duragesic®) 12 mcg/hr, 25 mcg/hr, 50 mcg/hr (*QL=15 patches/30 days)*	Duragesic®* (fentanyl patch) 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, *(QL=15 patches/30 days)*
Fentanyl Patch† (compare to Duragesic®) 75 mcg/hr, 100 mcg/hr (*QL=30 patches/30 days)*	Duragesic®* (fentanyl patch) 75 mcg/hr, 100 mcg/hr *(QL= 30 patches/30 days)*
ORAL	
Hydromorphone **All products require PA.**	Exalgo® (hydromorphone XR) tablet (*QL= 30 tablets/30 days (8 mg, 12 mg, 16 mg tabs), 60 tablets/30 days (32 mg tabs)* hydromorphone XR† (compare to Exalgo®) tablet (*QL= 30 tablets/30 days (8 mg, 12 mg, 16 mg tabs))*
Methadone **All products require PA.**	Dolophine® (methadone) tablets Methadone† (compare to Dolophine®) 5 mg, 10 mg tablets Methadone† oral solution 1 mg/ml (no PA required for patient less than 1 year old) Methadone† oral concentrate 10 mg/ml ****Maximum initial daily dose all products = 30 mg/day****
Morphine MORPHINE SULFATE CR 12 hr tablet† (compare to MS Contin®, formerly Oramorph SR®) (*QL=90 tablets/strength/30 days)*	Avinza® (morphine sulfate beads SR 24 hr) Cap *(QL= 30 capsules/strength/30 days)* Embeda® (morphine sulfate/naltrexone hydrochloride) Capsules *(QL=2 capsules/day)* Kadian® (morphine sulfate XR*)* *(QL= 60 capsules/strength/30 days)* MS Contin®* (morphine sulfate SR 12 hr) (*QL=90 tablets/strength/30 days)* Morphine sulfate SR 24hr† capsule (compare to Kadian®) *(QL= 60 capsules/strength/30 days)* Morphine sulfate SR beads 24hr capsule (compare to Avinza®) *(QL= 30 capsules/strength/30 days)*
Oxycodone **All products require PA.**	OxyContin® (Oxycodone ER) *(QL= 90 tablets/strength/30 days)*
Oxymorphone **All products require PA.**	Opana ER® (oxymorphone ER)(crush resistant) *(QL=60 tablets/strength/30 days)* Oxymorphone ER *(QL=60 tablets/strength/30 days)*
Table Continue Next Page	*Table Continue Next Page*

<u>Tapentadol</u> **All products require PA.**	Nucynta ER® (tapentadol ER) *(QL=2 tablets/day)*
<u>Tramadol</u> **All products require PA.**	Conzip® (tramadol ER biphasic release) Capsule *(QL = 1 capsule/day)* Tramadol SR† (compare to Ultram ER®) *(Qty Limit = 1 tablet/day)* Tramadol ER biphasic-release® Capsule *(Qty Limit = 1 capsule/day)(150 mg strength)* Tramadol ER biphasic-release† tablet (formerly Ryzolt®) *(Qty Limit = 1 tablet/day)* Ultram ER® (tramadol SR 24 hr) *(Qty Limit = 1 tablet/day)*

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ LONG ACTING OPIOIDS~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of long acting opioids. These limits and criteria are based on concerns about safety and the potential for abuse and diversion. In order for beneficiaries to receive coverage for this drug, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office:_____

Drug Requested:

Please indicate: □ Brand Name or □ Generic Equivalent

Dose /Frequency and Length of Therapy:

Diagnosis or Indication for Use:

Has the member previously tried any of the following preferred medications?

Check all that apply:	***Response, check all that apply:***
□ Fentanyl Patches□	□ side-effect □ non-response □ allergy□
□ Morphine Sulfate CR 12 hr Tablet □ □□	□ side-effect □ non-response □ allergy

For tramadol products, has the member previously tried the following preferred medication?

Check if applicable:	***Response, check all that apply:***
□ Tramadol immediate release	□ side-effect □ non-response □ allergy

Is this an initial request or a subsequent request? □ Initial □ Subsequent

Prescriber comments:

Prescriber Signature:_____**Date of this request:**_____

Anemia Medications: Hematopoietic/Erythropoietic Agents

LENGTH OF AUTHORIZATION: 3 months initially, 6 months subsequent requests

CRITERIA FOR APPROVAL:

Aranesp®, Procrit®

- The diagnosis or indication for the requested medication is anemia due to one of the following:
  - Chronic kidney disease/renal failure
  - Post-renal transplant
  - Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated)
  - Surgery patients at high risk for perioperative blood loss
  - Cancer chemotherapy
  - Use of ribavirin or interferon therapy for Hepatitis C
  - Myelodysplastic syndrome

- Hemoglobin level at initiation of therapy is <10 g/dL

  OR
- For patients currently maintained on therapy, hemoglobin level is ≤11 g/dL in dialysis patients with chronic kidney disease, ≤10 g/dL in non-dialysis patients with chronic kidney disease, or ≤12 g/dL in patients treated for other indications.

Epogen®

- The diagnosis or indication for the requested medication is anemia due to one of the following:
  - Chronic kidney disease/renal failure
  - Post-renal transplant
  - Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated)
  - Surgery patients at high risk for perioperative blood loss
  - Cancer chemotherapy
  - Use of ribavirin or interferon therapy for Hepatitis C
  - Myelodysplastic syndrome

- Hemoglobin level at initiation of therapy is <10 g/dL

  OR
- For patients currently maintained on therapy, hemoglobin level is ≤11 g/dL in dialysis patients with chronic kidney disease, ≤10 g/dL in non-dialysis patients with chronic kidney disease, or ≤12 g/dL in patients treated for other indications.

  AND
- The patient has had a documented side-effect, allergy, or treatment failure to both Aranesp® and Procrit®

LIMITATIONS:

Omontys® (peginesatide) is available only to dialysis units at this time and so will not be available through the pharmacy benefit. As of 2/23/2013 Omontys® is not being marketed due to new post marketing reports of serious hypersensitivity reactions.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anemia: Hematopoietic/Erythropoietic Agents

Length of Authorization: ***3 months initially, 6 months subsequent request***

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
ARANESP® (darbepoetin alfa) PROCRIT® (epoetin alpha)	Epogen® (epoetin alpha)

Ankylosing Spondylitis Medications: Injectables

***NOTE*: Ankylosing Spondylitis Self-Injectables (Enbrel®, Cimzia®, Humira® and Simponi®) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Enbrel, Cimzia, Humira or Simponi Prior Authorization/Patient Enrollment Form for instructions. Briova may supply Remicade® upon request or you may continue to obtain through your usual supplier.**

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira®

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Humira®

OR

Patient has a confirmed diagnosis of AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

Notes: Approval should be granted in cases where patients have been treated with infliximab, but have lost response to therapy.

Enbrel®

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Enbrel®

OR

Diagnosis is AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

Cimzia®

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Cimzia®

OR

Diagnosis is AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Remicade®

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Remicade®

OR

Diagnosis is AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Simponi®

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Simponi®

OR

Patient age ≥ 18 years

AND

Diagnosis is AS, and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

***** Patients with a documented diagnosis of active axial involvement should have a trial with two NSAIDs, but a trial with DMARD is not required. If no active axial skeletal involvement, then an NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira®, Cimzia®, Enbrel®, Remicade® or Simponi®

DOCUMENTATION:

- ✓ Document clinical information for **Enbrel®** or **Humira®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Simponi®** or **Cimzia®** on its **Prior Authorization/Patient Enrollment Form** or **Remicade®** on a **Remicade Prior Authorization Request Form**.

- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) require Prior Authorization through the Catamaran Clinical Call Center.

Ankylosing Spondylitis: Injectables

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
ENBREL® (etanercept) *(Quantity limit = 4 syringes/28 days(50 mg), 8 syringes/28 days (25 mg))* HUMIRA® (adalimumab) (*Quantity limit = 2 syringes/28 days)*	Cimzia® (certolizumab pegol) *(Quantity limit = 1 kit/28 days (starter X 1, then regular))* Remicade® (infliximab) Simponi® (golimumab) Subcutaneous *(Quantity Limit = 1 of 50 mg prefilled syringe or autoinjector/28 days)*

Anti-Anxiety: Anxiolytics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL

Non-preferred Benzodiazepines (except for alprazolam ODT, Niravam® and Intensol Products):

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred benzodiazepine medications. (If a product has an AB rated generic, one trial must be the generic formulation.)

alprazolam ODT and Niravam®:

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred benzodiazepine medications. (If a product has an AB rated generic, one trial must be the generic formulation.)

OR

- Patient has a medical necessity for disintegrating tablet administration (i.e. inability to swallow tablets)

AND

- The patient has a documented side effect, allergy, or treatment failure to clonazepam ODT.

Alprazolam Intensol, Diazepam Intensol, Lorazepam Intensol

- Patient has a medical necessity for the specialty dosage form (i.e. swallowing disorder)

AND

- The medication cannot be administered by crushing oral tablets.

Hydroxyzine Pamoate 100 mg strength ONLY:

- The patient is unable to use generic 50 mg capsules.

Vistaril®:

- The patient has a documented intolerance to the generic formulation.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Anti-Anxiety: Anxiolytics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Benzodiazepine	
ALPRAZOLAM† (compare to Xanax®) ALPRAZOLAM ER†, ALPRAZOLAM XR® (compare to Xanax XR®) CHLORDIAZEPOXIDE† (formerly Librium®) CLONAZEPAM† (compare to Klonopin®) CLONAZEPAM ODT† (formerly Klonopin Wafers®) CLORAZEPATE† tabs (compare to Tranxene T®) DIAZEPAM† (compare to Valium®) LORAZEPAM† (compare to Ativan®) OXAZEPAM† (formerly Serax®)	alprazolam ODT† (compare to Niravam®) Alprazolam Intensol® (alprazolam concentrate) Ativan®* (lorazepam) Diazepam Intensol® (diazepam concentrate) Klonopin®* (clonazepam) Lorazepam Intensol® (lorazepam concentrate) Niravam® (alprazolam ODT) Tranxene T®* (clorazepate tablets) Tranxene-SD® (clorazepate SR 24 hr tab) Valium®* (diazepam) Xanax®* (alprazolam) Xanax XR®* (alprazolam XR)
Non-Benzodiazepine	
BUSPIRONE† (formerly Buspar®) HYDROXYZINE HYDROCHLORIDE† (previously Atarax®) HYDROXYZINE PAMOATE† (compare to Vistaril®) (all strengths except 100 mg) MEPROBAMATE† (previously Miltown®)	Hydroxyzine Pamoate† (100 mg strength ONLY) (compare to Vistaril®) Vistaril®* (hydroxyzine pamoate)

Anticoagulants

LENGTH OF AUTHORIZATION: Xarelto**:** 6 months (or duration of need if less)

All Others: 6 months

CRITERIA FOR APPROVAL:

Arixtra®

- The patient has a documented intolerance to generic fondaparinux.

Coumadin®

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented intolerance to generic warfarin.

Eliquis®

- The diagnosis or indication is nonvalvular atrial fibrillation.

Enoxaparin

- The patient has a documented intolerance to brand Lovenox®.

Innohep®

- The diagnosis is treatment of acute, symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism, administered in conjunction with warfarin sodium.

AND

- The patient does not have a bleeding disorder or documented heparin-induced thrombocytopenia (HIT).

AND

- The prescriber must provide a clinically valid reason why one of Lovenox®, Fragmin® or fondaparinux cannot be used.

OR

- The patient has been started and stabilized on the requested medication in conjunction with warfarin.

Pradaxa®

- The diagnosis or indication is nonvalvular atrial fibrillation.

Xarelto® 15 mg and 20 mg

- The diagnosis or indication is nonvalvular atrial fibrillation.

AND

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented side effect, allergy, or contraindication (i.e. drug interactions) to warfarin therapy.

OR

- The patient has not been able to be adherent to coagulation monitoring or has not been able to achieve optimal INR control [INR 2-3] with warfarin therapy, despite dose titration attempts.

OR

- The prescriber has provided another clinically valid reason why generic warfarin cannot be used.

OR

- The indication is treatment of DVT or PE or reduction of risk of recurrent DVT or PE

AND

- The patient has been started and stabilized on the requested medication.

OR

- The prescriber has provided a clinically valid reason why low molecular weight heparins, fondaparinux or generic warfarin cannot be used.

Note: Xarelto 10 mg for the diagnosis of the need for thromboprophylaxis following knee and hip replacement surgery is available without PA in the limited durations required for these indications.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Request Form Prior Authorization**

Anticoagulants

Length of Authorization: 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL **Vitamin K Antagonist** WARFARIN † (compare to Coumadin®)	Coumadin®* (warfarin)
Direct Thrombin Inhibitor	Pradaxa® (dabigatran etexilate) (PA only requires NVAF FDA approved indication) *(Quantity Limit = 2 capsules/day)*
Factor Xa Inhibitor	Eliquis® (apixaban) (PA only requires NVAF FDA approved indication) *(Quantity Limit = 2 tablets/day)*
XARELTO® (rivaroxaban) 10 mg *(Quantity Limit = 1 tablet/day, maximum 30 day supply to complete total 35 days/every 180 days)*	Xarelto® (rivaroxaban) 15 mg and 20 mg *(Quantity Limit = 1 tablet/day)* *(Quantity limit 15 mg = 2 tablets/day for 21 days if indication is treatment of DVT or PE)*
UNFRACTIONATED HEPARIN HEPARIN †	
LOW MOLECULAR WEIGHT HEPARINS FRAGMIN® (dalteparin) LOVENOX® (enoxaparin) *(QL = 2 syringes/day calculated in ml volume)*	Enoxaparin † (compare to Lovenox®) *(QL = 2 syringes/day calculated in ml volume)* Innohep® (tinzaparin)
SELECTIVE FACTOR XA INHIBITOR FONDAPARINUX† (compare to Arixtra®)	Arixtra®* (fondaparinux)

Anticonvulsants

LENGTH OF AUTHORIZATION: lifetime for seizure disorders*♠; 1 year for other indications

CRITERIA FOR APPROVAL:

Depakene®, Depakote®, Depakote ER®, Keppra® tablets or oral solution, Klonopin®, Klonopin Wafers®, Lamictal® tablets or chewable tablets, Mysoline®, Neurontin® capsules/tablets/oral solution, Tegretol®, Tegretol® XR (200 & 400 mg), Topamax® tablets, Topamax® Sprinkles, Trileptal® tablets, Zarontin®, Zonegran®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented intolerance to the generic equivalent of the requested medication.

Aptiom®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The diagnosis is adjunctive therapy of partial-onset seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants, one of which is oxcarbazepine.

Banzel®

- The diagnosis or indication is treatment of Lennox-Gastaut Syndrome.

AND

- The patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants used for the treatment of Lennox-Gastaut syndrome (topiramate, lamotrigine, valproic acid)

AND

- For approval of the oral suspension, the patient must be unable to use Banzel tablets (i.e. swallowing disorder)

Felbamate, Felbatol®

- A patient information/consent describing aplastic anemia and liver injury has been completed.

AND

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.) Additionally, if brand is requested, the patient has a documented intolerance to the generic product.

OR

- The diagnosis is adjunctive therapy of partial-onset seizures or Lennox-Gastaut seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least THREE preferred anticonvulsants. Additionally, if brand is requested, the patient has a documented intolerance to the generic product.

Diazepam rectal gel

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented intolerance to Diastat rectal gel.

Divalproex sodium capsules (sprinkles), tiagabine, Oxcarbazepine oral suspension (generics)

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented intolerance to the brand name product.

Keppra XR®, Lamictal XR®, lamotrigine ER, levetiracetam ER, Oxtellar XR, Trokendi XR®

- The patient has been unable to be compliant with or tolerate twice daily dosing of the immediate release product. Additionally, if brand Keppra XR or Lamictal XR is requested, the patient has a documented intolerance to the generic product.

Lamictal ODT®

- Medical necessity for a specialty dosage form has been provided.

AND

- Lamotrigine chewable tablets cannot be used.

Lyrica® caps, Lyrica® oral solution

- The patient has a diagnosis of epilepsy.

OR

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class, if medication is being used for neuropathic pain.

OR

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Savella®, if medication is being used for fibromyalgia. (this indication not processed via automated step therapy)

AND

- If the request is for the oral solution, the patient is unable to use Lyrica capsules (eg. swallowing disorder).

Onfi®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The diagnosis or indication is adjunctive treatment of Lennox-Gastaut Syndrome.

AND

- The patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants used for the treatment of Lennox-Gastaut syndrome (topiramate, lamotrigine, valproic acid)

OR

- The diagnosis or indication is adjunctive treatment of refractory epilepsy (may include different types of epilepsy)

AND

- The patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least THREE preferred anticonvulsants

Fycompa®, Potiga®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The diagnosis is adjunctive therapy of partial-onset seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants

Sabril®

- The prescriber and patient are registered with the SHARE program.

AND

- The diagnosis is infantile spasms

OR

- The patient is ≥ 16 years old and the indication is adjunctive therapy in refractory complex partial seizures after failure of THREE other preferred anticonvulsants.

Stavzor®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented intolerance to divalproex sodium.

Vimpat®

- The patient has been started and stabilized on the requested medication. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The diagnosis is adjunctive therapy of partial-onset seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants

AND

- If the request is for the oral solution, the patient is unable to use Vimpat tablets (eg. swallowing disorder).

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anticonvulsants

Length of Authorization: lifetime for seizure disorders♠; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL CARBAMAZEPINE† (compare to Tegretol®) CARBAMAZEPINE EXTENDED RELEASE† (compare to Tegretol XR®) CARBATROL® (carbamazepine) CELONTIN® (methsuxamide) CLONAZEPAM† (compare to Klonopin®) CLONAZEPAM ODT† (compare to Klonopin Wafers®) DEPAKOTE SPRINKLES® (divalproex sodium caps) DILANTIN® (phenytoin) DIVALPROEX SODIUM † (compare to Depakote®) DIVALPROEX SODIUM ER† (compare to Depakote ER®) EPITOL† (carbamazepine) ETHOSUXAMIDE† (compare to Zarontin®) GABAPENTIN† 100 mg, 300 mg, 400 mg capsules, 600 mg, 800 mg tablets, 250 mg/5 ml oral solution (compare to Neurontin®) GABITRIL® (tiagabine) LAMOTRIGINE† chew tabs (compare to Lamictal® chew tabs) LAMOTRIGINE† tabs (compare to Lamictal® tabs) LEVETIRACETAM† tabs (compare to Keppra® tabs) LEVETIRACETAM† oral soln (compare to Keppra® oral soln) OXCARBAZEPINE† tablets (compare to Trileptal®) PEGANONE® (ethotoin) PHENYTEK® (phenytoin extended) PHENYTOIN† (compare to Dilantin®) PHENYTOIN EX† cap (compare to Phenytek®) PRIMIDONE† (compare to Mysoline®) TEGRETOL® XR (carbamazepine) 100 mg ONLY TOPIRAMATE† tabs (compare to Topamax® tabs) TOPIRAMATE† sprinkle caps (compare to Topamax® Sprinkles) TRILEPTAL® oral suspension (oxcarbazepine) VALPROIC ACID† (compare to Depakene®) ZONISIMIDE† (compare to Zonegran®)	Aptiom® (eslicarbazepine acetate) *QL = 1 tab/day (200, 400 and 800 mg) and 2 tabs/day (600 mg)* Banzel® (rufinamide) *QL = 8 tabs/day (400 mg) and 16 tabs/day (200 mg)* Banzel® (rufinamide) oral suspension *QL = 80 ml/day (3,200 mg/day)* Depakene®* (valproic acid) Depakote®* (divalproex sodium) Depakote ER®* (divalproex sodium) divalproex sodium capsules† (compare to Depakote Sprinkles®) felbamate (compare to Felbatol®) Felbatol® (felbamate) Fycompa® (perampanel) tablets *QL = 1 tablet/day* Keppra®* (levetiracetam) tablets, oral solution Keppra XR® (levetiracetam extended release) Klonopin®* (clonazepam) Klonopin Wafers®* (clonazepam ODT) Lamictal®* tabs (lamotrigine tabs) Lamictal®* chew tabs (lamotrigine chew tabs) Lamictal ODT® (lamotrigine orally disintegrating tablets) Lamictal XR® tablets (lamotrigine extended release) lamotrigine ER† (compare to Lamictal XR®) levetiracetam ER (compare to Keppra XR®) Lyrica® (pregabalin) § cap *(Quantity Limit = 3 capsules/day)* Lyrica® (pregabalin) oral solution Mysoline®* (primidone) Neurontin®* (gabapentin) capsules, tablets and oral solution Onfi® (clobazam) Oral Suspension 2.5 mg/ml *(Quantity limit = 16 ml/day)* Onfi® (clobazam) Tablets *(Quantity Limit = 3.5 tablets/day (10 mg), 2 tablets/day (20 mg))* Oxcarbazepine † oral suspension (compare to Trileptal®) Oxtellar® XR (oxcarbazapine ER) tablet Potiga® (ezogabine) tablets *(Quantity limit = 9 tablets/day (50mg), 3 tablets/day (all others)* Sabril® (vigabatrin) Stavzor® (valproic acid delayed release) Tegretol®* (carbamazepine) Tegretol XR®* (carbamazepine) (200 and 400 mg strength) tiagabine† (compare to Gabitril®) Topamax®* (topiramate) tablets Topamax®* (topiramate) Sprinkle Capsules Trileptal®* tablets (oxcarbazepine) Trokendi XR® (topiramate SR 24hr) Capsules *(Quantity limit = 2 caps/day (200mg), 1 cap/day all others)* Vimpat® (lacosamide) tablets, oral solution Zarontin®* (ethosuxamide) Zonegran®* (zonisamide)
RECTAL DIASTAT® (diazepam rectal gel)	Diazepam rectal gel

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

♠ For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Depressants: Miscellaneous

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*♠; 1 year for other indications

CRITERIA FOR APPROVAL:

Aplenzin:

- The patient has had a documented inadequate response to Budeprion XL/bupropion XL.

AND

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred)

Forfivo XL:

- The patient is unable to take the equivalent dose as generic bupropion XL.

Oleptro:

- The diagnosis for use is MDD (major depressive disorder).

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure/inadequate response to immediate release trazodone.

Remeron, Remeron SolTab, Wellbutrin, Wellbutrin SR, Wellbutrin XL:

- The patient has had a documented intolerance to the generic formulation of the requested medication.

Brintellix, Viibryd:

- The diagnosis or indication is Major Depressive Disorder (MDD)

AND

- The patient has had a documented side effect, allergy, or inadequate response (defined by at least 4 weeks of therapy) to at least 3 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred)

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Anti-Depressants: Miscellaneous

Length of Authorization: Duration of need for mental health indications♠; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
BUDEPRION® SR/BUPROPION SR† (compare to Wellbutrin SR®) *FDA maximum recommended dose = 400 mg/day* BUDEPRION XL/BUPROPION XL† (compare to Wellbutrin XL®) *FDA maximum recommended dose = 450 mg/day* BUPROPION† (compare to Wellbutrin®) *FDA maximum recommended dose = 450 mg/day* MAPROTILINE† (previously Ludiomil®) *FDA maximum recommended dose = 225 mg/day* MIRTAZAPINE† (compare to Remeron®) *FDA maximum recommended dose = 45 mg/day* MIRTAZAPINE RDT† (compare to Remeron Sol-Tab®) *FDA maximum recommended dose = 45 mg/day* NEFAZADONE† (previously Serzone®) *FDA maximum recommended dose = 600 mg/day* TRAZODONE HCL† (previously Desyrel®) *FDA maximum recommended dose = 600 mg/day*	Aplenzin® (bupropion hydrobromide) ER tablets *Quantity Limit = 1 tablet/day* Brintellix® (vortioxetine) Tablet *Quantity Limit = 1 tablet/day* Forfivo XL® (bupropion SR 24hr) 450 mg tablet *FDA maximum recommended dose = 450 mg/day* *Quantity Limit = 1 tablet/day* Oleptro® (trazodone) ER tablets *Quantity Limit = 2 tablets/day (150 mg) or 1 tablet/day (300 mg)* Remeron®* (mirtazapine) *FDA maximum recommended dose = 45 mg/day* Remeron Sol Tab®* (mirtazapine RDT) *FDA maximum recommended dose = 45 mg/day* Viibryd® (vilazodone) Tablet *Quantity Limit = 1 tablet/day* Wellbutrin®* (bupropion) *FDA maximum recommended dose = 450 mg/day* Wellbutrin SR®* (bupropion SR) *FDA maximum recommended dose = 400mg/day* Wellbutrin XL®* (bupropion XL) *FDA maximum recommended dose = 450 mg/day*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

♠ For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Depressants: SNRIs

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*; 1 year for other indications

CRITERIA FOR APPROVAL:

Venlafaxine IR:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred).

Venlafaxine ER tablet (generic), Venlafaxine ER tablet (brand), Effexor XR capsule (brand):

- The patient has had a documented intolerance to generic venlafaxine ER capsule

Fetzima, Pristiq:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The diagnosis or indication is Major Depressive Disorder (MDD)

AND

- The patient has had a documented side effect, allergy, or inadequate response to at least 3(three) different antidepressants from the SSRI, SNRI, TCA and/or Miscellaneous Antidepressant categories, one of which must be venlafaxine ER capsule (may be preferred or non-preferred).

Desvenlafaxine ER, Khedezla:

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories, one of which must be venlafaxine ER capsule (may be preferred or non-preferred).

AND

- The patient has had a documented intolerance with Pristiq.

Cymbalta, duloxetine:

Depression:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories, one of which must be venlafaxine ER capsule (may be preferred or non-preferred).

AND

- If the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta.

Generalized Anxiety Disorder:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least TWO different antidepressants from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) or ONE antidepressant from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) and buspirone.

AND

- If the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta.

Neuropathic pain:

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs in the tricyclic anrtidepressant (TCA) class and/or anticonvulsant class. (this indication not processed via automated step therapy).

AND

- If the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta.

Non-neuropathic musculoskeletal pain (osteoarthritis, chronic low back pain):

- The patient has had a documented side effect, allergy, inadequate response or contraindication to acetaminophen (Tylenol®) AND at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (oral and/or topical). (this indication not processed via automated step therapy)

AND

- If the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta.

Fibromyalgia:

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic anrtidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine, Lyrica® or Savella®.(this indication not processed via automated step therapy)

AND

- If the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Anti-Depressants: SNRI

Length of Authorization: Duration of need for mental health indications♠; 1 year for other indications*

Key: † Generic product

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Venlafaxine ER† capsule (compare to Effexor XR®) *FDA maximum recommended dose = 225 mg/day,* *Quantity limit = 1 capsule/day (37.5 mg & 75 mg)*	Cymbalta® **§** (duloxetine) Capsule *FDA maximum recommended dose = 120 mg/day(MDD and GAD), 60 mg/day all others* *Quantity limit = 2 capsules/day* Desvenlafaxine ER® (desvenlafaxine base SR) *FDA maximum recommended dose = 400 mg/day,* *Quantity limit = 1 tablet/day (50 mg tablet only)* Duloxetine† (compare to Cymbalta®) Capsule *FDA maximum recommended dose = 120 mg/day(MDD and GAD), 60 mg/day all others* *Quantity limit = 2 capsules/day* Effexor XR® (venlafaxine XR) capsule *FDA maximum recommended dose = 225 mg/day,* *Quantity limit = 1 capsule/day (37.5 mg & 75 mg)* Fetzima® (levomilnacipran ER) capsule *FDA maximum recommended dose = 120 mg/day,* *Quantity limit = 1 capsule/day* Fetzima® (levomilnacipran ER) capsule titration pack *(QL = 1 pack per lifetime)* *FDA maximum recommended dose = 120 mg/day,* Khedezla® (desvenlafaxine base SR) *FDA maximum recommended dose = 400 mg/day,* *Quantity limit = 1 tablet/day (50 mg tablet only)* Pristiq® **§** (desvenlafaxine succinate SR) *FDA maximum recommended dose = 400 mg/day,* *Quantity limit = 1 tablet/day (50 mg tablet only)* Venlafaxine ER®† tablet *FDA maximum recommended dose = 225 mg/day,* *Quantity limit = 1 tablet/day (37.5 mg & 75 mg)* Venlafaxine ER† tablet *FDA maximum recommended dose = 225 mg/day,* *Quantity limit = 1 tablet/day (37.5 mg & 75 mg)* venlafaxine IR †**§** (previously Effexor®) *FDA maximum recommended dose = 225 mg/day*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

♠ For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Depressants: SSRIs

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*; 1 year for other indications

CRITERIA FOR APPROVAL

Celexa, Paxil tablet, Prozac, Zoloft:

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be the generic formulation of the requested medication.)

Brisdelle:

- The indication for use is moderate to severe vasomotor symptoms (VMS) associated with menopause.

AND

- The patient has tried and failed generic paroxetine.

Luvox CR, fluvoxamine CR:

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic fluvoxamine IR.) If the request is for the brand product, the patient also has a documented intolerance to the generic equivalent.

Pexeva, Paroxetine CR, Paxil CR:

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic paroxetine.)

AND

- If the request is for Paxil CR, the patient has a documented intolerance to paroxetine CR.

Paroxetine suspension, Paxil suspension:

- The patient has a requirement for an oral liquid dosage form.

AND

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs.

Sarafem, Selfemra, Fluoxetine 60 mg Tablet, Fluoxetine (pmdd):

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic fluoxetine (regular, not pmdd).) In addition, for approval of Sarafem, either Selfemra or fluoxetine pmdd must have been tried.

Lexapro, escitalopram:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic citalopram).

AND

- If the request is for Lexapro, the patient has a documented intolerance with generic escitalopram.

Fluoxetine 90 mg, Prozac Weekly:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient failed and is not a candidate for daily fluoxetine.

AND

- The prescriber provides clinically compelling rationale for once-weekly dosing.

AND

- If the request is for Prozac Weekly, the patient has a documented intolerance of fluoxetine 90 mg capsules.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Anti-Depressants: SSRI

Length of Authorization: Duration of need for mental health indications; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CITALOPRAM† (compare to Celexa®) *FDA maximum recommended dose = 40 mg/day* FLUOXETINE† (compare to Prozac®) *FDA maximum recommended dose = 80 mg/day* FLUVOXAMINE† (previously Luvox®) *FDA maximum recommended dose = 300 mg/day* PAROXETINE tablet† (compare to Paxil®) *FDA maximum recommended dose = 60 mg/day* SERTRALINE† (compare to Zoloft®) *FDA maximum recommended dose = 200 mg/day, Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)*	Brisdelle® (paroxetine) *Quantity Limit = 1 capsule/day* Celexa®* (citalopram) *FDA maximum recommended dose = 40 mg/day* escitalopram† (compare to Lexapro®) *FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)* fluoxetine† (pmdd) *FDA maximum recommended dose = 80 mg/day* Fluoxetine® 60 mg Tablet *FDA maximum recommended dose = 80 mg/day* fluoxetine† 90 mg (compare to Prozac Weekly®) *FDA maximum recommended dose = 90 mg/week* fluvoxamine CR† (compare to Luvox CR®) *FDA maximum recommended dose = 300 mg/day, Quantity limit = 2 capsules/day* Lexapro® (escitalopram) *FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)* Luvox CR® (fluvoxamine CR) *FDA maximum recommended dose = 300 mg/day, Quantity limit = 2 capsules/day* paroxetine suspension† (compare to Paxil® susp) *FDA maximum recommended dose = 60 mg/day* Paroxetine CR† (compare to Paxil CR®) *FDA maximum recommended dose = 75 mg/day* Paxil®* (paroxetine) *FDA maximum recommended dose = 60 mg/day* Paxil® suspension (paroxetine) *FDA maximum recommended dose = 60 mg/day* Paxil CR® (paroxetine CR) *FDA maximum recommended dose = 75 mg/day* Pexeva® (paroxetine) *FDA maximum recommended dose = 60 mg/day* Prozac®* (fluoxetine) *FDA maximum recommended dose = 80 mg/day* Prozac Weekly® (fluoxetine) *FDA maximum recommended dose = 90 mg/week* Sarafem® (fluoxetine pmdd) *FDA maximum recommended dose = 80 mg/day* Selfemra®† (fluoxetine pmdd) *FDA maximum recommended dose = 80 mg/day* Zoloft®* (sertraline) *FDA maximum recommended dose = 200 mg/day, Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Anti-Depressants: Tricyclics & MAOIs

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*; 1 year for other indications

CRITERIA FOR APPROVAL:

Tricyclics (TCAs) (Brands with generic equivalents):

- The patient has had a documented side effect, allergy, or treatment failure to 2 or more TCAs not requiring prior-authorization. One trial must be the AB rated generic formulation.

OR

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

AND

- The patient has had a documented intolerance to the generic formulation

Surmontil®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization).

OR

- The patient has had a documented side effect, allergy, or treatment failure to one or more preferred TCAs.

MAOIs:

Marplan®

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to phenelzine and tranylcypromine.

Nardil®, Parnate®

- The patient has had a documented intolerance to generic equivalent product..

EMSAM®

- The patient has had a documented side effect, allergy, or treatment failure with at least 3 antidepressants from 2 of the major antidepressant classes (Miscellaneous, SNRIs, SSRIs, Tricyclic Antidepressants).

OR

- The patient is unable to tolerate oral medications.

LIMITATIONS:

Chlordiazepoxide/amitriptyline and amitriptyline/perphenazine combinations not covered. Generic agents may be prescribed separately**.**

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Anti-Depressants: Tricyclics & MAOIs

Length of Authorization: Duration of need for mental health indications; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
TRICYCLICS	
AMITRIPTYLINE† (previously Elavil®) *FDA maximum recommended dose = 300 mg/day* AMOXAPINE† (previously Asendin®) CLOMIPRAMINE† (compare to Anafranil®) DESIPRAMINE† (compare to Norpramin®) DOXEPIN† (previously Sinequan®) IMIPRAMINE† (compare to Tofranil®) *FDA maximum recommended dose = 300 mg/day* IMIPRAMINE PAMOATE† (compare to Tofranil PM®) NORTRIPTYLINE† (previously Aventyl®, compare to Pamelor®) NORTRIPTYLINE Oral Solution PROTRIPTYLINE† (compare to Vivactil®)	Anafranil®* (clomipramine) Norpramin®* (desipramine) Pamelor®* (nortriptyline) Surmontil® (trimipramine) Tofranil®* (imipramine) *FDA maximum recommended dose = 300 mg/day* Tofranil PM®* (imipramine pamoate) Vivactil®* (protriptyline)
MAOIs	
PHENELZINE SULFATE (compare to Nardil®) *FDA maximum recommended dose = 90 mg/day* TRANYLCYPROMINE (compare to Parnate®) *FDA maximum recommended dose = 60 mg/day*	EMSAM® (selegiline) *(QL = 1 patch/day)* Marplan® (isocarboxazid) Nardil®* (phenelzine) *FDA maximum recommended dose = 90 mg/day* Parnate®* (tranylcypromine) *FDA maximum recommended dose = 60 mg/day*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Anti-Diabetics: Insulin

LENGTH OF AUTHORIZATION: lifetime

CRITERIA FOR APPROVAL:

Apidra®

- The patient has had a documented side effect, allergy, or treatment failure to Novolog® or Humalog®

ReliOn R®, ReliOn N® or ReliOn 70/30®

- The patient has had a documented side effect, allergy, or treatment failure to the corresponding Novolin® or Humulin® product

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Insulins	*Length of Authorization: lifetime*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
RAPID-ACTING INJECTABLE NOVOLOG® (Aspart) HUMALOG® (insulin lispro)	Apidra® (insulin glulisine)
SHORT-ACTING INJECTABLE HUMULIN R® (Regular) NOVOLIN R® (Regular)	ReliOn R® (Regular)
INTERMEDIATE-ACTING INJECTABLE HUMULIN N® (NPH) NOVOLIN N® (NPH)	ReliOn N® (NPH)
LONG-ACTING ANALOGS INJECTABLE LANTUS® (insulin glargine) LEVEMIR® (insulin detemir)	
MIXED INSULINS INJECTABLE HUMULIN 70/30® (NPH/Regular) NOVOLIN 70/30® (NPH/Regular) NOVOLOG MIX 70/30® (Protamine/Aspart) HUMALOG MIX 75/25® (Protamine/Lispro) HUMALOG MIX 50/50® (Protamine/Lispro)	ReliOn 70/30® (NPH/Regular)

Anti-Diabetics: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ALPHA GLUCOSIDASE INHIBITORS

- For approval of Precose®, the patient must have a documented intolerance to generic acarbose.

BIGUANIDES AND COMBINATIONS

Fortamet, Glucophage XR, Glumetza, Metformin ER Osmotic

- The patient has had a documented intolerance to generic metformin XR. (If a product has an AB rated generic, there must have also been a trial of the generic.)

Glucophage, Glucovance, Metaglip

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred biguanide or biguanide combination product. (If a product has an AB rated generic, the trial must be the generic.)

DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS

Januvia, Onglyza

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

Nesina, Tradjenta

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred DDP-4 agent.

Janumet

- The patient has had an inadequate response with Januvia or metformin monotherapy.

OR

- The patient has been started and stabilized on Januvia and metformin combination therapy.

Kazano

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred DDP-4 combination agent.

Janumet XR

- The patient has had an inadequate response with Januvia or metformin/metformin XR monotherapy.

OR

- The patient has been started and stabilized on Januvia and metformin/ metformin XR combination therapy.

AND

- The patient is unable to take Januvia and metformin/metformin XR as the individual separate agents.

Jentadueto

- The patient has had an inadequate response with Tradjenta or metformin monotherapy.

OR

- The patient has been started and stabilized on Tradjenta and metformin combination therapy.

AND

- The patient is unable to take Tradjenta and metformin as the individual separate agents.

Juvisync:

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

AND

- The patient has been started and stabilized on Januvia and simvastatin combination therapy as individual agents.

Kombiglyze XR

- The patient has had an inadequate response with Onglyza or metformin/metformin XR monotherapy.

OR

- The patient has been started and stabilized on Onglyza and metformin/metformin XR combination therapy.

Oseni

- The patient is unable to take Nesina and Actos (pioglitazone) as the individual separate agents (after meeting clinical criteria for each individual agent).

MEGLITINIDES

Starlix

- The patient has had a documented intolerance to generic nateglinide.

Prandin, Repaglinide

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented side effect, allergy or treatment failure with Starlix.

AND

- If the request if for Prandin, the patient has a documented intolerance with generic repaglinide.

Prandimet

- The patient has been started and stabilized on Prandimet or on stable doses of the separate agents

OR

- The patient has had an inadequate response with repaglinide monotherapy

SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS

- The patient is 18 years of age or older.

AND

- The patient has a diagnosis of type 2 diabetes mellitus and has had an inadequate response to diet and exercise alone.

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

SULFONYLUREAS SECOND GENERATION

- The patient has had a documented side effect, allergy or treatment failure with glimepiride, and glipizide/glipizide ER, and glyburide/glyburide micronized.

THIAZOLIDINEDIONES AND COMBINATIONS

Actos *(pioglitazone),* ***Actoplus Met****,* ***Duetact, Pioglitazine, Pioglitazone/glimepiride*** *and* ***Pioglitazone/Metformin***

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

AND

- If the request is for brand Actos, Actos Met or Duetact, the patient has a documented intolerance to the generic product.

Actoplus Met XR

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented treatment failure with generic metformin XR.

OR

- The patient has had a documented treatment failure or has been unable to be adherent to a twice daily dosing schedule of Actoplus Met® resulting in a significant clinical impact.

Avandia *(rosiglitazone) and combinations*

- The patient has been started and stabilized on the requested medication and appears to be benefiting from it and the patient acknowledges that they understand the risks,

OR

- The patient is unable to achieve glycemic control using other medications (including a documented side effect, allergy, contraindication or treatment failure with metformin) and, in consultation with their health care professional, decide not to take pioglitazone for medical reasons and the patient acknowledges that they understand the risks.

WELCHOL®

- See Lipotropics: Bile Acid Sequestrants

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Diabetics: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALPHA GLUCOSIDASE INHIBITORS	
ACARBOSE† (compare to Precose®) GLYSET® (miglitol)	Precose®* (acarbose)
BIGUANIDES AND COMBINATIONS	
SINGLE AGENT METFORMIN† (compare to Glucophage®) METFORMIN XR† (compare to Glucophage XR®) RIOMET® (metformin oral solution)	Fortamet® (metformin ER Osmotic) Glucophage®* (metformin) Glucophage XR®* (metformin extended-release) Glumetza® (metformin extended-release) Metformin ER Osmotic† (compare to Fortamet®)
COMBINATION GLIPIZIDE/METFORMIN†(compare to Metaglip®) GLYBURIDE/METFORMIN† (compare to Glucovance®)	Glucovance®* (glyburide/metformin) Metaglip®*(glipizide/metformin)
DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS AND COMBINATIONS (after clinical criteria are met)	
SINGLE AGENT JANUVIA® (sitagliptin)**§** *(Quantity limit=1 tab/day)* ONGLYZA® (saxagliptin)**§** *(Qty limit=1 tab/day)*	Nesina® (alogliptin) *(Quantity limit=1 tab/day)* Tradjenta® (linagliptin) *(Qty limit=1 tab/day)*
COMBINATION JANUMET® (sitagliptin/metformin)**§** *(Quantity limit=2 tabs/day)* KOMBIGLYZE XR® (saxagliptin/metformin ER) **§** *(Quantity limit=1 tab/day)*	Janumet XR® (sitagliptin/metformin ER) *(Qty limit=1 tab/day of 50/500 mg or 100/1000 mg or 2 tabs/day of 50/1000 mg)* Jentadueto® (linagliptin/metformin) *(Quantity limit=2 tabs/day)* Juvisync® (sitagliptin/simvastatin) *(Quantity limit=1 tab/day)* Kazano® (alogliptin/metformin) *(Quantity limit=2 tabs/day)* Oseni® (alogliptin/pioglitazone) *(Quantity limit=1 tab/day)*
MEGLITINIDES **SINGLE AGENT** NATEGLINIDE† (compare to Starlix®)	Prandin® (repaglinide) repaglinide† (compare to Prandin®) Starlix®* (nateglinide)
COMBINATION	Prandimet® (repaglinide/metformin)
Table continued next page	*Table continued next page*

SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS (after clinical criteria are met)	
INVOKANA® (canagliflozin) **§** *(Quantity limit = 1 tablet/day)* FARXIGA® (dapagliflozin) *(Quantity limit = 1 tablet/day)*	
SULFONYLUREAS SECOND GENERATION	
GLIMEPIRIDE† (compare to Amaryl®) GLIPIZIDE† (compare to Glucotrol®) GLIPIZIDE ER† (compare to Glucotrol XL®) GLYBURIDE† (compare to Diabeta®) GLYBURIDE MICRONIZED† (compare to Glynase® PresTab®)	Amaryl®* (glimepiride) Diabeta®* (glyburide) Glucotrol®* (glipizide) Glucotrol XL®* (glipizide extended-release) Glynase® PresTab®* (glyburide micronized)
THIAZOLIDINEDIONES AND COMBINATIONS (after clinical criteria are met)	
SINGLE AGENT PIOGLITAZONE† (compare to Actos®)**§**	Actos® (pioglitazone) Avandia® (rosiglitazone)
COMBINATION PIOGLITAZONE/GLIMEPIRIDE† (compare to Duetact®) **§** *(Quantity Limit = 1 tablet/day)* PIOGLITAZONE/METFORMIN† (Compare to Actoplus Met®)**§**	Actoplus Met® (pioglitazone/metformin) Actoplus Met XR (pioglitazone/metformin ER) Avandamet® (rosiglitazone/metformin) Avandaryl® (rosiglitazone/glimeperide) Duetact® (pioglitazone/glimepiride) *(Quantity Limit = 1 tablet/day)*

Note: Please refer to “Lipotropics: Bile Acid Sequestrants” for Welchol®.

Anti-Diabetics: Peptide Hormones

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Bydureon**:**

- The patient has a diagnosis of type 2 diabetes.
  AND
- The patient is at least 18 years of age.
  AND
- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.
  AND
- The patient has had a documented side effect or treatment failure to Byetta
  OR
- The patient has been unable to be adherent to or tolerate twice daily dosing of Byetta

Byetta:

- The patient has a diagnosis of type 2 diabetes.
  AND
- The patient is at least 18 years of age.
  AND
- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

Symlin:

- The patient has a diagnosis of diabetes mellitus.
  AND
- The patient is at least 18 years of age.
  AND
- The patient is on insulin.

Victoza:

- The patient has a diagnosis of type 2 diabetes.
  AND
- The patient is at least 18 years of age.
  AND
- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Diabetics: Peptide Hormones	*Length of Authorization: 1 year*
PREFERRED AFTER CLINICAL CRITERIA ARE MET	**PA REQUIRED**
Incretin Mimetics VICTOZA® (liraglutide) *(Quantity Limit=3 pens/30 days)*	Bydureon® (exenatide extended-release) *(Quantity Limit=4 vials/28 days)* Byetta® (exenatide) (Quantity Limit=1 pen/30 days)
Amylinomimetics	Symlin® (pramlintide) *(No quantity limit applies)*

Antidiarrheals: HIV/AIDS

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval 1 year

CRITERIA FOR APPROVAL:

- Patient has HIV/AIDS and is receiving anti-retroviral therapy

AND

- Patient is at least 18 years of age

AND

- Patient requires symptomatic relief of noninfectious diarrhea

AND

- Infectious diarrhea (e.g. cryptosporidiosis, c. difficile, etc.) has been ruled out

AND

- Patient has tried and failed at least one anti-diarrheal medication (i.e. loperamide or atropine/diphenoxylate)

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of Fulyzaq® on a **General Prior Authorization Request Form**.

Reauthorizations for continued use shall be reviewed yearly. Renewal criteria shall confirm the following:

- Patient has an objective response to therapy, defined as improvement in diarrhea symptoms.

Antidiarrheals: HIV/AIDS

Length of Authorization: initial approval 3 months, subsequent approval 1 year

NO PA REQUIRED	PA REQUIRED
Diphenoxylate/atropine Loperamide	Fulyzaq®(crofelemer) 125 mg DR Tablets *QL = 2 tablets/day*

Anti-Emetics: 5-HT_3 Receptor Antagonists

LENGTH OF AUTHORIZATION: 6 months for Chemotherapy/Radiotherapy, 3 months for hyperemesis gravadarum and 1 time Post-Op

CRITERIA FOR APPROVAL (non-preferred agents):

Anzemet®

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to generic ondansetron.

Granisetron, Granisol®

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy or radiotherapy.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to generic ondansetron.

Zofran®

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy, radiotherapy, post-operative nausea and vomiting (1 time only) or hyperemesis gravadarum.

  AND
- The patient must have a documented intolerance to the corresponding generic ondansetron product (tablets, orally disintegrating tablets (ODT), oral solution or injection). If the request is for oral solution, the patient must be unable to use ondansetron ODT or ondansetron tablets.

Ondansetron oral solution

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy, radiotherapy, post-operative nausea and vomiting (1 time only) or hyperemesis gravadarum.

  AND
- The patient is unable to use ondansetron ODT or ondansetron tablets.

Ondansetron 24 mg

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy.

  AND
- The prescriber provides rationale why generic ondansetron 8 mg tablets cannot be used to achieve the desired dose.

Sancuso®

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy.

  AND
- The prescriber provides documentation of medical necessity for the transdermal formulation.

  OR
- The patient has had a documented side effect, allergy or treatment failure with generic ondansetron.

Zuplenz®

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy or radiotherapy.

  AND
- The prescriber provides documentation of medical necessity for the specialty dosage form (i.e. inability to swallow tablets, dysphagia) AND a clinical rationale as to why ondansetron ODT is not a suitable option for the patient.

CRITERIA FOR APPROVAL (to exceed quantity limit):

Ondansetron/Zofran 4 mg and 8 mg tablets and ODT, Zuplenz

- For nausea and vomiting associated with chemotherapy or radiation therapy, 3 tablets for each day of chemotherapy/radiation and 3 tablets for each day for 2 days after completion of chemotherapy/radiation may be approved.

Ondansetron/Zofran 4 mg and 8 mg tablets and ODT

- For hyperemesis gravadarum, three tablets per day of 4 mg or 8 mg may be approved for 3 months.

Anzemet®

- For nausea and vomiting associated with chemotherapy, 1 tablet for each day of chemotherapy and 1 tablet for 2 days after completion of chemotherapy may be approved.

Granisetron

- For nausea and vomiting associated with chemotherapy, 2 tablets for each day of chemotherapy and 2 tablets for 2 days after completion of chemotherapy may be approved.
- For nausea and vomiting associated with radiation therapy, 2 tablets for each day of radiation may be approved.

Sancuso®

- For nausea and vomiting associated with chemotherapy, 1 patch for each chemotherapy cycle may be approved.

LIMITATIONS:

Aloxi and Anzemet injection are not considered outpatient medications for the pharmacy benefit and so are not covered in the pharmacy benefit.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent, to exceed quantity limits of a preferred agent, or for a diagnosis outside of FDA approval on a **General Prior Authorization Request Form**.

Anti-Emetics: 5-HT_3 Receptor Antagonists

Length of Authorization: 6 months for Chemotherapy/Radiotherapy, 3 months for hyperemesis gravadarum, 1 time Post-Op

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Ondansetron Tablet and Orally Disintegrating Tablet† (compare to Zofran®) 4 mg, 8 mg *Quantity Limit = 12 tablets/28 days (4 mg), 6 tablets/28 days (8 mg)* Ondansetron Injection† (compare to Zofran®)	Anzemet® (dolasetron) *Quantity Limit = 4 tablets/28 days (50 mg), 2 tablets/28 days (100 mg)* Granisetron† (formerly Kytril®) *Quantity Limit = 6 tablets/28 days* Granisetron† (formerly Kytril®) Injectable Granisol® (granisetron) Oral Solution Ondansetron Solution† (compare to Zofran®) Ondansetron† 24 mg tablet (previously Zofran®) *Quantity Limit = 1 tablet/28 days or per course of chemotherapy* Sancuso® 3.1 mg/24 hrs Transdermal Patch (granisetron) *Quantiy Limit = 1 patch/28 days* Zofran®* (ondansetron) Tablet and Orally Disintegrating Tablet *Quantity Limit = 12 tablets/28 days (4 mg), 6 tablets/28 days (8 mg)* Zofran®* (ondansetron) Injection Zofran® (ondansetron) Solution Zuplenz® (ondansetron) Oral Soluble Film *Quantity Limit =12 films/28 days (4 mg),* *6 films/28 days (8 mg)*

Anti-Emetics: Miscellaneous (Pregnancy)

LENGTH OF AUTHORIZATION: 3 months

CRITERIA FOR APPROVAL:

- Patient has a diagnosis of nausea and vomiting of pregnancy

AND

- Patient has tried and had an inadequate response to conservative management (i.e. change in dietary habits, ginger, or acupressure)

AND

- Patient has tried and had an inadequate response to generic doxylamine and generic pyridoxine (Vitamin B6)

AND

- Patient has tried and had an inadequate response to generic ondansetron.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Emetics: Miscellaneous (Pregnancy)	*Length of Authorization: 3 months*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
	Diclegis® (10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride) DR tablet *(QL = 4 tablets/day)*

Anti-Emetics: NK1 Antagonists

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL WHEN QUANTITY LIMIT IS EXCEEDED:

Emend® (aprepitant) 80 mg, 125 mg, Tri-Fold pack

- The medication will be prescribed by an oncology practitioner.

AND

- The patient requires prevention of nausea and vomiting associated with moderate to highly emetogenic cancer chemotherapy.

AND

- The requested quantity does not exceed one 125 mg and two 80 mg capsules OR one Tri-Fold Pack per course of chemotherapy. Patients with multiple courses of chemotherapy per 28 days will be approved quantities sufficient for the number of courses of chemotherapy.

Emend® (aprepitant) 40 mg

- The patient requires prevention of postoperative nausea and vomiting.

AND

- The requested quantity does not exceed one 40 mg capsule per surgery or course of anesthesia. Patients with multiple surgeries or courses of anesthesia in a 28 day period will be approved quantities sufficient for the number of surgeries or courses of anesthesia.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the need to exceed the established quantity limits on the **General Prior Authorization Request Form.**

Anti-Emetics: NK1 Antagonists	*Length of Authorization: up to 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
EMEND® (aprepitant) 40 mg (Qty Limit =1 cap/28 days) ♣ EMEND® (aprepitant) 80 mg (Qty Limit = 2 caps/28 days) ♣ EMEND® (apreptiant) 125 mg (Qty Limit = 1 cap/28 days) ♣ EMEND® (aprepitant) Tri-fold Pack (Qty Limit = 1 pack/28 days) ♣ *To be prescribed by oncology pratitioners ONLY*	

Anti-Emetics: THC Derivatives

LENGTH OF AUTHORIZATION: 3 months initial, subsequent approval 6 months

PHARMACOLOGY:

Marinol® is a schedule III cannabinoid agent containing the same active ingredient, tetrahydrocannabinol, as marijuana. While its exact mechanism of action is unknown, it is speculated to inhibit medullary activity as well as suppress prostaglandin and endorphan synthesis. Cesamet® is a schedule II synthetic cannabinoid that acts by activating the endocannabinoid receptors, CB1 and CB2, which are involved in nausea/vomiting regulation. Both Marinol® and Cesamet® are FDA-approved for use in chemotherapy associated nausea and vomiting refractory to conventional antiemetics. In addition, Marinol® is indicated for patients with AIDS-related anorexia or wasting syndrome.

CRITERIA FOR APPROVAL:

Dronabinol, Marinol

- The patient has a diagnosis of chemotherapy-induced nausea/vomiting.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to **at least 2** antiemetic agents, of which, one must be a **preferred** 5HT3 receptor antagonist. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol.

  OR
- The patient has a diagnosis of AIDS associated anorexia.

  AND
- The patient has had an inadequate response, adverse reaction, or contraindication to megestrol acetate. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol.

Cesamet

- The patient has a diagnosis of chemotherapy-induced nausea/vomiting.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to **at least 2** antiemetic agents, of which, one must be a **preferred** 5HT3 receptor antagonist.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Emetics: THC Derivatives

*Length of Authorization: Initial approval **3 months,** subsequent approval up to **6 months***

PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Dronabinol† (compare to Marinol®) Marinol® (dronabinol) Cesamet® (nabilone)

Anti-Hypertensives: ACE Inhibitors and ACEI Combinations

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Epaned Oral Solution (Patients ≥ 12 years old):

- The patient has a requirement for an oral liquid dosage form (i.e. swallowing disorder, inability to take oral medications).

Other ACE Inhibitors:

- The patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

ACE Inhibitor/Hydrochlorothiazide combinations:

- The patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI/Hydrochlorothiazide combination. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

ACE Inhibitor/Calcium Channel Blocker combination:

- The patient has had a documented side effect, allergy, or treatment failure with a preferred ACEI/Calcium Channel Blocker combination. . If a medication has an AB rated generic, the trial must be the generic formulation.

LIMITATIONS:

Captopril/hydrochlorothiazide combination not covered. Agents may be prescribed separately**.**

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Hypertensives: ACE Inhibitors and ACEI Combinations

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA Required
ACE INHIBITORS: BENAZEPRIL† (compare to Lotensin®) CAPTOPRIL† (previously Capoten®) ENALAPRIL† (compare to Vasotec®) EPANED® (enalapril) oral solution (age < 12 years old) FOSINOPRIL† (previously Monopril®) LISINOPRIL† (compare to Zestril®, Prinivil®) MOEXIPRIL† (compare to Univasc®) QUINAPRIL† (compare to Accupril®) RAMIPRIL† (compare to Altace®) TRANDOLAPRIL† (compare to Mavik®)	Accupril®* (quinapril) Aceon® (perindopril) Altace®* (ramipril) Epaned® (enalapril) oral solution (age ≥ 12 years old) Lotensin®* (benazepril) Mavik®* (trandolapril) perindopril† (compare to Aceon®) Prinivil®* (lisinopril) Univasc®* (moexipril) Vasotec®* (enalapril) Zestril®* (lisinopril)
ACE INHIBITOR/HYDROCHLOROTHIAZIDE: BENAZEPRIL/HCTZ† (compare to Lotensin HCT®) ENALAPRIL/HCTZ† (compare to Vaseretic®) FOSINOPRIL/HCTZ† (previously Monopril HCT®) LISINOPRIL/HCTZ† (compare to Zestoretic®, Prinzide®) MOEXIPRIL/HCTZ† (compare to Uniretic®) QUINAPRIL/HCTZ† (compare to Accuretic®)	Accuretic®* (quinapril/HCTZ) Lotensin HCT®* (benazepril/HCTZ) Prinzide®* (lisinopril/HCTZ) Uniretic®* (moexipril/HCTZ) Vaseretic®* (enalapril/HCTZ) Zestoretic®* (lisinopril/HCTZ)
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER: amlodipine/benazepril† (compare to Lotrel®)	Lotrel®* (amlodipine/benazepril) Tarka® (trandolapril/verapamil)

Anti-Hypertensives: Angiotensin Receptor Blockers (ARBs) and ARB Combinations

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Benicar, Diovan, Irbesartan, Losartan, Telmisartan, Benicar HCT, Irbesartan/hydrochlorothiazide, Losartan hydrochlorothiazide, , telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, Exforge, Exforge HCT

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

Atacand, Avalide, Avapro, candesartan, Diovan HCT, Edarbi, Eprosartan, Micardis, Micardis HCT, Teveten

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination.

AND

- If brand name product with generic available, the patient has had a documented intolerance with the generic product.

Atacand HCT, candesartan/hydrochlorothiazide, Teveten HCT

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure with a preferred ARB/Hydrochlorothiazide combination.

AND

- If the request is for Atacand HCT, the patient has had a documented intolerance with the generic product.

Cozaar, Hyzaar (Brands)

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient has had a documented intolerance with the generic product.

Edarbyclor:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination.

AND

- The patient is unable to take the individual components separately.

Azor®, amlodipine/telmisartan, Tribenzor®, Twynsta®

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to take the individual components separately.

AND

- If the request is for Twynsta, the pastient has a documented intolerance to generic amlodipine/telmisartan.

Valturna

- The patient is NOT a diabetic

AND

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

OR

- The patient has had a documented treatment failure with Tekturna® alone.

<u>DOCUMENTATION:</u>

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Hypertensives: ARBs and ARB Combinations

Length of Authorization: 3 years

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
ANGIOTENSIN RECEPTOR BLOCKERS:	
BENICAR® (olmesartan) § DIOVAN® (valsartan) § IRBESARTAN† (compare to Avapro®) § LOSARTAN† (compare to Cozaar®)§ TELMISARTAN† (compare to Micardis®) §	Atacand® (candesartan) Avapro® (irbesartan) candesartan† (compare to Atacand®)§ Cozaar® (losartan) Edarbi® (azilsartan) Tablet *(Qty Limit = 1 tablet/day)* Eprosartan† (compare toTeveten®) § Micardis® (telmisartan) Teveten® (eprosartan)
ANGIOTENSIN RECEPTOR BLOCKER/DIURETIC:	
BENICAR HCT® (olmesartan/hydrochlorothiazide) § IRBESARTAN/HYDROCHLOROTHIAZIDE† (compare to Avalide®)§ LOSARTAN/HYDROCHLOROTHIAZIDE † (compare to Hyzaar®)§ TELMISARTAN/HYDROCHLOROTHIAZIDE † (compare to Micardis HCT®) § VALSARTAN/HYDROCHLOROTHIAZIDE † (compare to Diovan HCT®)§	Atacand HCT®(candesartan/hydrochlorothiazide) Avalide® (irbesartan/hydrochlorothiazide) candesartan/hydrochlorothiazide † (compare to Atacand HCT®)§ Diovan HCT® (valsartan/hydrochlorothiazide) Edarbyclor® (azilsartan/chlorthalidone) Tablet *(Qty Limit = 1 tablet/day)* Hyzaar® (losartan/hydrochlorothiazide) Micardis HCT® (telmisartan/hydrochlorothiazide) Teveten HCT® (eprosartan/hydrochlorothiazide) §
ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER:	
EXFORGE® (valsartan/amlodipine) § *(QL = 1 tab/day)*	Azor®(olmesartan/amlodipine) *(QL = 1 tablet/day)* amlodipine/telmisartan† (compare to Twynsta®) *(QL = 1 tablet/day)* Twynsta® (amlodipine/telmisartan) *(QL = 1 tablet/day)*
ANGIOTENSIN RECEPTOR BLOCKER/RENIN INHIBITOR:	
	Valturna® (aliskiren/valsartan) *(Qty Limit = 1 tablet/day)*
ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER/HYDROCHLOROTHIAZIDE:	
EXFORGE HCT® (amlodipine/valsartan/hydrochlorothiazide) § *(QL = 1 tab/day)*	Tribenzor® (amlodipine/olmesartan/hydrochlorothiazide) *(QL = 1 tablet/day)*

Anti-Hypertensives: Beta-Blockers

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL

Non-preferred drugs (except Coreg CR®):

- The patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)

Coreg CR®:

Indication: Heart Failure

- The patient has been started and stabilized on Coreg CR®. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to metoprolol SR or bisoprolol.

AND

- The patient has been unable to be compliant with or tolerate twice daily dosing of carvedilol IR.

Indication: Hypertension

- The patient has been started and stabilized on Coreg CR®. (Note: Samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to 3(three) preferred anti-hypertensive beta-blockers.

LIMITATIONS:

Inderal® XL is not covered as federal rebate is not offered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Hypertensives: Beta-Blockers

Length of Authorization: 3 years

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE AGENT	
ACEBUTOLOL† (compare to Sectral®)	Betapace®* (sotalol)
ATENOLOL† (compare to Tenormin®)	Betapace AF®* (sotalol)
BETAXOLOL† (compare to Kerlone®)	Bystolic® (nebivolol) *(QL = 1 tablet/day for 2.5 mg, 5 mg and 10 mg tablet strengths, 2 tablets/day for 20 mg)*
BISOPROLOL FUMARATE† (compare to Zebeta®)	Coreg®* (carvedilol)
CARVEDILOL† (compare to Coreg®)	Coreg CR® (carvedilol CR) *(QL = 1 tablet/day)*
LABETALOL† (compare to Trandate®)	Corgard®* (nadolol)
METOPROLOL TARTRATE† (compare to Lopressor®)	Inderal LA®* (propranolol ER)
METOPROLOL SUCCINATE XL† (compare to Toprol XL®)	InnoPran XL® (propranolol SR)
NADOLOL† (compare to Corgard®)	Kerlone®* (betaxolol)
PINDOLOL† (formerly Visken®)	Levatol® (penbutalol)
PROPRANOLOL† (formerly Inderal®)	Lopressor®* (metoprolol tartrate)
PROPRANOLOL ER† (compare to Inderal LA®)	Sectral®* (acebutolol)
SOTALOL† (compare to Betapace®, BetapaceAF®)	Tenormin®* (atenolol)
TIMOLOL† (formerly Blocadren®)	Toprol XL®* (metoprolol succinate XL)
	Trandate®* (labetaolol))
	Zebeta®* (bisoprolol)
BETA-BLOCKER/DIURETIC COMBINATION	
ATENOLOL/CHLORTHALIDONE† (compare to Tenoretic®)	Corzide®* (nadolol/bendroflumethiazide)
BISOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Ziac®)	Lopressor HCT®* (metoprolol/hydrochlorothiazide)
DUTOPROL® (metoprolol succinate XR/hydrochlorothiazide)	Propranolol/hydrochlorothiazide† (formerly Inderide®)
METOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Lopressor HCT®)	Tenoretic®* (atenolol/chlorthalidone)
NADOLOL/BENDROFLUMETHIAZIDE† (compare to Corzide®)	Ziac®* (bisoprolol/hydrochlorothiazide)

Anti-Hypertensives: Calcium Channel Blockers

LENGTH OF AUTHORIZATION: 3 years except Caduet® and amlodipine/atorvastatin = 1 year only

CRITERIA FOR APPROVAL (except as noted below):

- The patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)

Amlodipine/atorvastatin, Caduet®

- The prescriber must provide a clinically valid reason for the use of the requested medication. For approval of Caduet, the patient must have also had a documented intolerance to the generic equivalent. For combinations containing 40 mg or 80 mg atorvastatin, the individual generic components are available without PA and should be prescribed.

Exforge®, Exforge HCT®

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

Azor®, amlodipine/telmisartan, Tribenzor®, Twynsta®

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to take the individual components separately.

AND

- If the request is for Twynsta, the pastient has a documented intolerance to generic amlodipine/telmisartan.

Nymalize®

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a medical necessity for a specialty dosage form (i.e. dysphagia, swallowing disorder).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Hypertensives: Calcium Channel Blockers *Length of Authorization: **3** years*

Key: † Generic product, *Indicates generic equivalent is available without a PA,
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE AGENT	
Dihydropyridines	
AFEDITAB® CR † (nifedipine SR, compare to Adalat® CC) AMLODIPINE † (compare to Norvasc®) FELODIPINE ER† (previously Plendil®) NICARDIPINE † (formerly Cardene®) NIFEDIAC® CC † (nifedipine SR, compare to Adalat® CC) NIFEDICAL® XL † (nifedipine SR osmotic, compare to Procardia® XL) NIFEDIPINE IR † (compare to Procardia®) NIFEDIPINE SR osmotic † (compare to Procardia® XL) NIFEDIPINE SR † (compare to Adalat® CC) NIMODIPINE † (compare to Nimotop®)	Adalat® CC* (nifedipine SR) Cardene® SR (nicardipine SR) (no AB rated generic) Dynacirc® CR (isradipine CR) (no AB rated generic) Isradipine® (formerly Dynacirc®) Nimotop®* (nimodipine) Nisoldipine ER† (compare to Sular®) Norvasc®* (amlodipine) Nymalize® (nimodipine) Oral Solution Procardia®* (nifedipine IR) Procardia XL®* (nifedipine SR osmotic) Sular® (nisoldipine)
Miscellaneous	
CARTIA® XT † (diltiazem SR, compare to Cardizem® CD) DILT-CD® † (diltiazem SR, compare to Cardizem® CD) DILT-XR® † (diltiazem SR, compare to Dilacor® XR) DILTIAZEM† (compare to Cardizem®) DILTIAZEM ER† (formerly Cardizem® SR) DILTIAZEM ER† (compare to Tiazac®) DILTIAZEM SR † (compare to Cardizem®CD) DILTIAZEM SR † (compare to Dilacor®XR) TAZTIA® XT † (diltiazem ER, compare to Tiazac®) VERAPAMIL† (compare to Calan®) VERAPAMIL CR† (compare to Calan SR®, Isoptin® SR) VERAPAMIL SR† 120 mg, 180 mg 240 mg and 360 mg (compare to Verelan®) VERAPAMIL SR† 100 mg, 200 mg, 300mg (compare to Verelan PM®)	Calan®* (verapamil) Calan® SR* (verapamil CR) Cardizem®* (diltiazem) Cardizem® CD* (diltiazem SR) Cardizem® LA (diltiazem SR) Covera-HS® (verapamil SR) (no AB rated generic) Dilacor® XR* (diltiazem SR) Diltiazem ER† /Matzin LA† (compare to Cardizem® LA) Isoptin® SR* (verapamil CR) Tiazac®* (diltiazem ER) Verelan®* (verapamil SR 120 mg, 180 mg, 240 mg and 360 mg) Verelan® PM* (100 mg, 200 mg and 300 mg)
CALCIUM CHANNEL BLOCKER/OTHER COMBINATION **(preferred after clinical criteria are met)** EXFORGE® (valsartan/amlodipine) § *(QL = 1 tablet/day)* EXFORGE HCT® (amlodipine/valsartan/hydrochlorothiazide) § *(QL = 1 tab/day)*	Azor® (olmesartan/amlodipine) *(QL = 1 tablet/day)* Tribenzor® (amlodipine/olmesartan/hydrochlorothiazide) *(QL = 1 tablet/day)* amlodipine/telmisartan† (compare to Twynsta®) *(QL = 1 tablet/day)* Twynsta® (amlodipine/telmisartan) *(QL = 1 tablet/day)* Amlodipine/atorvastatin † (compare to Caduet®) *(Qty Limit = 1 tablet/day)* Caduet® (amlodipine/atorvastatin) *(Qty Limit = 1 tablet/day)*

Anti-hypertensives: Central Alpha Agonists

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Catapres®, Tenex®:

- The patient has a documented intolerance to the generic product.

Nexiclon XR® tablet:

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO agents (either separately or as a combination product) from the following antihypertensive classes: a thiazide diuretic, a beta blocker, an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB).

AND

- The patient has been unable to be adherent to or tolerate twice daily dosing of the generic clonidine immediate-release tablets.

Nexiclon XR® oral suspension:

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO agents (either separately or as a combination product) from the following antihypertensive classes: a thiazide diuretic, a beta blocker, an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB).

AND

- The patient has a medical necessity for a specialty dosage form (i.e. dysphagia, swallowing disorder).

Clonidine patches (generic):

- The patient has a medical necessity for a specialty topical dosage form (i.e. dysphasia, swallowing disorder, compliance, nausea/vomiting).

Catapres-TTS® patches:

- The patient has a medical necessity for a specialty topical dosage form (i.e. dysphasia, swallowing disorder, compliance, nausea/vomiting).

AND

- The patient has a documented intolerance to the generic product.

DOCUMENTATION:

✓ Document clinically compelling information supporting the use of this medication on a **General Prior Authorization Request Form**.

Anti-hypertensives: Central Alpha Agonists

Length of Authorization: 1 year

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL **Tablet** CLONIDINE IR† Tablets (compare to Catapress®) GUANFACINE IR† Tablets (compare to Tenex®) METHYLDOPA† Tablets	Catapres®* (clonidine) Tablet Nexiclon XR® (clonidine) Extended Release Tablets *(Quantity Limit = 3 tablets/day)* Tenex®* (guanfacine) Tablets
Suspension **All products require PA.**	Nexiclon XR® (clonidine) Extended Release Suspension
TRANSDERMAL **All products require PA.**	Catapres-TTS® (clonidine) Transdermal Patch *(Qty Limit = 1 patch/7 days)* Clonidine (compare to Catapres-TTS) Transdermal Patch *(Qty Limit = 1 patch/7 days)*

Anti-hypertensives: Ganglionic Blockers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Vecamyl® tablet:

- Patient has a diagnosis of moderately severe or severe hypertension

AND

- The patient has tried and failed, intolerant to, or contraindicated to at least THREE different antihypertension therapies of different mechanism of actions.

DOCUMENTATION:

✓ Document clinically compelling information supporting the use of this medication on a **General Prior Authorization Request Form**.

Anti-hypertensives: Ganglionic Blockers	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Vecamyl®* (mecamylamine) Tablet

Anti-hypertensives: Renin Inhibitors

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Tekturna®:

- The patient is NOT a diabetic who will continue on therapy with an ACEI or ARB

AND

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure with an Angiotensin Receptor Blocker (ARB). *Note:* Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor.

Amturnide®, Tekalmo®, Tekturna HCT®:

- The patient is NOT a diabetic who will continue on therapy with an ACEI or ARB

AND

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure with an Angiotensin Receptor Blocker (ARB). *Note:* Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor.

OR

- The patient has had a documented treatment failure with Tekturna® alone.

Valturna®:

- The patient is NOT a diabetic

AND

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

OR

- The patient has had a documented treatment failure with Tekturna® alone.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of this medication on a **General Prior Authorization Request Form**.

Anti-hypertensives: Renin Inhibitors	*Length of Authorization: 3 years*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	**Single Agent** Tekturna® (aliskiren) *(Qty Limit = 1 tablet/day)* **Combination** Amturnide® (aliskiren/amlodipine/hydrochlorothiazide) *(Qty Limit = 1 tablet/day)* Tekamlo® (aliskiren/amlodipine) *(Qty Limit = 1 tablet/day)* Tekturna HCT® (aliskiren/hydrochlorothiazide) *(Qty Limit = 1 tablet/day)* Valturna® (aliskiren/valsartan) *(Qty Limit = 1 tablet/day)*

Anti-Infectives: Antibiotics: Cephalosporins

LENGTH OF AUTHORIZATION: for the date of service, only: no refills

CRITERIA FOR APPROVAL:

Cephalexin Tablets:

- The patient has had a documented intolerance to cephalexin generic capsules.

Keflex®:

- The patient has had a documented side effect, allergy, or treatment failure to generic cefadroxil and cephalexin.

Cefaclor ER Tablets:

- The patient has had a documented intolerance to cefaclor capsules.

Ceftin® tablets:

- The patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor, cefprozil, and cefuroxime. If a product has an AB rated generic, one trial must be the generic formulation.

Ceftin suspension:

- The patient has had a documented side effect, allergy, or treatment failure to the following medication: cefprozil suspension.

OR

- The indication for use is Lyme disease.

Spectracef® tablet, Cedax® Capsule, Cefditoren tablet, Ceftibuten capsule:

- The patient is completing a course of therapy which was initiated in the hospital.

OR

- The patient has had a documented side effect, allergy, or treatment failure to both cefpodoxime and cefdinir.

AND

- If the request is for Spectracef®, the patient has a documented intolerance with generic cefditoren tablets

Cedax®suspension, Ceftibuten suspension:

- The patient is completing a course of therapy which was initiated in the hospital.

OR

- The patient has had a documented side effect or treatment failure to two of cefdinir, cefpodoxime and Suprax suspension.

Suprax® Chewable Tablets or Capsule:

- The patient is unable to use either Suprax regular tablets or suspension.

LIMITATIONS:

Cephalexin and Keflex 750 mg dosage strength not covered. Use alternative strengths.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Cephalosporins

Length of Authorization: Date of service only. No refills.

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
1st GENERATION:	
TABLETS/CAPSULES CEFADROXIL† Capsules, Tablets (formerly Duricef®) CEPHALEXIN† Capsules (compare to Keflex®) SUSPENSION CEFADROXIL† Suspension (formerly Duricef®) CEPHALEXIN† Suspension (formerly Keflex®) IV drugs are not managed at this time.	Cephalexin® Tablets Keflex®* (cephalexin) Capsules
2nd GENERATION:	
TABLETS/CAPSULES CEFACLOR† CAPSULE CEFPROZIL† (formerly Cefzil®) TABLET CEFUROXIME † (compare to Ceftin®) TABLET SUSPENSION CEFPROZIL† (formerly Cefzil®) SUSPENSION IV drugs are not managed at this time.	Cefaclor® ER Tablet Ceftin®* (cefuroxime) tablet Ceftin® (cefuroxime) suspension
3rd GENERATION:	
CAPSULES/TABLETS CEFDINIR† (formerly Omnicef®) CAPSULE CEFPODOXIME PROXETIL† (formerly Vantin®) TABLET SUPRAX® (cefixime) TABLET SUSPENSION CEFDINIR† (formerly Omnicef®) SUSPENSION CEFPODOXIME PROXETIL† (formerly Vantin®) SUSPENSION SUPRAX® (cefixime) suspension IV drugs are not managed at this time.	Cedax® (ceftibuten) capsule Cefditoren† (compare to Spectracef®) tablet Ceftibuten capsule (compare to Cedax®) Spectracef® (cefditoren) tablet Suprax® (cefixime) Capsule Suprax® (cefixime) Chewable Tablets Cedax® (ceftibuten) suspension Ceftibuten suspension (compare to Cedax®)

Anti-Infectives: Antibiotics: Ketolides

LENGTH OF AUTHORIZATION: Date of service only, no refills

CRITERIA FOR APPROVAL:

- The member is continuing a course of therapy initiated while an inpatient at a hospital.

OR

- The diagnosis or indication for the requested medication is community-acquired pneumonia.

AND

- The member is at least 18 years of age at the time of the request.

AND

- The member has no contraindication or a history of hypersensitivity or serious adverse event, from any macrolide antibiotic.

AND

- Infection is due to documented *Streptococcus pneumoniae* (including multi-drug resistant [MDRSP*] *s.pneumoniae*), *Haemophilus influenzae*, *Moraxella catarrhalis*, *Chlamydophila pneumoniae*, or *Mycoplasma pneumoniae*.

AND

- The member has had a documented therapeutic failure with all clinically appropriate alternatives.

AND

- The member does not have any of the following medical conditions: myasthenia gravis, hepatitis or underlying liver dysfunction, history of arrhythmias (e.g. QTc prolongation, or antiarrhythmic therapy), uncorrected hypokalemia or hypomagnasemia, clinically significant bradycardia, a history of therapy with Class IA (e.g. quinidine or procainamide) or Class III (e.g. dofetilide) antiarrhythmic medications.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**.

*MDRSP includes penicillin-resistant *S. pneumoniae* isolates (PRSP) that are resistant to ≥ 2 of the following antibiotics: penicillin, 2nd generation cephalosporins, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

Anti-Infectives: Antibiotics: Ketolides	*Length of Authorization: Date of Service Only; no refills*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
n/a	Ketek® (telithromycin)

Anti-Infectives: Antibiotics: Macrolides

LENGTH OF AUTHORIZATION: for the date of service, only; no refills (azithromycin/Zithromax packets)

Up to 6 months: refills permissible with extended duration PA approvals (other medications).

NON-PREFERRED AGENTS(EXCEPT AS BELOW):

- The patient has a documented side-effect, allergy, or treatment failure to at least two of the preferred medications. (If a product has an AB rated generic, one trial must be the generic.)

OR

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

BRAND NAME ERYTHROMCYIN PRODUCTS:

- The patient has had a documented side effect or treatment failure with one preferred erythromycin product.

AZITHROMYCIN/ZITHROMAX PACKETS:

- Is there a clinically valid reason why the dose cannot be obtained using generic azithromycin tablets?

AND

- If the request is for brand Zithromax, the patient has a documented intolerance to the generic product.

AZITHROMYCIN > 5 DAY SUPPLY:

- The patient has a diagnosis of Lyme Disease AND has had a documented side effect, allergy, or treatment failure to at least two of the following: doxycycline, amoxicillin, or a 2nd generation cephalosporin. For early Lyme disease, without neurologic or rheumatologic (arthritis) complications, the length of authorization is up to 10 days. For neurologic or rheumatologic Lyme disease, the length of authorization is up to 28 days

OR

- The patient has a diagnosis of Cystic Fibrosis. (length of authorization up to 6 months)

OR

- The patient has a diagnosis of HIV/immunocompromised status and azithromycin is being used for MAC or Toxoplasmosis treatment or prevention.(length of authorization up to 6 months)

OR

- The patient has a diagnosis of bacterial sinusitis AND has had a documented side effect, allergy, or treatment failure to penicillin, amoxicillin, or sulfamethoxazole/trimethoprim (Bactrim). (length of authorization up to 10 days)

OR

- The patient has a diagnosis of severe bronchiectasis with frequent exacerbations (length of authorization up to 6 months)

DIFICID:

- The patient's diagnosis or indication is Clostridium difficile associated diarrhea (CDAD)

AND

- The patient has had a side-effect, allergy, treatment failure or contraindication to metronidazole.

OR

- The prescriber provides a clinically compelling rationale why metronidazole is not appropriate for the patient. (E.g. patient has severe Clostridium difficile infection, history of recurrent infections).

AND

- The patient has had a side-effect, allergy, treatment failure or contraindication to oral vancomycin capsules (Vancocin®).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of a non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Macrolides

Length of Authorization: Date of service, only; no refills for generic and brand azithromycin packets; up to 6 months (others)Refills permissible with extended duration PA approvals

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Azithromycin AZITHROMYCIN† tabs, liquid (≤ 5 day supply) (compare to Zithromax®) (Maximum 10 days therapy/30 days)	azithromycin† tablets and liquid (if > 5 day supply) (compare to Zithromax®) (Maximum 10 days therapy/30 days) Azithromycin† packet (compare to Zithromax®) *(QL = 2 grams/fill)* Zithromax®* (azithromycin) tablets and liquid *QL = 5 days supply/RX, maximum 10 days therapy/30 days* Zithromax® (azithromycin) packet *(QL=2 grams/fill)* Zmax® Suspension (azithromycin extended release for oral suspension) *QL = 5 days supply/RX, maximum 10 days therapy/30 days*
Clarithromycin CLARITHROMYCIN† (compare to Biaxin®)	Biaxin®* (clarithromycin) Biaxin XL® (clarithromycin SR) Clarithromycin SR† (compare to Biaxin® XL)
Erythromycin E.E.S®† (erythromycin ethylsuccinate) ERY-TAB® (erythromycin base, delayed release) ERYTHROMYCIN BASE† ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S®) ERYTHROMYCIN W/SULFISOXAZOLE† (compare to Pediazole®)	Eryped® (erythromycin ethylsuccinate) Erythrocin (erythromycin stearate) PCE Dispertab® (erythromycin base) Pediazole®* (erythromycin-sulfisoxazole)
Fidaxomicin	Dificid® (fidaxomicin) tablet *(Quantity limit =2 tablets per day, 10 day supply per 30 days)*
IV drugs are not managed at this time.	

Anti-Infectives: Antibiotics: Oxazolidinones

LENGTH OF AUTHORIZATION: 28 days

CRITERIA FOR APPROVAL:

- The patient has been started on intravenous or oral linezolid in the hospital and will be finishing the course of therapy in an outpatient setting

OR

- The patient has a documented blood, tissue, sputum, or urine culture that is positive for Vancomycin-Resistant Enterococcus (VRE) species.

OR

- The patient has a documented blood or sputum culture that is positive for Methicillin-Resistant Staphylococcus species

OR

- The patient has a documented tissue or urine culture that is positive for Methicillin-Resistant Staphylococcus species

AND

- The patient has had a documented treatment failure with trimethoprim/sulfamethoxazole **OR** there is a clinically valid reason that the patient cannot be treated with trimethoprim/sulfamethoxazole.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent and quantities exceeding the established limit on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Oxazolidinones

Length of authorization: 28 days

PREFERRED DRUGS (No PA Required)	PA REQUIRED
IV form of this medication not managed at this time	Zyvox® (linezolid) *QL = 56 tablets per 28 days* Zyvox® (linezolid) suspension *QL = 60 ml/day, maximum 28 days supply*

Anti-infectives: Antibiotics: Penicillins (Oral)

LENGTH OF AUTHORIZATION: For the date of service only; no refills

CRITERIA FOR APPROVAL:

Augmentin:

- The patient has had a documented intolerance to the generic formulation of the requested medication.
  OR
- The patient is < 12 weeks of age and requires the 125 mg/5 mL strength of Augmentin.

Amoxicillin/Clavulanate ER, Augmentin XR, Moxatag:

- The prescriber must provide a clinically valid reason for the use of the requested medication. Additionally, for approval of brand Augmentin XR, the patient must have a documented intolerance to generic Amoxicillin/Clavulanate ER

LIMITATION

Brand Augmentin® Chewable tablets do not offer Federal Rebate and therefore cannot be provided.

DOCUMENTATION

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Penicillins (oral)

Length of Authorization: Date of service only. No refills.

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE ENTITY AGENTS	
Natural Penicillins	
PENICILLIN V POTASSIUM† (formerly Veetids®) tablets, oral solution	
Penicillinase-Resistant Penicillins	
DICLOXACILLIN† Capsules	
Aminopenicillins	
AMOXICILLIN† (formerly Amoxil®) capsules, tablets, chewable tablets, suspension AMPICILLIN† (formerly Principen®) capsules, suspension	Moxatag® (amoxicillin extended release) tablet *QL =1 tablet/day*
COMBINATION PRODUCTS	
AMOXICILLIN/CLAVULANATE† (compare to Augmentin®) tablets, chewable tablets, suspension AMOXICILLIN/CLAVULANATE† 600-42.9mg/5ml (formerly Augmentin ES®) suspension	Amoxicillin/clavulanate† ER (compare to Augmentin XR®) tablets Augmentin®*♣ (amoxicillin/clavulanate) tablets, suspension Augmentin XR® (amoxicillin/clavulanate) tablets ♣ PA will be granted for 125 mg/5 mL strength for patients < 12 weeks of age

Anti-Infectives: Antibiotics: Quinolones

LENGTH OF AUTHORIZATION: for the date of service, no refills

CRITERIA FOR APPROVAL:

Noroxin®:

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

OR

- The patient has had a documented side effect, allergy, or treatment failure to ciprofloxacin immediate-release tablets/solution or ofloxacin.

Cipro®, Cipro XR®, ciprofloxacin ER, ProQuin XR®:

- The patient has had a documented side effect, allergy, or treatment failure to generic ciprofloxacin immediate-release tablets or oral suspension..

AND

- If the request is for Cipro XR or Ciprothe patient has had a documented intolerance to the generic equivalent.

Avelox®, moxifloxacin, Factive®:

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

OR

- The patient has had a documented side effect, allergy, or treatment failure to levofloxacin.

AND

- If the request is for Avelox, the patient has had a documented intolerance to generic moxifloxacin.

Levaquin® (brand):

- The patient has a documented intolerance with the generic levofloxacin

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred quinolone on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Quinolones

Length of Authorization: Date of service only. No refills.

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CIPROFLOXACIN† (compare to Cipro®) tabs, oral suspension LEVOFLOXACIN † (compare to Levaquin®) tabs, sol OFLOXACIN† IV drugs are not managed this time	Avelox ® (moxifloxacin HCL) Avelox® ABC PACK (moxifloxacin HCL) Cipro®* (ciprofloxacin) tabs, oral suspension Cipro® XR (ciprofloxacin) ciprofloxacin ER† (compare to Cipro® XR) Factive® (gemifloxacin) Levaquin®* (levofloxacin) tabs,sol moxifloxacin† (compare to Avelox®) Noroxin® (norfloxacin) ProQuin XR® (ciprofloxacin extended-release)

Anti-Infectives: Antibiotics: Rifamycins

LENGTH OF AUTHORIZATION: Per indication, up to 1 year

Hepatic Encephalopathy: 1 year
Traveller's Diarrhea: for the date of service only
SIBO: 30 days
Irritable Bowel Syndrome: 14 days
Inflammatory Bowel Disease: Crohn's Disease: 3 months
Inflammatory Bowel Disease: Ulcerative Colitis: 1month
Clostridium difficile diarrhea: 14 days

Recertification for all of the above indications is contingent upon documentation of a clinical response.

CRITERIA FOR APPROVAL: Based on Indication

Hepatic Encephalopathy (Xifaxan 550 mg Tablets Only):

- The patient has a diagnosis of hepatic encephalopathy.

AND

- Patient has had a documented side effect, allergy, treatment failure or contraindication to lactulose.

AND

- Quantity limit is 2 tablets/day (550 mg tablets only).

Traveller's Diarrhea (Xifaxan 200 mg Tablets Only):

- The patient has a diagnosis of traveller's diarrhea caused by noninvasive strains of *Escherichia coli*.

AND

- Patient has had a documented side effect, allergy, treatment failure or contraindication with a fluoroquinolone.

AND

- Quantity limit is 9 tablets/RX (200 mg tablets only).

Small Intestinal Bacterial Overgrowth (Xifaxan 550 mg or 200 mg Tablets):

- The patient has a diagnosis of SIBO.

AND

- Patient has attempted dietary modification and has had a documented side effect, allergy, treatment failure or contraindication to (alone or in combination) one of the following: Amoxicillin-clavulanate, cephalosporin, metronidazole, fluoroquinolone, tetracycline, trimethoprim-sulfamethoxazole.

AND

- Quantity limit is 800 mg to 1,200 mg/day.

Irritable Bowel Syndrome (Xifaxan 550 mg or 200 mg Tablets):

- The patient has a diagnosis of irritable bowel syndrome without constipation or with symptoms of bloating.

AND

- Patient has attempted dietary modification and has had a documented side effect, allergy, treatment failure or contraindication to two of the following classes (one of which must be an antibiotic):
  • Antibiotics (alone or in combination: amoxicillin-clavulanate, cephalosporin, metronidazole, fluoroquinolone, tetracycline, trimethoprim-sulfamethoxazole)
  • SSRIs
  • TCAs
  • Antispasmodics
  • Antidiarrheals
  • Cholestyramine resin

AND

- Quantity limit is 1,200 mg to 1,650 mg/day.

Inflammatory Bowel Disease: Crohn's Disease (Xifaxan 550 mg or 200 mg Tablets):

- The patient has a diagnosis of Crohn's Disease.

AND

- Patient has had a documented side effect, allergy, treatment failure or contraindication to two of the following: 6-mercaptopurine, aminosalicylates, azathioprine, corticosteroids, fluoroquinolone and/or metronidazole.

AND

- Quantity limit is 600 mg to 1,600 mg/day.

Inflammatory Bowel Disease: Ulcerative Colitis (Xifaxan 200 mg Tablets):

- The patient has a diagnosis of Ulcerative Colitis.

AND

- Patient has had a documented side effect, allergy, treatment failure or contraindication to two of the following: 6-mercaptopurine, aminosalicylates, azathioprine, corticosteroids, fluoroquinolone and/or metronidazole.

AND

- Quantity limit is 800 mg/day (4 x 200 mg tablets/day).

***Clostridium difficile* Diarrhea (Xifaxan 200 mg Tablets):**

- The patient has a diagnosis of *C. difficile* diarrhea.

AND

- Patient has had a documented side effect, allergy, treatment failure or contraindication to metronidazole.

AND

- Quantity limit is 800 mg/day (4 x 200 mg tablets/day).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of a non-preferred agent and more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Rifamycins

Length of Authorization: Up to 1 year

PREFERRED DRUGS (No PA Required)	PA REQUIRED
All products require PA.	Xifaxan ® (rifaximin) 200 mg Tablets *(Qty limit = as above per indication)* Xifaxan ® (rifaximin) 550 mg Tablets *(Qty limit = as above per indication)*

Anti-Infectives: Antibiotics: Vancomycin

LENGTH OF AUTHORIZATION: Date of service only, no refills

CRITERIA FOR APPROVAL:

- The patient's diagnosis or indication is enterocolitis caused by *Staphylococcus aureus.*

OR

- The patient's diagnosis or indication is antibiotic-associated pseudomembranous colitis caused by *Clostridium difficile*

AND

- The patient has had a therapeutic failure, adverse reaction or contraindication to metronidazole.

OR

- The prescriber provides a clinically compelling rationale why metronidazole is not appropriate for the patient. (e.g. patient has severe *Clostridium difficile* infection, history of recurrent infections).

AND

- For approval of brand Vancocin, the patient must meet the above criteria and have a documented intolerance to the generic.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Vancomycin

Length of Authorization: Date of Service Only; no refills

PREFERRED DRUGS (No PA Required)	PA REQUIRED
All products require PA. IV vancomycin products are not managed at this time	Vancocin® (vancomycin) Capsules Vancomycin (compare to Vancocin®) Capsules

Anti-Infectives: Antifungals: Allylamines

LENGTH OF AUTHORIZATION: Up to 3 months

Onychomycosis (terbinafine):
Fingernails: 2 tablets (500mg) per day for 1 week/month for 2 months (pulse) or 1 tablet (250mg) per day for 6 weeks
Toenails: 2 tablets (500mg) per day for 1 week per month for 3 months (pulse) or 1 tablet (250mg) per day for 12 weeks

Tinea capitis: 6 weeks
Tinea pedis/Tinea cruris/Tinea corporis: up to 250 mg/day for up to 1 month (30 tabs/month)
Other indications: 3 months

CRITERIA FOR APPROVAL

Terbinafine Tablets:

- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, or fungal culture or physician clinical judgment).

AND

- The patient meets at least 1 of the following criteria:
  - Pain to affected area that limits normal activity
  - Diabetes Mellitus
  - Patient is immunocompromised
  - Patient has diagnosis of systemic dermatosis
  - Patient has significant vascular compromise

AND

- The quantity requested does not exceed 30 tablets per month for a maximum of 3 months.

OR

- The patient has a diagnosis of a *Tinea capitis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).

AND

- The quantity requested does not exceed 30 tablets per month for a maximum of 6 weeks.

OR

- The patient has a diagnosis of a *Tinea pedis*, *Tinea cruris*, or *Tinea corporis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).

AND

- The patient has a documented side-effect, allergy, or treatment failure to at least **THREE** different topical antifungal medications (one of the trials **must** have included a topical terbinafine product).

AND

- The quantity requested does not exceed 30 tablets per month for a maximum of 1 month.

- For approval of Lamisil®, the patient must have a documented intolerance to generic terbinafine.

Lamisil Granules:

- The patient has a diagnosis of a *Tinea capitis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).

AND

- The patient has a requirement for an oral liquid dosage form.

AND

- The patient had a documented side effect, allergy, or treatment failure with Griseofulvin suspension

LIMITATIONS:
Coverage of Onychomycosis agents will **NOT** be approved solely for cosmetic purposes.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of the non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Infectives: Antifungals: Allylamines

Length of Authorization: Up to 3 months

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
All products require PA.	terbinafine† (compare to Lamisil®) tablets *(QL: 30 tab/month post PA approval)* Lamisil® (terbinafine) granules *(QL: 125 mg packet (1 or 2 per day depending on dose) 187.5 mg packet (1 per day) post PA approval)* Lamisil® tablets (terbinafine) *(QL: 30 tab/month post PA approval)*

Please Note: Griseofulvin suspension is available without restrictions or PA for treatment of *Tinea Capitis* infections.

LENGTH OF AUTHORIZATION: Up to 3 months

Onychomycosis (Sporanox/itraconazole 100 mg capsules):
Fingernails: 2 capsules (200mg) twice daily for 1 week per month for 2 months (pulse) or
2 capsules (200mg) per day for 6 weeks
Toenails: 2 capsules (200mg) twice daily for 1 week per month for 3 months (pulse) or
2 capsules (200mg) per day for 12 weeks

Onychomycosis (Onmel 200 mg tablets):
Toenails: 1 tablet (200mg) per day for 12 weeks

Other medications/indications: 3 months

CRITERIA FOR APPROVAL ITRACONAZOLE 100 MG/SPORANOX®:

- The patient has a diagnosis of invasive aspergillosis, blastomycosis, or histoplasmosis

OR

- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, fungal culture or physician clinical judgment) **AND** has a documented side-effect, allergy, contraindication, or treatment failure to oral terbinafine **AND** meets at least 1 of the following criteria:
  - Pain to affected area that limits normal activity
  - Diabetes Mellitus
  - Patient is immunocompromised
  - Patient has diagnosis of systemic dermatosis
  - Patient has significant vascular compromise

OR

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

OR

- The patient has a documented side-effect, allergy, or treatment failure to at least **ONE** of the preferred medications.

- For approval of Sporanox®capsules, the patient must have a documented intolerance to generic itraconazole. For approval of Sporanox® solution, the patient must have a medical necessity for a liquid dosage form.

CRITERIA FOR APPROVAL ONMEL® 200 MG:

- The patient has a diagnosis of a toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, fungal culture or physician clinical judgment) **AND** has a documented side-effect, allergy, contraindication, or treatment failure to oral terbinafine **AND** there is a clinical reason that itraconazole 100 mg generic capsules cannot be used **AND** meets at least 1 of the following criteria:
  - Pain to affected area that limits normal activity
  - Diabetes Mellitus
  - Patient has significant vascular compromise

LIMITATIONS:
Coverage of Onychomycosis agents will **NOT be approved solely for cosmetic purposes.**

CRITERIA FOR APPROVAL OF VORICONAZOLE/VFEND®:

- Patient has a diagnosis of invasive aspergillosis.

OR

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

OR

- The patient has a documented side-effect, allergy, or treatment failure to **ONE** of the preferred medications **AND** itraconazole.

AND

- For approval of Vfend® tablets, the patient must have a documented intolerance to generic voriconazole.

AND

- For approval of voriconazolesuspenion, the patient must have a medical necessity for a liquid dosage form. For approval of Vfend® suspension, the patient must additionally have a documented intolerance to generic voriconazole suspension.

CRITERIA FOR APPROVAL OF NOXAFIL:

DR Tablet and Oral Suspension

- The patient has a diagnosis of HIV/immunocompromised status (neutropenia secondary to chemotherapy, hematopoietic stem cell transplant recipients) **AND** Noxafil is being used for the prevention of invasive *Aspergillosis*/*Candida* infections.

OR

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

OR

Oral Suspension ONLY

- The patient has a documented side-effect, allergy, or treatment failure to **ONE** of the preferred medications **AND** itraconazole **AND** the patient is being treated for oropharyngeal candidiasis.

CRITERIA FOR APPROVAL OF DIFLUCAN® (BRAND):

- For approval of Diflucan® brand name product, the patient must have a documented intolerance to generic fluconazole.

CRITERIA FOR APPROVAL OF ORAVIG:

- The indication for use is treatment of oropharyngeal candidasis.

AND

- The patient has had a documented side effect, allergy, treatment failure/inadequate response to both nystatin suspension and clotrimazole troche.

OR

- The patient is unable to be compliant with the nystatin suspension and/or clotrimazole troche dosing schedules.

DOCUMENTATION:

✓ Document clinically compelling information supporting provision of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antifungals: Azoles

Length of Authorization: Up to 3 months (see above)

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
FLUCONAZOLE† (compare to Diflucan®) tabs, suspension KETOCONAZOLE† (formerly Nizoral®) tabs CLOTRIMAZOLE Troche† (compare to Mycelex®) IV drugs are not managed at this time.	Diflucan®* (fluconazole) tabs, suspension itraconazole† (compare to Sporanox®) caps Noxafil® (posaconazole) oral suspension Noxafil® (posaconazole) DR Tablets *(QL=93 tablets/30 days)* Onmel® (itraconazole) 200 mg tablet *(QL=1 tab/day)* Oravig® (miconazole) buccal tabs *(QL=1 tab/day; 14 tabs per RX ONLY)* Sporanox® (itraconazole) caps, solution VFend® (voriconazole) tabs, suspension voriconazole† (compare to VFend®) tabs, suspension

Anti-Infectives: Antimalarials: Quinine

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is for the treatment of malaria. (Use for leg cramps not permitted.)

AND

- If the request is for brand Qualaquin®, the patient has a documented intolerance to the generic equivalent.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**.

Anti-Infectives: Antimalarials: Quinine	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Quinine sulfate† (compare to Qualaquin®) Qualaquin® (quinine sulfate)

Anti-Infectives: Antivirals: Herpes: Oral

LENGTH OF AUTHORIZATION: for duration of prescription, up to 6 months

CRITERIA FOR APPROVAL:

Famciclovir, Zovirax

- The patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir **AND** valacyclovir.

Famvir

- The patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir **AND** valacyclovir.

AND

- The patient has a documented intolerance to generic famciclovir.

Valtrex

- The patient has a documented intolerance to generic valacyclovir.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antivirals: Herpes: Oral

Length of Authorization: up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ACYCLOVIR† (compare to Zovirax®)	Famvir® (famciclovir)
	famciclovir† (compare to Famvir®)§
VALACYCLOVIR † (compare to Valtrex®)	Valtrex®* (valacyclovir)
	Zovirax®* (acyclovir) §

Anti-Infectives: Antivirals: Influenza Medications

Dosing information below is to be used in combination with the CDC and Vermont Department of Health recommendations:

http://www.cdc.gov/flu/

http://healthvermont.gov/prevent/flu/provider.aspx

Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza.

- Influenza antiviral prescription drugs can be used to **treat** influenza or to **prevent influenza**.
- Two FDA-approved influenza antiviral medications are recommended for use in the United States during the 2013-2014 influenza season: **oseltamivir** (Tamiflu®) and **zanamivir** (Relenza®). (Note: Recommendations pending CDC review for the 2013-2014 influenza season. However, information here should be considered current for clinical practice regarding the use of influenza antiviral medications.)
- Oseltamivir and zanamivir are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses.
- The greatest benefit is when antiviral treatment is started within 48 hours of influenza illness onset.
- Antiviral treatment may still be beneficial in patients with severe, complicated, or progressive illness, and in hospitalized patients when administered more than 48 hours from illness onset.
- Annual influenza vaccination is the best way to prevent influenza because vaccination can be given well before influenza virus exposures occur, and can provide safe and effective immunity throughout the influenza season. However, antiviral medications are **70%** to **90%** effective in preventing influenza and are useful adjuncts to vaccination.
- CDC does not recommend widespread or routine use of antiviral medications for chemoprophylaxis so as to limit the possibilities that antiviral resistant viruses could emerge.

LENGTH OF AUTHORIZATION: for duration of the prescription

CRITERIA FOR APPROVAL (Tamiflu, Relenza):

Tamiflu and Relenza will **NOT** require prior-authorization **at this time** when prescribed within the following quantity limits:

Relenza (zanamivir): 20 blisters per 30 days
Tamiflu (oseltamivir): 75 mg or 45 mg: 10 capsules per 30 days
30 mg: 20 capsules per 30 days
Suspension (6 mg/ml): 180 ml (3 bottles) per 30 days

Antiviral Medication Dosing Recommendations for Treatment and Chemoprophylaxis of Influenza, 2013 – 2014 Influenza Season.

Agent, group		**Treatment (5 days)**	**Chemoprophylaxis (7 days, 14 days or longer in long term care)**
Oseltamivir (Tamiflu®)			
Adult		75-mg capsule twice per day	75-mg capsule once per day
Children ≥ 12 months	≤15 kg	30 mg twice daily	30 mg once per day
	>15-23 kg	45 mg twice daily	45 mg once per day
	>23-40 kg	60 mg twice daily	60 mg once per day
	>40 kg	75 mg twice daily	75 mg once per day
Zanamivir (Relenza®)*			
Adult		10 mg (two 5 mg inhalations) twice daily	10 mg (two 5-mg inhalations) once daily
Children		10 mg (two 5 mg inhalations) twice daily (for **7 years or older**)	10 mg (two 5-mg inhalations) once daily (for **5 years or older**)

***Zanamivir, an inhaled medication, can induce bronchospasm and is not recommended for treatment for patients with underlying pulmonary disease such as asthma or chronic obstructive pulmonary disease.

LIMITATIONS:
Amantadine, Flumadine® and rimantadine are not CDC recommended for use in influenza treatment or chemoprophylaxis at this time and are not covered for this indication. For information regarding amantadine see "Parkinsons Medications". Flumadine®/rimantadine is not covered for any indication.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antivirals: Influenza Medications

Length of Authorization: up to 6 weeks

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS	PA REQUIRED
RELENZA® (zanamivir)(QL= 20 blisters/30 days) TAMIFLU® (oseltamivir)(QL = 10 caps/30 days (45 mg & 75 mg caps), 20 caps/30 days (30 mg caps), 180 ml (6 mg/ml)/30 days (suspension))	

Anti-Infectives: Antivirals: Influenza Vaccines

FluMist (Seasonal Influenza Nasal Vaccine)

LENGTH OF AUTHORIZATION: Up to 6 weeks

NOTE: Seasonal Influenza Nasal Vaccine is provided free of charge and without PA for patients ages 2 – 18 years to prescribers enrolled in the Vaccine for Children Program (VFC). Select injectable vaccine is also provided for those patients ages 6 months – 18 years. Providers order state-supplied vaccine online.

1 dose for children and adults aged 2-49 years, including children aged 2-8 years who have been previously vaccinated with influenza vaccine.

2 doses total, given at least one month apart, for children age 2-8 years who have not been previously vaccinated with influenza vaccine.

INDICATION: Seasonal Influenza Nasal Vaccine

Seasonal influenza nasal vaccine (live attenuated) is FDA approved for influenza prevention in healthy people 2 - 49 years of age who are not pregnant. It is different from the standard influenza vaccines, which contain inactivated viruses and are administered intramuscularly. Theoretically, viruses from the live vaccine may be transmitted to other people. The Advisory Committee on Immunization Practices (ACIP) publishes guidelines specifying groups of people who will benefit most from influenza vaccination, such as those with chronic medical conditions, nursing home residents, and pregnant women. However, the intranasal formulation is contraindicated in many patients that would benefit from influenza vaccination, due to the fact it is a live vaccine.

CRITERIA FOR APPROVAL (Flumist):

- Flumist is being requested for influenza prophylaxis during flu season

  AND
- The patient is between the ages of 19 and 49 years old,

  AND
- Prescriber provides documentation of a contraindication to an intramuscular injection (e.g., currently on warfarin; history of thrombocytopenia) or other compelling information to support the use of this dosage form.

EXCLUDED FROM APPROVAL:

- Hypersensitivity (severe allergy) to any FluMist® component including eggs and egg products.
- Children and adolescents aged 2 – 17 years receiving aspirin therapy (increased risk of Reye's Syndrome).
- History of Guillain-Barre Syndrome.
- People with a medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.
- Children <5 years old with a history of recurrent wheezing
- Pregnant women

Requests will be evaluated on a case-by-case basis, in the event of vaccine shortage and/or the issuing of prioritization orders from the Department of Public Health and Centers for Disease Control.

Age Group	Vaccination Status	Dosage Schedule
Children age 2 –8 years	Not previously vaccinated with seasonal influenza vaccine or received only one dose in 2010/11 and it was first time vaccination	2 doses (0.2 mL* each at least one month apart)
Children age 2 – 8 years	Previously vaccinated with seasonal influenza vaccine	1 dose (0.2 mL*) per season
Children & Adults age 9-49	Not Applicable	1 dose (0.2 mL*) per season

***** administered as 0.1 mL per nostril

CRITERIA FOR APPROVAL (Flucelvax):

- Flucelvax is being requested for influenza prophylaxis during flu season

AND

- The patient is ≥ 18 years old.

AND

- Prescriber provides clinical rationale why one of the preferred influenza vaccines cannot be used.

CRITERIA FOR APPROVAL (Flublok):

- Flublok is being requested for influenza prophylaxis during flu season

AND

- The patient is between the ages of ≥18 and < 50 years old.

AND

- The patient has an egg allergy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of Flumist® on the **General Prior Authorization Request Form**.

Anti-Infectives: Antivirals: Influenza Vaccines

Length of Authorization: up to 6 weeks

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SEASONAL Influenza Vaccine INJECTION **Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose (egg based)** AFLURIA® Injection FLUARIX® Injection FLULAVAL® Injection FLUVIRIN® Injection FLUZONE® Injection FLUZONE INTRADERMAL® Injection **Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose (egg based)** FLUZONE HIGH-DOSE® Injection	
	Inactivated Influenza Vaccine, Trivalent (ccIIV3), Standard Dose (cell culture based) (NOT egg free) Flucelvax® Injection **Recombinant Influenza Vaccine, Trivalent (RIV3) (egg FREE)** Flublok® Injection
Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose (egg based) FLUARIX® QUADRIVALENT Injection FLULAVAL® QUADRIVALENT Injection FLUZONE® QUADRIVALENT Injection	
SEASONAL Influenza Vaccine NASAL **Live Attenuated Influenza Vaccine, Quadrivalent (LAIV4) (egg based)**	FluMist® Quadrivalent Intranasal

Anti-Migraine: Triptans

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL (non-preferred agents):

Oral:

Amerge, Axert, Frova, Imitrex, Maxalt, Relpax, rizatriptan, Zomig, Zomig ZMT, zolmitriptan, zolmitriptan ODT:

- The patient has had a documented side-effect, allergy or treatment failure to Sumatriptan, Naratriptan and Rizatriptan ODT. If the request is for brand Maxalt, the patient must also have a documented intolerance to the generic product. If the request is for zolmitriptan or zolmitriptan ODT, the patient must also have a documented intolerance to the brand product.

Maxalt-MLT:

- The patient has had a documented side effect, allergy, or treatment failure with Sumatriptan and the patient must also have a documented intolerance to the generic product.

Naratriptan, rizatriptan ODT:

- The patient has had a documented side effect, allergy, or treatment failure with Sumatriptan.

Treximet:

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred Triptans

AND

- The patient is unable to take the individual components (sumatriptan and naproxen) separately

Nasal Spray: Zomig:

- The patient has had a documented side-effect, allergy or treatment failure Imitrex® Nasal Spray.

Nasal Spray: Sumatriptan

- The patient has had a documented intolerance to brand Imitrex®.

Injection: Alsuma, Sumatriptan, Sumavel DosePro

- The patient has had a documented intolerance to brand Imitrex®.

CRITERIA FOR APPROVAL (to exceed quantity limit):

- The patient is taking a medication for migraine prophylaxis

DOCUMENTATION:

✓ Document clinically compelling information supporting provision of a non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Migraine: Triptans

Length of Authorization: 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE AGENT **ORAL** SUMATRIPTAN† (compare to Imitrex®) *Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg),* **After Sumatriptan Trial** NARATRIPTAN† (compare to Amerge®) **§** (*Quantity Limit = 9 tablets/month)* RIZATRIPTAN ODT† (compare to Maxalt-MLT®) **§** *Quantity Limit = 12 tablets/month*	Amerge® (naratriptan) *Quantity Limit = 9 tablets/month* Axert® (almotriptan) *Quantity Limit = 6 tablets/month* Frova® (frovatriptan) *Quantity Limit = 9 tablets/month* Imitrex®* (sumatriptan) *Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg),* Maxalt® (rizatriptan) tablet *Quantity Limit = 12 tablets/month* Maxalt-MLT® (rizatriptan ODT) *Quantity Limit = 12 tablets/month* Relpax® (eletriptan) *Quantity Limit = 12 tablets/month* rizatriptan† (compare to Maxalt®) *Quantity Limit = 12 tablets/month* Zomig® (zolmitriptan) tablets *Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg))* Zomig® ZMT (zolmitriptan ODT) *Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)* Zolmitriptan† (compare to Zomig®) tablets *Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)* Zolmitriptan† ODT (compare to Zomig® ZMT) *Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)*
Table Continued on next page	*Table continued on next page*

NASAL SPRAY IMITREX® (sumatriptan) *Quantity Limit =12 units/month (5 mg nasal spray), 6 units/month (20 mg nasal spray)*	Sumatriptan† (compare to Imitrex®) *Quantity Limit =12 units/month (5 mg nasal spray), 6 units/month (20 mg nasal spray)* Zomig® (zolmitriptan) *Quantity Limit = 12 units/month (2.5 mg or 5 mg nasal spray)*
INJECTABLE IMITREX® (sumatriptan) *Quantity Limit =4 injections/month (4 or6 mg injection)*	Alsuma® (sumatriptan) 6 mg/0.5ml *Quantity Limit =4 injections/month* sumatriptan† (compare to Imitrex®) *Quantity Limit =4 injections/month (4 or 6 mg injection)* Sumavel DosePro® (sumatriptan) 6 mg/0.5ml *Quantity Limit =4 injections/month*
COMBINATION PRODUCT	Treximet® (sumatriptan/naproxen) *Quantity Limit = 9 tablets/month*

Anti-Obesity Agents

Effective 10/12/2011, anti-obesity agents (weight loss agents) are no longer a covered benefit for all Vermont Pharmacy Programs. This change is resultant from Drug Utilization Review (DUR) Board concerns regarding safety and efficacy of these agents.

Antipsychotics: Atypical and Combination
(Children/Adolescents < 18 years old)

LENGTH OF AUTHORIZATION: 1 year (all medication require prior authorization for children < 18 years old)

CRITERIA FOR APPROVAL: (Children/Adolescents < 18 years old) Note: All requests for patients < 5 years old will be reviewed by the DVHA Medical Director.

Target symptoms or Diagnoses that will be accepted for approval:

Target Symptom:	Diagnosis:
Grandiosity/euphoria/mania	Autism with Aggression and/or Irritability
Obsessions/compulsions	Bipolar Disorder
Psychotic symptoms	Intellectual Disability with Aggression and/or Irritability
Tics (motor or vocal)	Obsessive Compulsive Disorder
	Schizophrenia/Schizoaffective Disorder
	Tourette's Syndrome

PREFERRED AFTER CLINICAL CRITERIA ARE MET:

TABLETS/CAPSULES:

Olanzapine, Risperidone, Ziprasidone:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

Quetiapine:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

Note: Quetiapine will not be approved for indications of insomnia, for sleep or as an hypnotic.

ORAL SOLUTIONS:

Risperidone Oral Solution:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

NON-PREFERRED:

TABLETS/CAPSULES:

Invega®:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND
- The patient has had a documented side effect, allergy or treatment failure with at least two preferred after clinical criteria are met products (typical or atypical antipsychotics) (see tables), one of which is risperidone.

Clozaril®, Geodon®, Risperdal®, Seroquel®, Zyprexa®:

- The patient meets clinical criteria for the generic equivalent

AND

- The patient has a documented intolerance to the generic equivalent.

Clozapine:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics), two of which are preferred after clinical criteria are met products (see tables).

Seroquel XR®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has not been able to be adherent to a twice daily dosing schedule of quetiapine immediate release resulting in a significant clinical impact.

Abilify®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The indication or use is treatment of autism with aggression and/or irritability, intellectual disability with aggression and/or irritability or Tourette's syndrome/tics (motor or vocal) AND the patient has had a documented side effect, allergy or treatment failure with risperidone.

OR

- The indication or use is treatment of autism with aggression and/or irritability, intellectual disability with aggression and/or irritability or Tourette's syndrome/tics (motor or vocal) AND the prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.

OR

- The medication is being requested for one of the other target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least two preferred after clinical criteria are met products (typical or atypical antipsychotics) (see tables), one of which is risperidone.

OR

- The prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes.

<u>ORAL SOLUTIONS:</u>

Abilify® Oral Solution:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with risperidone oral solution.

OR

- The prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.

Versacloz® Oral Suspension:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics).

AND

- The patient is unable to use clozapine orally disintegrating tablets.

Risperdal®:

- The patient meets clinical criteria for the generic equivalent

AND

- The patient has a documented intolerance to the generic product risperidone.

ORALLY DISINTEGRATING TABLETS:

Olanzapine orally disintegrating tablets, Risperdal® M-Tab, Risperidone† ODT, Zyprexa Zydis®

- The patient meets clinical criteria for non-orally disintegrating oral dosage forms of the same medication.

AND

- Medical necessity for a specialty dosage form has been provided.

AND

- If the request is for Risperdal M-Tab or Zyprexa Zydis, the patient has a documented intolerance to the generic equivalent.

Clozapine orally disintegrating tablets, FazaClo®

- The patient has been started and stabilized on any form of the requested medication. (Note: samples are not considered adequate justification for stabilization.)

AND

- Medical necessity for a specialty dosage form has been provided.

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics)

AND

- Medical necessity for a specialty dosage form has been provided.

AND

- If the request is for a brand product with a generic equivalent, the patient has a documented intolerance to generic product.

Abilify® Discmelt

- The patient has been started and stabilized on any form of the requested medication. (Note: samples are not considered adequate justification for stabilization.)

AND

- Medical necessity for a specialty dosage form has been provided.

OR

- The medication is being requested for one of the target symptoms or patient diagnoses listed above.

AND

- The patient has had a documented side effect, allergy or treatment failure with Risperdal M-Tab.

OR

- The prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.

AND

- Medical necessity for a specialty dosage form has been provided.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of any agent on an **Antipsychotic Medications (Pediatric) Prior Authorization Request Form**.

LIMITATIONS:

Approval for use in Children < 18 years old will not be granted for the following medications or dosage forms due to no FDA approval for use in children and little or no literature to support their use in this population.

Exceptions will be made for patients who have been started and stabilized on the requested medication or dosage form. (Note: samples are not considered adequate justification for stabilization.)

Fanapt® (iloperidone)
Latuda® (lurasidone)
Saphris® (asenapine)
Geodon® IM (ziprasidone intramuscular injection)
Abilify® IM (aripiprazole intramuscular injection)
Olanzapine† IM (compare to Zyprexa® IM)
Zyprexa® IM (olanzapine intramuscular injection)
Abilify Maintena® (aripiprazole monohydrate)
Invega Sustenna® (paliperidone palmitate)
Risperdal Consta® (risperidone microspheres)
Zyprexa Relprevv® (olanzapine pamoate)
Symbyax® (olanzapine/fluoxetine)
Olanzapine/fluoxetine† (compare to Symbyax®)

Antipsychotics: Atypical and Combination (Children/Adolescents < 18 years old)

Length of authorization: 1 year

Key: † Generic product

PREFERRED AFTER CLINICAL CRITERIA ARE MET (PA Required)	PA REQUIRED
TABLETS/CAPSULES	
OLANZAPINE† (compare to Zyprexa®) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)* RISPERIDONE† (compare to Risperdal®) *FDA maximum recommended dose = 16 mg/day* QUETIAPINE† (compare to Seroquel®) *FDA maximum recommended dose = 800 mg/day* ZIPRASIDONE† (compare to Geodon®) *FDA maximum recommended dose = 160 mg/day*	Abilify® (aripiprazole) *FDA maximum recommended dose = 30 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)* Clozapine† (compare to Clozaril®) *FDA maximum recommended dose = 900 mg/day* Clozaril® *(clozapine)* *FDA maximum recommended dose = 900 mg/day* Geodon® (ziprasidone) *FDA maximum recommended dose = 160 mg/day* Invega® (paliperidone) *FDA maximum recommended dose = 12 mg/day* *Quantity limit = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)* Risperdal® (risperidone) *FDA maximum recommended dose = 16 mg/day* Seroquel® (quetiapine) *FDA maximum recommended dose = 800 mg/day* Seroquel XR® (quetiapine XR) *FDA maximum recommended dose = 800 mg/day Quantity Limit = 1 tab/day (150 mg & 200 mg tablet strengths), 2 tabs/day (50 mg strength)* Zyprexa® (olanzapine) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)*
ORAL SOLUTIONS	
RISPERIDONE† (compare to Risperdal®) oral solution *FDA maximum recommended dose = 16 mg/day*	Abilify® (aripiprazole) oral solution *FDA maximum recommended dose = 25 mg/day* Risperdal® (risperidone) oral solution *FDA maximum recommended dose = 16 mg/day* Versacloz® (clozapine) Oral Suspension *FDA maximum recommended dose = 900 mg/day* *Quantity limit = 18 ml/day*
Table continued Next Page	Table Continued Next Page

ORALLY DISINTEGRATING TABLETS	
	Abilify® Discmelt (aripiprazole) *FDA maximum recommended dose = 30 mg/day,* *Quantity limit = 2 tabs/day (10 mg & 15 mg tabs)* clozapine orally disintegrating tablets† *(*Compare to FazaClo®) *FDA maximum recommended dose = 900 mg/day* FazaClo® (clozapine orally disintegrating tablets) *FDA maximum recommended dose = 900 mg/day* Olanzapine orally disintegrating tablets† (compare to Zyprexa Zydis®) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)* Risperdal® M-Tab (risperidone orally disintegrating tablets) *FDA maximum recommended dose = 16 mg/day* Risperidone† ODT (compare to Risperdal® M-Tab) *FDA maximum recommended dose = 16 mg/day* Zyprexa Zydis® (olanzapine orally disintegrating tablets) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ ANTIPSYCHOTIC MEDICATIONS (PEDIATRIC) (AGE < 18 YEARS OLD)~

Prior Authorization Request Form

In order for beneficiaries to receive Medicaid coverage for medications that require prior authorization, the prescriber must telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ **Sex:**_____

Contact Person at Office:_____

The following target symptoms or diagnoses for which the requested medication is being prescribed are documented in the patient chart: □ YES □ NO **Please check all that apply:**

Target Symptom	Diagnosis
□ Grandiosity/euphoria/mania	□ Autism with Aggression and/or Irritability □ Bipolar Disorder
□ Obsessions/compulsions	□ Intellectual Disability with Aggression and/or Irritability
□ Psychotic symptoms	□ Obsessive Compulsive Disorder □ Tourette's Syndrome
□ Tics (motor or vocal)	□ Schizophrenia/ Schizoaffective Disorder
□ Other: _____	□ Other: _____

1. **Drug Requested: check below Strength, Route & Frequency:**_____ **Dosage Form:**_____

Preferred After Clinical Criteria Are Met	Non-Preferred	
□ RISPERIDONE† (compare to Risperdal®)	□ Abilify® (aripiprazole)	□ Risperdal® (risperidone)
□ QUETIAPINE† (compare to Seroquel®)	□ Clozapine† (compare to Clozaril®)	□ Seroquel® (quetiapine)
□ ZIPRASIDONE† (compare to Geodon®)	□ Clozaril® (clozapine)	□ Seroquel XR® (quetiapine XR)
□ OLANZAPINE (compare to Zyprexa®)	□ Geodon® (ziprasidone)	□ Versacloz® (clozapine)
	□ Invega® (paliperidone)	□ Zyprexa® (olanzapine)

Key: † Generic product

2. **Please list preferred medications previously tried and failed for this condition:**

Name of medication	Reason for failure	Date
_____	_____	_____
_____	_____	_____
_____	_____	_____

3. **Was patient seen by any other provider for this condition? □ YES □ NO**

   Who? _____ **What specialty?** _____

4. **Please include any other pertinent information that supports this request (suggest attach chart notes):**

Prescriber Signature:_____ **Date of this request:**_____

Antipsychotics: Atypical and Combination
(ADULTS ONLY ≥ 18 years old)

LENGTH OF AUTHORIZATION: Duration of need *♠ (except as noted below)
Quetiapine/Seroquel ≤ 50 mg/day = 1 year

CRITERIA FOR APPROVAL: (Adult Patients ≥ 18 years old)

NON-PREFERRED TABLETS:

Fanapt®:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The indication for use is the treatment of schizophrenia/schizoaffective disorder or bipolar disorder.

AND
- The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics).

Invega®:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) (Prior therapy with injectable Invega Sustenna® is not considered to be started and stabilized for oral Invega. Patients transferring to oral therapy from Invega Sustenna® should transition to oral risperidone unless patient previously failed such treatment)

OR
- The indication for use is the treatment of schizophrenia/schizoaffective disorder.

AND
- The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics), one of which is risperidone.

Saphris®:
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The indication for use is the treatment of schizophrenia/schizoaffective disorder or bipolar disorder.

AND
- The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics).

Clozaril®, Geodon®, Risperdal®, Zyprexa®:
- The patient has a documented intolerance to the generic equivalent.

Latuda®:
- The patient is pregnant and the diagnosis is schizophrenia/schizoaffective disorder or Bipolar I depression.

OR
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR
- The indication for use is schizophrenia/schizoaffective disorder.

AND
- The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics), one of which is ziprasidone.

OR
- The indication for use is schizophrenia/schizoaffective disorder.

AND

- The patient has had a documented side effect, allergy or treatment failure with ziprasidone and the prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes.

OR

- The indication for use is Bipolar I depression.

AND

- The patient has had a documented side effect, allergy or treatment failure with generic quetiapine.

OR

- The indication for use is Bipolar I depression.

AND

- The prescriber feels that quetiapine would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.

Quetiapine/Seroquel® < or = 50 mg/day:

- The patient is being prescribed > 50 mg/day with combinations of tablet strengths.

OR

- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.

OR

- The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories) or at least 2 antidepressants from the SSRI, SNRI, and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at < 150 mg/day and bupropion would not be considered trials for this indication.

OR

- The indication for use is a mental health indication (other than the two above indications or a sleep disorder).

AND

- If the request if for brand Seroquel, the patient has a documented intolerance to generic quetiapine.

Note: Quetiapine in doses of ≤ 50 mg/day will not be approved for indications of insomnia, for sleep or as an hypnotic.

Seroquel XR®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder (bipolar mania, bipolar depression, bipolar maintenance).

OR

- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.

OR

- The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at < 150 mg/day and bupropion would not be considered trials for this indication.

AND

- The patient has not been able to be adherent to a twice daily dosing schedule of quetiapine immediate release resulting in a significant clinical impact

Abilify®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics)

OR

- The patient has had a documented side effect, allergy or treatment failure with ziprasidone and the prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes.

OR

- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.

OR

- The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at <150 mg/day and bupropion would not be considered trials for this indication.

AND

- The patient has had a documented side effect, allergy or treatment failure with one preferred atypical antipsychotic product being used as adjunctive therapy.

OR

- The indication for use is treatment of aggression, psychosis, or agitation secondary to Alzheimer's disease or other dementias AND the patient has had a documented side effect, allergy or treatment failure with two preferred products (typical or atypical antipsychotics). (**Note:** Please consider FDA Black Box Warning)

OR

- The indication or use is treatment of irritability associated with autistic disorder AND the patient has had a documented side effect, allergy or treatment failure with risperidone.

OR

- The indication or use is treatment of Tourette's syndrome AND the patient has had a documented side effect, allergy or treatment failure with guanfacine or clonidine and also risperidone.

NON-PREFERRED ORAL SOLUTIONS

Abilify®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.

OR

- The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at <150 mg/day and bupropion would not be considered trials for this indication.

AND

- The patient has had a documented side effect, allergy or treatment failure with preferred risperidone oral solution being used as adjunctive therapy.

OR

- The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder.

OR

- The indication for use is treatment of aggression, psychosis, or agitation secondary to Alzheimer's disease or other dementias. (**Note:** Please consider FDA Black Box Warning)

OR

- The indication or use is treatment of irritability associated with autistic disorder.

OR

- The indication or use is treatment of Tourette's syndrome AND the patient has had a documented side effect, allergy or treatment failure with guanfacine or clonidine.

AND

- The patient has had a documented side effect, allergy or treatment failure with preferred risperidone oral solution.

Risperdal®:

- The patient has a documented intolerance to the generic product risperidone.

Versacloz®:

- The patient has a medical necessity for a non-solid oral dosage form and is unable to use clozapine orally disintegrating tablets.

NON-PREFERRED SHORT-ACTING INJECTABLE PRODUCTS:

- Medical necessity for a specialty dosage form has been provided.

AND

- The patient has had a documented side effect, allergy, or treatment failure with Geodon IM. In addition, for approval of Zyprexa® IM, the patient must have had a documented intolerance to generic olanzapine IM.

LONG-ACTING INJECTIONS:

Risperdal Consta®

- The patient has been started and stabilized on the medication

OR

- Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications)

AND

- Tolerability has been established previously with oral risperidone.

Invega Sustenna®

- The patient has been started and stabilized on the medication

OR

- Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications)

AND

- Tolerability has been established previously with oral/injectable risperidone or oral paliperidone.

Zyprexa Relprevv®

- The patient has been started and stabilized on the medication

OR

- Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications)

AND

- Tolerability has been established previously with oral olanzapine.

Abilify Maintena®

- The patient has been started and stabilized on the medication

OR

- Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications)

AND

- Tolerability has been established previously with oral aripiprazole for at least 2 weeks.

ORALLY DISINTEGRATING TABLETS:

- Medical necessity for a specialty dosage form has been provided.

AND

- If the request is for FazaClo, Risperdal M-Tab or Zyprexa Zydis, the patient has a documented intolerance to the generic equivalent.

COMBINATION PRODUCTS:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy or treatment failure with two preferred products (ziprasidone, risperidone, and quetiapine).

OR

- The prescriber provides a clinically valid reason for the use of the requested medication.

AND

- If the request is for brand product, the patient has a documented intolerance to the generic product,

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

✓ Document clinically information supporting the prescribing of Quetiapine in doses of ≤ 50 mg/day on a **Quetiapine Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Antipsychotics: Atypical and Combination (ADULTS ONLY ≥ 18 years old)

Length of authorization: Duration of Need♠*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
TABLETS/CAPSULES	
CLOZAPINE† (compare to Clozaril®) *FDA maximum recommended dose = 900 mg/day* OLANZAPINE† (compare to Zyprexa®) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)* RISPERIDONE† (compare to Risperdal®) *FDA maximum recommended dose = 16 mg/day* QUETIAPINE† (compare to Seroquel®) > 50 mg/day QUETIAPINE† (compare to Seroquel®) ≤ 50 mg/day (children < 18 years old) *FDA maximum recommended dose = 800 mg/day* ZIPRASIDONE† (compare to Geodon®) *FDA maximum recommended dose = 160 mg/day*	Abilify® (aripiprazole) *FDA maximum recommended dose = 30 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)* Clozaril®* *(clozapine)* *FDA maximum recommended dose = 900 mg/day* Fanapt® (iloperidone) *FDA maximum recommended dose = 24 mg/day* *Quantity limit = 2 tablets/day* Geodon® (ziprasidone) *FDA maximum recommended dose = 160 mg/day* Invega® (paliperidone) *FDA maximum recommended dose = 12 mg/day* *Quantity limit = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)* Latuda® (lurasidone) *FDA maximum recommended dose = 160 mg/day* *Quantity limit = 1 tablet/day all strengths except 80 mg = 2 tablets/day* Quetiapine† (compare to Seroquel®) ≤ 50 mg/day (adults ≥ 18 years old) Risperdal®* (risperidone) *FDA maximum recommended dose = 16 mg/day* Saphris® (asenapine) sublingual tablet *FDA maximum recommended dose = 20 mg/day* Seroquel® (quetiapine) *FDA maximum recommended dose = 800 mg/day* Seroquel XR® (quetiapine XR) *FDA maximum recommended dose = 800 mg/day Quantity Limit = 1 tab/day (150 mg & 200 mg tablet strengths), 2 tabs/day (50 mg strength)* ZYPREXA®* (olanzapine) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)*
ORAL SOLUTIONS	
RISPERIDONE† (compare to Risperdal®) oral solution *FDA maximum recommended dose = 16 mg/day*	Abilify® (aripiprazole) oral solution *FDA maximum recommended dose = 25 mg/day* Risperdal® (risperidone) oral solution *FDA maximum recommended dose = 16 mg/day* Versacloz® (clozapine) oral suspension *FDA maximum recommended dose = 900 mg/day* *Quantity limit = 18 ml/day*
SHORT-ACTING INJECTABLE PRODUCTS	
GEODON® IM (ziprasidone intramuscular injection) *FDA maximum recommended dose = 40 mg/day* *Table continued on next page*	Abilify® IM (aripiprazole intramuscular injection) *FDA maximum recommended dose = 30 mg/day* Olanzapine† IM (compare to Zyprexa® IM) *FDA maximum recommended dose = 30 mg/day* Zyprexa® IM (olanzapine intramuscular injection) *FDA maximum recommended dose = 30 mg/day* *Table continued on next page*

LONG-ACTING INJECTABLE PRODUCTS	
	Abilify Maintena® (aripiprazole monohydrate) *FDA maximum recommended dose = 400 mg/month* *Quantity limit = 1 vial/28 days* Invega Sustenna® (paliperidone palmitate) *FDA maximum recommended dose = 234 mg/month* Risperdal Consta® (risperidone microspheres) *FDA maximum recommended dose = 50 mg/14 days* Zyprexa Relprevv® (olanzapine pamoate) *FDA maximum recommended dose = 600 mg/month* *Quantity limit = 1 vial/28 days (405 mg) or 2 vials/month (210 or 300 mg)*
ORALLY DISINTEGRATING TABLETS	
	Abilify® Discmelt (aripiprazole) *FDA maximum recommended dose = 30 mg/day,* *Quantity limit = 2 tabs/day (10 mg & 15 mg tabs)* clozapine orally disintegrating tablets† *(*Compare to FazaClo®*)* *FDA maximum recommended dose = 900 mg/day* FazaClo® (clozapine orally disintegrating tablets) *FDA maximum recommended dose = 900 mg/day* Olanzapine orally disintegrating tablets† (compare to Zyprexa Zydis®) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)* Risperdal® M-Tab (risperidone orally disintegrating tablets) *FDA maximum recommended dose = 16 mg/day* Risperidone† ODT (compare to Risperdal® M-Tab) *FDA maximum recommended dose = 16 mg/day* Zyprexa Zydis® (olanzapine orally disintegrating tablets) *FDA maximum recommended dose = 20 mg/day,* *Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*
COMBINATION PRODUCTS	
	olanzapine/fluoxetine† (compare to Symbyax®) *FDA maximum recommended dose = 18 mg/75 mg (per day)* Symbyax® (olanzapine/fluoxetine) *FDA maximum recommended dose = 18 mg/75 mg (per day)*

* For brand name products when generic equivalent preferred, length of authorization is 1 year.
♠ For generic product when brand name product preferred, length of authorization is 1 year.

Antipsychotics: Typical

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*

CRITERIA FOR APPROVAL:

ORAL

- The patient has had a documented side effect, allergy or treatment failure with at least two preferred products. (If a product has an AB rated generic, one trial must be the generic.)

LONG ACTING INJECTABLE PRODUCTS

- For approval of Haldol® deconaoate, the patient has a documented intolerance to the generic product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Antipsychotics: Typical *Length of authorization: Duration of need for mental health indication*s*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL TABLETS/CAPSULES	
CHLORPROMAZINE† (formerly Thorazine®)	Haldol®* (haloperidol)
FLUPHENAZINE† (formerly Prolixin®)	Loxitane®* (loxapine)
HALOPERIDOL† (compare to Haldol®)	Navane®* (thiothixene) 2 mg, 5 mg, 10 mg
LOXAPINE† (compare to Loxitane®)	
NAVANE® (thiothixene) (20 mg ONLY)	
PERPHENAZINE† (formerly Trilafon®)	
THIORIDAZINE† (formerly Mellaril®)	
THIOTHIXENE† (compare to Navane®)	
TRIFLUOPERAZINE† (formerly Stelazine®)	
LONG ACTING INJECTABLE PRODUCTS	
fluphenazine decanoate† (formerly Prolixin® decanoate)	Haldol® decanoate* (haloperidol decanoate)
haloperidol decanoate † (compare to Haldol® decanoate)	

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Bone Resorption Inhibitors

LENGTH OF AUTHORIZATION: 3 years except Forteo® (2 years only, no renewal)

CRITERIA FOR APPROVAL:

Actonel®, Risedronate:

- The patient has a diagnosis/indication of Paget's Disease

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a six-month trial) to generic alendronate.

OR

- The patient has a diagnosis/indication of postmenopausal osteoporosis**,** osteoporosis in men or glucocorticoid induced osteoporosis.

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a 1 year trial) to generic alendronate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

AND

- If the request is for brand Actonel®, the patient has also had a documented intolerance to generic risedronate.

Altelvia®, Boniva® Oral, Ibandronate

- The patient has a diagnosis/indication of postmenopausal osteoporosis**.**

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a 1 year trial) to generic alendronate®. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

AND

- If the request is for brand Boniva®oral, the patient has also had a documented intolerance to generic Ibandronate.

Binosto®

- The patient has a diagnosis/indication of postmenopausal osteoporosis or osteoporosis in men.

AND

- The prescriber provides documentation of medical necessity for the specialty dosage form (i.e. inability to swallow tablets, dysphagia).

Calcitonin Nasal Spray (generic), Fortical®, Miacalcin® Nasal Spray:

- The patient is started and stabilized on the requested medication. If the request is for generic Calcitonin Nasal Spray, the patient has had a documented intolerance to brand Miacalcin.
- Note: Calcitonin Nasal Spray (brand and generic) no longer recommended for osteoporosis

Miacalcin Injection®:

- The patient has a diagnosis/indication of Paget's Disease

Evista® Tablet:

- The patient has had a documented intolerance to generic raloxifene.

Fosamax® Tablet:

- The patient has had a documented intolerance to generic alendronate.

Fosamax Plus D®:

- There is a clinical reason why the patient is unable to take generic alendronate and vitamin D separately.

Didronel®, Etidronate, Skelid®:

- The patient has a diagnosis/indication of Paget's Disease

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a six-month trial) to generic alendronate. If a medication has an AB rated generic, there must have also been a trial of the generic formulation.

Forteo®:

- The patient has a dignosis/indication of postmenopausal osteoporosis in females, primary or hypogonadal osteoporosis in males or glucocorticoid induced osteoporosis.

AND

- The patient has had a documented side effect, allergy, or treatment failure to an oral bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

AND

- The prescriber has verified that the patient has been counseled about osteosarcoma risk.

AND

- The quantity requested does not exceed 1 pen (3 mL) per 28 days with a lifetime maximum duration of treatment of 2 years.

Boniva®Injection, ibandronate Injection:

- The patient has a diagnosis/indication of postmenopausal osteoporosis**.**

AND

- The patient has had a documented side effect or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

AND

- The quantity requested does not exceed four (4) 3 mg doses per year.

Prolia® Injection:

- The diagnosis or indication is osteopenia in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer

OR

- The diagnosis or indication is osteopenia in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

OR

- The patient has a diagnosis/indication of postmenopausal osteoporosis

AND

- The patient has had a documented side effect, allergy, or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

AND

- The quantity requested does not exceed 1 syringe per 6 months.

Reclast® Injection, Zoledronic Acid Injection:

- The patient has a diagnosis/indication of Paget's disease of bone.

  OR

- The patient has a diagnosis/indication of postmenopausal osteoporosis**.**

  OR

- The patient is male with a diagnosis of osteoporosis**.**

  OR

- The patient has a diagnosis of glucocorticoid induced osteoporosis**.**

  AND

- The patient has had a documented side effect or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

  AND

- The quantity requested does not exceed a single 5 mg dose per year.

  AND

- If the request is for Reclast, the patient has a documented intolerance to generic zoledronic acid injection.

Xgeva® Injection:

- The diagnosis or indication is bone metastases from solid tumors (e.g. prostate, breast, thyroid, non-small lung cancer)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Boniva IV, Forteo, Prolia, Reclast, Xgeva or Zoledronic Acid on a **Bone Resorption Inhibitor Injectable Prior Authorization Request Form**.

- ✓ Document clinically compelling information supporting the choice of other non-preferred agents on a **General Prior Authorization Request Form**

- ✓ All requests for denosumab (Prolia® or Xgeva®) (whether billed through the pharmacy or medical benefit (J0897)) require Prior Authorization through the Catamaran Clinical Call Center.

Bone Resorption Inhibitors

Length of Authorization:3 years (Forteo® 2 years only, no renewal)

Key: † Generic product,

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL BISPHOSPHONATE **TABLETS/CAPSULES** ALENDRONATE† (compare to Fosamax®)	Actonel® (risedronate) Altelvia (risedronate) Delayed Release Tablet *(Quantity Limit = 4 tablets/28 days)* Binosto® (alendronate) 70 mg effervescent tablet *(Quantiy Limit=4 tablets/28 days)* Boniva® (ibandronate) *(Quantity Limit = 150 mg tablet/1 tablet per 28 days)* Didronel® (etidronate) Etidronate† (compare to Didronel®) Fosamax®* (alendronate) Fosamax Plus D® (alendronate/vitamin D) Ibandronate† (compare to Boniva®) *(Quantity Limit = 150 mg tablet/1 tablet per 28 days)* Risedronate† (compare to Actonel®) Skelid® (tiludronate)
INJECTABLE BISPHOSPHONATE	Boniva® Injection (ibandronate) *(QL=3 mg/3 months (four doses)/year)* ibandronate Injection† (compare to Boniva®) *(QL=3 mg/3 months (four doses)/year)* Reclast® Injection (zoledronic acid) *(QL=5 mg (one dose)/year)* Zoledronic Acid Injection† (compare to Reclast®) *(QL=5 mg (one dose)/year)*
ESTROGEN AGONIST/ANTAGONIST RALOXIFENE† (compare to Evista®) Tablet *(QL=1 tablet/day)*	Evista® (raloxifene) Tablet *(QL = 1 tablet/day)*
INJECTABLE RANKL INHIBITOR	Prolia® Injection (denosumab) *(QL=60 mg/6 months (two doses)/year)* Xgeva® (denosumab) (*QL=120 mg/28 days*)
CALCITONIN NASAL SPRAY	Calcitonin† Nasal Spray (compare to Miacalcin®) Fortical® (calcitonin) Miacalcin® (calcitonin)
CALCITONIN INJECTION	Miacalcin® (calcitonin)
PARATHYROID HORMONE INJECTION	Forteo® (teriparatide) *(Quantity Limit = 1 pen (3 ml)/28 days* *(Lifetime max duration of treatment = 2 years)*

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ BONE RESORPTION INHIBITORS INJECTABLE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of injectable bone resorption inhibitors. For beneficiaries to receive coverage for these agents, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

Will this medication be billed through the: ☐ **pharmacy benefit** or ☐ **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name):_____NPI #:_____

Pharmacy (if known):_____ Phone:_____ &/or FAX:_____

Drug requested: ☐ Boniva IV ☐ Forteo ☐ Ibandronate IV ☐ Prolia

☐ Reclast ☐ Xgeva ☐ Zoledronic Acid

Dose & frequency: _____

Diagnosis/indication:

☐ Treatment of postmenopausal osteoporosis ☐ Treatment of male osteoporosis

☐ Paget's Disease ☐ Treatment of glucocorticoid induced osteoporosis

☐ Bone metastases from solid tumors (tumor type: _____)

☐ Other (Please Explain) _____

Has the member previously tried the following preferred medication?

Drug:	***Response:***
☐ Alendronate Oral	☐ side-effect ☐ treatment failure* dates of use: _____

*Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with the bisphosphonate.

Prescriber comments: _____

_____

_____

Prescriber Signature:_____ **Date of this request:**_____

Botulinum Toxins

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 12 months

CRITERIA FOR APPROVAL:

BOTOX (onabotulinumtoxinA),:

- The indication for use is:
  - Strabismus and blepharospasm associated with dystonia, including essential blepharospasm, VII cranial nerve disorders/hemifacial spasm
  - Focal dystonias, including cervical dystonia, spasmodic dysphonia, oromandibular dystonia
  - Limb spasticity (e.g., due to cerebral palsy, multiple sclerosis, or other demyelinating CNS diseases)
  - Focal spasticity (e.g., due to hemorrhagic stroke, anoxia, traumatic brain injury)
  - Axillary Hyperhidrosis (if member has failed an adequate trial of topical therapy)
  - Overactive bladder or detrusor overactivity (if member has failed an adequate trial of at least TWO urinary antispasmodics (either short- or long-acting formulations)
  - Chronic migraine (>15 days per month with headache lasting 4 hours a day or longer) and the member has failed or has a contraindication to an adequate trial of at least TWO medications for migraine prophylaxis from at least two different classes (tricyclic antidepressants, beta-blockers, calcium channel blockers or anticonvulsants). For re-approval after 3 months, the patient must have had an improvement in symptoms.

AND

- The patient is >12 years of age if for blepharospasm or strabismus, >16 years of age for cervical dystonia, and >18 years of age for hyperhidrosis, chronic migraine or overactive bladder/detrusor overactivity.

Dysport (abobotulinumtoxinA):

- The patient has a diagnosis of cervical dystonia or spasmodic torticollis

AND

- The patient is ≥18 years of age

AND

- The patient has had a treatment failure with BOTOX®.

Myobloc (rimabotulinumtoxinB):

- The patient has a diagnosis of focal dystonias, including cervical dystonia, spasmodic dysphonia, oromandibular dystonia

AND

- The patient is ≥16 years of age

Xeomin (incobotulinumtoxinA):

- The patient has a diagnosis of cervical dystonia or blepharospasm.

AND

- The patient is ≥18 years of age

AND

- The patient has had a documented intolerance or treatment failure with BOTOX®.

LIMITATIONS:

Coverage of botulinum toxins will not be approved for cosmetic use (e.g., glabellar lines, vertical glabellar eyebrow furrows, facial rhytides, horizontal neck rhytides, etc.). (BOTOX® Cosmetic (onabotulinumtoxinA) is not covered)

IMPORTANT NOTE:

Botulinum neurotoxins are used to treat various disorders of focal muscle spasm and excessive muscle contractions, such as focal dystonias. When injected intramuscularly, botulinum neurotoxins produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings. As a consequence of the chemistry and clinical pharmacology of each botulinum neurotoxin product, botulinum neurotoxins are not interchangeable, even among same serotype products. Units of biological activity are unique to each preparation and cannot be compared or converted into units of another. It is important that providers recognize there is no safe dose conversion ratio—i.e., one unit of BOTOX® (onabotulinumtoxinA, formerly type A)does not equal one unit of Myobloc® (rimabotulinumtoxinB, formerly type B) does not equal one unit of Dysport (abobotulinumtoxinA) does not equal one unit of Xeomin (incobotulinumtoxinA). Failure to understand the unique characteristics of each formulation of botulinum neurotoxin can result in under or over dosage. It is expected that use of these products will be based on each product's individual dosing, efficacy and safety profiles.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the request of the agent on a **General Prior Authorization Request Form**.
- ✓ All requests for botulinum toxin (whether billed through the pharmacy or medical benefit) require Prior Authorization through the Catamaran Clinical Call Center: Botox (J0585), Dysport (J0586), Myobloc (J0587) or Xeomin (J0588)

Botulinum Toxins

Length of Authorization: initial approval 3 months, subsequent approval up to 12 months

PREFERRED DRUGS (No PA Required)	PA REQUIRED
	BOTOX® (onabotulinumtoxinA) Myobloc® (rimabotulinumtoxinB) **Available after a BOTOX® treatment failure for select indications:** Dysport® (abobotulinumtoxinA) Xeomin® (incobotulinumtoxinA)

BPH Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Alpha Blockers

- **Cardura®, Cardura XL®:** The patient has had a documented side effect, allergy or treatment failure with two alpha blockers, one of which must be generic doxazosin.

- **Flomax®:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers, one of which must be generic tamsulosin.

- **alfuzosin ER, Rapaflo®, Uroxatral®:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers. In addition, for approval of Uroxatral, the patient must have a documented intolerance to generic alfuzosin ER.

Androgen Hormone Inhibitors

- **Avodart:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented side effect, allergy or treatment failure to generic finasteride.

- **Proscar:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented intolerance to generic finasteride.

- **Finasteride for males age < 45:** The patient has a diagnosis of BPH (benign prostatic hypertrophy)

Combination Product

- **Jalyn:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented treatment failure/inadequate response to combination therapy with generic tamsulosin and finasteride.

LIMITATIONS:
Coverage of androgen hormone inhibitors will not be approved for cosmetic use in men or women (male-pattern baldness/alopecia or hirsutism). (This includes Propecia® (finasteride) and its generic equivalent whose only FDA approved indication is for treatment of male pattern hair loss.)
Current clinical guidelines recommend the use of Cialis® (tadalafil) only in men with concomitant erectile dysfunction or pulmonary hypertension. Medicaid programs do not receive Federal funding for drugs used in the treatment of erectile dysfunction so Cialis® will not be approved for use in BPH.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

BPH Agents

Length of authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALPHA BLOCKERS	
DOXAZOSIN† (compare to Cardura®) TAMSULOSIN† (compare to Flomax®) *Quantity Limit = 2 capsules/day* TERAZOSIN† (previously Hytrin®)	alfuzosin ER† (compare to Uroxatral®) *Quantity Limit = 1 tablet/day* Cardura®* (doxazosin) Cardura XL® (doxazosin) *Quantity Limit = 1 tablet/day* Flomax®* (tamsulosin) *Quantity Limit = 2 capsules/day* Rapaflo® (silodosin) *Quantity Limit = 1 capsule/day* Uroxatral® (alfuzosin) *Quantity Limit = 1 tablet/day*
ANDROGEN HORMONE INHIBITORS	
FINASTERIDE† (compare to Proscar®) *(QL = 1 tablet/day)*	Avodart® (dutasteride) (*QL = 1 capsule/day)* finasteride† (compare to Proscar®) females; males age < 45 *(QL = 1 tablet/day)* Proscar®*(finasteride) *(QL = 1 tablet/day)*
COMBINATION PRODUCT	
	Jalyn® (dutasteride/tamsulosin) (*QL = 1 capsule/day)*

Cardiac Glycosides

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Cardiac Glycosides

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DIGOXIN† DIGOXIN† Oral Solution LANOXIN® (digoxin)	

Chemical Dependency: Alcohol and Opiate Dependency

LENGTH OF AUTHORIZATION: Vivitrol - 6 months, no renewal

All others – Up to 1 year

CRITERIA FOR APPROVAL:

Alcohol/Opiate Dependency: Revia, Antabuse, Campral

- The patient has had a documented intolerance to the generic equivalent product.

Alcohol/Opiate Dependency: Vivitrol

- Diagnosis of alcohol dependency

  AND
- An inadequate response, adverse reaction, or contraindication to 1 out of 3 oral formulations used for alcohol dependence including: oral naltrexone, acamprosate, and disulfiram OR a compelling clinical reason for use (e.g. multiple hospital admissions for alcohol detoxification)

  AND
- Patient should be opiate free for > 7 – 10 days prior to initiation of Vivitrol

  OR
- Diagnosis is prevention of relapse to opioid dependency

  AND
- The patient has failed Suboxone therapy or is not a candidate for Suboxone therapy (eg. Patient is opiate free and prescriber wishes to prevent relapse to opioid dependence without using maintenance therapy) or patient requires injectable therapy (compliance, tolerance, etc).

  AND
- Patient should be opiate free for > 7 – 10 days prior to initiation of Vivitrol

  ALSO
- Available only through the Pharmacy Benefit (J-Code 2315 blocked from Medical Benefit) from a pharmacy provider that will deliver directly to the physician's office (Medicare Part B to be billed first if applicable)

Opiate Dependency: Suboxone, Buprenorphine/Naloxone, Buprenorphine

- Diagnosis of opiate dependence confirmed (will not be approved for alleviation of pain).

  AND
- Prescriber has an DATA 2000 waiver ID number ("X-DEA license") in order to prescribe

  AND
- A "Pharmacy Home" for all prescriptions has been selected (Pharmacy located or licensed in VT)

  AND
- Patients new to Buprenorphine/Nalone (no claims in last 60 days) will be prescribed Suboxone Film (not SL tablet).

  AND
- Patients new to Suboxone (no claims in last 60 days) will be subject to a quantity limit of 16 mg/day.

  AND
- Requests for Buprenorphine/Naloxone SL tablet after documented intolerance of Suboxone Film must include a completed MedWatch form that will be submitted by DVHA to the FDA.

  AND
- If buprenorphine (formerly Subutex) is being requested,
  - Patient is either pregnant and history (copy of positive pregnancy test) has been submitted (duration of PA will be one 1 month post anticipated delivery date)

    OR
  - Patient is breastfeeding a methadone or morphine dependent baby and history from the neonatologist or pediatrician has been submitted.

Smoking Cessation Products: See "Smoking Cessation Therapies"

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of Vivitrol® or Suboxone®/buprenorphine on the **Vivitrol® or Buprenorphine Prior Authorization Request Forms**.
- ✓ Document clinically compelling information supporting the choice of Revia® on a **General Prior Authorization Request Form**.

Chemical Dependency: Alcohol and Opiate Dependency

Length of authorization: Vivitrol 6 months, no renewal; all others up to 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALCOHOL DEPENDENCY Acamprosate† (compare to Campral®) DISULFIRAM† 250 mg, 500 mg tab (compare to Antabuse®) NALTREXONE oral † (compare to Revia®)	Antabuse®* (disulfiram) Campral®* (acamprosate) Revia®* (naltrexone oral) Vivitrol® (naltrexone for extended-release injectable suspension) *(QL = 1 injection (380 mg) per 30 days)*
OPIATE DEPENDENCY NALTREXONE oral † (compare to Revia®) **Preferred Agent after Clinical Criteria are Met** SUBOXONE® sublingual FILM (buprenorphine/nalaxone) *QL = 2 films per day (8 mg strength),* *3 films per day (2 mg strength)* *or 1 film per day (4 mg, 12 mg strengths)* *(Maximum daily Dose = 16 mg/day)* ***Maximum days supply for Suboxone is 14 days*** Note: Methadone for opiate dependency may only be prescribed through a Methadone Maintenance Clinic	buprenorphine† sublingual TABLET(formerly Subutex®) *QL = 3 tablets per day (2 mg strength)* *or 2 tablets/day (8 mg strength)* *(Maximum Daily Dose = 16 mg/day)* Revia®* (naltrexone oral) Buprenorphine/Naloxone† (formerlySuboxone®) sublingual TABLET *QL = 2 tablets per day (8 mg strength)* *or 3 tablets per day (2 mg strength)* *(Maximum daily Dose = 16 mg/day)* ****Maximum days supply for buprenorphine/naloxone or buprenorphine is 14 days**** **For Prevention of Relapse to Opioid Dependency** Vivitrol® (naltrexone for extended-release injectable suspension) *(QL = 1 injection (380 mg) per 30 days)*

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~BUPRENORPHINE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of buprenorphine/Suboxone®). These criteria are based on concerns about safety and the potential for abuse and diversion. All requests must be submitted using this fax form.

Submit request via Fax (only): 1-866-767-2649

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

►Please answer the following questions:

Is buprenorphine being prescribed for opiate dependency?	☐ Yes ☐ No
Does the prescriber signing this form have a DATA 2000 waiver ID number ("X-DEA license")?	☐ Yes ☐ No
Has the prescriber queried the VPMS (Vermont Prescription Monitoring System) to review patient's scheduled II-IV medication history?	☐ Yes ☐ No ☐ Not signed up
A "Pharmacy Home" for **ALL** prescriptions has been selected **AND** discussed with patient? (Pharmacy must be located/licensed in VT) Pharmacy Name:_____ Pharmacy Phone #: _____	☐ Yes ☐ No
Has patient filled a Suboxone RX in last 60 days	☐ Yes ☐ No ☐ Don't know
Request is for the following medication: Sublingual **FILM**	☐ Suboxone® (buprenorphine/naloxone)
Request is for the following medication: Sublingual **TABLET**	☐ Buprenorphine/Naloxone (formerly Suboxone®) ☐ Buprenorphine (formerly Subutex®)
Anticipated maintenance dose/frequency: (target dose of no more than 16 mg/day) (maximum 14 day supply per prescription fill) Dose:_____ Frequency:_____ (recommended once daily)	
If this request is for Buprenorphine mono (formerly Subutex®), please answer the following questions: Is the member pregnant? (please provide positive pregnancy test copy) If yes, anticipated date of delivery: _____	☐ Yes ☐ No
Is the member breastfeeding a methadone or morphine dependent baby? (please provide history from neonatologist or pediatrician)	☐ Yes ☐ No
Would you have referred your patient to a methadone clinic if this option was conveniently located and available?	☐ Yes ☐ No
Additional clinical information to support PA request:	

Prescriber Signature: _____ (stamps not acceptable)

Prescriber X-DEA License #: _____ Date of request: _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~VIVITROL~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of Vivitrol (naltrexone for IM extended release suspension). These criteria are based on concerns about safety. In order for beneficiaries to receive coverage for Vivitrol, it will be necessary for the prescriber to complete and fax this prior authorization request to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via Fax: 1-866-767-2649

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____Sex:_____

Contact Person at Office: _____

Administering physician:

Name: _____ Address: _____

Pharmacy (required)**:**_____ Phone:_____ &/or FAX:_____

QUALIFICATIONS

MDs	Prescribers must secure direct delivery of Vivitrol from the pharmacy to the physician's office. Pharmacies may not dispense Vivitrol directly to the patient. Vivitrol **may not** be billed through the Medical Benefit as a J-Code J2315.

PROCESS

► Please answer the following questions:

Patient diagnosis ?	□ Alcohol dependence □ Prevention of relapse to opioid dependency
Has the patient been opiate free for > 7 – 10 days	□ Yes □ No
For alcohol dependence: **(1)** Has the patient tried any of the following? Please document below. oral naltrexone: □ side-effect □ non-response □ allergy acamprosate: □ side-effect □ non-response □ allergy disulfiram: □ side-effect □ non-response □ allergy	□ Yes □ No
(2) Has patient had a recent hospital admission for alcohol detoxification?	□ Yes □ No If yes, date: ____/_____/____
For prevention of relapse to opioid dependency **(1)** Has the patient failed buprenorphine therapy? **(2)** Is the patient not a candidate for buprenorphine therapy? **(3)** Patient requires injectable therapy?	□ Yes □ No □ Yes □ No □ Yes □ No
Comments and additional patient history:	

Prescriber Signature: _____ **Date of request:** _____

Compounded Products

Review Guidelines for Appropriateness of Compounded Products

Compounding of medication may be allowed:

- For making a strength of a medication when specific doses are not commercially available and when a significantly different dosage form is clinically needed.
- For preparation of a medication that has been withdrawn from the marketplace due to economic concerns, NOT safety.
- For those patients that cannot swallow or have trouble swallowing and require a different dosage form than is currently available.
- For those patients who have sensitivity to dyes, preservatives, or fillers in commercial products and require allergy-free medications.
- For children who require liquid medications that are not commercially available.

A compound drug will only be covered if it is

- Considered medically necessary according to specified criteria as detailed below **and**
- Commercially available alternative agents have been previously tried with therapeutic failure or patient intolerance

Medically necessary criteria for a compound drug

- All ingredients are FDA approved for medical use in the United States (for example, domperidone has not been approved by the FDA for any indication in the United States).
- It is not a copy of a commercially available FDA approved product.
- It is not a substitution for an available FDA approved product (for example, there are multiple commercially available hormonal products for use in menopause. Bioidentical individualized hormonal products will not be covered). One or more prescription ingredients is included in the compound; a compound whose primary active ingredient is OTC will only be covered if that particular OTC is covered under the beneficiary's program
- Safety and effectiveness of use for the prescribed indication is supported by FDA approval or adequate medical and scientific evidence or medical literature.

An ingredients is not covered if it is

- From a manufacturer that does not offer Federal Rebate
- Considered a "bulk chemical or powder". CMS has clarified that bulk products are not considered covered outpatient drugs because they are not prescription drug products approved under section 505,505(j), or 507 of the Federal Food Drug and Cosmetic Act.
- Bulk powders used to compound products for the prevention of pre-term labor will continue to be covered after Prior Authorization when this practice is acceptable to the FDA and there are not commercially available products.

Constipation: Chronic, IBS-C or Opioid-Induced

LENGTH OF AUTHORIZATION: Amitiza, Linzess: Initial PA of 3 months, and 12 months thereafter

Relistor: 3 months

CRITERIA FOR APPROVAL:

AMITIZA®

- The patient has a diagnosis of chronic idiopathic constipation (CIC) (24 mcg capsules)

  OR
- The patient is a woman and has a diagnosis of irritable bowel syndrome with constipation (IBS-C) (8 mcg capsules)

  AND
- The patient has had documented treatment failure to lifestyle and dietary modification (increased fiber and fluid intake and increased physical activity).

  AND
- The patient has had documented side effect, allergy or treatment failure to a 1 week trial each of at least 2 preferred laxatives from the Bulk-Producing Laxative or Osmotic Laxative categories (see below).

LINZESS®

- The patient is 18 years of age or older.

  AND
- The patient has a diagnosis of chronic idiopathic constipation (CIC) (145 mcg capsules)

  OR
- The patient has a diagnosis of irritable bowel syndrome with constipation (IBS-C) (290 mcg capsules)

  AND
- The patient has had documented treatment failure to lifestyle and dietary modification (increased fiber and fluid intake and increased physical activity).

  AND
- The patient has had documented side effect, allergy or treatment failure to a 1 week trial each of at least 2 preferred laxatives from the Bulk-Producing Laxative or Osmotic Laxative categories (see below).

RELISTOR®

- The patient must have documented opioid-induced constipation and be receiving palliative care

  AND
  - The patient must have had documented treatment failure to a 1 week trial of at least 2 preferred laxatives from 2 different laxative classes (see below) used in combination.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Constipation: Chronic, IBS-C or Opioid-Induced

Length of Authorization: Amitiza: Initial PA of 3 months, and 12 months thereafter , Relistor: *3 months*

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Bulk-Producing Laxatives PSYLLIUM† **Osmotic Laxatives** LACTULOSE† POLYETHYLENE GLYCOL 3350 (PEG)† (compare to Miralax®) **Stimulant Laxative** BISACODYL† SENNA† **Stool Softener** DOCUSATE†	Amitiza® (lubiprostone) *(Qty limit = 2 caps/day)* Linzess® (linaclotide) *(Qty limit = 1 cap/day)* Relistor® (methylnatrexone)

Contraceptives: Vaginal Ring

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Contraceptives: Vaginal Ring	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
NUVARING® (etonogestrel/ethinyl estradiol vaginal ring)	

Coronary Vasodilators/Antianginals: Oral and Topical

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Dilatrate-SR®, Imdur®:

- The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate ER tablet, isosorbide mononitrate ER tablet, nitroglycerin ER capsule or Nitro-time®. If a product has an AB rated generic, one trial must be the generic formulation.

Ismo®, Isordil®, Monoket®, Isosorbide dinitrate SL tablet:

- The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate tablet or isosorbide mononitrate tablet. If a product has an AB rated generic, one trial must be the generic formulation.

Nitro-Dur®:

- The patient has had a side effect, allergy, or treatment failure to Nitrek® or generic nitroglycerin transdermal patches.

Bidil®:

- The prescriber provides a clinically valid reason why the patient cannot use isosorbide dinitrate and hydralazine as separate agents.

Ranexa®:

- The patient has had a diagnosis/indication of chronic angina.

AND

- The patient has had a documented side effect, allergy, or treatment failure with at least one medication from two of the following classes: beta-blockers, maintenance nitrates, or calcium channel blockers.

AND

- The patient does not have any of the following conditions:
  - Hepatic insufficiency
  - Concurrent use of medications which may interact with Ranexa®:
    - CYP450 3A4 inducers (rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, St.John's wort)
    - CYP450 3A4 inhibitors (diltiazem, verapamil, ketoconazole, protease inhibitors, grapefruit juice, macrolide antibiotics)
    - Note: doses of digoxin or drugs metabolized by CYP450 2D6 (TCAs, some antipsychotics) may need to be adjusted if used with Ranexa®.

AND

- The dose requested does not exceed 3 tablets/day (500 mg) or 2 tablets/day (1000 mg).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Coronary Vasodilators/Antianginals: Oral and Topical

Length of Authorization: 3 years

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL	
ISOSORBIDE DINITRATE† tab (compare to Isordil®) ISOSORBIDE DINITRATE† ER tablet ISOSORBIDE MONONITRATE† tab (compare to, Ismo®, Monoket®) ISOSORBIDE MONONITRATE† ER tab (compare to Imdur®) NITROGLYCERIN† SL tablet NITROGLYCERIN† ER capsule NITROLINGUAL PUMP SPRAY® NITROGLYCERIN SPRAY LINGUAL† (compare to Nitroglycerin Pump Spray®) NITROMIST® Lingual Spray NITROQUICK® (nitroglycerin SL tablet) NITROSTAT® (nitroglycerin SL tablet) NITRO-TIME® (nitroglycerin ER capsule)	Dilatrate-SR® (isosorbide dinitrate SR cap) Imdur®* (isosorbide mononitrate ER tablet) Ismo®* (isosorbide mononitrate tablet) Isosorbide dinitrate SL tablet Isordil®* (isosorbide dinitrate tab) Monoket®* (isosorbide mononitrate tablet) BiDil® (isosorbide dinitrate/hydralazine) Ranexa® (ranolazine) *(QL = 3 tablets/day (500 mg), 2 tablets/day (1000 mg))*
TOPICAL	
NITREK® (nitroglycerin transdermal patch) NITRO-BID® (nitroglycerin ointment) NITROGLYCERIN TRANSDERMAL PATCHES† (compare to Nitro-Dur®)	Nitro-Dur®* (nitroglycerin transdermal patch)

Corticosteroids: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL (NON-PREFERRED):

Rayos®:

- The patient has had a trial of generic immediate release prednisone and has documented side effects that are associated with the later onset of activity of immediate release prednisone taken in the morning.

All Others:

- The patient has been started and stabilized on the requested medication.

OR

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred medications. If a product has an AB rated generic, one trial must be the generic formulation.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Corticosteroids: Oral

Length of authorizations: 1 year

Key : † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CORTISONE ACETATEtablets DEXAMETHASONE† tablets, elixir, intensol, solution DEXPAK® tabs (dexamethasone taper pack) HYDROCORTISONE† tab (compare to Cortef®) MEDROL® (methylprednisolone) 2mg tablets METHYLPREDNISOLONE† (compare to Medrol®) tabs METHYLPREDNISOLONE DOSE PACK† (compare to Medrol Dose Pack®) tabs ORAPRED® ODT (prednisolone sod phosphate) (age < 12 yrs) PREDNISOLONE† 3 mg/ml oral solution, syrup (compare to Prelone®) PREDNISOLONE SODIUM PHOSPHATE† 3 mg/ml oral solution (compare to Orapred®) PREDNISOLONE SOD PHOSPHATE ORAL SOLUTION† 6.7mg/5ml (5mg/5ml base) (compare to Pediapred®) PREDNISONE† intensol, solution, tablets	Celestone® (betamethasone) oral solution Cortef®* (hydrocortisone) tablets Flo-Pred® (prednisolone acetate) oral suspension Medrol®* (methylprednisolone) tablets Medrol Dose Pak®* (methylprednisolone) tabs Millipred® (prednisolone) tabletsMillipred® (prednisolone sodium phos) oral solution Millipred DP® (prednisolone) dose pack tablets Orapred®* oral solution* (prednisolone sod phos) Orapred® ODT (prednisolone sod phos) (age ≥ 12 yrs) Pediapred®* (prednisolone sod phosphate) oral solution prednisolone sodium phosphate oral solution 25 mg/5ml Rayos® (prednisone) Delayed Release Tablet *(Quantity limit = 1 tablet/day)* Veripred® 20 oral solution (prednisolone sodium phosphate) All other branded products

See "Gastrointestinal: Inflammatory Bowel Agents" for Budesonide 24 hr, Entocort EC® and Uceris®.

Cough and Cold Preparations

LENGTH OF AUTHORIZATION: date of service only, no refills

CRITERIA FOR APPROVAL:

Tussionex®, TussiCaps®, Hydrocodone/chlorpheniramine suspension (generic)

- The patient has had a documented side effect, allergy, or treatment failure to two of the following generically available cough or cough/cold products: hydrocodone/homatropine (compare to Hycodan®), promethazine/codeine (previously Phenergan® with Codeine), guaifenesin/codeine (Cheratussin AC®) or benzonatate.

AND

- The patient is 6 years old of age or greater.

AND

- The quantity requested does not exceed 60 ml (Tussionex®) or 12 capules (TussiCaps®).

AND

- If the request is for Tussionex®, the patient has a documented intolerance to generic hydrocodone/chlorpheniramine suspension.

All Other Brands

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available preparations would not be a suitable alternative.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Cough and Cold Preparations *Length of Authorization: date of service only, no refills*

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
All generics MUCINEX® (guaifenesin) PA required for Age < 2 years old for all products (brand and generic)	Hydrocodone/chlorpheniramine (compare to Tussionex®) *(QL = 60 ml)* Tussionex® (hydrocodone/chlorpheniramine) *(QL = 60 ml)* TussiCaps® (hydrocodone/chlorpheniramine) *(QL = 12 capsules/RX)* All other brands Age < 2 years old for all products (brand and generic)

Cystic Fibrosis: Medications

***NOTE*: Kalydeco®, TOBI® and Pulmozyme®must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Cystic Fibrosis Prior Authorization/Patient Enrollment Form for instructions. Briova will not be supplying Cayston® at this time (obtainable through several other specialty pharmacies).**

LENGTH OF AUTHORIZATION: Kalydeco®: 3 months initial, then 1 year

All others: 1 year

CRITERIA FOR APPROVAL:

Bethkis®, Cayston®, Pulmozyme®, TOBI®, tobramycin inhalation solution, TOBI® Podhaler:

- The diagnosis or indication is cystic fibrosis.

  AND
- For approval of Bethkis® or generic tobramycin inhalation solution, the patient has a documented intolerance to branded TOBI®.

Kalydeco®:

- The patient has a diagnosis of Cystic Fibrosis with documented G551D mutation (documentation provided).

  AND
- The patient is ≥ 6 years old.

Note: Renewal of Prior Authorization will require documentation of member response.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of **Cayston** on a **General Prior Authorization Request Form**.
- ✓ Document clinical information for **Pulmozyme®** and **TOBI®/TOBI® Podhaler** on its **Prior Authorization/Patient Enrollment Form.**
- ✓ Document clinical information for **Kalydeco®** on a **General Specialty Prior Authorization/Patient Enrollment Form.**

Cystic Fibrosis: Medications	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
	Bethkis® (tobramycin) inhalation solution *(Quantity Limit = 56 vials/56 days; maximum days' supply = 56 days)(2 vials/day for 28 days, then 28 days off)* Cayston® (aztreonam) inhalation solution *(Quantity Limit = 84 vials/56 days; maximum days' supply = 56 days)(3 vials/day for 28 days, then 28 days off)* Kalydeco® (ivacaftor) tablets *(Quantity Limit = 2 tablets/day, maximum days' supply = 30 days)* Pulmozyme® (dornase alfa) inhalation solution *(Quantity Limit =60/30 days; maximum days' supply=30 days)* TOBI® (tobramycin) Podhaler Capsules for inhalation *(Quantity Limit = 224 capsules/56 days; maximum days' supply = 56 days)(4 capsules twice daily for 28 days, then 28 days off)* TOBI® (tobramycin) inhalation solution *(Quantity Limit = 56 vials/56 days; maximum days' supply = 56 days)(2 vials/day for 28 days, then 28 days off)* Tobramycin inhalation solution† (compare to Tobi®) *(Quantity Limit = 56 vials/56 days; maximum days' supply = 56 days)(2 vials/day for 28 days, then 28 days off)*

VERMONT

CYSTIC FIBROSIS MEDICATION – Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

Please Note: Cayston® and pancreatic enzymes are not obtained though Briova Specialty Pharmacy.

3

Department of Vermont Health Access

PRIOR AUTHORIZATION REQUEST/PRESCRIPTION

CYSTIC FIBROSIS INHALATION MEDICATION

Patient Diagnosis:

☐ Cystic Fibrosis ☐ Other:_____

(Requires Review by DVHA Medical Director)

Product:

☐ Pulmozyme® (dornase alfa inhalation) 1 mg/ml 2.5 ml ampules

☐ Administer via nebulizer once daily.
Dispense # 30 Refill ____ times

☐ Administer via nebulizer twice daily.
Dispense # 60 Refill ____ times

☐ TOBI® (tobramycin) Podhaler 28 mg capsules
(capsules for use with Podhaler only)

Administer 4 capsules via Podhaler twice daily,
alternating 28 days on and 28 days off

Dispense # 224 Refill ____ times

☐ TOBI® (tobramycin solution for inhalation) 300 mg/5 ml ampules

Administer via nebulizer twice daily,
alternating 28 days on and 28 days off

Dispense # 56 Refill ____ times

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

Dermatological Agents: Actinic Keratosis Therapy

LENGTH OF AUTHORIZATION: Picato: date of service only
All others: 16 weeks

CRITERIA FOR APPROVAL:

Imiquimod (generic) cream:

- The patient has had a documented intolerance to brand Aldara®.

Efudex:

- The patient has had a documented intolerance with generic topical fluorouracil 5% cream or solution

Picato:

- The diagnosis or indication is actinic keratosis

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure with a generic topical fluorouracil product.

OR

- The patient has had a documented side effect, allergy, contraindication or treatment failure with preferred brand Aldara.

Solaraze Gel, Diclofenac Gel:

- The diagnosis or indication is actinic keratosis

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure with generic topical fluorouracil product.

Zyclara Cream:

- The diagnosis or indication is actinic keratosis on the face or scalp

AND

- The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil and Aldara® or generic imiquimod 5% cream.

OR

- The treatment area is greater than 25 cm^2 on the face or scalp.

AND

- The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Actinic Keratosis Therapy

Length of Authorization: Picato: date of service only, All others:16 weeks

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALDARA® (imiquimod) 5 % Cream FLUOROURACIL† (compare to Efudex®) 5% cream, 5%, 2% solution CARAC® (fluorouracil) 0.5% cream FLUOROPLEX® (fluorouracil) 1% cream	Efudex®* (fluorouracil) 5% cream, solution Diclofenac Sodium 3 % Gel (compare to Solaraze®) *Qty Limit = 1 tube/30 days* Imiquimod† (compare to Aldara®) 5 % cream Picato® (ingenol mebutate) 0.015 % Gel *Qty Limit = 3 tubes* Picato® (ingenol mebutate) 0.05 % Gel *Qty Limit = 2 tubes* Solaraze® (diclofenac sodium) 3 % Gel *Qty Limit = 1 tube/30 days* Zyclara (imiquimod) 3.75 % Cream *Qty Limit = 56 packets/6 weeks* Zyclara (imiquimod) 2.5 %, 3.75 % Cream Pump *Qty Limit = 2 pumps/8 weeks*

Dermatological Agents: Antibiotics: Topical

LENGTH OF AUTHORIZATION: for the date of service, no refills

CRITERIA FOR APPROVAL:

Altabax®:

- The patient is being treated for impetigo.

AND

- The patient has had a documented side effect, allergy, or treatment failure with mupirocin ointment

AND

- MRSA (methicillin resistant staph aureus) has been ruled out by culture

Bactroban® Cream or Ointment, mupirocin cream, Centany Ointment:

- The patient has had a documented intolerance with generic mupirocin ointment

AND

- If the request is for brand Bactroban Cream, the patient has also had a documented intolerance to the generic equivalent.

Cortisporin® Cream or Ointment, Gentamicin Cream or Ointment:

- The patient has had a documented side-effect, allergy or treatment failure with at least one preferred generic topical antibiotic

Neosporin®/ Polysporin®:

- The patient has had a documented intolerance with a generic equivalent of the requested medication

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antibiotics: Topical

Length of Authorization: for date of service, no refills

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Single Agent BACITRACIN† MUPIROCIN OINTMENT† (compare to Bactroban®)	Altabax® (retapamulin) *QL = 1 tube* Bactroban® (mupirocin) Cream Bactroban®* (mupirocin) Ointment Centany® Ointment (mupirocin) Gentamicin Cream or Ointment Mupirocin cream† (compare to Bactroban®)
Combination Products BACITRACIN-POLYMYXIN† NEOMYCIN-BACITRACIN-POLYMYXIN†	Cortisporin® Cream (neomycin-polymyxin-hydrocortisone) Cortisporin® Ointment(bacitracin-neomycin-polymyxin-hydrocortisone) Neosporin®* (neomycin-bacitracin-polymyxin) Polysporin®* (bacitracin-polymixin) **All other branded products**

Note: Bactroban® Nasal Ointment is not included in this managed category.

Dermatological Agents: Antifungals: Onychomycosis

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL (CICLOPIROX/PENLAC SOLUTION):

- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, or fungal culture or physician clinical judgment).

AND

- The patient meets at least 1 of the following criteria:
  - Pain to affected area that limits normal activity
  - Diabetes Mellitus
  - Patient is immunocompromised
  - Patient has diagnosis of systemic dermatosis
  - Patient has significant vascular compromise

- For approval of Penlac®, the patient must have a documented intolerance to generic ciclopirox.

LIMITATIONS:
Coverage of Onychomycosis agents will **NOT be approved solely for cosmetic purposes.**
Kits with multiple drug products or non-drug items not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of the non-preferred agent on a **General Prior Authorization Request Form**.

Dermatological Agents: Antifungals: Onychomycosis

Length of Authorization: 1 year
Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
All products require PA.	ciclopirox† 8 % solution (compare to Penlac® Nail Lacquer) *(QL=1 bottle (6.6 ml)/90 days)* Penlac® Nail Lacquer (ciclopirox 8 % solution) *(QL=1 bottle (6.6 ml)/90 days)*

Dermatological Agents: Antifungals: Topical

LENGTH OF AUTHORIZATION: Up to 3 months

All drugs (except Vusion): All indications: 3 months
Vusion: Diaper dermatitis: up to 50 g/month (1 tube) for up to 1 month

CRITERIA FOR APPROVAL:

All Brands (except Vusion):

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO different preferred generic topical antifungal agents. (If a product has an AB rated generic, one trial must be the generic equivalent of the requested product.)

OR

- The patient has a contraindication that supports the need for a specific product or dosage form of a brand topical antifungal.

Ketoconazole Foam:

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO different preferred generic topical antifungal agents.

Vusion®:

- The patient has a diagnosis of diaper dermatitis complicated by documented candidiasis

AND

- The patient is at least 4 weeks of age.

AND

- The patient has had two trials (with two different preferred antifungal agents) used in combination with a zinc oxide diaper rash product resulting in documented side effects, allergy, or treatment failures.

LIMITATIONS:
Foam products (eg Ecoza® (econazole nitrate)) not covered. Other topical dosage preparations preferred.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antifungals: Topical *Length of Authorization: up to 3 months*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Single Agent CICLOPIROX † (compare to Loprox®) 0.77% C, Sus, G; 1%Sh CLOTRIMAZOLE†(formerly Lotrimin®) 1% C, S ECONAZOLE † (formerly Spectazole®) 1% C KETOCONAZOLE † (compare to Kuric®, Nizoral®) 2% C, 2% Sh MICONAZOLE † all generic/OTC products NYSTATIN † O, C, P (compare to Mycostatin®, Nystop®, Pedi-Dri®, Nyamyc®) TOLNAFTATE † (compare to Tinactin®) 1% C, P, Sp, S	Ertaczo® (sertaconazole) 2% C Exelderm® (sulconazole) 1% C, S Extina® (ketoconazole) 2% F Ketoconazole† (compare to Extina®) 2 % Foam Kuric®* (ketoconazole) 2% C Lamisil RX/OTC® (terbinafine) 1% C, S, Sp, G Loprox®* (ciclopirox) 0.77% C, S, G; 1% Sh Lotrimin AF®* OTC (clotrimazole) 1% C, S, L Luzu® (luliconazole) 1% Cream Mentax®/ Lotrimin Ultra® OTC (butenafine) 1% C Mycostatin®* (nystatin) C, P Naftin® (naftifine) 1% & 2% C, 1%, 2% G Nizoral®* (ketoconazole) 2% Sh Nizoral A-D® OTC (ketoconazole) 1% Sh Nystop®, Pedi-Dri®, Nyamyc®* (nystatin) P Oxistat® (oxiconazole) 1% C, L Tinactin®/Tinactin AT OTC* (tolnaftate) 1% C, P, Sp, S Xolegel® (ketoconazole) 2% G **All other branded products**
Combination Products CLOTRIMAZOLE W/BETAMETHASONE † (compare to Lotrisone®) C, L NYSTATIN W/TRIAMCINOLONE † (formerly Mycolog II®) C, O	Lotrisone®* (clotrimazole w/betamethasone) C, L Vusion® (miconazole w/zinc oxide) O *(QL=50 g/30 days)* **All other branded products**

C=cream, F=foam, G=gel, L=lotion, P=powder, S=solution, Sh=shampoo, Sp=spray, Sus=suspension

Note: Please refer to "Anti-Infectives: Antifungals: Topical: Onychomycosis" for ciclopirox solution and Penlac® Nail Lacquer

Dermatological Agents: Antivirals: Topical

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

Denavir®:
- The patient has a diagnosis of oral herpes simplex infection.

Acyclovir, Zovirax®:
- If prescribed for the treatment of oral herpes simplex infection, the patient has had a documented side effect, allergy, or treatment failure (at least one course of four or more days) with Denavir®.
- In addition, for approval of Zovirax® Ointment, the patient has a documented intolerance to generic acyclovir ointment.

LIMITATIONS:
Xerese® (acyclovir/hydrocortisone) 5-1% cream combination not covered. Agents may be prescribed separately.

** Topical antiviral therapy offers minimal clinical benefit in the treatment of genital herpes and its use is discouraged by the CDC so topical antiviral therapy will not be approved for this indication. **

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antivirals: Topical *Length of Authorization: 6 months*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ABREVA OTC (docosanol) 10% C	Acyclovir (compare to Zovirax®) 5 % O Denavir® (penciclovir) 1% C Zovirax® (acyclovir) 5% C, O

C=cream, O=ointment

Dermatological Agents: Corticosteroids

LENGTH OF AUTHORIZATION: For the duration of prescription (up to 6 months)

CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS):

- The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of *similar* potency. (If a product has an AB rated generic, one trial must be the generic.)

LIMITATIONS:
Corticosteroid spray formulations (eg. Topicort® Spray) not covered – use alternate dosage forms.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Dermatological Agents: Corticosteroids

Length of Authorization: up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
LOW POTENCY ALCLOMETASONE 0.05% C, O† (compare to Aclovate®) DESONIDE† 0.05% C, L, O (compare to DesOwen®) FLUOCINOLONE 0.01% C, S oil† (compare to Derma-Smoothe, Synalar®) HYDROCORTISONE† 0.5%, 1%, 2.5% C; 1%, 2.5% L, 0.5%, 1%, 2.5% O HYDROCORTISONE ACETATE† 1% C; 1% O (all generics)	Aclovate®* (alclometasone) 0.05% C, O Capex® (fluocinolone) 0.01% shampoo Derma-Smoothe®* (fluocinolone 0.01%) oil Desonate® (desonide) 0.05% G DesOwen®* (desonide) 0.05% C, L, O Nucort 2% lotion (hydrocortisone acetate) Synalar®* (fluocinolone) 0.01% S Verdeso® (desonide) 0.05% F All other brands
MEDIUM POTENCY BETAMETHASONE DIPROPIONATE† 0.05% L (formerly Diprosome®) BETAMETHASONE VALERATE† 0.1% C, L (formerly Beta-Val®) FLUOCINOLONE† 0.025% C, O (compare to Synalar®) FLUTICASONE † 0.05% C; 0.005% O (compare to Cutivate®) HYDROCORTISONE BUTYRATE† 0.1% C, O, S (compare to Locoid®) HYDROCORTISONE VALERATE† 0.2% C, O (compare to Westcort®) MOMETASONE FUROATE† 0.1% C, L, O (compare to Elocon®) TRIAMCINOLONE ACETONIDE† 0.025%, 0.1% C, L, O (formerly Aristocort®, Kenalog®)	Cloderm® (clocortolone) 0.1% C Cordran® (all products) Cutivate®*(fluticasone) 0.05% C; 0.005% O Cutivate®(fluticasone) 0.05% L Dermatop® (prednicarbate) 0.1% C, O desoximetasone 0.05% C, O (compare to Topicort®) Elocon®* (all products) fluticasone† (compare to Cutivate®) 0.05% L Locoid®* (hydrocortisone butyrate) 0.1% C, O, S Locoid® (hydrocortisone butyrate) 0.1% L Luxiq® (betamethasone valerate) F prednicarbate† (compare to Dermatop®) 0.1% C, O Synalar®* (fluocinolone) 0.025% C, O Topicort®* (desoximetasone) 0.05% C, O Trianex®* (triamcinolone) 0.05% O Westcort®* (hydrocortisone valerate) all products All other brands
HIGH POTENCY AMCINONIDE† (formerly Cyclocort®) AUGMENTED BETAMETHASONE† 0.05% C (compare to Diprolene® AF) BETAMETHASONE VALERATE† 0.1% O (formerly Beta-Val®) DESOXIMETASONE† 0.05% G; 0.25% C, O (compare to Topicort®) FLUOCINONIDE† 0.05% C, G, O, S (formerly Lidex®) TRIAMCINOLONE ACETONIDE† 0.5% C, O (formerly Aristocort®)	Apexicon E® (diflorasone) 0.05% C Diflorasone diacetate 0.05% C (compare to Apexicon E®) Diprolene® AF* (augmented betamethasone) 0.05% C Halog® (halcinonide) all products Topicort®* (desoximetasone) 0.05% G; 0.25% C, O All other brands
VERY HIGH POTENCY ALPHATREX (augmented betamethasone) 0.05% G APEXICON (diflorasone) 0.05% O AUGMENTED BETAMETHASONE† 0.05% L, O (compare to Diprolene®), 0.05% G CLOBETASOL PROPIONATE† (compare to Temovate®/Cormax®) CLOBETASOL PROPIONATE† 0.05% F (compare to Olux®) CORMAX (clobetasol propionate) 0.05% C, O, S DIFLORASONE DIACETATE† 0.05% O (compare to Apexicon®, formerly Psorcon E®) HALOBETASOL PROPRIONATE† (compare to Ultravate®)	Clobetasol propionate† (compare to Clobex®) 0.05% L, Sh clobetasol propionate emulsionn† (compare to Olux E®) 0.05% F Clobex® (clobetasol propionate) 0.05% L, shampoo, spray Diprolene®* (augmented betamethasone) 0.05% L, O fluocinonide † (compare to Vanos®)0.1% C Olux® * /Olux E® (clobetasol propionate) 0.05% F Temovate®* (clobetasol propionate) 0.05% C, G, O, S Vanos® (fluocinonide) 0.1% C Ultravate®* (halobetasol propionate) 0.05% C, O All other brands

C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution

Dermatological Agents: Genital Wart Therapy

LENGTH OF AUTHORIZATION: up to 16 weeks

Veregen, imiquimod: up to 16 weeks

Zyclara: up to 8 weeks

All other products: up to 1 month

CRITERIA FOR APPROVAL:

Condylox® gel, Veregan®:

- The patient has had a documented side effect, allergy, or treatment failure with Aldara®.

Condylox®* solution:

- The patient has had a documented intolerance to generic podofilox solution.

Imiquimod (generic) cream:

- The patient has had a documented intolerance to brand Aldara®.

Zyclara® cream:

- The diagnosis or indication is external genital/perianal warts or condyloma acuminata

AND

- The patient has had a documented side effect or treatment failure with Aldara®

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Dermatological Agents: Genital Wart Therapy *Length of Authorization: up to 16 weeks*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALDARA® (imiquimod 5%)	Imiquimod† 5 %(compare to Aldara®) cream
PODOFILOX SOLUTION† (compare to Condylox®)	Condylox® Gel (podofilox gel) Condylox®* solution (podofilox solution) Veregan® (sinecatechins ointment) *(Quantity limit = 15 grams (1 tube)/per 30 days)* Zyclara® (imiquimod 3.75%) Cream *(Quantity limit = 56 packets/per 8 weeks)* Zyclara® (imiquimod 3.75%) Cream Pump *(Quantity limit = 2 pumps/per 8 weeks)*

Dermatological Agents: Immunomodulators

At the September 2006 meeting of the DUR Board, the class of topical immunomodulators was reviewed for efficacy and safety. Included in this review was the January 20, 2006, U.S. Food and Drug Administration (FDA) updated labeling and March 17, 2005 FDA Public Health Advisory regarding Elidel® Cream (pimecrolimus) and Protopic® Ointment (tacrolimus). The labeling changes include a BOXED WARNING about the possible risk of cancer and a medication guide that is to be distributed with each prescription to ensure that the parents of patients using these medications are aware of this concern. Although a causal link has not been established, rare reports of cancer (e.g. skin and lymphoma) have been reported in patients who had been receiving these products. The FDA has advised that Protopic® and Elidel® be used only as labeled. The new labeling clarifies that these drugs are recommended for use as *second-line* treatments for the short-term and non-continuous chronic treatment of mild to moderate (Elidel® Cream) or moderate to severe (Protopic® Ointment) atopic dermatitis. The FDA also advises clinicians to avoid use in children less than 2 years of age.

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL:

Age < 2 years (requests will be approved for up to 6 months):

- The patient has a diagnosis of atopic dermatitis (eczema). AND
- The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND
- The quantity requested does not exceed 30 grams/fill and 90 grams/6 months.

Age > 2 years (requests will be approved for up to 1 year):

- The patient has a diagnosis of atopic dermatitis (eczema). AND
- The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND
- The quantity requested does not exceed 30 grams/fill and 90 grams/6 months.

Dermatological Agents: Immunomodulators *Length of Authorization: up to 1 year*

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

NO PA REQUIRED *(For age > 2 after prerequisite trial of one topical corticosteroid)*	PA REQUIRED
ELIDEL® Cream (pimecrolimus) § *(Quantity Limit = 30 grams/fill and 90 grams/6 months)* **PROTOPIC® Ointment (tacrolimus)** § *(Quantity Limit = 30 grams/fill and 90 grams/6 months)* Note: Protopic ointment concentration limited to 0.03% for age < 16 years old.	**Elidel® Cream (pimecrolimus)** age < 2 years *(Quantity Limit = 30 grams/fill and 90 grams/6 months)* **Protopic® Ointment (tacrolimus)** age < 2 years *(Quantity Limit = 30 grams/fill and 90 grams/6 months)* Note: Protopic ointment concentration limited to 0.03% for age < 16 years old.

Dermatological Agents: Scabicides and Pediculicides

LENGTH OF AUTHORIZATION: date of service only, no refills

CRITERIA FOR APPROVAL:

NON-PREFERRED SCABICIDES:

- The patient has had a documented side effect or allergy to permethrin cream or treatment failure with two treatments of permethrin cream.

PEDICULICIDES:

Natroba:

- The patient has had a documented side effect or allergy to OTC permethrin and piperonyl butoxide and pyrethrins or treatment failure with two treatments of OTC permethrin or piperonyl butoxide and pyrethrins.

Non-Preferred Pediculicides:

- The patient has had a documented side effect or allergy to OTC permethrin and piperonyl butoxide and pyrethrins and Natroba or treatment failure with two treatments of OTC permethrin and/or piperonyl butoxide and pyrethrins and one treatment of Natroba.
- For approval of Ovide® Lotion, the patient must also have a documented intolerance to the generic equivalent product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Dermatological Agents: Scabicides and Pediculicides *Length of Authorization: date of service only, no refills*

Key: † Generic product, *Indicates generic equivalent is available without a PA, § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SCABICIDES	
ACTICIN† (permethrin 5 %) *C*	Eurax® (crotamiton 10 %) *C, L*
PERMETHRIN† 5 % (compare to Elimite®) *C*	Lindane† *L*
PEDICULICIDES (lice treatment)	
PERMETHRIN† 1 % *CR, L*	Lindane† *Sh*
PIPERONYL BUTOXIDE AND PYRETHRINS† *G, S, Sh*	Malathion †*L* (compare to Ovide®)
	Ovide® (malathion) *L*
	Sklice® (Ivermectin 0.5 %) *L*
Preferred after clinical criteria are met (2 Preferred Pediculocide treatments first)	Spinosad† (compare to Natroba) *Ss*
NATROBA® (spinosad 0.9 %) *Ss* **§**	Ulesfia® (benzyl alcohol 5%) *L*
	All other brand and generic Scabicides and Pediculicides

C=cream, CR=crème rinse, G=gel, L=lotion, S=solution, Sh=shampoo, Sp=spray, Ss=suspension

Desmopressin: Intranasal/Oral

LENGTH OF AUTHORIZATION: 2 years

CRITERIA FOR APPROVAL: Intranasal

- The diagnosis or indication for the requested medication is (1) Diabetes Insipidus, (2) hemophilia type A, or (3) Von Willebrand disease

AND

- If the request is for brand DDAVP, the patient has a documented intolerance to generic desmopressin spray or solution.

CRITERIA FOR APPROVAL: non-preferred oral

- The diagnosis or indication for the requested medication is (1) Diabetes Insipidus and/or (2) primary nocturnal enuresis

AND

- The patient has had a documented intolerance to generic desmopressin tablets

LIMITATIONS:
Desmopressin intranasal formulations will not be approved for the treatment of primary nocturnal enuresis (PNE) due to safety risks of hyponatremia. Oral tablets may be prescribed for this indication.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Desmopressin: Intranasal *Length of Authorization: 2 years* Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
Intranasal **All products require PA.**	DDAVP® (desmopressin) Nasal Solution or Spray 0.01% Desmopressin † Nasal Solution or Spray 0.01 % (compare to DDAVP®) Minirin † (desmopressin) Nasal Spray 0.01% Stimate® (desmopressin) Nasal Solution 1.5 mg/ml
Oral	
DESMOPRESSIN†	DDAVP®* (desmopressin) tablets

Diabetic Testing Supplies

LENGTH OF AUTHORIZATION: 5 years

CRITERIA FOR APPROVAL:

- The prescriber demonstrates that the patient has a medical necessity for clinically significant features that are not available on any of the preferred meters/test strips.

LIMITATIONS:
Talking monitors are not covered under the pharmacy benefit.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Diabetic Testing Supplies	*Length of Authorization:5 years*
PREFERRED PRODUCTS (No PA Required)	**PA REQUIRED**
DIABETIC MONITORS/METERS FREESTYLE LITE® SYSTEM KIT FREESTYLE FREEDOM LITE® SYSTEM KIT FREESTYLE INSULINX® SYSTEM KIT *QL – 1 meter/3 years* ONE TOUCH® ULTRA 2 KIT ONE TOUCH® ULTRA MINI KIT ONE TOUCH® ULTRA SMART KIT PRECISION XTRA® SYSTEM KIT	Accucheck® Ascensia® Assure® Exactech® Prodigy® All other brands and store brands
DIABETIC TEST STRIPS FREESTYLE®* FREESTYLE INSULINX®* FREESTYLE LITE®* ONE TOUCH® ULTRA* PRECISION XTRA®* PRECISION XTRA® BETA KETONE (10 count)	Accucheck® Ascensia® Assure® Exactech® Prodigy® All other brands and store brands
LANCETS All brands and store brands	

* 50 and 100 count package sizes

Epinephrine: Auto-injector

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

The patient has a documented intolerance to the preferred product.

Epinephrine: Auto-injector

Length of Authorization: 1 year

PREFERRED DRUGS (No PA Required)	PA REQUIRED
EPIPEN® 2-PAK INJ 0.3 MG (epinephrine 0.3 mg/0.3 ml (1:1000)) EPIPEN-JR® 2-PAK INJ 0.15 MG (epinephrine 0.15 mg/0.3 ml (1:2000))	All other branded and generic products.

Estrogens: Vaginal

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Estrogens: Vaginal	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
Estradiol ESTRACE VAGINAL® Cream ESTRING® Vaginal Ring VAGIFEM® Vaginal Tablets **Conjugated Estrogens** PREMARIN VAGINAL® Cream **Estradiol Acetate** FEMRING® Vaginal Ring	

Fibromyalgia Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Savella®:

- The diagnosis or indication is treatment of fibromyalgia.

AND

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Lyrica®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Fibromyalgia Agents	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
	Savella® (milnacipran) tablet, titration pack *Quantity Limit = 2 tablets/day*

Note: Please refer to "Anticonvulsants" for clinical criteria for **Lyrica®** and "Anti-Depressants – SNRIs" for clinical criteria for **Cymbalta®**.

Gastrointestinals: Crohn's Disease Medications: Injectables

***NOTE*: Crohn's Disease Self-Injectables (Humira® and Cimzia®) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Humira and Cimzia Prior Authorization/Patient Enrollment Form for instructions. Briova may supply Remicade® upon request or you may continue to obtain through your usual supplier. Briova will not be supplying Tysabri® at this time – please continue to obtain through your usual supplier.**

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira®, Remicade®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on the medication.

OR

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

Note: Humira® and Cimzia have been shown to be effective in patients who have been treated with infliximab but have lost response to therapy.

Cimzia®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on Cimzia®

OR

Patient age > 18 years

AND

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

AND

The prescriber must provide a clinically valid reason why Humira® cannot be used.

Tysabri®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on Tysabri®.

OR

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

AND

The patient has a documented side effect, allergy, treatment failure, or contraindication to BOTH, Remicade® and Humira®,

DOCUMENTATION:

- ✓ Document clinical information for **Humira®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form** or **Cimzia®** on its **Prior Authorization/Patient Enrollment Form** or **Tysabri®** on a **General Prior Authorization Request Form**.

- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or natalizumab (Tysabri®) (whether billed through the pharmacy or medical benefit (J2323)) require Prior Authorization through the Catamaran Clinical Call Center.

Gastrointestinals: Crohn's Disease: Injectables

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
HUMIRA® (adalimumab) *Quantity limit = 6 syringes/28 days for the first month (Crohn's starter kit);2 syringes/28 days subsequently* REMICADE® (infliximab)	Cimzia® (certolizumab pegol) *Quantity limit = 1 kit/28 days (starter X 1, then regular)* Tysabri® (natalizumab)

Gastrointestinals: H.Pylori Combination Therapy

LENGTH OF AUTHORIZATION: Date of service only

CRITERIA FOR APPROVAL:

- The patient has a documented treatment failure with combinations of individual proton pump inhibitors or H2 antagonists given together with two appropriate antibiotics

  OR
- The patient has been unable to be compliant with individual agents prescribed separately.

  AND
- For approval of brand Prevpac®, the patient has a documented intolerance to the generic equivalent combination product.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Gastrointestinals: H.Pylori Combination Therapy

Length of Authorization: Date of service only

PREFERRED DRUGS (No PA Required)	PA REQUIRED, any dose
	Helidac® (bismuth subsalicylate, metronidazole, tetracycline) *(Quantity limit=224 caps & tabs/14 days)* Lansoprazole, amoxicillin, clarithromycin (compare to Prevpac®) *(Quantity limit = 112 caps & tabs/14 days)* Omeclamox-Pak® (omeprazole, clarithromycin, amoxicillin) *(Quantity limit = 80 caps & tabs/10 days)* Prevpac® (lansoprazole, amoxicillin, clarithromycin) *(Quantity limit = 112 caps & tabs/14 days)* Pylera® (bismuth subcitrate, metronidazole, tetracycline) capsules (*Quantity limit=120 capsules/10 days)*

Gastrointestinals: Histamine-2 Receptor Antagonists

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Axid®capsule, nizatidine capsule, Pepcid® tablet, ranitidine capsule, Tagamet® tablet, Zantac®tablets:

- The patient has had a documented side effect, allergy, or treatment failure to at least one preferred medication. If a medication has an AB rated generic, the trial must be the generic formulation. For approval of ranitidine capsules, the patient must have had a trial of ranitidine tablets.

Axid® Oral Solution, Famotidine Oral Suspension, Nizatidine Oral Solution, Pepcid® Oral Suspension, Zantac® Effervescent, Zantac® Oral Syrup:

- The patient has had a documented side effect, allergy, or treatment failure to ranitidine syrup or cimetidine oral solution. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

Gastrointestinals: Histamine-2 Receptor Antagonists

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CIMETIDINE† (compare to Tagamet®) tablet FAMOTIDINE† (compare to Pepcid®) tablet RANITIDINE† (compare to Zantac®) tablet	Axid® (nizatidine) capsule § nizatidine† (compare to Axid®) capsule § Pepcid®* (famotidine) tablet§ ranitidine† capsule § Tagamet®* (cimetidine) tablet § Zantac®* (ranitidine) tablet §
SYRUP & SPECIAL DOSAGE FORMS CIMETIDINE † ORAL SOLUTION RANITIDNE † syrup (compare to Zantac®)	Axid® (nizatidine) Oral Solution § famotidine† (compare to Pepcid®) oral suspension § Nizatidine †Oral Solution (compare to Axid®) Pepcid® (famotidine) Oral Suspension § Zantac (ranitidine) Effervescent® § Zantac®* (ranitidine) Syrup§

Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Azulfidine®*, Colazal®*:

- The patient has had a documented intolerance to the generic equivalent of the requested medication.

Asacol HD®:

- The patient has had a documented side effect, allergy, or treatment failure with two (2) preferred oral mesalamine products.

Entocort EC®:

The patient had a documented intolerance to the generic budesonide 24 hr capsules.

Giazo®:

- The diagnosis is ulcerative colitis

  AND
- The patient is male and ≥ 18 years old.

  AND
- The patient has a documented intolerance to generic balsalazide.

Sfrowasa®:

- The patient has had a documented intolerance to mesalamine enema.

LIMITATIONS:

Kits with non-drug products are not covered.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
MESALAMINE PRODUCTS **Oral** APRISO® (mesalamine capsule extended-release) ASACOL® (mesalamine tablet delayed-release) DELZICOL® (mesalamine capsule delayed-release) *QL = 6 capsules/day* LIALDA® (mesalamine tablet extended-release) PENTASA® (mesalamine cap CR)	Asacol HD® (mesalamine tablet delayed release)
Rectal CANASA® (mesalamine suppository) MESALAMINE ENEMA† (formerly Rowasa®)	Sfrowasa® (mesalamine enema sulfite free)
CORTICOSTEROIDS **Oral** BUDESONIDE 24HR (compare to Entocort EC®) *QL = 3 capsules/day* UCERIS® (budesonide) ER Tablet *QL = 1 tablet/day*	Entocort EC®* (budesonide 24 hr cap) *QL = 3 capsules/day*
OTHER BALSALAZIDE† (compare to Colazal®) DIPENTUM® (olsalazine) SULFASALAZINE† (compare to Azulfidine®)	Azulfidine®* (sulfasalazine) Colazal®* (balsalazide) Giazo (balsalazide disodium) tablet *QL = 6 tablets/day*

Gastrointestinals: Prokinetic Agents

LENGTH OF AUTHORIZATION: Up to 3 months

CRITERIA FOR APPROVAL:

Metozolv ODT®

- The patient has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder, inability to take oral medications)

AND

- Generic metoclopramide oral solution cannot be used

Reglan®

- The patient has had a documented intolerance to generic metoclopramide tablets.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Gastrointestinals: Prokinetic Agents ***Length of Authorization: up to 3 months***	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
Tablets METOCLOPRAMIDE† tabs (compare to Reglan®)	Reglan®* (metoclopramide)
Oral Solution METOCLOPRAMIDE† (formerly Reglan®) oral solution	
Orally Disintegrating Tablets	Metozolv ODT® (metoclopramide) *(QL= 4 tabs/day)*

Gastrointestinals: Proton Pump Inhibitors

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL:

Nexium powder for suspension, Prevacid Solutabs (for patients ≥ 12 years old), Prilosec packet, Protonix packet

- The patient has a requirement for a non-solid oral dosage form (e.g. an oral liquid, dissolving tablet or sprinkle).

Aciphex Sprinkle

- The patient has a requirement for a non-solid oral dosage form

AND

- The member has had a documented side effect, allergy, or treatment failure to omeprazole capsule opened and sprinkled, omeprazole or lansoprazole suspension or Prevacid solutab.

Other non-preferred medications:

- The member has had a documented side effect, allergy, or treatment failure to Omeprazole RX 20 mg or 40 mg generic capsules AND Pantoprazole generic tablets.

- If the request is for Prevacid 24 hr OTC or Prevacid RX, the patient must also have a documented intolerance to lansoprazole generic RX capsules. If the request is for brand Zegerid OTC capsules, the patient must also have a documented intolerance to the generic equivalent.

CRITERIA FOR APPROVAL (twice daily dosing):

- Gastroesophageal Reflux Disease (GERD) – If member has had an adequate trial (e.g. 8 weeks) of standard once daily dosing for GERD, twice daily dosing may be approved.

- Zollinger-Ellison (ZE) syndrome – Up to triple dose PPI may be approved.

- Hypersecretory conditions (endocrine adenomas or systemic mastocytosis) – Double dose PPI may be approved.

- Erosive Esophagitis, Esophageal stricture, Barrett's esophagitis (complicated GERD) – Double dose PPI may be approved.

- Treatment of ulcers caused by H. Pylori – Double dose PPI may be approved for up to 2 weeks.

- Laryngopharyngeal reflux – Double dose PPI may be approved.

LIMITATIONS:

Zegerid® (omeprazole/sodium bicarbonate) RX capsules, powder for suspension not covered as no Federal Rebate offered.
First-Lansoprazole® and First-Omeprazole® Suspension Kits not covered as Federal Rebate no longer offered.
Nexium 24HR OTC (esomeprazole) capsules OTC Plan Exclusion - these products are not covered

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Gastrointestinals: PPIs

Length of Authorization: 1 year

Key: † Generic product

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED, any dose
ORAL CAPULES/TABLETS OMEPRAZOLE† 20 mg or 40 mg RX capsule (compare to Prilosec®) *(Quantity limit = 1 capsule/day)* PANTOPRAZOLE† tablets (compare to Protonix®) *(Quantity limit=1 tab/day)*	Aciphex® (rabeprazole) tablets § *(Quantity limit=1 tab/day)* Dexilant® (dexlansoprazole) capsules *(Quantity limit=1 cap/day)* Esomeprazole® Strontium capsules *(Quantity limit = 1 cap/day)* lansoprazole generic RX (compare to Prevacid®) § capsules *(Quantity limit = 1 cap/day)* Nexium® (esomeprazole) capsules § *(Quantity limit=1 cap/day)* omeprazole †♣ generic 10 mg RX (compare to Prilosec®) capsules § *(Quantity limit=1 cap/day)* omeprazole † generic OTC tablets *(Quantity limit=1 tab/day)* omeprazole magnesium† generic OTC 20 mg capsules§ *(Quantity limit=1 cap/day)* omeprazole/sodium bicarb) capsules RX (compare to Zegerid®RX) *(Quantity limit=1 cap/day)* omeprazole/sodium bicarb† (compare to Zegerid OTC®) capsules *(Quantity limit=1 cap/day)* Prevacid® RX (lansoprazole) capsules *(Quantity limit=1 cap/day)* Prevacid® 24 hr OTC (lansoprazole) capsules *(Quantity limit=1 cap/day)* Prilosec OTC® 20mg (omeprazole magnesium) tablets *(Quantity limit = 1 tablet/day)* Prilosec®* RX (omeprazole) capsules *(Quantity limit=1 cap/day)* Protonix®* (pantoprazole) tablets *(Quantity limit=1 tab/day)* rabeprazole † (compare to Aciphex®) tablets *(Quantity limit = 1 tab/day)* Zegerid OTC® (omeprazole/sodium bicarb)caps *(Quantity limit=1 cap/day)*
SUSPENSION & SPECIAL DOSAGE FORMS	Aciphex® Sprinkle (rabeprazole) DR Capsule *(Quantity limit=1 cap/day)* Nexium® (esomeprazole) powder for suspension *(Quantity limit=1 packet/day)* Prevacid Solutabs®♠ (lansoprazole) *(Quantity limit=1 tab/day)* Prilosec (omeprazole magnesium) packet *(Quantity limit=2 packets/day)* Protonix® (pantoprazole) packet *(Quantity limit=1 packet/day)*

♣No PA required for patients < 16 years ♠ No PA required for patients < 12 years

Gastrointestinals: Ulcerative Colitis Medications: Injectables

NOTE: Ulcerative Colitis Self-Injectable (Humira® and Simponi®) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Humira or Simponi Prior Authorization/Patient Enrollment Form for instructions. Briova Specialty may supply Remicade® upon request or you may continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira®, Remicade®

Patient has a diagnosis of Ulcerative Colitis and has already been stabilized on the medication.

OR

The patient has a diagnosis of Ulcerative Colitis and has had a documented side effect, allergy, or treatment failure with at least 2 of the following 3 agents: aminosalicylates (e.g. sulfasalazine, mesalamine, etc.), corticosteroids, or immunomodulators (e.g. azathioprine, 6-mercaptopurine, cyclosporine, etc.).

Simponi®

Patient has a diagnosis of Ulcerative Colitis and has already been stabilized on Simponi®

OR

Patient age $\geq$ 18 years

AND

Patient has a diagnosis is Ulcerative Colitis and has demonstrated corticosteroid dependence or has had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

AND

The prescriber must provide a clinically valid reason why Humira® cannot be used.

DOCUMENTATION:

- ✓ Document clinical information for **Humira®** or **Simponi®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form**
- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) require Prior Authorization through the Catamaran Clinical Call Center.

Gastrointestinals: Ulcerative Colitis Medications: Injectables

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
HUMIRA® (adalimumab) *Quantity limit = 6 syringes/28 days for the first month (starter kit);2 syringes/28 days subsequently* REMICADE® (infliximab)	Simponi® (golimumab) Subcutaneous *(Quantity Limit = 3 of 100 mg prefilled syringe or autoinjector X 1,then 1 of 100 mg/28 days)*

Gaucher Disease Medications

LENGTH OF AUTHORIZATION: initial approval 6 months, subsequent approval 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is Gaucher disease (GD) type I.

AND

- The diagnosis has been confirmed by molecular or enzymatic testing.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a PA required agent on a **General Prior Authorization Request Form**.
- ✓ All requests for imiglucerase (Cerezyme®) (J1786), Elelyso (taliglucerase) (C9294) or Vpriv (velaglucerase) (J3385) (whether billed through the pharmacy or medical benefit) require Prior Authorization through the Catamaran Clinical Call Center.

Gaucher Disease Medications

Length of Authorization: initial approval 6 months, subsequent approval 1 year

NO PA REQUIRED	PA REQUIRED
All products require PA.	Cerezyme® (imiglucerase for injection) Elelyso® (taliglucerase alfa for injection) Vpriv® (velaglucerase alfa for injection) ****Maximum days' supply per fill for all drugs is 14 days****

Gout Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Colcrys®:

- The diagnosis or indication for the requested medication is Familial Mediterranean Fever (FMF)

OR

- The diagnosis or indication for the requested medication is gout

AND

- The patient has had a documented side effect or treatment failure with at least one drug from the NSAID class.

OR

- The patient is not a candidate for therapy with at least one drug from the NSAID class due to one of the following:
  - The patient is 60 years of age or older
  - Patient has a history of GI bleed
  - Patient is currently taking an anticoagulant (warfarin or heparin)
  - Patient is currently taking an oral corticosteroid
  - Patient is currently taking methotrexate

Krystexxa®:

- The diagnosis or indication is treatment of chronic gout.

AND

- The patient has had a documented side effect, allergy, treatment failure or a contraindication to BOTH allopurinol and febuxostat. NOTE: Treatment failure is defined as inability to reduce serum uric acid levels to < 6 mg/dl with allopurinol doses of 600 mg/day taken consistently. Additionally, renal impairment is not considered a contraindication to allopurinol use.

Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

Uloric®:

- The diagnosis or indication is treatment of gout.

AND

- The patient has had a documented side effect, allergy, treatment failure or a contraindication to allopurinol. NOTE: Treatment failure is defined as inability to reduce serum uric acid levels to < 6 mg/dl with allopurinol doses of 600 mg/day taken consistently. Additionally, renal impairment is not considered a contraindication to allopurinol use.

Zyloprim®:

- The patient has had a documented intolerance to generic allopurinol.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.
- ✓ All requests for pegloticase (Krystexxa®) (J2507) (must be billed through the medical benefit) require Prior Authorization through the Catamaran Clinical Call Center.

Gout Agents:

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE INGREDIENT COLCHICINE	Colcrys® (colchicine) tablet *QL = 3 tablets/day (gout) or 4 tablets/day (FMF)*
SINGLE INGREDIENT URICOSURIC AGENTS PROBENECID†	
XANTHINE OXIDASE INHIBITORS ALLOPURINOL† (compare to Zyloprim®)	Uloric® (febuxostat) *QL (40 mg tablets) = 1 tablet/day* Zyloprim®* (allopurinol)
COMBINATION PRODUCTS COLCHICINE/PROBENECID†	
PEG-URICASE AGENTS	Krystexxa (pegloticase) Vials for IV Infusion *QL = 2 vials/28 days*

Note: Please see Analgesics: Cox-II Inhibitors and NSAID for preferred NSAID options

Growth Stimulating Agents

***NOTE:* These drugs must be obtained and billed through our specialty pharmacy vendor, Briova. Please see Growth Stimulating Agents Prior Authorization/Enrollment Form for instructions.**

GROWTH HORMONE

►See next pages for growth hormone products.

LENGTH OF AUTHORIZATION: Up to 1 year

CRITERIA FOR APPROVAL:

PEDIATRIC:
1) The patient must have one of the following indications for growth hormone:

- Turner syndrome confirmed by genetic testing.
- Prader-Willi Syndrome confirmed by genetic testing.
- Growth deficiency due to chronic renal failure.
- Patient who is Small for Gestational Age (SGA) due to Intrauterine Growth Retardation (IUGR)and catch up growth not achieved by age 2 (Birth weight less than 2500g at gestational age of <37 weeks or a birth weight or length below the 3rd percentile for gestational age).

OR

- Pediatric Growth Hormone Deficiency confirmed by results of two provocative growth hormone stimulation tests (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <10ng/ml.

2) The requested medication must be prescribed by a pediatric endocrinologist (or pediatric nephrologist if prescribed for growth deficiency due to chronic renal failure).

3) Confirmation of non-closure of epiphyseal plates (x-ray determining bone age) must be provided for females > age 12 and males > age 14.

4) Initial requests can be approved for 6 months. Subsequent requests can be approved for up to 1 year with documentation of positive response to treatment with growth hormone.

ADULT:
The patient must have one of the following indications for growth hormone:

- Panhypopituitarism due to surgical or radiological eradication of the pituitary.

OR

- Adult Growth Hormone Deficiency confirmed by one growth hormone stimulation test (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <5ng/ml. Growth hormone deficient children must be retested after completion of growth.

LIMITATIONS:
Coverage of Growth Hormone products will not be approved for patients who have Idiopathic Short Stature.

GENOTROPIN®, HUMATROPE®, NUTROPIN®, NUTROPIN® AQ, OMNITROPE®, SAIZEN®, TEV-TROPIN®

- The patient has a documented side effect, allergy, or treatment failure to Norditropin

- **INCRELEX®**

INDICATION: Long-term treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD)

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

- Member has growth hormone gene deletion AND neutralizing antibodies to growth hormone, OR primary insulin-like growth factor (IGF-1) deficiency (IGFD), defined by the following:
  - Height standard deviation score < -3 AND
  - Basal IGF-1 standard deviation score < -3 AND
  - Normal or elevated growth hormone level
- Member is ≥ 2 years old (safety and efficacy has not been established in patients younger than 2), AND
- Member has open epiphysis, AND
- Member is under the care of an endocrinologist or other specialist trained to diagnose and treat growth disorders.

- **SEROSTIM®**

INDICATION: AIDS associated wasting/anorexia

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

- A diagnosis of AIDS associated wasting/anorexia

- **ZORBTIVE®**

INDICATION: Short Bowel Syndrome

LENGTH OF AUTHORIZATION: 4 weeks

CRITERIA FOR APPROVAL:

- A diagnosis of short bowel syndrome
- Concomitant use of specialized nutritional support (specialty TPN)
- Prescription by gastroenterologist (specialist)

DOCUMENTATION:

✓ Document information for the indication of the use of these medications on a **Growth Stimulating Agents Prior Authorization/Enrollment Form**.

Growth Stimulating Agents	*Length of Authorization: up to1 year*
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	**NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**
NORDITROPIN®	Genotropin® Humatrope® Nutropin®/Nutropin® AQ Omnitrope® Saizen® Tev-Tropin® **Specialized Indications – See Specific Criteria** Increlex® (mecasermin) Serostim® Zorbtive®

VERMONT

GROWTH STIMULATING AGENTS - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access GROWTH STIMULATING AGENTS PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

Requested DVHA **PREFERRED** Growth Stimulating Agent

☐ Norditropin®

Growth Hormone Stimulation Test # 1	Test:	result:
Growth Hormone Stimulation Test # 2	Test:	result:
Patient's Height:		
Patient's Bone Age:		
Patient's Chronological Age:		
Growth Velocity:		
IGF-1 results:		

Please explain the medical necessity for a **'NON-PREFERRED'** product:

☐ Genotropin® ☐ Humatrope® ☐ Nutropin® ☐ Omnitrope® ☐ Saizen® ☐ Tev-Tropin®

Medical justification: _____

_____

Request is for a **'SPECIALIZED INDICATION'** product: (Criteria in Clinical Criteria Manual)

☐ Increlex® ☐ Serostim® ☐ Zorbtive®

Other information/ Prescriber comments:

4 PRESCRIPTION

☐ Norditropin® FlexPro 5 mg/1.5 ml ☐ Norditropin® FlexPro 10 mg/1.5 ml

☐ Norditropin® FlexPro 15 mg/1.5 ml ☐ Norditropin® NordiFlex 30 mg/3 ml

☐ Other Product: (Please Specify) _____

Dosage Form / Strength: _____

Dose/Route & Frequency (Sig): _____

Dispense Quantity: ☐ One month supply or _____ Refill X _____

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

HEMOPHILIA FACTORS - Patient Enrollment and Prescription Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access PRESCRIPTION HEMOPHILIA FACTORS

Patient Diagnosis:

☐ Hemophilia A – Factor VIII Disease

☐ Hemophilia B – Factor IX Disease

☐ von Willebrand Disease

Patient Weight (kg):	Native Factor Level:

Product Name:

Dose / Frequency Instructions:

# of doses ordered: _____ Refills: _____

If doses of different units are ordered, specific number of doses of each

Reason(s) for Use:

☐ Prophylaxis only ☐ Episodic only ☐ Prophylaxis and PRN

☐ Acute Bleeding Episode ☐ Surgical Prophylaxis ☐ Dental Procedure

Recent bleed while on Prophylaxis:

Date of bleed: _____/_____/_____

Location of bleed:_____ Severity of bleed:_____

# of Doses already administered prior to this order:_____ IU/Dose:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

☐ Needles/syringes: quantity sufficient for factor supply

Prescriber's Signature: _____ **Date:** _____

Hepatitis C Medications

***NOTE:* These drugs must be obtained and billed through our specialty pharmacy vendor, Briova. Please see Hepatitis C Medications Prior Authorization/Enrollment Form and Hepatitis C Supplemental Clinical Form for instructions. Both forms must be completed and a recent clinical note must accompany the request. All requests will be reviewed on a case by case basis by the DVHA Medical Director. Combination therapy will be either approved or denied in its entirety.**

LENGTH OF AUTHORIZATION (maximum): Ribavirin/Peg-interferon = 48 weeks; Olysio = 12 weeks, Sovaldi = 12, 16 or 24 weeks (48 weeks if hepatocellular carcinoma), Incivek = 12 weeks; Victrelis = 44 weeks

CRITERIA FOR APPROVAL:

Preferred Ribavirin and Pegasys

- The diagnosis or indication for the requested medication is Hepatitis C.

AND

- The prescriber is, or has consulted with, a Gastroenterologist or Infectious Disease Specialist.

AND

- DVHA Medical Director will review case details to determine eligibility for requested medication.

Non-preferred Ribavirin Brands/Strengths

- The diagnosis or indication for the requested medication is Hepatitis C.

AND

- The patient has a documented intolerance to generic ribavirin 200 mg tablets.

Rebetol® Oral Solution

- The diagnosis or indication for the requested medication is Hepatitis C.

AND

- The patient is unable to use generic ribavirin 200 mg tablets.

Peg-Intron®

- The diagnosis or indication for the requested medication is Hepatitis C.

AND

- The patient has had a documented side effect, allergy, or treatment failure to Pegasys®.

Olysio® (simeprevir) or Sovaldi (sofosbuvir)

- The diagnosis or indication for the requested medication is Hepatitis C.

AND

- DVHA Medical Director will review case details to determine eligibility for requested medication.

Incivek® (telaprevir) or Victrelis® (boceprevir)

- The diagnosis or indication for the requested medication is hepatitis C (genotype 1) (however, these medications are no longer considered standard of care.)

AND

- DVHA Medical Director will review case details to determine eligibility for requested medication.

DOCUMENTATION:

- ✓ Document information for the indication of the use of these medications on a **Hepatitis C Medications Order/Patient Enrollment Form** and **Hepatitis C Supplemental Clinical Form. Include a recent clinical note.**

Hepatitis C Medications

Length of Authorization: up to 48 weeks

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
RIBAVIRIN	
Tablets/Capsules RIBAVIRIN† 200 mg tabletsRIBASPHERE† 200 mg tablets	Copegus®* (ribavirin 200 mg tablet) Moderiba® 200 mg/400 mg Dose Pack (ribavirin) Ribapak® 400 mg/600 mg, 200 mg/400 mg Dose Pack (ribavirin) Rebetol®* (ribavirin 200 mg capsule) Ribasphere® (ribavirin) 400 mg, 600 mg tablet Ribasphere† 200 mg capsules Ribavirin† 200 mg capsules All other strengths/brands of ribavirin tablets/capsules
Oral Solution	Rebetol® (ribavirin 40 mg/ml) oral solution
PEGYLATED INTERFERON	
PEGASYS® (peg-interferon alpha-2a) (*QL = 4 vials/28 days)* PEGASYS CONVENIENCE PACK® (peg-interferon alfa-2a) (*QL = 1 kit/28 days)* PEGASYS PROCLICK® (peg-interferon alfa-2a) (*QL = 4 autoinjectors/28 days)*	Peg-Intron®/ Peg-Intron Redipen® (peg-interferon alpha-2b) *(QL=4 pens per 28 days)* Peg-Intron Redipen Pak 4® (peg-interferon alpha-2b) *(QL=1 kit (4 pens) per 28 days)*
HEPATITIS C PROTEASE INHIBITORS	
OLYSIO (simeprevir)150 mg Capsule (*QL = 1 capsule/day)(Maximum 12 weeks/lifetime)*	Incivek® (telaprevir) (*QL = 6 tablets/day)(Maximum 12 weeks/lifetime)* Victrelis® (boceprevir) (*QL = 12 capsules/day)(Maximum 44 weeks/lifetime)*
POLYMERASE INHIBITOR	
SOVALDI (sofosbuvir) 400 mg Tablet (*QL = 1 tablet/day)(Maximum 24 weeks/lifetime unless hepatocellular carcinoma (48 weeks))*	

VERMONT

HEPATITIS C MEDICATIONS

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access HEPATITIS C MEDICATIONS/PRIOR AUTHORIZATION REQUEST

Patient Diagnosis: Hepatitis C YES ☐ NO ☐

If YES, Hepatitis C Supplemental Clinical Form must be completed and submitted for PA request to be considered.

Requested DVHA **PREFERRED** Ribavirin Hepatitis C Product?

☐ Ribavirin 200 mg Tablet (compare to Copegus®) **or**

Product: _____ Medical justification: _____

Requested DVHA **PREFERRED** Injectable Pegylated Interferon Hepatitis C Product?

☐ Pegasys® Prefilled Syringe ☐ Pegasys® Single Dose Vial ☐ Pegasys® Proclick **or**

Product: _____ Medical justification: _____

Polymerase Inhibitor

☐ Sovaldi® (sofosbuvir) 400 mg Tablet

Protease Inhibitor

☐ Olysio® (simeprevir) 150 mg Capsule **or**

Product: _____

Medical justification: _____

4 PRESCRIPTION

Oral Ribavirin:

☐ Ribavirin 200 mg Tablet Refill for total:_____ weeks

Sig: Dose/Frequency: _____ Quantity:28 days' supply

Injectable Pegylated Interferon:

☐ Pegasys® Prefilled Syringe 180 mcg/0.5 ml "Convenience Kit" (4 syringes/box)

☐ Pegasys® 180 mcg/1 ml Single Dose Vial

☐ Pegasys® ProClick ☐ 180 mcg/0.5 ml or ☐ 135 mcg/0.5 ml

Sig: Dose/Route/Frequency:_____

Quantity: 28 days' supply Refill for total: _____ weeks

Oral Polymerase Inhibitor:

☐ Sovaldi® (sofosbuvir) 400 mg Tab Sig: Take one tablet (400 mg) by mouth once daily.

Dispense Quantity: 28 (4 weeks) Refill for total: _____ weeks

Oral Protease Inhibitor:

☐ Olysio® (simeprevir) 150 mg Sig: Take one cap (150 mg) by mouth once daily with food.

Dispense Quantity: 28 (4 weeks) Refill for total: _____ weeks

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

HEPATITIS C – SUPPLEMENTAL CLINICAL FORM

THIS FORM UST BE SUBMITTED WITH ALL REQUESTS FOR HEPATITIS C MEDICATION THERAPY

1 PATIENT IDENTIFICATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Does patient have other health insurance providing a pharmacy benefit? YES ☐ NO ☐

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Contact Person at Office

Telephone Number

Fax Number

Prescriber Specialty
☐ Board Certified Gastroenterology
☐ Board Certified Infectious Disease
☐ Other:_____

If therapy recommended by Specialist, please attach consult note. Attached: YES ☐ NO ☐

3 PATIENT CLINICAL INFORMATION (PART 1)

Diagnosis: **Hepatitis C** YES ☐ NO ☐ **Date of Initial Diagnosis:** ____/____/_____

Genotype: 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐

If Genotype 1: **Genotype 1a** YES ☐ NO ☐

If Yes and Prescribing Olysio®: **Q80K Polymorphism** YES ☐ NO ☐ N/A ☐

Fibrosis Score: 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ Unknown ☐

Decompensated Liver Disease: YES ☐ NO ☐

Hepatocellular carcinoma & awaiting liver transplant YES ☐ NO ☐

Status post-liver transplant YES ☐ NO ☐

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

4 PATIENT CLINICAL INFORMATION (PART 2)

Patient is: **Treatment Naïve** ☐ **Has received Prior Therapy** ☐

If Prior Therapy: Relapser ☐ Partial Responder ☐ Null Responder ☐ New Infection ☐

Prior regimen:_____

Dates of Prior Therapy/Duration: _____

Did Patient **Complete Planned Therapy**: YES ☐ NO ☐

If No, **Reason for Non-Completion:** Adverse Reaction ☐ Did Not Meet RGT Criteria ☐
Lost to Follow-Up ☐ Other ☐ Please explain: _____

HIV + YES ☐ NO ☐

Is Patient **IFN ineligible:** YES ☐ NO ☐
If YES, reason: _____

Does patient have a history of **alcohol abuse:** YES ☐ NO ☐
If YES, date of last alcoholic drink: ___/___/_____

If YES, is patient currently enrolled in an **alcohol support program**: YES ☐ NO ☐
If YES, how is this independently **verified**:_____

Does patient have a history of **substance abuse**: YES ☐ NO ☐
If YES, clean date: ___/___/_____

If YES, is patient currently enrolled in a **substance use program:** YES ☐ NO ☐
If YES, how is this independently **verified**:_____

Has the patient been **educated to the possible side effects of therapy**: YES ☐ NO ☐

Proposed Therapy (complete Hepatitis Medication Order Form)

Attached: YES ☐ NO ☐

Rate the **Likelihood of Patient Completing the Proposed Therapy**:

High ☐ Moderate ☐ Indeterminate ☐

Pertinent Extenuating Circumstances (explain):_____

_____

NB: Recent Clinical Note Must be Attached for PA Consideration

5

Prescriber's Signature: _____ **Date:** _____

Hereditary Angioedema Medications

***NOTE*: Firazyr® must be obtained and billed through our specialty pharmacy vendor, Briova.**

LENGTH OF AUTHORIZATION: initial approval 6 months, subsequent approval 1 year

CRITERIA FOR APPROVAL:

Berinert:

- The diagnosis or indication is **treatment** of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).

Cinryze:

- The diagnosis or indication is **prophylaxis** of Hereditary Angioedema (HAE) attacks.

AND

- The patient has had a documented side effect, allergy, treatment failure or a contraindication to androgen therapy (i.e. danazol).

OR

- The medication is to be used for the **treatment** of an acute Hereditary Angioedema (HAE) attack.

Firazyr:

- The diagnosis or indication is **treatment** of an acute Hereditary Angioedema (HAE) attack.

Kalbitor:

- The diagnosis or indication is **treatment** of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Hereditary Angioedema Medications

Length of Authorization: initial approval 6 months, subsequent approval 1 year

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
Kalbitor® (ecallantide) *(QL = 6 vials (2 packs) per fill*	Berinert® (human C1 inhibitor) Cinryze® (human C1 inhibitor) *(QL = 20 vials/28 days for prophylaxis; 4 vials per fill for acute attacks)* Firazyr® (icatibant) Prefilled Subcutaneous Syringe *(QL = 3 syringes (9 ml)/fill)*

Interleukin (IL)-1 Receptor Blockers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Ilaris®:

- The diagnosis is Cryopyrin-Associated Periodic Syndrome (CAPS)

OR

- The diagnosis is Familial Cold Autoinflammatory Syndrome (FCAS)

OR

- The diagnosis or indication for the requested medication is Muckle-Wells Syndrome (MWS)

AND

- The patient is ≥ 4 years old

OR

- The diagnosis is systemic juvenile idiopathic arthritis (sJIA) **with** active systemic features and varying degrees of synovitis with continued disease activity after initial therapy (Initial therapy defined as 1 month of anakinra (Kineret®), 2 weeks of glucocorticoid monotherapy (oral or IV) or one month of NSAIDs).

AND

- The patient is ≥ 2 years of age

Arcalyst®:

- The diagnosis is Cryopyrin-Associated Periodic Syndrome (CAPS)

OR

- The diagnosis is Familial Cold Autoinflammatory Syndrome (FCAS)

OR

- The diagnosis is Muckle-Wells Syndrome (MWS)

AND

- The patient is ≥ 12 years old

AND

- The patient must have a documented side effect, allergy, treatment failure or a contraindication to Ilaris® (canakinumab)

Note: Medical Records to support the above diagnosis must accompany the Prior Authorization Request.

Authorization for continued use shall be reviewed at least every 12 months to confirm patient has experienced disease stability or improvement while on therapy.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of Arcalyst® or Ilaris® on a **General Prior Authorization Form**.

✓ All requests for canakinumab (Ilaris®) (whether billed through the pharmacy or medical benefit (J0638)) or rilonacept (Arcalyst®) (whether billed through the pharmacy or medical benefit (J2793)) require Prior Authorization through the Catamaran Clinical Call Center.

Interleukin (IL)-1 Receptor Blockers

Length of Authorization: 1 year

PREFERRED AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
Ilaris® (canakinumab) *(QL = 1 vial/56 days)(CAPS diagnosis)* *(QL = 2 vials/28 days)(sJIA diagnosis)*	Arcalyst® (rilonacept) *(QL = 2 vials for loading dose, then 1 vial per week)*

Lipotropics: Bile Acid Sequestrants

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Questran®*

- The patient has had a documented intolerance to cholestyramine powder.

Questran Light®*

- The patient has had a documented intolerance to cholestyramine light powder.

Colestid®*

- The patient has had a documented intolerance to colestipol tablets or granules.

Welchol®

- If being prescribed for lipid reduction, the patient has had a documented side effect, allergy, or treatment failure to cholestyramine and colestipol.

OR

- If being prescribed for additional improved glycemic control, the patient must have been unable to obtain a satisfactory hemoglobin A1C reduction with metformin and one other oral anti-diabetic agent.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Bile Acid Sequestrants

Length of Authorization: 3 years

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CHOLESTYRAMINE† powder (compare to Questran®) CHOLESTYRAMINE LIGHT† powder (compare to Questran Light®) PREVALITE† powder (cholestyramine light)	Questran®* powder (cholestyramine) Questran Light®* powder (cholestyramine light)
COLESTIPOL† tablets, granules (compare to Colestid®)	Colestid®* tablets, granules (colestipol) Welchol® (colesevelam)

Lipotropics: Fibric Acid Derivatives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Lopid®*

- The patient has had a documented intolerance to generic gemfibrozil.

Tricor®, TriLipix®

- The patient has been started and stabilized on either Tricor® or TriLipix® (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient is taking a statin concurrently.

OR

- The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil.

Antara®, fenofibrate, fenofribrate micronized, fenofibric acid, Fenoglide®, Fibricor®, Lipofen®, Lofibra® and Triglide®

- The patient is taking a statin concurrently and has had a documented side effect, allergy, or treatment failure with Tricor® or TriLipix®. (If a product has an AB rated generic, there must have been a trial with the generic formulation.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil and Tricor® or TriLipix®. (If a product has an AB rated generic, there must have been a trial with the generic formulation.)

fenofibrate nanocrystallized (generic for Tricor), fenofibric acid (generic for Trilipix)

- The patient is taking a statin concurrently,

OR

- The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil.

AND

- The patient has had a documented intolerance with the brand equivalent.

(Note regarding fibrates: For patients receiving statin therapy, fenofibrate appears less likely to increase statin levels and thus may represent a safer choice than gemfibrozil for coadministration in this group of patients - *Am J Med* 2004;116:408-416)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Fibric Acid Derivatives

Length of Authorization: 1 year.

Key: † Generic product, *Indicates generic equivalent is available without a PA
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
GEMFIBROZIL† (compare to Lopid®) 600 mg **On statin concurrently or after gemfibrozil trial** TRICOR® (fenofibrate nanocrystallized) § 48 mg, 145 mg *Quantity Limit = 1 tablet/day* TRILIPIX (fenofibric acid) § 45 mg, 135 mg delayed release capsule *Quantity Limit = 1 capsule/day*	Antara® (fenofibrate micronized) 30 mg, 43 mg, 90 mg, 130 mg fenofibrate tablets†(compare to Lofibra® tablets) § 54 mg, 160 mg fenofibrate capsule† (compare to (Lipofen®) § 50 mg, 150 mg fenofibrate micronized capsule†(compare to Lofibra® capsules) § 67 mg, 134 mg, 200 mg fenofibrate micronized† (compare to Antara®) § 43 mg, 130 mg fenofibrate nanocrystallized† (compare to Tricor®) 48 mg, 145 mg fenofibric acid (compare to Trilipix®) 45 mg, 135 mg delayed release capsule *Quantity Limit = 1 capsule/day* fenofibric acid § 35 mg, 105 mg *Quantity Limit = 1 capsule/day* Fenoglide® (fenofibrate MeltDose) § 40 mg, 120 mg Fibricor® (fenofibric acid) § 35 mg, 105 mg *Quantity Limit = 1 capsule/day* Lipofen® (fenofibrate) § 50 mg, 150 mg Lofibra® (fenofibrate micronized) Capsules § 67mg, 134 mg, 200 mg Lofibra® (fenofibrate) Tablets § 54 mg, 160 mg Lopid®* (gemfibrozil) § 600 mg Triglide® (fenofibrate) § 50 mg, 160 mg

Lipotropics: Homozygous Familial Hypercholesterolemia (HoFH) Agents

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

- Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH)

AND

- Medication will be used as adjunct to a low-fat diet and other lipid-lowering treatments

AND

- Patient does not have any of the following contraindications to therapy:
  - Pregnancy (Juxtapid)
  - Concomitant use with strong or moderate CYP3A4 inhibitors (Juxtapid)
  - Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests (Juxtapid, Kynamro)

AND

- Patient has tried and had an inadequate response, intolerance or contraindication to BOTH atorvastatin and Crestor

AND

- After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

Note: Re-approval requires confirmation that the patient has responded to therapy (i.e. decreased LDL levels) AND the patient does not have any contraindications to therapy.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Homozygous Familial Hypercholesterolemia (HoFH) Agents

Length of Authorization: 6 months

NO PA REQUIRED	PA REQUIRED
All products require PA.	Juxtapid® (lomitapide) Capsule *QL = 5 and 10 mg caps (1 per day), 20 mg cap (3 per day)* Kynamro® (mipomersen) Syringe for Subcutaneous Injection *QL = 4 syringes(4 ml)/28 days* Maximum days' supply per fill for all drugs is 28 days

Lipotropics: Nicotinic Acid Derivatives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Niacin extended release (generic)

- The patient has a documented intolerance to the branded product.

Lipotropics: Nicotinic Acid Derivatives *Length of Authorization: 1 year* **Key: † Generic product, *Indicates generic equivalent is available without a PA**	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
Immediate Release Products NIACIN† NIACOR® (niacin) **Extended Release Products** NIASPAN® (niacin extended release)	 Niacin extended release† (compare to Niaspan®)

Lipotropics: Statins

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

HIGH INTENSITY STATINS

Lipitor® 40 or 80 mg

- The patient has had a documented intolerance to generic atorvastatin.

MODERATE INTENSITY STATINS

Atorvastatin/Lipitor® 10 or 20 mg

- The patient has had a documented side effect, allergy, or contraindication to generic simvastatin.

OR

- The patient has had an inadequate response to a six week trial of simvastatin 40 mg/day

AND

- If the request is for Lipitor, the patient has had a documented intolerance to generic atorvastatin.

Altoprev® 40 or 60 mg, fluvastatin 40 mg BID, Lescol® 40 mg BID, Lescol® XL, Livalo® 2 or 4 mg

- The patient has had a documented side effect, allergy, or contraindication to all 3 of generic lovastatin, pravastatin and simvastatin.

OR

- The patient has had inadequate responses to six week trial of each of lovastatin 40 mg/day, pravastatin 80 mg/day, simvastatin 40 mg/day and Crestor 10 mg/day.

AND

- If the request is for Lescol, the patient has had a documented intolerance to generic fluvastatin.

Mevacor® 40 mg, Pravachol® 40 or 80 mg, Zocor® 20 or 40 mg

- The patient has had documented intolerance to the generic equivalent.

LOW INTENSITY STATINS

Altoprev® 20 mg, fluvastatin 20 or 40 mg, Lescol® 20 or 40 mg, Livalo® 1 mg

- The patient has had a documented side effect, allergy, or contraindication to all 3 of generic lovastatin, pravastatin and simvastatin.

OR

- The patient has had inadequate responses to six week trial of each of lovastatin 20 mg/day, pravastatin 20 mg/day and simvastatin 10 mg/day.

AND

- If the request is for Lescol, the patient has had a documented intolerance to generic fluvastatin.

Mevacor® 10 or 20 mg, Pravachol® 20 mg, Zocor® 5 or 10 mg

- The patient has had documented intolerance to the generic equivalent.

LIMITATIONS:
Simvastatin 80 mg: initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis. Patients may only continue on this dose when new to Medicaid if the patient has been taking this dose for 12 or more months without evidence of muscle toxicity. If the request is for Zocor 80 mg, the patient must have met the prior treatment length requirement and have a documented intolerance to the generic equivalent.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Statins

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
HIGH INTENSITY STATINS	
ATORVASTATIN† 40 or 80 mg (compare to Lipitor®) *(QL = 1 tablet/day)* CRESTOR® 20 or 40 mg (rosuvastatin calcium) *(QL = 1 tablet/day)*	Lipitor®* (atorvastatin) 40 or 80 mg *(QL = 1 tablet/day)*
MODERATE INTENSITY STATINS	
CRESTOR® 5 or 10 mg (rosuvastatin calcium) *(QL = 1 tablet/day)* LOVASTATIN† 40 mg (compare to Mevacor®) *(QL = 1 tablet/day)* PRAVASTATIN† 40 or 80 mg (compare to Pravachol®)) *(QL = 1 tablet/day* SIMVASTATIN† 20 or 40 mg (compare to Zocor®) *(QL = 1 tablet/day)*	Altoprev® 40 or 60 mg (lovastatin SR) *(QL = 1 tablet/day)* atorvastatin† 10 or 20 mg (compare to Lipitor®) *(QL = 1 tablet/day)* fluvastatin† 40 mg (compare to Lescol®) *(QL = 2 tabs/day)* Lescol® 40 mg (fluvastatin) *(QL = 2 tabs/day)* Lescol® XL 80 mg (fluvastatin XL) *(QL = 1 tablet/day)* Lipitor® (atorvastatin) 10 or 20 mg *(QL = 1 tablet/day)* Livalo® 2 or 4 mg (pitavastatin) *(QL = 1 tablet/day)* Mevacor®* 40 mg (lovastatin)) *(QL = 1 tab/day)* Pravachol®* 40 or 80 mg (pravastatin) *(QL = 1 tab/day)* Zocor®* (simvastatin) 20 or 40 mg *(QL = 1 tablet/day)*
LOW INTENSITY STATINS LOVASTATIN† 10 or 20 mg (compare to Mevacor®) *(QL = 1 tablet/day)* PRAVASTATIN† 10 or 20 mg (compare to Pravachol®)) *(QL = 1 tablet/day* SIMVASTATIN† 5 or 10 mg (compare to Zocor®) *(QL = 1 tablet/day)*	Altoprev® 20 mg (lovastatin SR) *(QL = 1 tablet/day)* fluvastatin† 20 or 40 mg (compare to Lescol®) *(QL = 1 tab/day (20mg) or 2 tabs/day (40 mg))* Lescol® 20 or 40 mg(fluvastatin) *(QL = 1 tab/day (20mg) or 2 tabs/day (40 mg))* Livalo® 1 mg (pitavastatin) *(QL = 1 tablet/day)* Mevacor®* 10 or 20 mg (lovastatin)) *(QL = 1 tablet/day)* Pravachol®* 20 mg (pravastatin) *(QL = 1 tab/day)* Zocor®* (simvastatin) 5 or 10 mg *(QL = 1 tablet/day)*

Note: Please refer to "Lipotropics: Miscelaneous/Combinations" for statin combinations

Lipotropics: Miscellaneous/Combinations

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Lovaza®, Vascepa®, Omega-3-acid ethyl esters

- The patient has been started and stabilized on this medication (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has triglyceride levels > 500 mg/dL

AND

- The patient has a documented contraindication, side effect, allergy, or treatment failure to a fibric acid derivative and niacin.

AND

- If the request is for brand Lovaza, the patient has a documented intolerance to the generic equivalent.

Amlodipine/atorvastatin, Caduet®

- The prescriber must provide a clinically valid reason for the use of the requested medication. For approval of Caduet, the patient must have also had a documented intolerance to the generic equivalent. For combinations containing 40 mg or 80 mg atorvastatin, the individual generic components are available without PA and should be prescribed.

Advicor®

- The patient is unable to take the individual drug components separately.

Juvisync®

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

AND

- The patient has been started and stabilized on Januvia and simvastatin combination therapy as individual agents.

Liptruzet®, Vytorin®

- The patient has had an inadequate response to atorvastatin or Crestor®.

AND

- If the request is for Vytorin 10/80, the patient has been taking this dose for 12 or more months without evidence of muscle toxicity.

Zetia®

- The patient has a documented side effect, allergy or contraindication (eg. drug interaction) to a statin.

OR

- The patient has a diagnosis of homozygous sitosterolemia.

OR

- The patient has had an inadequate response to atorvastatin or Crestor®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Miscellaneous/Combination

Length of Authorization: 1 year

PREFERRED DRUGS (No PA Required)	PA REQUIRED
MISCELLANEOUS	
All products require PA.	Lovaza® (omega-3-acid ethyl esters) Omega-3-acid ethyl esters† (compare to Lovaza®) Vascepa® (icosapent ethyl) *(QL = 4 capsules/day)*
CHOLESTEROL ABSORPTION INHIBITORS/COMBINATIONS	
All products require PA.	Liptruzet® (ezetimibe/atorvastatin) *(QL = 1 tablet/day)* Vytorin® (ezetimibe/simvastatin) *(QL = 1 tablet/day)* Zetia® (ezetimibe) *(Qty Limit = 1 tablet/day)*
OTHER STATIN COMBINATIONS	
SIMCOR® (simvastatin/extended release niacin) *(Qty Limit = 1 tablet/day)* ±	Advicor® (lovastatin/extended release niacin) *(Qty Limit = 1 tablet/day)* Amlodipine/atorvastatin † (compare to Caduet®) *(Qty Limit = 1 tablet/day)* Caduet® (atorvastatin/amlodipine) *(Qty Limit = 1 tablet/day)* Juvisync® (sitagliptin/simvastatin) *(Qty limit = 1 tablet/day)*

± Recommended to be used only when goal is not met in patients previously having experience with any niacin derivative or statin.

Management of Mental Health Medications

1. Patients on certain existing non-preferred mental health drugs as of 01/01/06 were "grandparented" and their mental health drug use was not subject to the Preferred Drug List (PDL).

   Patients of any age who were using:

   - antipsychotics,
   - antidepressants,
   - mood stabilizers,
   - and/or CNS Stimulants/ADD/ADHD drugs

   were grandfathered so as not to risk destabilization. Changes in therapy or lapses in therapy of greater than 4 (four) months resulted in the application of the PDL.

   Use of sedative hypnotics and/or anxiolytics by patients using antipsychotics, antidepressants, mood stabilizers, and/or CNS Stimulants/ADD/ADHD drugs was also grandfathered until such time as there was a change or lapse in the sedative hypnotic/anxiolytic treatment of greater than 4(four) months. If patients end all antipsychotics, antidepressants, mood stabilizers, or CNS Stimulants/ADD/ADHD drug treatment but continue sedative hypnotic or anxiolytic treatment, non-preferred sedative hypnotic or anxiolytic drugs will not be subject to PA for one year from the end of the antipsychotics, antidepressants, mood stabilizers, or CNS Stimulants/ADD/ADHD drug treatment unless there is a change or lapse in the sedative hypnotic/anxiolytic treatment of greater than 4(four) months. In either case, if there is a change or lapse in sedative hypnotic/anxiolytic therapy of greater than 4(four) months, the PDL will apply.

2. The PDL applies to new patients, patients who are prescribed a change in therapy, and patients who have had a lapse in therapy of greater than 4 (four) months.

   The PDL represents a clinically effective array of mental health products that are cost effective. The classes include:

   - SSRI Antidepressants
   - SNRI Antidepressants
   - Miscellaneous Antidepressants
   - Tricyclic and MAOI Antidepressants
   - Atypical Antipsychotics
   - Typical Antipsychotics
   - Mood Stabilizers (including some anticonvulsants)
   - CNS Stimulants/ADD/ADHD Drugs (Antihyperkinesis medications)
   - Sedative Hypnotics
   - Anxiolytics

3. The PDL also may include FDA maximum recommended adult daily doses.

   With some exceptions, prior authorization will be required if FDA maximum recommended daily doses are exceeded by 25%. These FDA maximum recommended daily doses were not applied to current patients on 01/01/06. As part of drug utilization review (DUR) activities, prescribers may be contacted by mail where patients are prescribed quantities above these doses.

4. The prescribing of brands when generic equivalents are available will require prior authorization.

   Patients on current therapies (brand where generic equivalent available) were allowed to continue these drugs without prior authorization until October 2, 2006. Prescribers were contacted by mail and provided with lists to assist them in identifying patients who might readily transition to a preferred generic and those who would require a PA. New patients and patients who are prescribed a change in therapy require a PA for the use of a branded drug when a generic equivalent is available. A prior authorization granted for a brand name medication when a generic equivalent exists will expire after one year after which a new PA must be obtained for continuation of the brand.

5. Beginning 12/11/2012, all atypical antipsychotic medications for children (< 18 years old) require prior authorization which will need to be renewed annually to give prescribers an opportunity to evaluate the need for ongoing therapy.

Miscellaneous: Benlysta® (for Systemic Lupus Erythematosus (SLE))

LENGTH OF AUTHORIZATION: initial approval 2 months, subsequent approval 1 year

CLINICAL CONSIDERATIONS:

How supplied: 120 mg or 400 mg single use vials for injection
Dose: initial, 10 mg/kg at 2-week intervals for first 3 doses; maintenance, 10 mg/kg at 4-week intervals

CRITERIA FOR APPROVAL:

- The diagnosis or indication is active systemic lupus erythematosus (SLE)

AND

- The patient is positive for autoantibodies (anti-nuclear antibody (ANA) and/or anti-double-stranded DNA (anti-dsDNA).

AND

- The patient has had a documented inadequate response or intolerance to at least TWO of the following agents: NSAIDs, hydroxychloroquine, prednisone, azathioprine, methotrexate, mycophenolate.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a Benlysta® on a **General Prior Authorization Request Form**.
- ✓ All requests for Benlysta® (belimumab) (whether billed through the pharmacy or medical benefit (J0490)) require Prior Authorization through the Catamaran Clinical Call Center.

Note: The efficacy of Benlysta® has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Benlysta® has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of Benlysta® is not recommended in these situations.

Miscellaneous: Benlysta®

Length of Authorization: initial approval 2 months, subsequent approval 1 year

NO PA REQUIRED	PA REQUIRED
All products require PA.	Benlysta® (belimumab) Vials Maximum days supply = 28 days

Miscellaneous: Carbaglu®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is hyperammonemia due to N-acetylglutamate synthetase (NAGS) deficiency

AND

- The prescriber is a specialist in metabolic disorders (e.g., medical geneticist) or prescriber is in consultation with a specialist

Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Carbaglu®	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Carbaglu® dispersible tablets (carglumic acid) *(Maximum days supply per fill = 14 days)*

Miscellaneous: Elaprase® (Hunter's Syndrome Injectable)

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

How supplied: 6 mg glass vials (one vial per package)
Dose: 0.5 mg/kg every week

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Hunter's Syndrome.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Elaprase® on a **General Prior Authorization Request Form**.

J code (J1743) will NOT be accepted in the Medical Benefit.

Miscellaneous; Elaprase®

Length of Authorization: 1 year

NO PA REQUIRED	PA REQUIRED
All products require PA.	Elaprase® (idursulfase) *(QL = calculated weekly dose)*

Miscellaneous: Gattex® (for Patients with Short Bowel Syndrome on Parenteral Nutrition)

LENGTH OF AUTHORIZATION: 6 months

CLINICAL CONSIDERATIONS:

How supplied: 5 mg vial (maximum 3.8 mg available from vial)
Dose: 0.05 mg/kg administered by subcutaneous injection once daily.

CRITERIA FOR APPROVAL:

- Patient has a diagnosis of short bowel syndrome

  AND
- Patient is receiving specialized nutritional support administered intravenously (i.e. parenteral nutrition)

  AND
- Patient is 18 years of age or older

  AND
- Patient does not have an active gastrointestinal malignancy (gastrointestinal tract, hepatobiliary, pancreatic), colorectal cancer, or small bowel cancer.

  AND
- After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

  Note: Re-approval requires evidence of decreased parenteral nutrition support from baseline.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a Gattex® on a **General Prior Authorization Request Form**.

Miscellaneous: Gattex®	*Length of Authorization: 6 months*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Gattex® (teduglutide) Vials Maximum days' supply = 30 days

Miscellaneous: Glycopyrrolate

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cuvposa®:

- The diagnosis or indication for the requested medication is Sialorrhea or a neurologic condition associated with excessive drooling (e.g. cerebral palsy, mental retardation, Parkinson's disease).

AND

- The dose cannot be obtained from the tablet formulation.

AND

- (For patients >18 years of age) The patient has had a documented side effect, allergy, treatment failure, or a contraindication to scopolamine patches.

Glycate®:

- The indication for use is adjunctive therapy in the treatment of peptic ulcer.

AND

- The patient has had a documented intolerance to generic glycopyrrolate.

Robinul®, Robinul Forte®:

- The patient has had a documented intolerance to generic glycopyrrolate.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Glycopyrrolate	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
GLYCOPYRROLATE 1 mg, 2 mg tablets (compare to Robinul®, Robinul Forte®)	Cuvposa® oral solution (glycopyrrolate)* **Maximum days supply per fill is 30 days** Glycate® 1.5 mg tablet (glycopyrrolate) *Quantity limit = 5 tablets/day* Robinul® 1 mg tablet (glycopyrrolate) Robinul® Forte 2 mg tablet (glycopyrrolate)

Miscellaneous: Korlym®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- Patient is ≥18 years of age
  AND
- Patient has a diagnosis of endogenous Cushing's syndrome
  AND
- Patient is diagnosed with type 2 diabetes mellitus or glucose intolerance
  AND
- Patient has hyperglycemia secondary to hypercortisolism
  AND
- Patient has failed or is not a candidate for surgery
  AND
- Patient has a documented side effect, allergy, treatment failure or contraindication to at least 2 adrenolytic medications (eg. ketoconazole, etomidate)
  AND
- Patient does not have any of the following contraindications to Korlym:
  - Pregnancy (pregnancy must be excluded before the initiation of therapy or if treatment is interrupted for >14 days in females of reproductive potential. Nonhormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential)
    OR
  - Patient requires concomitant treatment with systemic corticosteroids for serious medical conditions/illnesses (immunosuppression for organ transplant)
    OR
  - Patient has a history of unexplained vaginal bleeding
    OR
  - Patient has endometrial hyperplasia with atypia or endometrial carcinoma
    OR
  - Patient is concomitantly taking simvastatin, lovastatin, or a CYP3A substrate with a narrow therapeutic index (e.g., cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, or tacrolimus)

Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Korlym®	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Korlym® tablets (mifepristone) *Quantity limit = 4 tablets/day*

Miscellaneous: Makena®

LENGTH OF AUTHORIZATION: 6 months (PA start to be no more than 2 weeks prior to first dose to allow for product shipment)

CLINICAL CONSIDERATIONS:

Makena is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered < 37 weeks of gestation.

How supplied: 5-mL multi-dose vial (250 mg/mL) containing 1250 mg hydroxyprogesterone caproate
Dose: administered intramuscularly as a 250-mg (1-mL) weekly injection

CRITERIA FOR APPROVAL:

- Patient is 16 years of age or older

AND

- Patient has a history of singleton spontaneous preterm birth

AND

- Patient is having a singleton (single offspring) pregnancy

AND

- Therapy will be started between 16 weeks, 0 days and 27 weeks, 0 days of gestation.

AND

- Therapy will be continued until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Makena® on a **General Prior Authorization Request Form**.
- ✓ All requests for Makena® (hydroxyprogesterone caproate) (whether billed through the pharmacy or medical benefit (J1725)) require Prior Authorization through the Catamaran Clinical Call Center. Requests received for coverage in the Medical Benefit will be dated for day of prior authorization submission if first dose is administered on day of PA submission and patient meets clinical criteria.

Note: While there are many risk factors for preterm birth, safety and efficacy of Makena® has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Miscellaneous: Makena®

Length of Authorization: 6 months

PREFERRED AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
Makena® (hydroxyprogesterone caproate) injection 250 mg/ml 5 ml vials Maximum fill = 5 ml/fill (35 day supply)	

Miscellaneous: Nuedexta®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is pseudobulbar affect (PBA) secondary to amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)

AND

- The patient does not have any contraindications to use:

Concomitant use with quinidine, quinine, or mefloquine
History of quinidine, quinine or mefloquine-induced thrombocytopenia, hepatitis
MAOI use within 14 days of starting Nuedexta
Prolonged QT interval, congenital long QT syndrome, Torsades de Pointes, or heart failure
Complete atrioventricular (AV) block or patients at high risk for AV block
Concomitant use with drugs that prolong QT interval and are metabolized by CYP2D6 (eg. thioridazine, pimozide)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Nuedexta®	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Nuedexta® capsules (dextromethorphan/quinidine) *Quantity limit = 2 capsules/day*

Miscellaneous: Otrexup® (methotrexate auto-injector)

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The patient has a diagnosis of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA) or psoriasis.

AND

- The patient has been intolerant to oral methotrexate

AND

- The patient has been unable to be compliant with a non-auto-injector form of injectable methotrexate (includes difficulty with manual dexterity).

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Otrexup®	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Otrexup® Single-dose auto-injector for subcutaneous use (methotrexate) *(Quantity Limit = 4 syringes (1.6ml)/28 days)*

Miscellaneous: Samsca® (for Hyponatremia)

LENGTH OF AUTHORIZATION: 1 month

CLINICAL CONSIDERATIONS:

How supplied: 15 or 30 mg tablets

Dose: Initial, 15 mg once daily;
After at least 24 hours, titrate dose up to 30 mg once daily to a maximum of 60 mg once daily to achieve desired sodium level;
Maximum dose, 60 mg once daily

Patients should be in a hospital for initiation and reinitiation of tolvaptan therapy to evaluate its therapeutic response. Doses can be administered without regard to meals. Avoid fluid restriction during the first 24 hours of therapy. Patients taking tolvaptan should be advised to continue ingesting fluids in response to thirst.

Initiate and Reinitiate in a Hospital and Monitor Serum Sodium
Samsca® should be initiated and reinitiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.

CRITERIA FOR APPROVAL:

- The agent is being used for the treatment of euvolemic or hypervolemic hyponatremia

AND

- Despite optimal fluid restriction, the patient's serum sodium < 120 mEq/L or the patient is symptomatic with a serum sodium < 125 mEq/L.

AND

- The treatment will be initiated or is being reinitiated in a hospital setting where serum sodium can be monitored

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Samsca®	*Length of Authorization: 1 month*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Samsca® tablets (tolvaptan) *Quantity limit = 15 mg tablets (1 tablet/day), 30 mg tablets (2 tablets/day)* *Maximum duration of therapy = 30 days.*

Miscellaneous: Signifor® (for Cushing's Disease)

LENGTH OF AUTHORIZATION: 6 months

CLINICAL CONSIDERATIONS:

How supplied: 0.3 mg, 0.6 mg, 0.9 mg ampules
Dose: 0.3 – 0.9 mg administered by subcutaneous injection twice daily.

CRITERIA FOR APPROVAL:

- Patient has a diagnosis of (pituitary) Cushing's disease

  AND
- Patient is 18 years of age or older

  AND
- Pituitary surgery is not an option or has not been curative.

  AND
- After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

  Note: Re-approval requires confirmation that the patient has experienced an objective response to therapy (i.e., clinically meaningful reduction in 24-hour urinary free cortisol levels and/or improvement in signs or symptoms of the disease).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a Signifor® on a **General Prior Authorization Request Form**.

Miscellaneous: Signifor®	*Length of Authorization: 6 months*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Signifor® (pasireotide) Ampules *QL (all strengths) = 2 ml (2 amps)/day* Maximum days' supply = 30 days

Miscellaneous: Solesta®

LENGTH OF AUTHORIZATION: Up to 2 months

CRITERIA FOR APPROVAL:

- The diagnosis or indication is treatment of fecal incontinence.

AND

- The patient is 18 years of age or older

AND

- The patient has had an inadequate response with conservative therapy, including diet, fiber supplementation, and anti-diarrheal medication

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Solesta®	*Length of Authorization: Up to 2 months*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Solesta® submucosal injection gel 50 mg/15 ml *(Quantity Limit = 4 syringes/28 days)*

Miscellaneous: Soliris®

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval 1 year

CLINICAL CONSIDERATIONS:
How supplied: 10 mg/mL (30 mL)

CRITERIA FOR APPROVAL:

- The patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) documented by flow cytometry.

AND

- The patient has received the meningococcal vaccine at least 2 weeks prior to therapy initiation.

OR

- The patient has a diagnosis of atypical hemolytic uremic syndrome (aHUS).

AND

- The patient has received the meningococcal vaccine at least 2 weeks prior to therapy initiation.

Authorization for continued use shall be reviewed to confirm that the patient has experienced an objective response to the therapy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.
- ✓ All requests for eculizumab (whether billed through the pharmacy or medical benefit (J1300)) require Prior Authorization through the Catamaran Clinical Call Center.

Miscellaneous: Soliris®

Length of Authorization: initial approval 3months, subsequent approval 1 year

NO PA REQUIRED	PA REQUIRED
All products require PA.	Soliris® (eculizumab) *(Quantity Limit = 12 vials(360 ml) /28 days)* *Maximum days' supply per fill = 28 days*

Miscellaneous: Somatuline® (Acromegaly Injectable)

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

How supplied: 60, 90 or 120 mg pre-filled syringes
Dose: initial dose is 90 mg deep subcutaneous every 4 weeks x 3 months, then dose adjusted to between 60 mg and 120 mg every 4 weeks based on lab values and symptoms

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Acromegaly.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

This drug must be billed through the DVHA POS prescription processing system using NDC values.
J code or other code will NOT be accepted for processing through medical benefit.

Miscellaneous: Somatuline®	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Somatuline® Depot Injection (lanreotide) *(QL = 0.2 ml/28 days (60 mg syringe), 0.3 ml/28 days (90 mg syringe) and 0.5 ml/28 days (120 mg syringe))*

Miscellaneous: Tranexamic Acid

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

Dose: Tranexamic Acid is dosed as two 650 mg tablets three times daily for up to 5 days during menstruation.

CRITERIA FOR APPROVAL:

- The diagnosis or indication is clinically significant heavy menstrual bleeding

AND

- The patient has been started and stabilized on oral tranexamic acid within the previous 360 days

OR

- The patient does not have a contraindication to therapy with oral tranexamic acid (i.e., active thrombotic disease, history of thrombosis/thromboembolism, or an intrinsic risk of thrombosis/thromboembolism), and if oral tranexamic acid is to be used concomitantly with an estrogen containing hormonal contraceptive product, the risks of combination therapy have been discussed with the patient.

AND

- The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one oral contraceptive or progestin containing product despite an adequate trial of at least 90 days, or a rationale for why these products cannot be used (e.g. actively attempting to conceive).

AND

- The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one regulary scheduled (not PRN) NSAID or a rationale for why these products cannot be used (e.g. actively attempting to conceive).

AND

- If the request is for brand Lysteda, the patient has had a documented intolerance to the generic product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Tranexamic Acid

Length of Authorization: 1 year

Key: † Generic product

NO PA REQUIRED	PA REQUIRED
All products require PA.	Lysteda® tablets (tranexamic acid) *Quantity limit = 30 tablets/28 days* tranexamic acid† (compare to Lysteda®) *Quantity limit = 30 tablets/28 days*

Miscellaneous: Xenazine® (for Huntington's Disease with chorea)

LENGTH OF AUTHORIZATION: 1 month initially, subsequent approvals up to 1 year

CLINICAL CONSIDERATIONS:

How supplied: 12.5 or 25 mg tablets
Dose: initial dose is 12.5 mg/day increasing by 12.5 mg/day at weekly intervals

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Huntington's disease with chorea.

AND

- Age ≥ 18 years.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Xenazine® *Length of Authorization: 1 month initially, subsequent approvals up to 1 year*	
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Xenazine® tablets (tetrabenazine) *Quantity limit = 50 mg/day at initial approval (12.5 mg tablets ONLY), up to 100 mg/day at subsequent approvals (12.5 mg or 25 mg tablets)* *Maximum 1 month supply per fill*

Mood Stabilizers (See also Anticonvulsants)

LENGTH OF AUTHORIZATION: Duration of Need*

CRITERIA FOR APPROVAL:

Lithobid®:

- The patient has had a documented side effect, allergy, or treatment failure with the generic equivalent of the requested medication.

Equetro®:

- The patient has had a documented side effect, allergy, or treatment failure with a carbamazepine product from the anticonvulsant therapeutic drug category

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Mood Stabilizers

*Length of authorization: Duration of Need**

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
LITHIUM CARBONATE† (formerly Eskalith®) LITHIUM CARBONATE SR† (compare to Lithobid®, formerly Eskalith CR®) LITHIUM CITRATE SYRUP†	Equetro® (carbamazepine SR) Lithobid ®* (lithium carbonate SR)

* For brand name products with generic equivalents, length of authorization is 1 year.

Mucosal Coating Agents

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

MuGard

- Patient is receiving radiation and/or chemotherapy.

AND

- The patient has had a documented side effect, allergy or treatment failure with at least one oral mucosal coating agent (e.g. aluminum hydroxide suspension, Mylanta®) or a topical anesthetic (e.g. viscous lidocaine or diphenhydramine solutions) or combinations of similar agents.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Mucosal Coating Agents

Length of Authorization: 6 months

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALUMINUM HYDROXIDE† (formerly Amphojel®) GELCLAIR® (povidone sodium hyaluronate glycyrrhetinic acid gel) EPISIL® (wound barrier) MYLANTA/DIPHENYDRAMINE/LIDOCAINE VISCOUS (aka "Magic Mouthwash") Or other similar single or combination products	MuGard® (mucoadhesive oral wound rinse) *(QL = 4 bottles/month)*

Multiple Sclerosis Medications

***NOTE*: Multiple Sclerosis Self-Injectables (Avonex®, Betaseron®, Copaxone®, Extavia® and Rebif®) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see Multiple Sclerosis Patient Enrollment/Order Form for instructions. Briova will not be supplying Tysabri® at this time – please continue to obtain through your usual supplier. Aubagio®,Gilenya® and Tecfidera® must be obtained and billed through our specialty pharmacy vendor, Briova. Please see Multiple Sclerosis Oral Patient Enrollment/PA Form for instructions. Briova will not be supplying Ampyra® at this time.**

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Ampyra®

Patient has a diagnosis of multiple sclerosis.

AND

Patient age ≥ 18 years.

Aubagio®

Patient is at least 18 years of age or older

AND

Patient has a diagnosis of relapsing forms of multiple sclerosis (relapsing-remitting multiple sclerosis and progressive-relapsing multiple sclerosis)

AND

Patient does not have any of the following contraindications to teriflunomide:

- Severe hepatic impairment
- Current treatment with leflunomide (Arava®)
- Patients who are pregnant or women of childbearing potential not using reliable contraception

Copaxone® 40 mg Syringe

Patient has a diagnosis of multiple sclerosis.

AND

The patient has a documented side effect, allergy, treatment failure, or contraindication to at least one preferred drug (not Copaxone 20 mg).

AND

The patient is unable to tolerate or be compliant with Copaxone 20 mg daily dosing.

Extavia®

Patient has a diagnosis of multiple sclerosis.

AND

The provider provides a clinical reason why Betaseron cannot be prescribed.

Gilenya®

Patient has a diagnosis of relapsing multiple sclerosis.

AND

Patient has tolerated first dose under observation for a minimum of 6 hours with hourly pulse and blood pressure measurement and pre and post electrocardiogram.

Tysabri®

Patient has a diagnosis of relapsing multiple sclerosis and has already been stabilized on Tysabri®.

OR

Diagnosis is relapsing multiple sclerosis and the patient has a documented side effect, allergy, treatment failure, or contraindication to at least two preferred drugs.

OR

Diagnosis is relapsing multiple sclerosis and the patient has a documented side effect, allergy, treatment failure, or contraindication to one preferred drug and has tested negative for anti-JCV antibodies.

DOCUMENTATION:

- ✓ Document request for self-injectable medications on the **Multiple Sclerosis Self Injectables Patient Enrollment/Order Form**
- ✓ Document clinically compelling information supporting the choice of Ampyra® or Tysabri® on a **General Prior Authorization Request Form**.
- ✓ Document request and clinical information for **Aubagio®**,**Gilenya®** or **Tecfidera** on the **Multiple Sclerosis Oral Medication Prior Authorization/Patient Enrollment Form**
- ✓ All requests for natalizumab (Tysabri®) (whether billed through the pharmacy or medical benefit (J2323)) require Prior Authorization through the Catamaran Clinical Call Center.

Multiple Sclerosis Medications

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED DRUGS (No PA Required)	PA REQUIRED
INJECTABLES	
Interferons	
AVONEX® (interferon beta-1a) BETASERON® (interferon beta-1b) REBIF® (interferon beta-1a)	Extavia® (interferon beta-1b)
Other	
COPAXONE® 20 mg (glatiramer) *(QL = 1 kit/30 days)*	Copaxone® 40 mg (glatiramer) *(QL = 12 syringes(12 ml)/28 days)*
	Tysabri® (natalizumab)
ORAL	
TECFIDERA® (dimethyl fumarate) *(QL = 2 capsules/day, maximum 30 day supply per fill)*	Aubagio® (teriflunamide) tablet *(QL = 1 tablet/day, maximum 28 day supply per fill)*
PREFERRED AFTER CLINICAL CRITERIA ARE MET AMPYRA® (dalfampridine) tablet *(QL = 2 tablets/day, maximum 30 day supply per fill)*	Gilenya® (fingolimod) capsule *(QL = 1 capsule/day, maximum 28 day supply per fill)*

VERMONT

MULTIPLE SCLEROSIS Oral Medication

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access MULTIPLE SCLEROSIS Oral Medication PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Multiple Sclerosis

Complete for Aubagio (teriflunomide):

☐ Patient does not have any of the following contraindications to teriflunomide:

- Severe hepatic impairment
- Current treatment with leflunomide (Arava®)
- Patients who are pregnant or women of childbearing potential not using reliable contraception

Complete for Gilenya (fingolimod):

☐ Initial Request (please complete remainder of section)

☐ Patient has tolerated first dose under observation for a minimum of 6 hours with hourly pulse and blood pressure measurement and pre and post electrocardiogram.

Date of observed first dose: _____/_____/_____

☐ Subsequent Request (PA Renewal)

Prescriber Additional Comments:

4 PRESCRIPTION

☐ Aubagio 7 mg tablet or ☐ Aubagio 14 mg tablet Dispense Quantity: 28
Sig: Take one tablet once daily. Refill X:_____

☐ Gilenya 0.5 mg capsule Dispense Quantity: 28
Sig: Take one capsule once daily. Refill X:_____

☐ Tecfidera Capsules
Month 1 - Titration Starter Pack
Sig: 120 mg PO BID x 7 days # 14 capsules
240 mg PO BID x 23 days # 46 capsules
No refills

Maintenance Rx
Sig: 240 mg PO BID x 30 days Dispense Quantity: 60 Refill X:_____

Prescriber's Signature: _____ **Date:** _____

VERMONT

MULTIPLE SCLEROSIS SELF INJECTABLES - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access
PRESCRIPTION
MULTIPLE SCLEROSIS SELF INJECTABLES

Patient Diagnosis:

Product:

☐ Avonex 30 mcg/0.5 ml Prefilled Syringe (4 per box)

☐ Avonex 30 mcg Kit (Single Dose Vials) (4 per box)

☐ Betaseron 0.3 mg Prefilled Syringe

☐ Copaxone 20 mg Prefilled Syringe (30 per kit)

☐ Rebif Titration Pack X 1 **(Therapy initiation ONLY-No Refills)**
(contains 6 - 8.8 mcg and 6 – 22 mcg Prefilled Syringes)

☐ Rebif 22 mcg/0.5 ml Prefilled Syringes

☐ Rebif 44 mcg/0.5 ml Prefilled Syringes

(Please Note: This form not to be used for Tysabri PA request or ordering)

Quantity:	**Refills:**

Dose / Route/ Frequency Instructions (Sig):

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Prescriber's Signature: _____ **Date:** _____

Nutritionals: Enteral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

EleCare®, EleCare® Jr

- The patient is an infant or child who needs an amino acid-based medical food or who cannot tolerate intact or hydrolyzed protein.

AND

- The product is being requested for the dietary management of protein maldigestion, malabsorption, severe food allergies, short-bowel syndrome, eosinophilic GI disorders, GI-tract impairment, or other conditions for which an amino acid-based diet is required.

All others:

- Requested nutritional supplement will be administered via tube feeding.

OR

- Patient has one of the following conditions where feeding is difficult or malabsorption or maldigestion occurs.

AIDS	Cognitive Impairment	Inflammatory Bowel Disease
Cancer	Cystic Fibrosis	Parkinson's
Celiac Disease	Dementia (includes Alzheimer's)	Short Gut
Cerebral Palsy	Developmental Delays	
Chronic Diarrhea	Difficulty with chewing/swallowing food	

OR

- Patient has experienced unplanned weight loss or is extremely low weight (see further definitions below)

OR

- Patient has demonstrated nutritional deficiency identified by low serum protein levels (albumin or pre-albumin levels to be provided) (albumin $\leq$3.5 g/dL /pre-albumin $\leq$15 mg/dL)

Unplanned Weight Loss/Low Weight	
Adult	• Involuntary loss of $\geq$ 10 % of body weight within 6 months • Involuntary loss of $\geq$ 5% of body weight within 1 month • Loss of $\geq$ 2% of body weight within one week • BMI of $\leq$ 18.5 kg/m^2
Elderly: ($\geq$ 65)	• Involuntary loss of $\geq$ 10 % of body weight within 6 months • Involuntary loss of $\geq$ 5 % of body weight within 3 months • Loss of $\geq$ 2 % of body weight within one month • BMI of $\leq$ 18.5 kg/m^2
Children	• < 80 % of expected weight-for-height • < 90 % of expected height-for-age • Mid-upper arm circumference/head circumference ratio < 0.25

LIMITATIONS:

Infant formulas are not covered under the pharmacy benefit. Please contact WIC.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Nutritionals Prior Authorization Request Form**.

Nutritionals: Enteral	*Length of authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
	All Note: Nutritional supplements administered via tube feeds may be provided through the Medical Benefit.

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~NUTRITIONALS ~

Prior Authorization Request Form

Effective February 2002, Vermont Medicaid established coverage limits and criteria for prior authorization of Nutritional supplements. These limits and criteria are based on concerns about appropriate use and medical necessity. In order for beneficiaries to receive coverage for nutritionals, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address: _____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

Nutritional supplement will be administered via Tube Feeding? ☐ Yes ☐ No **(Proceed to diagnosis question)**

Patient Diagnosis/Condition:

☐ AIDS ☐ Chronic Diarrhea ☐ Dementia (includes Alzheimer's) ☐ Inflammatory Bowel Disease
☐ Cancer ☐ Cognitive Impairment ☐ Developmental Delays ☐ Parkinson's
☐ Celiac Disease ☐ Cystic Fibrosis ☐ Difficulty with chewing/swallowing food ☐ Short Gut
☐ Cerebral Palsy ☐ Request is for weight loss/low weight or low serum protein **(complete appropriate section below)**
☐ Other: _____

Unplanned Weight Loss/Extremely Low Weight:

Baseline: Date: ___/___/____ Height: _____ Weight: _____ BMI: _____

Current: Date: ___/___/____ Height: _____ Weight: _____ BMI: _____

Children: Mid-Upper Arm Circumference: _____ Head Circumference: _____

Laboratory Values: Date: ___/___/____ Albumin: _____ Pre-Albumin:_____

Additional clinical information to support PA request:

Requested Supplement: _____

Strength & Frequency: _____

Anticipated duration of supplementation: _____

Prescriber Signature: _____**Date of this request**: _____

VERMONT

ORAL ONCOLOGY/SELECT ADJUNCT - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access PRESCRIPTION ORAL ONCOLOGY/SELECT ADJUNCT

Patient Diagnosis:

BSA(m2) _____ Patient height (cm) _____ Patient weight(kg)_____

☐Maintenance Therapy # of Refills _____

☐Cycle Specific Therapy NO REFILLS Cycle # _____

☐Treatment / Dosage Change Reason : ☐Toxicity ☐Progression of Disease

☐Change in BSA ☐Other: _____

MEDICATION	Normalized Dose	Strength/ Frequency/ Route of Administration	QTY
☐GLEEVEC			
☐HEXALEN			
☐LUPRON DEPOT*			
☐MERCAPTOPURINE*			
☐MESNEX			
☐NEULASTA*			
☐NEUPOGEN*			
☐REVLIMID*			
Authorization # _____		New RX Required every 28 days	
☐SPRYCEL			
☐SUTENT			
☐TARCEVA			
☐TEMODAR			
☐XELODA			
Other:			
Additional RX Instructions:			

Prescriber's Signature: _____ **Date:** _____

* Not required to use Briova

Ophthalmics: Antibiotics

LENGTH OF AUTHORIZATION: duration of therapy requested

CRITERIA FOR APPROVAL:

Aminoglycosides:

- **Single Agent:** The patient has had a documented side effect, allergy or treatment failure with at least ONE preferred ophthalmic aminoglycoside. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)
- **Combination Product:** The patient has had a documented intolerance with generic tobramycin/dexamethasone ophthalmic.

Macrolides:

- The patient has had a documented side effect, allergy or treatment failure with generic erythromycin. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)

Miscellaneous Antibiotics:

- The patient has had a documented side effect, allergy or treatment failure with at least TWO preferred ophthalmic miscellaneous antibiotics. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)

Quinolones:

- The patient has had a documented side effect, allergy or treatment failure with ciprofloxacin or ofloxacin.

AND

- If the request is for Quixin or Zymaxid, the patient also has a documented intolerance to the generic equivalent.

OR

- The request is for Vigamox or Zymar as part of a regimen to prevent postoperative infection in patients receiving any ophthalmologic surgery.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Antibiotics

Length of Authorization: duration of therapy requested

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
QUINOLONES CIPROFLOXACIN HCL† (compare to Ciloxan®) solution OFLOXACIN† (compare to Ocuflox®) solution	Besivance® (besifloxacin) suspension Ciloxan®*(ciprofloxacin) ointment, solution gatifloxacin 0.5% solution (compare to Zymaxid®) Iquix® (levofloxacin 1.5 %) (preservative free) soln levofloxacin† 0.5 % (compare to Quixin®) soln Moxeza® (moxifloxacin 0.5%) (preservative free) soln Ocuflox®*(ofloxacin) solution Quixin® (levofloxacin 0.5 %) solution Vigamox® (moxifloxacin 0.5%) (preservative free) solution Zymar® (gatifloxacin 0.3%) solution Zymaxid® (gatifloxacin 0.5%) solution
MACROLIDES ERYTHROMYCIN† ointment ILOTYCIN† (erythromycin) ointment	Azasite®(azithromycin) solution All other brands
AMINOGLYCOSIDES **Single Agent** AK-TOB† (tobramycin) solution GARAMYCIN† (gentamicin) ointment GENTAK† (gentamicin) ointment, solution GENTAMICIN† ointment, solution TOBRAMYCIN † sol (compare to Tobrex®) **Combination** TOBRAMYCIN W/DEXAMETHASONE† (compare to Tobradex®) suspension	Garamycin® (gentamicin) solution Tobrex® sol* (tobramycin) Tobrex® ointment (tobramycin) Tobradex®* (tobramycin/dexamethasone) susp Tobradex® (tobramycin/dexamethasone) oint TobraDex ST®(tobramycin/dexamethasone) susp Zylet® (tobramycin/loteprednol) suspension Pred-G® (gentamicin/prednisolone) suspension Pred-G® S.O.P. (gentamicin/prednisolone) oint All other brands
MISCELLANEOUS **Single Agent** BACITRACIN ointment SULFACETAMIDE SODIUM† (compare to Bleph-10®) solution **Combination** AK-POLY-BAC† (bacitracin/polymyxin) ointment BACITRACIN ZINC W/POLYMYXIN B† (formerly Polysporin®) ointment NEOMYCIN/BACITRACIN/POLYMYXIN (formerly Neosporin®) ointment NEOMYCIN/POLYMYXIN W/DEXAMETHASONE† (compare to Maxitrol®) ointment, suspension NEOMYCIN/POLYMYXIN W/GRAMICIDIN† soln (compare to Neosporin®) NEOMYCIN/POLYMYXIN W/HYDROCORTISONE suspension NEOMYCIN/POLYMYXIN/BACITRACIN/ HYDROCORTISONE† ointment POLYMYXIN B W/TRIMETHOPRIM† (compare to Polytrim®) solution SULFACETAMIDE W/PREDNISOLONE SOD PHOSPHATE solution	Bleph-10®* (sulfacetamide) solution All other brands Blephamide® (sulfacetamide/prednisolone acetate) suspenion Blephamide® S.O.P. (sulfacetamide/prednisolone acetate) oint Maxitrol®* (neomycin/polymyxin/dexamethasone) suspension, ointment Neosporin®* (neomycin/polymyxin/gramicidin) soln Poly-pred® (neomycin/polymyxin B/prednisolone acetate) suspension Polytrim®* (polymyxin B/trimethoprim) soln All other brands

Ophthalmics: Antihistamines

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Pataday®/Patanol®

- The patient has had a documented side effect, allergy, or treatment failure to ketotifen.

Azelastine, Bepreve®, Elestat®, Epinastine, Optivar ®

- The patient has had a documented side effect, allergy, or treatment failure to Pataday® or Patanol®.
- If the product has a generic equivalent, the patient must also have had a documented intolerance to the generic equivalent.

Lastacaft®, Emadine®

- The patient is pregnant and the diagnosis is allergic conjunctivitis

OR

- The patient has had a documented side effect, allergy, or treatment failure to ketotifen.

AND

- The patient has had a documented side effect, allergy, or treatment failure to Patanol®/Pataday®

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Antihistamines

Length of Authorization: 1 year

Key: † Generic product. § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
KETOTIFEN† 0.025 % (eg. Alaway®, Zaditor® OTC, others) *(QL = 1 bottle/month)* **After trial of ketotifen 0.025 %** PATADAY® § (olopatadine 0.2%)/PATANOL® § (olopatadine 0.1%) *(QL = 1 bottle/month)*	Azelastine † (compare to Optivar®) *(QL = 1 bottle/month)* Bepreve® (bepotastine besilate) *(QL = 1 bottle/month)* Elestat® (epinastine) *(QL = 1 bottle/month)* Epinastine† (compare to Elestat®) *(QL = 1 bottle/month)* Emadine® (emedastine) *(QL = 2 bottles/month)* Lastacaft® (alcaftadine) *(QL = 1 bottle/month)* Optivar® (azelastine) *(QL = 1 bottle/month)*

Ophthalmics: Corticosteroids: Topical

LENGTH OF AUTHORIZATION: up to 3 months

CRITERIA FOR APPROVAL:

Lotemax® ointment:

- The patient has had a documented side effect, allergy, or treatment failure with one preferred generic ophthalmic corticosteroid.

OR

- The patient has a documented hypersensitivity to the preservative benzalkonium chloride.

All Others:

- The patient has had a documented side effect, allergy, or treatment failure with one preferred generic ophthalmic corticosteroid. (If a product has an AB rated generic, there must have been a trial of the generic formulation)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Corticosteroids: Topical

Length of Authorization: up to 3 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DEXAMETHASONE SODIUM PHOSPHATE 0.1% Sol† FLUOROMETHOLONE 0.1% S† PREDNISOLONE ACETATE 1% S†	Alrex® (loteprednol) 0.2% S Durezol® (difluprednate) 0.05% E FML® (fluorometholone) 0.1% O FML Forte® (fluorometholone) 0.25% S FML Liquifilm®/Flarex® (fluorometholone) 0.1% S Lotemax® (loteprednol) 0.5% O (pres. free) Lotemax® (loteprednol) 0.5% G,S Pred Forte®/Omnipred® (prednisolone acetate) 1% S Pred Mild® (prednisolone acetate) 0.12% S Vexol® (rimexolone) 1% S All other brands

E=emulsion, G=gel, O=ointment, S=suspension, Sol=solution

Ophthalmics: Cystaran®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The indication for use is corneal cystine accumulation in patients with cystinosis.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Cystaran®	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Cystaran® (cysteamine) 0.44% ophthalmic solution (*QL=4 bottles (60 ml)/ 28 days)* *Maximum days' supply/RX = 28 days*

Ophthalmics: Dry Eye Syndrome

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The patient has a diagnosis of moderate to severe keratoconjunctivitis sicca (dry eye syndrome) or Sjogren syndrome with suppressed tear production due to ocular inflammation

  AND
- The member does not have any of the following contraindications or exclusions to therapy:
  A) An active ocular infection
  B) Concurrent topical anti-inflammatory drugs
  C) Concurrent punctal plug use

  AND
- The patient has had a documented side effect, allergy, or treatment failure to two ocular lubricants (e.g., artificial tears, lubricant gels, etc.).

LIMITATIONS:

OTC branded ocular lubricants are not covered (as part of DVHA's comprehensive OTC policy). There is no PA opportunity for branded OTC ocular lubricants.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Dry Eye Syndrome	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
Generic OTC Ocular Lubricants ARTIFICIAL TEARS† Ointment ARTIFICIAL TEARS† Solution REFRESH TEARS† Solution TEARS NATURALE† Solution LUBRIFRESH P.M.† Ointment And all other generics	Restasis® (cyclosporine ophthalmic emulsion) 0.05% (*QL=60 vials per 30 days).*

Ophthalmics: Glaucoma Agents / Miotics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ALPHA 2 ADRENERGIC AGENTS

Single Agent:

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic alpha 2 adrenergic agent. If the request is for brimonidine tartrate 0.15%, the patient must have a documented intolerance of brand name Alphagan P 0.15%.

Combination Product:

Simbrinza®:

- The patient has had a documented treatment failure with either an alpha adrenergic agent or a carbonic anhydrase inhibitor.

BETA BLOCKERS

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic beta blocker.

PROSTAGLANDIN INHIBITORS

Lumigan®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy or treatment failure with generic latanoprost and Travatan Z.

Travoprost®:

- The patient has had a documented intolerance to Travatan Z.

Zioptan®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy or treatment failure with generic latanoprost and Travatan Z.

OR

- The patient has a sensitivity to preservatives used in ophthalmic preparations

Xalatan®

- The patient has a documented intolerance to the generic product.

AND

- The patient has had a documented side effect, allergy or treatment failure with Travatan Z.

CARBONIC ANHYDRASE INHIBITORS

Single Agent:

- The patient has had a documented side effect, allergy or treatment failure with a preferred carbonic anhydrase inhibitor.

Combination Product:

Cosopt®:

- The patient has had a documented intolerance to the generic equivalent product.

Cosopt PF®:

The patient has had a documented intolerance to the preservatives in the generic combination product.

Simbrinza®:

- The patient has had a documented treatment failure with either an alpha adrenergic agent or a carbonic anhydrase inhibitor.

MISCELLANEOUS

- The patient has had a documented side effect, allergy or treatment failure with a preferred miscellaneous ophthalmic agent. If a product has an AB rated generic, there must have also been a trial of the generic formulation)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Glaucoma Agents / Miotics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALPHA 2 ADRENERGIC	
Single Agent	
ALPHAGAN P® 0.1 %, 0.15 % (brimonidine tartrate) BRIMONIDINE TARTRATE† 0.2 % (formerly Alphagan®)	apraclonidine† (compare to Iopidine®) brimonidine tartrate 0.15 % † (compare to Alphagan P®) Iopidine® (apraclonidine)
Combination	
COMBIGAN® (brimonidine tartrate/timolol maleate)	Simbrinza® (brinzolamide 1% and brimonidine 0.2%) Susp
BETA BLOCKERS	
BETAXOLOL HCL† (formerly Betoptic®) CARTEOLOL HCL† (formerly Ocupress®) LEVOBUNOLOL HCL† (compare to Betagan®) METIPRANOLOL† (compare to Optipranolol®) TIMOLOL MALEATE† (compare to Istalol®, Timoptic®) TIMOLOL MALEATE †gel (compare to Timotic XE®)	Betagan®* (levobunolol) Betimol® (timolol) Betoptic S® (betaxolol suspension) Istalol®* (timolol) Optipranolol®* (metipranolol) Timoptic®* (timolol maleate) Timoptic XE®* (timolol maleate gel)
PROSTAGLANDIN INHIBITORS	
LATANOPROST† (compare to Xalatan®) TRAVATAN Z® (travoprost) (BAK free)	Lumigan® 0.01 %/0.03 % (bimatoprost) Travoprost® (travoprost) Xalatan® (latanoprost) Zioptan® (tafluprost)
CARBONIC ANHYDRASE INHIBITORS	
Single Agent	
DORZOLAMIDE 2 % (compare to Trusopt®)	Azopt® (brinzolamide 1%) Trusopt®* (dorzolamide 2 %)
Combination	
DORZOLAMIDE w/TIMOLOL (compare to Cosopt®)	Cosopt®* (dorzolamide w/timolol) Cosopt PF® (dorzolamide w/timolol) (pres-free) Simbrinza® (brinzolamide 1% and brimonidine 0.2%) Susp
MISCELLANEOUS	
DIPIVEFRIN HCL† (compare to Propine®) ISOPTO® CARBACHOL (carbachol) ISOPTO® CARPINE (pilocarpine) PILOCARPINE HCL† (formerly Pilocar®) PILOPINE® HS (pilocarpine) gel PHOSPHOLINE IODIDE® (echothiophate) PROPINE® (dipivefrin)	Miochol-E® (acetylcholine)

Ophthalmics: Mast Cell Stabilizers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The patient has had a documented side effect, allergy, or treatment failure with generic cromolyn sodium.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Mast Cell Stabilizers

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CROMOLYN SODIUM † (formerly Crolom®)	Alocril® (nedocromil sodium) Alomide® (lodoxamide)

Ophthalmics: Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Acuvail®

- The patient has had a documented side effect, allergy, or treatment failure to Acular® or Acular LS®

OR

- The patient has a documented hypersensitivity to the preservative benzalkonium chloride.

Bromday®, Bromfenac, Diclofenac, Ilevro®, Nevanac®, Prolensa®, Voltaren®, Xibrom®,

- The patient has had a documented side effect, allergy, or treatment failure to Acular® or Acular LS®. In addition, if a product has an AB rated generic, there must have also been a trial of the generic formulation.

Ketorolac 0.4 %/0.5 %

- The patient has had a documented intolerance to brand Acular®/Acular LS® ophthalmic solution.

Ocufen®

- The patient has had a documented intolerance to generic flurbiprofen ophthalmic solution.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: NSAIDs

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ACULAR® (ketorolac 0.5% ophthalmic sol.) ACULAR LS ® (ketorolac 0.4% ophthalmic sol.) FLURBIPROFEN 0.03% ophthalmic sol. † (compare to Ocufen®)	Acuvail (ketorolac 0.45 %) Ophthalmic Solution *(Quantity Limit = 30 unit dose packets/15 days)* Bromday® ophthalmic sol (bromfenac 0.09%) Bromfenac† 0.09 % ophthalmic sol (compare to Xibrom®) Diclofenac† 0.1% ophthalmic sol (compare to Voltaren®) Ketorolac † 0.4 % ophthalmic sol (compare to Acular LS®) Ketorolac † 0.5 % ophthalmic sol (compare to Acular®) Ilevro® ophthalmic susp. (nepafenac 0.3%) Nevanac® ophthalmic susp. (nepafenac 0.1%) Ocufen®* ophthalmic sol. (flurbiprofen 0.03%) Prolensa® ophthalmic sol. (bromfenac 0.07%) Voltaren® (diclofenac 0.1% ophthalmic sol.) Xibrom® ophthalmic sol. (bromfenac 0.09%)

Otic: Anti-Infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Ciprofloxacin 0.2%

- The patient has a documented side effect, allergy, or treatment failure to one of the following: any generic neomycin/polymyxin B/hydrocortisone product, Ciprodex® otic suspension, or generic ofloxacin otic solution.

Cipro-HC®, Coly-Mycin S®, Cortisporin TC®

- The patient has had a documented side effect, allergy, or treatment failure to neomycin/polymyxin B sulfate/hydrocortisone and one other preferred product.

Cortisporin® Otic:

- The patient has had a documented intolerance to the generic product.

Acetasol HC, Acetic Acid/Hydrocortisone†, Auralgan®, Myoxin, Otic Care®, Otic Edge®, PR Otic®, Treagan®, TriOxin®, Zinotic®/Zinotic ES®:

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred otic anti-infectives.

Vosol HC®:

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred otic anti-infectives. In addition, the patient has had a documented intolerance to a generic acetic acid/hydrocortisone product.

LIMITATION:

Cetraxal no longer covered due to Federal Rebate not offered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Otic: Anti-Infectives

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Anti-infective Single Agent	
OFLOXACIN† 0.3% Otic Soln (previously Floxin®)	Ciprofloxacin† 0.2% (compare to Cetraxal®) otic solution *(Qty limit = 14 unit dose packages/ 7 days)*
Anti-infective/Corticosteroid Combination	
CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension	Cipro-HC® (ciprofloxacin 0.2%/hydrocortisone 1%) otic suspension
NEOMYCIN/POLYMYXIN B SULFATE/HYDROCORTISONE† (compare to Cortisporpin otic®)	Coly-Mycin S®/Cortisporin TC® (neomycin/colistin/thonzium/hydrocortisone)
CORTOMYCIN† (neomycin/polymyxin B sulfate/hydrocortisone) Otic soln, susp	Cortisporin otic®* (neomycin/polymyxin B sulfate /hydrocortisone) otic solution/suspension
Miscellaneous Agents	
ACETIC ACID† Otic soln	Acetasol HC† (acetic acid 2%/hydrocortisone 1% otic soln)
ACETIC ACID-ALUMINUM ACETATE† Otic soln	Acetic Acid/Hydrocortisone† Otic Soln
VOSOL® (Acetic Acid 2%) Otic soln	Auralgan®/Otic Care®/ Otic Edge®/PR Otic® /Treagan® (acetic acid/antipyrine/benzocaine/polycosanol)
	TriOxin®/ Myoxin (benzocaine/chloroxylenol/hydrocortisone susp)
	Vosol HC® (acetic acid 2%/hydrocortisone 1% otic soln)
	Zinotic®/Zinotic ES® (chloroxylenol/glycerin/pramoxine/zinc acetate)

Over-theCounter (OTC) Drug Class Coverage

Managed on Preferred Drug List (PDL) Refer to PDL categories listed below for details	Limited to Generics Only	Class Not Covered
Anti-diabetics: Insulin	Analgesics, Oral	Alternative Medicines
Analgesics: NSAIDs	Antacids	Analgesics - Topical
Cough and Cold Preparations	Antidiarheals	Anesthetics - Local, Topical & Oral
Acne Drugs: Topical Anti-Infectives	Antiemetics	Antiflatulents
Dermatological Agents: Antivirals: Topical	Anytipruritics - Topical	Antihistamines -Topical
Dermatological Agents: Corticosteroids	Antiseptics, topical (Chlorine/Iodine)	Anti-infectives-Throat
Dermatological Agents: Antifungals: Topical	Decongestants, Nasal & Oral	Anti-Obesity Agents (Alli®)
Dermatological Agents: Antibiotics: Topical	Digestive Enzymes (example; Acidophilus)	Antiseborrheic Products
Dermatological Agents: Scabicides and Pediculocides	Emollient/Keratolytic/Antimitotic Agents	Antiseptics - Mouth/Throat
Diabetic Testing Supplies	Fluoride Dental Products	Antiseptics & Disinfectives
Gastrointestinals: Histamine-2 Receptor Antagonists	Glucosamine-Chondroitin	Bulk Chemicals
Gastrointestinals: Proton Pump Inhibitors	Hematopoietic Agents - Folic Acid/Folates	Charcoal Antidote
Nutritionals, Oral Liquid	Iron Preparations - Ferrous Sulfate/Ferrous Gluconate	Contact Lens Solution
Ophthalmics: Antihistamines	Laxatives	Depigmenting Agents
Pulmonary: Antihistamines: 1st Generation	Melatonin (as a Single Agent only)	Hair Growth Agents
Pulmonary: Antihistamines: 2nd Generation	Minerals	Hematopoietic Agents - Cobalamins & Mixtures
Smoking Cessation Therapies	Calcium	Homeopathic Products
Vitamins: Prenatal Vitamins	Magnesium/Magnesium SR (brand Mag Tab SR® OK)	Infant Foods (refer to WIC)
	Sodium	Liniments
	Ophthalmics	Minerals
	Artificial Tears and Lubricants	Manganese
	Decongestants	Potassium (OTC)
	Hyperosmolar Products	Trace Minerals
	Oral Electrolyte Solution	Zinc
	Otic Agents - Miscellaneous	Mouthwashes
	Proteins/Amino Acids	Nutritional Substances, Miscellaneous
	Rectal Local Anesthetics	Nutritional Substitutes - Sweeteners
	Sleep Aids	Pigmenting Agents
	Tar Products	Scar Treatment Products
	Vaginal Anti-infectives	Shampoos
	Vitamins	Skin Cleansers
	Multiple Vitamins with Minerals	Skin Protectants
	Multivitamins (see next line)	Soaps
	(Aquadek®, Source CF® and Vitamax® brands covered)	Sunscreens
	Pediatric Vitamins	Throat Lozenges
	Vitamin B Complex, B1, B2, B3, B5, B6, B12 (some strengths)	Topicals, Miscellaneous
	Vitamin D	Vitamins
		Vitamin A
		B-Complex with Minerals, B7
		Bioflavanoids
		Biotin
		Vitamin C
		Vitamin E
		Wound Dressings

Pancreatic Enzyme Products

LENGTH OF AUTHORIZATION: 2 years

CRITERIA FOR APPROVAL:

Pancrelipase 5,000 (generic)

- The patient has a documented intolerance to brand Zenpep® 5,000

All others:

- The patient has been started and stabilized on the requested product.

OR

- The patient has had treatment failure or documented intolerance with both Creon® and Zenpep®.

Pancreatic Enzyme Products *Length of Authorization = 2 years* **Key: † Generic product**	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
CREON® DR Capsule ZENPEP® DR Capsule	Pancreaze® DR Capsule Pancrelipase† 5,000 (compare to Zenpep® 5,000) Pertzye® DR Capsule Ultresa® DR Capsule Viokace® DR Capsule

Abbreviations: DR=delayed release

Parkinson's Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Sinemet®, Sinemet® CR, Mirapex®, Parcopa®, Parlodel®, Requip®, Eldepryl®

- The patient has had a documented intolerance to the generic product.

Amantadine tablets

- The patient has had a documented intolerance to generic amantadine capsules.

Azilect®

- The diagnosis or indication is Parkinson's disease.

AND

- The patient has had a documented side effect, allergy, or treatment failure with selegiline.

AND

- The dose requested does not exceed 1 mg/day

carbidopa/levodopa/entacapone

- The patient has had a documented intolerance to brand Stalevo.

Mirapex ER®, Requip XL®, ropinirole XL

- The diagnosis or indication is Parkinson's disease. Requests will not be approved for Restless Leg Syndrome (RLS)

AND

- The patient has had an inadequate response (i.e. wearing off effect or "off" time) with the immediate release product.

OR

- The patient has not been able to be adherent to a three times daily dosing schedule of the immediate release release product resulting in a significant clinical impact.

AND

- If the requested product has an AB rated generic, the patient has a documented intolerance to the generic product.

Neupro®:

- The patient is ≥18 years of age

AND

- The patient has a diagnosis of Parkinson's disease.

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure to generic immediate release ropinirole or pramipexole AND ropinirole XL or Mirapex ER®.

OR

- The prescriber provides medical necessity for the transdermal formulation (eg. swallowing disorder or difficulty taking oral medications).

Tasmar®

- The diagnosis or indication is Parkinson's disease.

AND

- The patient has had a documented side effect, allergy, or treatment failure with Comtan®.

Zelapar®

- The diagnosis or indication is Parkinson's disease.

AND

- The patient is on current therapy with levodopa/carbidopa.

AND

- Medical necessity for disintegrating tablet administration is provided (i.e. inability to swallow tablets or drug interaction with oral selegiline).

AND

- The dose requested does not exceed 2.5 mg/day.

LIMITATIONS:

To prevent the use of amantadine in influenza treatment/prophylaxis, days supply ≤ 10 days will require PA.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Parkinson's Medications

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DOPAMINE PRECURSOR/DOPA DECARBOXYLASE INHIBITORS CARBIDOPA/LEVODOPA† (compare to Sinemet®) CARBIDOPA/LEVODOPA† ER (compare to Sinemet® CR) CARBIDOPA/LEVODOPA† ODT (compare to Parcopa®)	Parcopa®* (carbidopa/levodopa ODT) Sinemet®* (carbidopa/levodopa) Sinemet CR®*(carbidopa/levodopa ER)
DOPAMINE AGONISTS (ORAL) BROMOCRIPTINE† (compare to Parlodel®) PRAMIPEXOLE † (compare to Mirapex®) ROPINIROLE† (compare to Requip®)	Mirapex®* (pramipexole) Mirapex ER® (pramipexole ER) *QL = 1 tab/day* Parlodel®* (bromocriptine) Requip®* (ropinirole) Requip XL® (ropinirole XL) *QL = 1 tab/day (all strengths except 12 mg), QL = 2 tabs/day (12 mg)* ropinirole XL† (compare to Requip XL®) *QL = 1 tab/day (all strengths except 12 mg), QL = 2 tabs/day (12 mg)*
DOPAMINE AGONISTS (TRANSDERMAL) **All products require PA.**	Neupro® (rotigotine) transdermal patch *(Quantity Limit = 1 patch/day)* *(2mg, 4 mg, 6 mg and 8 mg patches)*
COMT INHIBITORS COMTAN® (entacapone) ENTACAPONE† (compare to Comtan®)	Tasmar® (tolcapone)
MAO-B INHIBITORS SELEGILINE† (compare to Eldepryl®)	Azilect® (rasagiline) *(QL = 1 mg/day)* Eldepryl®* (selegiline) Zelapar® (selegiline ODT) *(QL = 2.5 mg/day)*
OTHER AMANTADINE†capsules, syrup (formerly Symmetrel®) (PA required for ≤ 10 day supply) STALEVO® (carbidopa/levodopa/entacapone)	Amantadine† tablets (formerly Symmetrel®) (Quantity limit PA also required for ≤ 10 day supply) carbidopa/levodopa/entacapone† (compare to Stalevo®)

ODT = orally disintegrating tablets

Phosphodiesterase-4 (PDE-4) Inhibitor Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The indication for the requested medication is treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

AND

- The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled long-acting anticholinergic AND at least one inhaled long-acting beta-agonist.

AND

- The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled corticosteroid.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Phosphodiesterase-4 (PDE-4) Inhibitors	*Length of Authorization: 1 year*
NO PA REQUIRED	**PA REQUIRED**
All products require PA.	Daliresp® tablet (roflumilast) *Quantity limit = 1 tablet/day*

Phosphodiesterase-5 (PDE-5) Inhibitor Medications

Effective 7/1/06, phosphodiesterase-5 (PDE-5) inhibitors are no longer a covered benefit for all Vermont Pharmacy Programs for the treatment of erectile dysfunction. This change is resultant from changes set into effect on January 1, 2006 and as detailed in Section 1903(i)(21)(K) of the Social Security Act (the Act), precluding Medicaid Federal Funding for outpatient drugs used for the treatment of sexual or erectile dysfunction. Sildenafil will remain available for coverage via prior authorization for the treatment of Pulmonary Arterial Hypertension.

LENGTH OF AUTHORIZATION: Revatio IV: Date of service

All Others: 1 year

CRITERIA FOR APPROVAL:

Adcirca® (tadalafil) 20 mg, Revatio® (sildenafil citrate) 20 mg, sildenafil citrate 20 mg:

- Clinical diagnosis of pulmonary hypertension

  AND
- No concomitant use of organic nitrate-containing products

  AND
- For approval of Revatio, the patient has a documented intolerance to the generic equivalent.

Viagra® (sildenafil citrate) 25 mg, 50 mg, and 100 mg:

- Clinical diagnosis of pulmonary hypertension

  AND
- No concomitant use of organic nitrate-containing products

  AND
- Inadequate response to Revatio (sildenafil) 20 mg or currently maintained on a sildenafil dose of 25 mg TID or higher

Revatio IV®

- Clinical diagnosis of pulmonary hypertension

  AND
- No concomitant use of organic nitrate-containing products

  AND
- The patient has a requirement for an injectable dosage form.

  AND
- Arrangements have been made for IV bolus administration outside of an inpatient hospital setting.

DOCUMENTATION:

- ✓ Document clinical information supporting the choice of agent on a **General Prior Authorization Request Form**.

Phosphodiesterase 5 (PDE-5)Inhibitors	
	Length of Authorization:Date of Service or 1 year
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Adcirca® (tadalafil) *(Quantity Limit = 2 tablets/day)* Revatio® (sildenafil citrate) tablet *(Quantity Limit = 3 tablets/day)* Revatio® (sildenafil citrate) vial *(Quantity Limit = 3 vials/day, maximum 14 days supply per fill)* sildenafil citrate (compare to Revatio®) *(Quantity Limit = 3 tablets/day)* Viagra® (sildenafil citrate) *(Quantity Limit = 3 tablets/day)*

Note: Please refer to “Pulmonary Arterial Hypertension Medications” for Endothelian Receptor Antagonists and Prostanoids.

Platelet Inhibitors

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Agrylin®, Persantine®, Plavix®, Pletal®:

- The patient has had a documented intolerance to the generic formulation of the medication.

Brilinta®:

- The patient is started and stabilized on the medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, inadequate response or has a contraindication to at least one preferred platelet inhibitor.

LIMITATIONS:

Plavix®/clopidogrel 300mg is not an outpatient dose and is not covered in the pharmacy benefit.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Platelet Inhibitors *Length of Authorization: 1 year* **Key: † Generic product, *Indicates generic equivalent is available without a PA**	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
AGGREGATION INHIBITORS CILOSTAZOL† (compare to Pletal®) EFFIENT® (prasugrel) Tablet *QL = 1 tablet/day* CLOPIDOGREL 75 mg (compare to Plavix®) TICLOPIDINE† (previously Ticlid®)	Brilinta® (ticagrelor) Tablet *QL = 2 tablets/day* Plavix® 75 mg (clopidogrel bisulfate) Pletal®* (cilostazol)
OTHER AGGRENOX® (dipyridamole/Aspirin) ANAGRELIDE† (compare to Agrylin®) ASPIRIN† DIPYRIDAMOLE† (compare to Persantine®)	Agrylin®* (anagrelide) Persantine®* (dipyridamole)

Post-herpetic Neuralgia Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Gralise®:

- The patient has a diagnosis of post-herpetic neuralgia (PHN)

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure with at least one drug from the tricyclic antidepressant class.

AND

- The patient has had an inadequate response to the generic gabapentin immediate-release.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Post-herpetic Neuralgia Agents	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All products require PA.	Gralise® (gabapentin) tablet, starter pack *Quantity Limit = 3 tablets/day* *(Maximum 30 day supply per fill)*

Note: Please refer to "Analgesics: Miscellaneous: Transdermal Patch" for clinical criteria for **Lidoderm®** and **Qutenza®**, "Anticonvulsants" for clinical criteria for **Lyrica®** and "Anti-Depressants – SNRIs" for clinical criteria for **Cymbalta®**.

Psoriasis Medications: Injectables

***NOTE*: Psoriasis Self-Injectables (Enbrel® and Humira®) must be obtained and billed through our specialty pharmacy vendor, Briova. Stelara® may either be obtained and billed through our specialty pharmacy vendor, Briova or through the medical benefit. Please see the Enbrel, Humira or Stelara Prior Authorization/Patient Enrollment Form for instructions. Briova may supply Remicade® upon request or you may continue to obtain through your usual supplier.**

LENGTH OF AUTHORIZATION: Initial PA of 3 months (Stelara 4 months), and 12 months thereafter upon recertification

CRITERIA FOR APPROVAL:

Enbrel®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Enbrel®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.
Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.
Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

Humira®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Humira®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.
Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.
Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

Remicade®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Remicade®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.
Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.
Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

AND

The prescriber must provide a clinically valid reason why either Enbrel® or Humira® cannot be used.

Stelara®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Stelara®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.
Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.
Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

AND

The prescriber must provide a clinically valid reason why either Enbrel® or Humira® cannot be used.

DOCUMENTATION:

- ✓ Document clinical information for **Enbrel®**, **Humira® or Stelara®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form.**

- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or ustekinumab (Stelara®) (whether billed through the pharmacy or medical benefit (J3357)) require Prior Authorization through the Catamaran Clinical Call Center.

Psoriasis Medications: Injectables

Length of authorization: Initial PA of 3 months (Stelara 4 months); 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
ENBREL® (etanercept) *Quantity limit = 8 syringes/28 days for the first 3 months; then 4 syringes/28 days(50 mg) or 8 syringes/28 days (25 mg) subsequently* HUMIRA® (adalimumab) *Quantity limit = 4 syringes/28 days for one month month; 2 syringes/28 days subsequently*	Remicade® (infliximab) Stelara® (ustekinumab) *(Quantity limit = 45 mg (0.5 ml) or 90 mg (1 ml) per dose)* *(90 mg dose only permitted for pt weight > 100 kg)*

Psoriasis: Non-Biologics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Acritretin Capsules

- The patient has a documented intolerance to brand Soriatane capsules.

Calcitrene Ointment

- The patient has a documented intolerance to Calcipotriene ointment.

Calcipotriene Cream

- The patient has a documented intolerance to the brand Dovonex cream.

Dovonex Solution

- The patient has a documented intolerance to the generic product.

Taclonex or calcipotriene/betamethasone diproprionate Ointment or Scalp Suspension

- The patient has had an inadequate response to a 24 month trial of a betamethasone dipropionate product and Dovonex (or generic calcipotriene), simultaneously, with significant non-adherence issues.

AND

- The patient has had a documented side effect, allergy, or treatment failure with Tazorac 0.05% or 0.1% cream or gel.

Note: If approved, initial fill of Taclonex® or calcipotriene/betamethasone diproprionate will be limited to 60 grams.

Vectical Ointment, Calcitriol Ointment

- The patient ≥ 18 years of age

AND

- The patient has a diagnosis of mild-to-moderate plaque psoriasis

AND

- The patient has demonstrated inadequate response, adverse reaction or contraindication to calcipotriene

AND

- If the request is for brand Vectical, the patient has hads a documented intolerance to the generic product.

Sorilux

- The patient ≥ 18 years of age

AND

- The patient has a diagnosis of plaque psoriasis

AND

- The patient has demonstrated inadequate response or intolerance to other dosage forms of calcipotriene (brand or generic)

LIMITATIONS:

Kits with non-drug products or combinations of 2 drug products are not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Psoriasis: Non-Biologics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ORAL	
CYCLOSPORINE† (all brand and generic) METHOTREXATE† (all brand and generic) OXSORALEN-ULTRA® (methoxsalen) SORIATANE® (acitretin) capsules	Acitretin† (compare to Soriatane®) capsules
TOPICAL	
CALCIPOTRIENE† Solution (compare to Dovonex®) CALCIPOTRIENE® OINTMENT (formerly Dovonex®) DOVONEX® (calcipotriene cream) PSORIATEC®, DRITHO-SCALP® (anthralin cream) TAZORAC® (tazarotene cream, gel)	Calcitrene® (calcipotriene) ointment calcitriol† (compare to Vectical®) Ointment *(Quantity Limit = 200 g (2 tubes)/week)* Calcipotriene† cream (compare to Dovonex®) Calcipotriene/betamethasone ointment† (compare to Taclonex®) *(QL for initial fill = 60 grams)* Dovonex®* Solution (calcipotriene) Sorilux® (calcipotriene) foam Taclonex® (calcipotriene/betamethasone ointment/scalp suspension) *(QL for initial fill = 60 grams)* Vectical® Ointment (calcitriol) *(Quantity Limit = 200 g (2 tubes)/week)*

Pulmonary: Anticholinergics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Anoro Ellipta

- The patient has a diagnosis of COPD (not FDA approved for asthma).

Duoneb Nebulizer

- The patient has a documented intolerance to generic ipratropium/albuterol nebulizer.

Tudorza Pressair

- The patient has a documented side effect, allergy, or treatment failure with Spiriva.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Anticholinergics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
METERED DOSE INHALER (SINGLE AGENT) **Short Acting** ATROVENT HFA® (ipratropium) *Quantity Limit = 2 inhalers/25 days*	
Long Acting SPIRIVA® (tiotropium) *Quantity Limit = 1 capsule/day*	Tudorza® Pressair (aclidinium bromide) *Quantity Limit = 1 inhaler/30 days*
NEBULIZER (SINGLE AGENT) IPRATROPIUM SOLN FOR INHALATION	
INHALER (COMBINATION) **Short Acting** COMBIVENT® (ipratropium/albuterol) MDI *Quantity Limit = 2 inhalers/30 days* COMBIVENT® RESPIMAT (ipratropium/albuterol) *Quantity Limit = 1 inhaler (4 grams)/30 days*	
Long Acting **All require PA**	Anora® Ellipta (umeclidinium/vilanterol) *Quantity Limit = 1 inhaler(60 blisters)/30 days*
NEBULIZER (COMBINATION) IPRATROPIUM/ALBUTEROL† (compare to Duoneb®)	Duoneb®* (ipratropium/albuterol)

Pulmonary: Antihistamines: Intranasal

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ASTELIN, ASTEPRO, AZELASTINE, DYMISTA, PATANASE

- The diagnosis or indication for the requested medication is allergic rhinitis.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) **OR** cetirizine (OTC) **AND** a preferred nasal corticosteroid used in combination.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: Intranasal	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
SINGLE AGENT **All products require PA.**	Astelin® (azelastine) Nasal Spray *Quantity Limit = 1 bottle (30 ml)/30 days* azelastine (compare to Astelin®) Nasal Spray *Quantity Limit = 1 bottle (30 ml)/30 days* Astepro® (azelastine) Nasal Spray *Quantity Limit = 1 bottle (30 ml)/30 days* Patanase® (olopatadine 0.6%) Nasal Spray *Quantity Limit = 1 bottle (31 gm)/30 days*
COMBINATION WITH CORTICOSTEROID **All products require PA.**	Dymista® (azelastine/fluticasone) Nasal Spray *Quantity Limit = 1 bottle (23 gm)/30 days*

Pulmonary: Antihistamines: 1st Generation

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available products would not be a suitable alternative.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: 1st Generation *Length of Authorization: 1 year* Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
All generic antihistamines	All brand antihistamines (example: Benadryl®)
All generic antihistamine/decongestant combinations	All brand antihistamine/decongestant combinations (example: Deconamine SR®, Rynatan®, Ryna-12®)

Pulmonary: Antihistamines: 2nd Generation

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

SINGLE AGENT TABLET

FEXOFENADINE 60MG/180 MG TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) AND cetirizine (OTC).

CLARINEX TABLETS, CLARITIN TABLETS, DESLORATADINE TABLETS, LEVOCETIRIZINE TABLETS, XYZAL TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) AND cetirizine (OTC).

AND

- The patient has had a documented side effect, allergy, or treatment failure to fexofenadine.

AND

- If the request is for Clarinex or Xyzal, the patient must also have a documented intolerance to the generic equivalent tablets.

CHEWABLE/ORALLY DISINTEGRATING TABLET

CERTIRIZINE CHEWABLE TABLETS, CLARINEX REDITABS, CLARITIN CHEWABLE TABLETS, CLARITIN REDITABS, DESLORATADINE ODT, ZYRTEC ALLERGY OTC DISINTEGRATING TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) rapidly disintegrating tablets or requires less than a 10 mg dose of loratadine.

AND

- If the request is for Clarinex Reditabs, the patient must also have a documented intolerance to the generic equivalent tablets.

SINGLE AGENT ORAL LIQUID

CLARINEX SYRUP, CLARITIN OTC SYRUP, LEVOCETIRIZINE SOLUTION, XYZAL SOLUTION, ZYRTEC CHILDREN'S ALLERGY ORAL LIQUID

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine syrup AND cetirizine syrup.

AND

- If the request is for Xyzal, the patient must also have a documented intolerance to levocetirizine solution.

COMBINATION WITH PSEUDOEPHEDRINE

CETIRIZINE D, CLARINEX-D, CLARITIN-D

- The diagnosis or indication for the requested medication is allergic rhinitis.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine-D (OTC).

LIMITATIONS:

Many Allegra® and Zyrtec® brand products as well as Claritin® capsules are not covered as no Federal Rebate is offered.
Fexofenadine suspension not covered as no Federal Rebate is offered.
Fexofenadine/pseudoephedrine combination products) (brand and generic) are not covered – individual components may be prescribed separately.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: 2nd Generation

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE AGENT TABLET LORATADINE † (OTC) (Allergy Relief®, Alavert®) (compare to Claritin®) 10 mg tablet CETIRIZINE† OTC (formerly Zyrtec®) 5 mg, 10 mg tablets **After loratadine OTC and cetirizine OTC trials** FEXOFENADINE † 60 mg, 180 mg (OTC) tablets (formerly Allegra®)	Clarinex® (desloratadine) 5 mg tablet Claritin®* tablets OTC (loratadine) 10 mg desloratadine† (compare to Clarinex®) 5 mg tablet Levocetirizine† (compare to Xyzal®) 5 mg tablet Xyzal® (levocetirizine) 5 mg tablet All other brands
COMBINATION WITH PSEUDOEPHEDRINE LORATADINE/PSEUDOEPHEDRINE SR 12hr 5 mg/120 MG † (OTC) (Alavert Allergy/Sinus®) (compare to Claritin D® 12 hr) LORATADINE/PSEUDOEPHEDRINE SR 24hr 10 mg/240 MG † (OTC) (compare to Claritin D® 24 hr)	Cetirizine/Pseudoephedrine SR 12hr 5 mg/120 mgOTC† Clarinex-D® 12 hr (desloratadine/pseudoephedrine 2.5 mg/120 mg) Clarinex-D® 24 hr (desloratadine/pseudoephedrine 5 mg/240 mg) Claritin-D 12 hr®*§ (loratadine/pseudoephedrine 5 mg/120 mg) Claritin-D 24 hr®*§ (loratadine/pseudoephedrine 10 mg/240 mg) All other brands
SINGLE AGENT ORAL LIQUID LORATADINE † (OTC) syrup (Allergy Relief®) (compare to Claritin®) CETIRIZINE † (OTC, RX) syrup	Clarinex Syrup® (desloratadine) Claritin OTC Syrup®* (loratadine) Levocetirizine (compare to Xyzal®) Solution Xyzal® (levocetirizine) Solution Zyrtec®* Children's Allergy (cetirizine) (only one NDC) All other brands
CHEWABLE/ORALLY DISINTEGRATING TABLET LORATADINE † (OTC) (Allergy Relief®, Alavert®) rapidly disintegrating tablet (RDT) (compare to Claritin®) 10 mg	Certirizine † OTC Chewable Tablets 5 mg, 10 mg Clarinex Reditabs® (desloratadine) 2.5 mg, 5 mg Claritin (loratadine) OTC Chewable Tablets®§ 5 mg Claritin (loratadine) OTC Reditabs®§ 5 mg, 10 mg* Desloratadine ODT (compare to Clarinex Reditabs®) 2.5 mg, 5 mg Zyrtec Allergy® OTC (cetirizine orally disintegrating tablet) 10 mg All other brands

Pulmonary: Beta-Adrenergic Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Metered Dose Inhalers (Long-Acting)
Effective 11/1/06, prior-authorization will be required for long-acting beta-adrenergic (LABA) MDIs for patients who have not been on a controller medication in the past 6 months or who do not have a diagnosis of COPD.

Foradil, Serevent:

- The patient has a diagnosis of COPD
  OR
- The patient has a diagnosis of asthma and is prescribed an inhaled corticosteroid as a controller medication.

Arcapta:

- The patient has a diagnosis of COPD (not FDA approved for asthma).
  AND
- The patient has a documented side effect, allergy, or treatment failure to either Foradil or Serevent.

Accuneb® nebulizer solution 0.63 mg/3 ml and 1.25 mg/3 ml

- The patient must have had a documented intolerance to the generic formulation.

Levalbuterol nebulizer solution (age ≤ 12 years)

- The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.

Levalbuterol nebulizer solution (age > 12 years)

- The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer.
  AND
- The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.

Xopenex® nebulizer solution (age >12 years)

- The patient must have been started and stabilized on the requested medication.
  OR
- The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer.

Brovana® or Perforomist® Nebulizer Solution

- The patient must have a diagnosis of COPD**.**
  AND
- The patient must be unable to use a non-nebulized long-acting bronchodilator or anticholinergic (Foradil®, Serevent® or Spiriva®) due to a physical limitation

Metaproterenol tablets/syrup

- The patient has had a documented side effect, allergy or treatment failure with generic albuterol tablets/syrup.

Terbutaline, Brethine® tablets

- The medication is not being prescribed for the prevention/treatment of preterm labor.
  AND
- If Brethine is requested, the patient must have had a documented side effect, allergy, or treatment failure to generic terbutaline tablets.

Ventolin HFA, Xopenex HFA

- The patient must have had a documented side effect, allergy, or treatment failure to ONE preferred short acting metered dose inhaler.

Vospire ER® tablets

- The patient must have had a documented side effect, allergy, or treatment failure to generic albuterol ER tablets.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Beta-Adrenergic Agents *Length of Authorization: 1 year* **Key: † Generic product, *Indicates generic equivalent is available without a PA**	
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
METERED-DOSE INHALERS (SHORT-ACTING)	
PROAIR® HFA (albuterol) PROVENTIL® HFA (albuterol) MAXAIR® Autohaler (pirbuterol)	Ventolin® HFA (albuterol) Xopenex® HFA (levalbuterol)
METERED-DOSE INHALERS (LONG-ACTING)	
SEREVENT® DISKUS (salmeterol) (*after criteria for LABA are met)* *Quantity Limit = 60 blisters/30 days* FORADIL® (formoterol) (*after criteria for LABA are met)* *Quantity Limit = 60 capsules/30 days*	Arcapta® Neohaler (indacaterol) *Quantity Limit = 1 capsule/day*
NEBULIZER SOLUTIONS (SHORT-ACTING)	
ALBUTEROL † 0.63 mg/3 ml and 1.25 mg/3 ml neb solution (compare to Accuneb®) ALBUTEROL † 2.5 mg/3 ml neb solution ALBUTEROL † 5 mg/ml neb solution XOPENEX® neb solution (levalbuterol) (age ≤ 12 years)	Accuneb®* (albuterol sulfate neb solution 0.63 mg/3 ml and 1.25 mg/3 ml) Levalbuterol † neb solution (compare to Xopenex®) (all ages) Xopenex® neb solution (levalbuterol) (age >12 years)
NEBULIZER SOLUTIONS (LONG-ACTING)	
All products require PA.	Brovana® (arformoterol) *QL = 2 vial/day* Perforomist® (formoterol) *QL = 2 vial/day*
TABLETS/SYRUP (SHORT-ACTING)	
ALBUTEROL tablets/syrup †	Brethine®* (terbutaline) metaproterenol tablets/syrup † terbutaline tablets † (compare to Brethine®)
TABLETS (LONG-ACTING)	
ALBUTEROL ER tablets †	Vospire ER®* (albuterol)

Pulmonary: Corticosteroids/Combinations: Inhaled

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Metered-dose inhalers (single agent):

- The patient has been started and stablized on the medication.

OR

- The patient has had a documented side effect, allergy, or treatment failure to at least two preferred agents.

Breo Ellipta:

- The patient has a diagnosis of COPD (Note: Will not be approved for use in asthma).

AND

- The patient has had a documented side effect, allergy, or treatment failure to Advair or Symbicort.

Budesonide Inh Suspension (all ages):

- The patient requires a nebulizer formulation.

AND

- The patient has a documented intolerance to the brand product.

Pulmicort Respules® (age > 12 years):

- The patient requires a nebulizer formulation.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Corticosteroids/Combinations: Inhal

Length of Authorization: 1 year

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
METERED-DOSE INHALERS (SINGLE AGENT)	
AEROSPAN (flunisolide HFA) *(QL = 6 inhalers (53.4 gm)/90 days)* ASMANEX® 110 or 220 mcg/inh (mometasone furoate) *(QL =3 inhalers/90 days)* FLOVENT DISKUS® (fluticasone propionate) *(QL = 3 inhalers/90 days)* FLOVENT HFA® (fluticasone propionate) *(QL = 36 gm (3 inhalers)/90 days)* PULMICORT FLEXHALER® (budesonide) *(QL = 6 inhalers/90 days)* QVAR® 40 mcg/inh (beclomethasone) *(QL = 17.4 gm (2 inhalers)/90 days)* QVAR® 80 mcg/inh (beclomethasone) *(QL = 58.4 gm (8 or 6 inhalers)/90 days)*	Alvesco® (ciclesonide) *(QL = 18.3 gm (3 inhalers)/90 days)) (80 mcg/inh)* *(QL =36.6 gm (6 inhalers)/90 days)) (160 mcg/inh)*
METERED-DOSE INHALERS (COMBINATION PRODUCT)	
ADVAIR® DISKUS (fluticasone/salmeterol) *(QL = 3 inhalers/90 days)* ADVAIR® HFA (fluticasone/salmeterol) *(QL = 36 gm (3 inhalers)/90 days)* DULERA® (mometasone/formoterol) *(QL = 39 gm (3 inhalers)/90 days)* SYMBICORT® (budesonide/formoterol) *(QL = 30.6 gm (3 inhalers)/90 days)*	Breo Ellipta® (fluticasone furoate/vilanterol) *(QL = 180 blisters(3 inhalers)/90 days)*
NEBULIZER SOLUTIONS	
PULMICORT RESPULES® (budesonide) (age ≤ 12 yrs)	Budesonide Inh Suspension (compare to Pulmicort Respules®) (all ages) Pulmicort Respules® (budesonide) (age > 12 years)

Pulmonary: Corticosteroids: Intranasal

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Single Agent:

Beconase AQ®, Flonase®, Flunisolide 25 mcg/spray, Flunisolide 29 mcg/spray, Nasacort AQ®, Omnaris®, QNASL®, Rhinocort Aqua®, triamcinolone, Veramyst®, Zetonna®:

The patient has had a documented side effect, allergy, or treatment failure to BOTH preferred nasal glucocorticoids. If the request is for Nasacort AQ®, the patient has also had a documented intolerance to the generic equivalent.

Combination Agent with Antihistamine:

Dymista®:

- The diagnosis or indication is allergic rhinitis.

AND

- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) **OR** cetirizine (OTC) **AND** a preferred nasal corticosteroid used in combination.

LIMITATIONS:

Nasacort Allergy® OTC not covered as no Federal Rebate is offered. Nasacort AQ® RX available after PA obtained.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Corticosteroids: Intranasal

Length of Authorization: 1 year

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SINGLE AGENT FLUTICASONE Propionate† (compare to Flonase®) *QL = 16 gm (1 inhaler)/30 days* NASONEX® (mometasone) *QL = 17 gm (1 inhaler)/30 days*	Beconase AQ® (beclomethasone) *QL =50 gm (2 inhalers)/30 days* Flonase®* (fluticasone propionate) *QL = 16 gm (1 inhaler)/30 days* flunisolide † 25 mcg/spray (previously Nasalide®) *QL = 50 ml (2 inhalers)/30 days* flunisolide† 29 mcg/spray (formerly Nasarel®) *QL = 50 ml (2 inhalers)/30 days* Nasacort AQ® (triamcinolone) *QL = 16.5 gm (1 inhaler)/30 days* Omnaris® (ciclesonide) *QL = 12.5 gm (1 inhaler)/30 days* QNASL® (beclomethasone diproprionate) HFA *QL = 8.7 gm (1 inhaler)/30 days* Rhinocort Aqua® (budesonide) *QL = 8.6 gm (1 inhaler)/30 days* triamcinolone † (compare to Nasacort AQ®) *QL = 16.5 gm (1 inhaler)/30 days* Veramyst® (fluticasone furoate) *QL = 10 gm (1 inhaler)/30 days* Zetonna® (ciclesonide) *QL = 6.1 gm (1 inhaler)/30 days*
COMBINATION WITH ANTIHISTAMINE **All products require PA.**	Dymista® (azelastine/fluticasone) *QL = 23 gm (1 inhaler)/30 days*

Pulmonary: Leukotriene Modifiers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Montelukast, Singulair®

- The diagnosis or indication for the requested medication is asthma.

  OR
- The diagnosis or indication for the requested medication is allergic rhinitis.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to a second generation non-sedating antihistamine **AND** a nasal corticosteroid.

  OR
- The diagnosis or indication for the requested medication is urticaria.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred 2nd generation antihistamines (i.e. loratadine (OTC), cetirizine (OTC), fexofenadine).

  AND
- If the request is for brand Singulair tablets, chew tablets or granules, the patient has a documented intolerance to the generic equivalent montelukast preparation.

Zafirlukast, Accolate®

- The diagnosis or indication for the requested medication is asthma.

  AND
- If the request is for Accolate, the patient has a documented intolerance to generic zafirlukast.

Zyflo CR®

- The diagnosis or indication for the requested medication is asthma.

  AND
- The patient has had a documented side effect, allergy, or treatment failure to Accolate® or Singulair®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Leukotriene Modifiers

Length of Authorization: 1 year

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Note: Children 5 years old and under not subject to PA criteria for Singulair®.	Accolate® (zafirlukast) *Quantity Limit = 2 tablets/day* Montelukast sodium† (compare to Singulair®) tablets, chew tabs, granules **§** *QL = 1 tablet or packet per day* Singulair® (montelukast sodium) **§** tablets, chew tabs, granules *QL = 1 tablet or packet per day* zafirlukast (compare to Accolate®) **§** *Quantity Limit = 2 tablets/day* Zyflo CR® (zileuton SR) *Quantity Limit = 4 tablets/day*

Asthma Diagnosis: POS looks back for beta agonist rescue inhaler or inhaled coticosteroids/corticosteroid combinations for inferred diagnosis.
Allergic Rhinitis Diagnosis: POS looks back for second generation non-sedating antihistamine and nasal corticosteroid.

Pulmonary: Synagis®

***NOTE*: Synagis® must be obtained and billed through our specialty pharmacy vendor for Synagis®, Wilcox Home Infusion. Please see Synagis Prior Authorization/Enrollment Form for instructions.**

LENGTH OF AUTHORIZATION: Only one dose (based on recipient weight) will be approved per thirty-day period. Dose is given once monthly between November 1st and March 31st (up to 5 doses depending on gestational age).

INDICATION:

Palivizumab is indicated for the prevention of RSV lower respiratory tract disease in selected infants and children with chronic lung disease of prematurity (CLD [formerly called bronchopulmonary dysplasia]) or with a history of preterm birth (< 35 weeks' gestation) or with congenital heart disease.

CRITERIA FOR APPROVAL:

- Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under twelve months of age at the start of the RSV season (maximum 5 doses).
- Infants born at 29-32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses).
- Infants born at 32-35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)
    - Infant attends child care
    - One of more older siblings (or other child permanently in house) < 5 years of age (multiple births younger than 1 year of age do not qualify)
- Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses).
- Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease (CHD) (maximum 5 doses):
    - Receiving medication to control congestive heart failure
    - Moderate to severe pulmonary hypertension
    - Have cyanotic heart disease
- Infants under 12 monthsof age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old -maximum 5 doses)
    - Congenital abnormalities of the airways
    - Neuromuscular condition compromising handling of respiratory tract secretions

EXCLUDED FROM APPROVAL:

- Infants and children with hemodynamically insignificant heart disease.
- Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure.
- Infants with mild cardiomyopathy who are not receiving medical therapy.
- Established RSV disease.

This drug must be obtained and billed through our specialty pharmacy vendor for Synagis®, Wilcox Home Infusion, and processed through the DVHA POS prescription processing system using NDC values.
Under no circumstances will claims processed through the medical benefit be accepted.

DOCUMENTATION:

Document clinically compelling information supporting the use of Synagis on the **Synagis® Prior Authorization/Patient Enrollment Form**.

SYNAGIS® PALIVIZUMAB

VERMONT RSV Season 2013-2014

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

Supervising Physician's Name (If Required for Mid-Level Practitioner)	NPI Number

WILCOX MEDICAL

Wilcox Home Infusion
250 Stratton Road
Rutland, Vermont 05701
A subsidiary of bioscrip

Form Last Updated 09/2013

Fax Completed Form to:

Fax Number: 855-775-7824

Phone Number: 800-639-1210

3 Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST SYNAGIS® (PALIVIZUMAB)

Gestational Age: weeks: days:	Current Weight: (kg)	Dose: 15mg / kg (weight verified monthly)

Diagnosis:

☐ Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under 12 months of age at the start of the RSV season (maximum 5 doses)

☐ Infants born at 29 - 32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses)

☐ Infants born at 32 - 35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)

☐ Infant attends child care ☐ One or more older siblings (or other child permanently in house) < 5 years of age (multiple births younger than 1 year of age do not qualify)

☐ Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses)

☐ Treatment: ☐ Dates of Use:

☐ Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease(CHD)

☐ Receiving medication to control congestive heart failure

☐ Moderate to severe pulmonary hypertension (maximum 5 doses)

☐ Have cyanotic heart disease

☐ Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old – maximum 5 doses)

☐ Congenital abnormalities of the airways

☐ Neuromuscular condition compromising handling of respiratory tract secretions

☐ Other:

NICU HISTORY

Did the patient spend time in the NICU?
☐ Yes ☐ No (If yes, please attach the NICU summary)

Was RSV prophylaxis recommended by the NICU/Hospital physician for this patient?
☐ Yes ☐ No

Was a NICU/Hospital /Clinic dose administered?
☐ Yes, Date(s): ☐ No

4 PRESCRIPTION

Synagis (palivizumab) 50 and/or 100 mg vials and supplies for administration.

Sig: Inject 15 mg/kg IM once every 4 weeks; expected date of first home injection:_____

Dispense Quantity: Quantity sufficient for prophylaxis thru 03/2014

Deliver product to: ☐ MD office ☐ Patient's home ☐ Clinic

☐ Home health nurse to administer injection Home Health Agency:_____

If delivery is to clinic, please give location:_____

Pediatric Anaphylaxis: Administer 0.01 ml/kg (max 0.3ml) of 1:1000 epinephrine solution subcutaneously or intramuscularly, and contact EMS or physician, as appropriate.

Other:_____

Sig: _____

Physician will monitor patient's response to therapy. Any complications in therapy will be reported to the physician either by the patient's caregiver, or the skilled nursing service (If other than physician's office or Wilcox Home Infusion)

Prescriber's Signature: _____ **Date:** _____

Supervising Physician's Signature: _____

This order is valid for the entire upcoming season if signed prior to the November dose, or for the remainder of the present season if signed after November.

Pulmonary: Xolair® (for Persistent Asthma)

LENGTH OF AUTHORIZATION: ***3 months initially,*** subsequent approvals will be granted for one year upon verification of marked clinical improvement. Yearly pulmonologist/allergist/immunologist consult required.

CRITERIA FOR APPROVAL:

- Patient must have a diagnosis of moderate to severe persistent asthma.

AND

- Patient is 12 years of age or older

AND

- Patient has tried and failed an inhaled oral corticosteroid (with or without chronic oral corticosteroid therapy) *or* has a contraindication to an inhaled corticosteroid.

AND

- Patient has tried and failed a leukotriene receptor antagonist *or* has a contraindication to a leukotriene receptor antagonist.

AND

- Patient has tried and failed a long acting beta-agonist *or* has a contraindication to a long acting beta-agonist.

AND

- A pulmonologist/allergist/immunologist consult has been obtained within the past year.

AND

- Patient has tested positive to at least one perennial aeroallergen by a skin or blood test (i.e.: RAST, CAP, intracutaneous test).

AND

- Patient has an IgE level ≥ 30 and ≤ 700 IU/ml prior to beginning therapy with Xolair®.

This drug must be billed through the DVHA POS prescription processing system using NDC values.
J codes will NOT be accepted.

LIMITATIONS:
Xolair® use will not be approved if requested for prevention of peanut related allergic reaction.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Xolair® on the **Xolair Prior Authorization Request Form**.

Pulmonary: Xolair® *Length of Authorization: 3 months initially, subsequent approvals for 1 year*	
NO PA REQUIRED	**PA REQUIRED**
	Xolair® (omalizumab) 150 mg subcutaneous injection vial *Quantity limit = 6 vials every 28 days*

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ XOLAIR ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Xolair. In order for beneficiaries to receive Medicaid coverage for Xolair, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to Catamaran. Please complete this form as directed and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing Physician:

Name:_____

Phone #:_____

Fax #:_____

Address: _____

Specialty: _____

Contact Person at Office: _____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Patient Diagnosis: ☐Moderate/Severe Persistent Asthma

☐Other: _____

If requesting prescriber is not a pulmonologist, allergist, or immunologist, date of last visit to one (required yearly):

Specialist name: _____ **Specialist Type**: _____ **Date:** _____

☐ **Initial Prior Authorization Request:** Please complete all portions of form below

☐ **Subsequent PA Request:** Has patient shown marked clinical improvement ☐ **Yes** ☐ **No**

List all previous therapies tried and failed for this condition:

Therapy	Specific Drug	Reason for Discontinuation
Inhaled Corticosteroid		
Chronic Oral Corticosteroid		
Leukotriene Receptor Antagonist		
Long-Acting Beta Agonist		

Has the member tested positive to at least one perennial aeroallergen by a skin or blood test (i.e. RAST, CAP, intracutaneous test)? ☐**Yes** ☐**No**
Please explain: _____

Is the member's IgE level ≥ 30 and ≤ 700 IU/ml? ☐**Yes** ☐ **No** Please provide IgE level: _____

Prescriber Signature:_____ **Date of this request:**_____

Pulmonary Arterial Hypertension Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Adempas®

- The patient has a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II or III.

OR

- The patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) AND the patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable.

AND

- The patient is 18 years of age or older

AND

- The patient will not use Adempas concomitantly with the following:
  - Nitrates or nitric oxide donors (such as amyl nitrate) in any form.
  - Phosphodiesterase (PDE) inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or non-specific PDE inhibitors (such as dipyridamole or theophylline)

AND

- The patient is not pregnant

AND

- Female patients are enrolled in the Adempas REMS Program

Flolan®

- Clinical diagnosis of pulmonary hypertension

AND

- The patient has had a documented intolerance to the generic epoprostenol.

Opsumit®

- Patient has a diagnosis of PAH WHO Group 1 with NYHA Functional Class II or III

AND

- Patient is not pregnant

AND

- Female patients have been enrolled in the Opsumit REMS Program

Pulmonary Arterial Hypertension Medications

Length of Authorization: One year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ENDOTHELIAN RECEPTOR ANTAGONISTS LETAIRIS® (ambrisentan) Tablet *Quantity Limit = one tablet/day* TRACLEER® (bosentan) Tablet *Quantity Limit = 2 tablets/day*	Opsumit® (macitentan) Tablet *Quantity Limit = one tablet/day*
PROSTANOIDS **Injection** EPOPROSTENOL † (compare to Flolan®) REMODULIN® (treprostinil sodium injection) VELETRI® (epoprostinil) **Inhalation** TYVASO® (treprostinil inhalation solution) VENTAVIS® (iloprost inhalation solution)	Flolan®* (epoprostenol)
sGC STIMULATOR	Adempas® (riociguat) Tablets *Quantity Limit = 3 tablets/day*
****Maximum days supply for all drugs is 30 days****	

Note: Please refer to "Phosphodiesterase Inhibitor Medications" for Adcirca® and Revatio®.

Renal Disease: Phosphate Binders

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Eliphos, PhosLo

- The patient must have a documented intolerance to the generic equivalent calcium acetate tablet or capsule.

Phoslyra

- The patient has a requirement for a liquid dosage form.

Renvela Oral Suspension Packet

- The patient has a requirement for a liquid dosage form.

Renvela tablet

- The patient must have a documented side effect, allergy, or inadequate response to Renagel® (sevelamer hydrochloride).

Velphoro Chew Tablet

- The patient must have a documented side effect, allergy, or inadequate response to one preferred phosphate binder.

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Renal Disease: Phosphate Binders

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CALCIUM ACETATE † (compare to PhosLo®) capsule CALCIUM ACETATE † (compare to Eliphos®) tablet FOSRENOL® (lanthanum carbonate) RENAGEL® (sevelamer hydrochloride) tablet	Eliphos® (calcium acetate) tablet PhosLo®* (calcium acetate) capsule Phoslyra® (calcium acetate) oral solution Renvela® (sevelamer carbonate) Oral Suspension packet *(QL = 2 packs/day (0.8 g strength only))* Renvela® (sevelamer carbonate) tablet Velphoro® (sucroferric oxyhydroxide) Chew Tablet

Restless Leg Syndrome Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Mirapex®, Requip®

- The patient has had a documented intolerance to the generic product.

Horizant®:

- The patient has a diagnosis of restless legs syndrome (RLS).

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure to generic immediate release ropinirole AND pramipexole.

AND

- The patient has had an inadequate response or adverse reaction to generic gabapentin immediate-release.

Neupro®:

- The patient is ≥18 years of age

AND

- The patient has a diagnosis of moderate to severe restless legs syndrome (RLS).

AND

- The patient has had a documented side effect, allergy, contraindication or treatment failure to generic immediate release ropinirole AND pramipexole.

OR

- The prescriber provides medical necessity for the transdermal formulation (eg. swallowing disorder or difficulty taking oral medications).

LIMITATIONS:

Requests for Mirapex ER® and Requip XL® will not be approved for Restless Leg Syndrome (RLS).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Restless Leg Syndrome Medications

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DOPAMINE AGONISTS (ORAL) PRAMIPEXOLE † (compare to Mirapex®) ROPINIROLE† (compare to Requip®)	Mirapex®* (pramipexole) Requip®* (ropinirole)
DOPAMINE AGONISTS (TRANSDERMAL) **All products require PA.**	Neupro® (rotigotine) transdermal patch *(Quantity Limit = 1 patch/day)* *(1mg, 2 mg and 3 mg patches ONLY)*
GAMMA-AMINOBUTYRIC ACID ANALOG **All products require PA.**	Horizant®(gabapentin enacarbil) ER Tablet *(Quantity Limit = 1 tablet/day)*

Rheumatoid, Juvenile Idiopathic & Psoriatic Arthritis Medications: Injectables/Oral

NOTE*: Rheumatoid, Juvenile Idiopathic and Psoriatic Arthritis Self-Injectables/Oral (Actemra® Subcutaneous, Cimzia®, Enbrel®, Humira®, Kineret®, Orencia® Subcutaneous, Simponi, Stelara and Xeljanz) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Actemra, Cimzia, Enbrel, Humira, Kineret, Orencia, Simponi, Stelara or Xeljanz Prior Authorization/Patient Enrollment Form for instructions. Briova may supply Remicade® upon request or you may continue to obtain through your usual supplier. Briova will not be supplying Actemra® or Orencia® Intravenous Infusion at this time – please continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira®

Patient has a diagnosis of rheumatoid arthritis (RA), juvenile idiopathic arthritis or psoriatic arthritis and has already been stabilized on Humira®

OR

Diagnosis is RA, juvenile idiopathic arthritis or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ *should be tried prior to approving Humira®.

Note: Approval should be granted in cases where patients have been treated with infliximab, but have lost response to therapy.

Enbrel®

Patient has a diagnosis of RA, juvenile RA (JRA), or psoriatic arthritis and has already been stabilized on Enbrel®

OR

Diagnosis is RA, JRA, or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ * should be tried prior to approving Enbrel®.

Actemra® Intraveous Infusion

Patient has a diagnosis of RA or juvenile RA (JRA) and has already been stabilized on Actemra®

OR

Patient age ≥ 18 years (RA) or ≥ 2 years (JRA).

AND

Diagnosis is RA or juvenile RA (JRA) and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 other DMARD¶ (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used. For RA, patient must have had an inadequate response to one or more TNF inhibitors.

Actemra® Subcutaneous

Patient has a diagnosis of RA and has already been stabilized on Actemra® (Subcutaneous or Intravenous)

OR

Patient age ≥ 18 years (RA)

AND

Diagnosis is RA and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 other DMARD (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used. The patient must have had an inadequate response to one or more TNF inhibitors.

Cimzia®

Patient has a diagnosis of RA or psoriatic arthritis and has already been stabilized on Cimzia®

OR

Patient age ≥ 18 years

AND

Diagnosis is RA or psoriatic arthritis and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD* (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Remicade®

Patient has a diagnosis of RA or psoriatic arthritis and has already been stabilized on Remicade®

OR

Diagnosis is RA or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD* should be tried prior to approving Remicade®.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Simponi®

Patient has a diagnosis of RA or psoriatic arthritis and has already been stabilized on Simponi®

OR

Patient age ≥ 18 years

AND

Diagnosis is RA or psoriatic arthritis, and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD* (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Simponi Aria®

Patient has a diagnosis of RA and has already been stabilized on Simponi Aria®

OR

Patient age ≥ 18 years

AND

Diagnosis is RA and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD*(other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The patient has not responded adequately to Simponi subcutaneous.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Kineret®

Patient has a diagnosis of RA and has already been stabilized on Kineret®

OR

Diagnosis is RA or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic

reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried prior to approving Kineret®.

Note: Kineret® may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Kineret® should not be administered concomitantly with any TNF antagonists (i.e. Enbrel®, Humira®, or Remicade®).

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Xeljanz®

Patient has a diagnosis of RA and has already been stabilized on Xeljanz®

OR

Patient age ≥ 18 years

AND

Diagnosis is RA and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 non-biologic DMARD (other DMARDs include leflunomide, sulfasalazine, hydroxychloroquine, azathioprine, and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Orencia® Intravenous Infusion

Patient has a diagnosis of RA or juvenile RA (JRA) and has already been stabilized on Orencia®

OR

Diagnosis is RA or juvenile RA (JRA) and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ should be tried prior to approving Orencia®. **Note:** Orencia® may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Orencia® should not be administered concomitantly with TNFantagonists (i.e. Enbrel®, Humira®, or Remicade®) and is not recommended for use with Kineret®.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

AND

If the diagnosis is RA, there is a clinically valid reason why Orencia® Subcutaneous cannot be used.

Orencia® Subcutaneous

Patient has a diagnosis of RA and has already been stabilized on Orencia®

OR

Diagnosis is RA and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried prior to approving Orencia®. **Note:** Orencia® may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Orencia® should not be administered concomitantly with TNFantagonists (i.e. Enbrel®, Humira®, or Remicade®) and is not recommended for use with Kineret®.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Stelara®

Patient has a diagnosis of psoriatic arthritis and has already been stabilized on Stelara®

OR

Diagnosis is psoriatic arthritis, and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD* (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Patients with systemic juvenile arthritis (SJRA/SJIA) and fever are not required to have a trial of a DMARD, including methotrexate. Patients with systemic juvenile arthritis without fever should have a trial of methotrexate, but a trial of another DMARD in case of a contraindication to methotrexate, is not required before Enbrel®, Humira®, Actemra®, or Orencia® is approved.
***** Patients with psoriatic arthritis with a documented diagnosis of active axial involvement should have a trial of NSAID therapy, but a trial with DMARD is not required before a TNF-blocker is approved. If no active axial skeletal involvement, then an NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira®, Enbrel®, Remicade®, Cimzia®, Stelara®or Simponi®

DOCUMENTATION:

- ✓ Document clinical information for **Actemra® Subcutaneous, Cimzia®**, **Enbrel®**, **Humira®**, **Kineret®, Orencia® Subcutaneous**, **Simponi®**, **Stelara® or Xeljanz®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form** or **Actemra®** or **Orencia® Intravenous Infusion** on a **General Prior Authorization Request Form**.

- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or tocilizumab (Actemra®) (J3262) or abatacept (Orencia Intravenous Infusion) (J0129) (both are billed through the medical benefit) require Prior Authorization through the Catamaran Clinical Call Center.

Rheumatoid, Juvenile Idiopathic and Psoriatic Arthritis: Injectables/Oral

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
Injectable ENBREL® (etanercept) *(Quantity limit = 4 syringes/28 days(50 mg) and 8 syringes/28 days (25 mg))* HUMIRA® (adalimumab) (*Quantity limit = 4 syringes/28 days)* **Oral**	Actemra® (tocilizumab) Intraveous Infusion *(Qty limit = 4 vials/28 days (80 mg vial), 3 vials/28 days (200 mg vial) or 2 vials/28 days (400 mg vial))* Actemra® (tocilizumab) Subcutaneous *(Qty limit = 4 prefilled syringes (3.6ml)/28 days)* Cimzia® (certolizumab pegol) *(Quantity limit = 1 kit/28 days (starter X 1, then regular))* Kineret® (anakinra) *(Quantity limit = 1 syringe/day)* Orencia® (abatacept) Subcutaneous Injection *(Quantity limit = 4 syringes/28 days)* Orencia® (abatacept) Intravenous Infusion Remicade® (infliximab) Simponi® (golimumab) Subcutaneous *(Qty limit = 1 of 50 mg prefilled syringe or autoinjector/28 days)* Simponi Aria® (golimumab) 50 mg/4 ml Vial for Intravenous Infusion Stelara® (ustekinumab) *(Quantity limit = 45 mg (0.5 ml) or 90 mg (1 ml) per dose)* *(90 mg dose only permitted for pt weight > 100 kg)* Xeljanz® (tofacitinib) *(Qty limit = 2 tablets/day)* Maximum 30 days supply

Saliva Stimulants

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

SALAGEN®

- The patient has had a documented side effect, allergy, or treatment failure to generic pilocarpine.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Saliva Stimulants

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
PILOCARPINE† (compare to Salagen®) EVOXAC® (cevimeline) CEVIMELINE† (compare to Evoxac®)	Salagen®* (pilocarpine)

Sedative Hypnotics: Benzodiazepine

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

The patient has had a documented side effect, allergy, or treatment failure with two preferred benzodiazepine sedative/hypnotics. If a product has an AB rated generic, one trial must be the generic.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Sedative Hypnotics: Benzodiazepine

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ESTAZOLAM† (compare to Prosom®) FLURAZEPAM† (formerly Dalmane®) TEMAZEPAM 15 mg, 30 mg † (compare to Restoril®)	Doral® (quazepam) Halcion® (triazolam) Prosom®* (estazolam) Quazepam† (compare to Doral®) Restoril®* (temazepam) temazepam† 7.5 mg, 22.5 mg (compare to Restoril®) triazolam † (compare to Halcion®)

Sedative Hypnotics: Non-benzodiazepine, Non-barbiturate

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Ambien®:

The patient has had a documented intolerance to generic zolpidem.

Ambien CR®, Lunesta®, eszopiclone, Zolpidem CR:

The patient has had a documented side effect, allergy or treatment failure to generic zolpidem. If the request is for brand Ambien CR, there has also been a documented intolerance to the generic. If the request is for generic eszopiclone, there has also been a documented intolerance to the brand Lunesta.

Edluar®:

The patient has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder).

AND

The patient has a documented intolerance to Zolpimist®.

Intermezzo®:

The patient has insomnia characterized by middle-of-the night awakening followed by difficulty returning to sleep

AND

The patient has had a documented inadequate response to zolpidem IR AND zaleplon.

Rozerem®: The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem.

OR

There is a question of substance abuse with the patient or family of the patient.

Note: If approved, initial fill of Rozerem® will be limited to a 14 day supply.

Silenor®: The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem.

AND

The patient has had a documented intolerance with generic doxepin or there is another clinically valid reason why a generic doxepin (capsule or oral solution) cannot be used.

Sonata®:

The patient has had a documented intolerance to generic zaleplon

Zolpimist®:

The patient has a medical necessity for a non-oral dosage form (i.e. swallowing disorder).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 196 for a description of the management of mental health drugs.

Sedative Hypnotics: Non-benzodiazepine, Non-barbiturate

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ZOLPIDEM † (compare to Ambien®) *(Quantity Limit = 1 tab/day)* ZALEPLON † (compare to Sonata®) *(Quantity limit = 1 capsule/day (5 mg) or 2 capsules/day (10 mg))*	Ambien®* (zolpidem) *(Quantity Limit = 1 tab/day)* Ambien CR® (zolpidem) *(Quantity Limit = 1 tab/day)* Edluar® (zolpidem) sublingual tablet *(Quantity Limit = 1 tab/day)* eszopiclone† (compare to Lunesta®) *(Quantity Limit = 1 tab/day)* Intermezzo® (zolpidem) Sublingual Tablet *(Quantity Limit = 1 tab/day)* Lunesta® (eszopiclone) *(Quantity Limit = 1 tab/day)* Rozerem® (ramelteon) *(Quantity Limit = 1 tab/day)* Silenor® (doxepin) *(Quantity limit = 1 tab/day)* Sonata® (zaleplon) *(Quantity limit = 1 cap/day (5 mg) or 2 caps/day (10 mg))* Zolpidem CR† (compare to Ambien CR®) *(Quantity Limit = 1 tab/day)* Zolpimist® (zolpidem) Spray (5 mg/spray) *(Quantity Limit = 1 canister/30 days)*

Skeletal Muscle Relaxants: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

MUSCULOSKELETAL AGENTS:

Amrix, cyclobenzaprine ER, cyclobenzaprine 7.5 mg, Fexmid

- The prescriber must provide a clinically valid reason why a preferred generic cyclobenzaprine cannot be used. For approval of Fexmid, the patient must also have a documented intolerance to the generic equivalent.

Brand skeletal muscle relaxants with generics available (Flexeril, Parafon Forte DSC, Robaxin):

- The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents (One trial must be the AB rated generic).

carisoprodol, carisoprodol/ASA, carisoprodol/ASA/codeine, Soma, metaxolone, Skelaxin:

- The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents. Additionally, if a brand name product is requested where an AB rated generic exists, the patient must also have had a documented intolerance to the generic product.

Lorzone

- The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents.

orphenadrine/ASA/caffeine

- The prescriber must provide a clinically valid reason why generic orphenadrine in combination with aspirin (or another analgesic) cannot be used.

ANTISPASTICITY AGENTS:

Dantrium, Zanaflex tablets:

- The patient must have a documented side effect, allergy, or treatment failure with the AB rated generic product.

Tizanadine capsules, Zanaflex capsules:

- The prescriber must provide a clinically valid reason why generic tizanidine tablets cannot be used.

AND

- If the request is for Zanaflex capsules, the patient must have a documented intolerance to generic tizanadine capsules.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Skeletal Muscle Relaxants: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
Musculoskeletal Agents	
Single Agent CHLORZOXAZONE† (compare to Parafon Forte DSC®) CYCLOBENZAPRINE† (compare to Flexeril®) METHOCARBAMOL† (compare to Robaxin®) ORPHENADRINE CITRATE ER† (previously Norflex®)	Amrix®(cyclobenzaprine sustained-release) carisoprodol 250 mg carisoprodol†350 mg (compare to Soma®) cyclobenzaprine ER† (compare to Amrix®) cyclobenzaprine 7.5 mg† (compare to Fexmid®) Fexmid® (cyclobenzaprine) Flexeril®* (cyclobenzaprine) Lorzone® (chlorzoxazone) tablets metaxalone† (compare to Skelaxin®) Parafon Forte DSC®* (chlorzoxazone) Robaxin®* (methocarbamol) Skelaxin® (metaxalone) Soma® (carisoprodol)
Combination Product *ASA = aspirin*	carisoprodol, ASA† (previously Soma Compound®) carisoprodol, ASA, codeine† (previously Soma Compound with Codeine®) Orphenadrine, ASA, caffeine† (previously Norgesic®, Norgesic Forte®)
Antispasticity Agents	
BACLOFEN† (previously Lioresal®) DANTROLENE† (compare to Dantrium®) TIZANIDINE† (compare to Zanaflex®) tablets	Dantrium®* (dantrolene) tizanidine† (compare to Zanaflex®) capsules Zanaflex® (tizanidine) capsules Zanaflex®* (tizanidine) tablets

Smoking Cessation Therapies

LENGTH OF AUTHORIZATION: up to 16 weeks (2 x 8 weeks) for non-preferred nicotine replacement OR up to 24 weeks (2 x 12 weeks) for oral therapy (per rolling 365 days)

CRITERIA FOR APPROVAL:

Nicoderm CQ patch

- The patient has had a documented intolerance to generic nicotine patch.

Nicorette gum

- The patient has had a documented intolerance to generic nicotine gum.

nicotine lozenge

- The patient has had a documented side effect or allergy to Nicorette lozenge or Commit lozenge.

Nicotrol Inhaler

- The patient has had a documented treatment failure with BOTH generic nicotine patch and generic nicotine gum.

Nicotrol Nasal Spray

- The prescriber must provide a clinically valid reason for the use of the requested medication.

Zyban

- The patient has had a documented intolerance to generic bupropion SR.

Smoking Cessation Counseling is encouraged with the use of smoking cessation therapies

***The combined prescribing of long acting (patch) and faster acting (gum or lozenge) nicotine replacement therapy is encouraged for greater likelihood of quit success. ***

Vermont QUIT LINE (available free to all patients) 1-800-QUIT-NOW (1-800-784-8669)
GETQUIT™ Support Plan available free to all Chantix® patients 1-877-CHANTIX (242-6849)

LIMITATIONS:
Nicotine System Kit® not covered – prescribe multiple strengths separately.

DOCUMENTATION:

- Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Smoking Cessation Therapies

Length of Authorization: see table

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
NICOTINE REPLACEMENT	
NICOTINE GUM† NICOTINE PATCH OTC† COMMIT LOZENGE® NICORETTE LOZENGE®	Nicoderm CQ Patch®* Nicorette Gum®* Nicotine lozenge† Nicotrol inhaler® Nicotrol Nasal Spray® **(Maximum duration is 16 weeks (2 x 8 weeks)/365 days) for non-preferred NRT products♠**
ORAL THERAPY	
BUPROPION SR† (compare to Zyban®) CHANTIX® (varenicline) (Limited to 18 years and older, quantity Limit = 2 tabs/day, maximum duration 24 weeks (2 x 12 weeks)/365 days)♠	Zyban®* (bupropion SR) (maximum duration 24 weeks (2 x 12 weeks)/365 days)♠

♠ For approval of therapy beyond the established maximum duration, the prescriber must provide evidence that the patient is engaged in a smoking cessation counseling program.

Testosterone: Topical

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Andoderm®, Axiron®, Fortesta®, Testim® Testosterone Gel (generic for Testim)

- The patient has had a documented side effect, allergy, or treatment failure to AndroGel® Gel or Pump.

LIMITATIONS:
Coverage of testosterone products is limited to males.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Testosterone: Topical

Length of Authorization: 1 year

Key: † Generic product

PREFERRED DRUGS (No PA Required)	PA REQUIRED
ANDROGEL® GEL (testosterone 1%, 1.62% gel packets) *Quantity limit = 1.25 gm packet (1.62%)* *(1 packet/day)* *2.5 gm packet (1%) (1 packet/day)* *2.5 gm packet (1.62%)* *(2 packets/day)* *5 gm packet (2 packets/day)* ANDROGEL® PUMP (testosterone pump bottles) *Quantity limit = 1 % (4 bottles/30 days)* *1.62% (2 bottles/30days)*	Androderm® Transdermal 2 mg, 4 mg (testosterone patch) *Quantity limit = 1 patch/day/strength* Axiron (testosterone 2% solution) 90 ml Pump Bottle *Quantiy limit = 2 bottles/30 days* Fortesta® (testosterone 2 % Gel) 60 gm Pump Bottle *Quantity limit = 2 bottles/30 days* Testim® Gel 5 gm (testosterone 1% gel tube) *Quantity limit = 2 tubes/day* Testosterone† 1% gel tube (compare to Testim® Gel 5 gm) *Quantity limit = 2 tubes/day*
*** Maximum days supply all products is 30 days ***	*** Maximum days supply all products is 30 days ***

Thrombopoietin Receptor Agonists

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approvals 6 months

CRITERIA FOR APPROVAL:

- The patient is at least 18 years of age.

AND

- The diagnosis or indication is chronic immune (idiopathic) thrombocytopenic purpura (ITP).

AND

- The patient's platelet count is less than 30,000/µL (< 30 x 10^9/L) or the patient is actively bleeding.

AND

- The patient has had a documented side effect, allergy, treatment failure or a contraindication to therapy with corticosteroids.

OR

- The patient has a documented insufficient response following splenectomy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

- ✓ All requests for romiplostim (Nplate®) (J2796) (billed ONLY through the medical benefit) require Prior Authorization through the Catamaran Clinical Call Center.

Thrombopoietin Receptor Agonists

Length of Authorization: initial approval 3 months, subsequent approvals 6 months

PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Nplate® (romiplostim) Subcutaneous Injection Promacta® (eltrombopag) Oral Tablets

Urinary Antispasmodics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL: (for patients >21 and <65 years of age):

Please note: Patients <21 years of age are exempt from all ORAL ANTIMUSCARINIC Urinary Antispasmodics PA requirements (Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan/Ditropan XL and an adequate trial of tolterodine SR will be required before approval of Detrol LA will be granted for all patients) and patients ≥ 65 years of age are exempt from the short acting oxybutynin trial requirement.

Ditropan, flavoxate, Enablex, Vesicare

- The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin.

Detrol, Detrol LA, Ditropan XL, Oxybutynin XL, Sanctura, Sanctura XR, tolterodine (generic), tolterodine SR (generic), trospium (generic), trospium ER (generic), Toviaz

- The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin.

  AND
- The patient has had a documented side effect, allergy, or treatment failure with 2 preferred long-acting agents. If a medication has an AB rated generic, there must have also been a trial of the generic formulation.

Gelnique 3%, 10%, Oxytrol

- The patient is unable to swallow a solid oral formulations (e.g. patients with dysphagia)

  OR
- The patient is unable to be compliant with solid oral dosage forms.

Myrbetriq

- The patient has had a documented side effect, allergy, treatment failure, or contraindication with one preferred long-acting urinary antimuscarinic agent.

LIMITATIONS:

Oxytrol® (for Women) OTC not covered. Oxytrol® RX is available but subject to prior authorization.

DOCUMENTATION:

- ✓ Document clinically information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Urinary Antispasmodics

Length of Authorization: 1 year

Key : † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
SHORT-ACTING AGENTS	
OXYBUTYNIN† (compare to Ditropan®)	Ditropan®* (oxybutynin) Flavoxate † (formerly Urispas®)
LONG-ACTING AGENTS (after clinical criteria are met)	
ANTIMUSCARINIC **Twice Daily** ***(Qty Limit = 2 per day)***	Detrol® (tolterodine) Sanctura® (trospium) tolterodine (compare to Detrol®) trospium† (compare to Sanctura®)
Once Daily ***(Qty Limit = 1 per day)*** ENABLEX® (darifenacin) VESICARE® (solifenacin)	Detrol LA® (tolterodine SR) Ditropan XL® (oxybutynin XL) oxybutynin XL† (compare to Ditropan® XL) Sanctura XR® (trospium) tolterodine SR† (compare to Detrol LA®) Toviaz® (fesoterodine) trospium ER† (compare to Sanctura XR®)
Transdermal/Topical	Gelnique 3%® (oxybutynin topical gel) *(Qty limit = 1 pump bottle (92gm)per 30 days)* Gelnique 10%® (oxybutynin topical gel) *(Qty limit = 1 sachet/day)* Oxytrol® (oxybutynin transdermal) *(Qty limit = 8 patches/28 days)*
BETA-3 ADRENERGIC AGONISTS	Myrbetriq® (mirabegron) ER Tablet *(Qty limit = 1 tablet/day)*
Note: *♦Patients under the age of 65 must fail an adequate trial of generic oxybutynin before approval will be granted for either Vesicare® or Enablex®.* *♦ A therapeutic failure on two preferred long acting products is required before a PA will be approved on any non-preferred long acting medication.* *♦Recipients < 21 years of age are exempt from all ORAL ANTIMUSCARINIC PA Requirements.(Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan®/ Ditropan® XL will be granted and tolterodine SR before approval of Detrol LA®)*	

Vaginal Anti-Infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cleocin®, Clindesse®**:**

- The patient has had a documented side effect, allergy, or treatment failure to generic clindamycin vaginal (clindamycin vaginal)

Metrogel Vaginal®:

- The patient has had a documented side effect, allergy, or treatment failure to generic metronidazole vaginal gel 0.75 % or Vandazole.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Vaginal Anti-Infectives

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CLINDAMYCIN	
CLINDAMYCIN VAGINAL† (clindamycin vaginal cream 2%)	Cleocin®* (clindamycin vaginal cream 2%) Cleocin® Vaginal Ovules (clindamycin vaginal suppositories) Clindesse® (clindamycin vaginal cream 2%)
METRONIDAZOLE	
METRONIDAZOLE VAGINAL GEL 0.75%† VANDAZOLE† (metronidazole vaginal 0.75%)	Metrogel Vaginal®* (metronidazole vaginal gel 0.75%)

Vitamins: Prenatal Multivitamins

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

DHA Containing Prenatal Vitamins

- The patient is unable to obtain a sufficient amount of DHA from diet alone.

All Other Non-Preferred

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the preferred products would not be a suitable alternative.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Vitamins: Prenatal Multivitamins	*Length of Authorization: 1 year*
PREFERRED DRUGS (No PA Required)	**PA REQUIRED**
PRENAPLUS® PRENATAL PLUS/IRON® PRENATAL PLUS® PRENATAL VITAMINS PLUS	All others including DHA containing products.

II. Prior Authorization Request & Specialty Pharmacy Order Forms

- **Antipsychotic Medications (Pediatric)** Prior Authorization Request Form
- **Bone Resorption Inhibitors Injectable** Prior Authorization Request Form
- **Buprenorphine** Prior Authorization Request Form
- **Cimzia®** Prior Authorization Request/Order Form
- **Cystic Fibrosis** Medication Order Form
- **Enbrel®** Prior Authorization Request/Order Form
- **General** Prior Authorization Request Form
- **General SPECIALTY** Prior Authorization Request/Order Form
- **Growth Stimulating Agents** Prior Authorization Request/Order Form
- **Hemophilia Factors** Order Form
- **Hepatitis C Medications**Prior Authorization Request/Order Form
- **Hepatitis C – Supplemental Clinical Form**
- **Humira®** Prior Authorization Request/Order Form
- **Kineret®** Prior Authorization Request/Order Form
- **Long Acting Opioids** Prior Authorization Request Form
- **Multiple Sclerosis ORAL** Order Form
- **Multiple Sclerosis SELF INJECTABLES** Order Form
- **Nutritionals** Prior Authorization Request Form
- **Oncology: ORAL** (Select Agents) Order Form
- **Quetiapine** Prior Authorization Request Form

- **Remicade®** Prior Authorization Request/Order Form
- **Simponi®** Prior Authorization Request/Order Form
- **Stelara®** Prior Authorization Request/Order Form
- **Synagis®** Prior Authorization Request/Order Form
- **Vivitrol®** Prior Authorization Request Form
- **Xeljanz®** Prior Authorization Request/Order Form
- **Xolair®** Prior Authorization Request Form

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

ANTIPSYCHOTIC MEDICATIONS (PEDIATRIC) (AGE < 18 YEARS OLD)~

Prior Authorization Request Form

In order for beneficiaries to receive Medicaid coverage for medications that require prior authorization, the prescriber must telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician**:**

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ **Sex:**_____

Contact Person at Office:_____

The following target symptoms or diagnoses for which the requested medication is being prescribed are documented in the patient chart: □ YES □ NO **Please check all that apply:**

Target Symptom	Diagnosis
□ Grandiosity/euphoria/mania	□ Autism with Aggression and/or Irritability □ Bipolar Disorder
□ Obsessions/compulsions	□ Intellectual Disability with Aggression and/or Irritability
□ Psychotic symptoms	□ Obsessive Compulsive Disorder □ Tourette's Syndrome
□ Tics (motor or vocal)	□ Schizophrenia/ Schizoaffective Disorder
□ Other: _____	□ Other: _____

1. **Drug Requested: check below Strength, Route & Frequency:**_____ **Dosage Form:**_____

Preferred After Clinical Criteria Are Met	Non-Preferred	
□ RISPERIDONE† (compare to Risperdal®)	□ Abilify® (aripiprazole)	□ Risperdal® (risperidone)
□ QUETIAPINE† (compare to Seroquel®)	□ Clozapine† (compare to Clozaril®)	□ Seroquel® (quetiapine)
□ ZIPRASIDONE† (compare to Geodon®)	□ Clozaril® (clozapine)	□ Seroquel XR® (quetiapine XR)
□ OLANZAPINE (compare to Zyprexa®)	□ Geodon® (ziprasidone)	□ Versacloz® (clozapine)
	□ Invega® (paliperidone)	□ Zyprexa® (olanzapine)

Key: † Generic product

2. **Please list preferred medications previously tried and failed for this condition:**

Name of medication	Reason for failure	Date
_____	_____	_____
_____	_____	_____
_____	_____	_____

3. **Was patient seen by any other provider for this condition? □ YES □ NO**

   Who? _____ **What specialty?** _____

4. **Please include any other pertinent information that supports this request (suggest attach chart notes):**

Prescriber Signature:_____ **Date of this request:**_____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ BONE RESORPTION INHIBITORS INJECTABLE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of injectable bone resorption inhibitors. For beneficiaries to receive coverage for these agents, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

Will this medication be billed through the: ☐ **pharmacy benefit** or ☐ **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name):_____NPI #:_____

Pharmacy (if known):_____ Phone:_____ &/or FAX:_____

Drug requested: ☐ Boniva IV ☐ Forteo ☐ Ibandronate IV ☐ Prolia

☐ Reclast ☐ Xgeva ☐ Zoledronic Acid

Dose & frequency: _____

Diagnosis/indication:

☐ Treatment of postmenopausal osteoporosis ☐ Treatment of male osteoporosis

☐ Paget's Disease ☐ Treatment of glucocorticoid induced osteoporosis

☐ Bone metastases from solid tumors (tumor type: _____)

☐ Other (Please Explain) _____

Has the member previously tried the following preferred medication?

Drug:	***Response:***
☐ Alendronate Oral	☐ side-effect ☐ treatment failure* dates of use: _____

*Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with the bisphosphonate.

Prescriber comments:_____

_____

Prescriber Signature:_____ **Date of this request:**_____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~BUPRENORPHINE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of buprenorphine/Suboxone®. These criteria are based on concerns about safety and the potential for abuse and diversion. All requests must be submitted using this fax form.

Submit request via Fax (only): 1-866-767-2649

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

► Please answer the following questions:

Is buprenorphine being prescribed for opiate dependency?	☐ Yes ☐ No
Does the prescriber signing this form have a DATA 2000 waiver ID number ("X-DEA license")?	☐ Yes ☐ No
Has the prescriber queried the VPMS (Vermont Prescription Monitoring System) to review patient's scheduled II-IV medication history?	☐ Yes ☐ No ☐ Not signed up
A "Pharmacy Home" for **ALL** prescriptions has been selected **AND** discussed with patient? (Pharmacy must be located/licensed in VT) Pharmacy Name:_____ Pharmacy Phone #: _____	☐ Yes ☐ No
Has patient filled a Suboxone RX in last 60 days	☐ Yes ☐ No ☐ Don't know
Request is for the following medication: Sublingual **FILM**	☐ Suboxone® (buprenorphine/naloxone)
Request is for the following medication: Sublingual **TABLET**	☐ Buprenorphine/Naloxone (formerly Suboxone®) ☐ Buprenorphine (formerly Subutex®)
Anticipated maintenance dose/frequency: (target dose of no more than 16 mg/day) (maximum 14 day supply per prescription fill) Dose:_____ Frequency:_____ (recommended once daily)	
If this request is for Buprenorphine mono (formerly Subutex®), please answer the following questions: Is the member pregnant? (please provide positive pregnancy test copy) If yes, anticipated date of delivery: _____	☐ Yes ☐ No
Is the member breastfeeding a methadone/morphine dependent baby? (please provide history from neonatologist or pediatrician)	☐ Yes ☐ No
Would you have referred your patient to a methadone clinic if this option was conveniently located and available?	☐ Yes ☐ No
Additional clinical information to support PA request:	

Prescriber Signature: _____ (stamps not acceptable)
Prescriber X-DEA License #: _____ Date of request: _____

VERMONT

CIMZIA® (certolizumab pegol) - Prior Authorization/Prescription/Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3

Department of Vermont Health Access

CIMZIA® (certolizumab pegol)

PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis ☐ Psoriatic Arthritis ☐ Ankylosing Spondylitis ☐ Crohn's Disease

If requesting prescriber is not a Rheumatologist or Gastroenterologist, has one of these specialties been consulted on this case? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral/injectable)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

4

PRESCRIPTION

Dosage Form and Quantity:

☐ Cimzia 200 mg/1 ml prefilled syringe (kit) Dispense Quantity: 1 (2 syringes)

or

☐ Cimzia 200 mg lyophilized vial (kit)
(for Health Care Professional administration) Dispense Quantity: 1 (2 vials)

or

☐ Cimzia 200 mg/1 ml prefilled syringe (Starter kit-6) Dispense Quantity: 1 (6 syringes)
400 mg (given as two subcutaneous injections of 200 mg) initially, and at Weeks 2 and 4

Sig: Dose/Route/Frequency:

☐ As above

or

☐ 400 mg (given as two subcutaneous injections of 200 mg) every four weeks (Crohn's, RA, PsA or AS)

or

☐ 200 mg (given as one subcutaneous injection) every two weeks (RA, PsA, AS)

Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

CYSTIC FIBROSIS MEDICATION – Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

Please Note: Cayston® and pancreatic enzymes are not obtained though Briova Specialty Pharmacy.

3

Department of Vermont Health Access

PRIOR AUTHORIZATION REQUEST/PRESCRIPTION

CYSTIC FIBROSIS INHALATION MEDICATION

Patient Diagnosis:

☐ Cystic Fibrosis ☐ Other:_____

(Requires Review by DVHA Medical Director)

Product:

☐ Pulmozyme® (dornase alfa inhalation) 1 mg/ml 2.5 ml ampules

☐ Administer via nebulizer once daily.
Dispense # 30 Refill ____ times

☐ Administer via nebulizer twice daily.
Dispense # 60 Refill ____ times

☐ TOBI® (tobramycin) Podhaler 28 mg capsules
(capsules for use with Podhaler only)

Administer 4 capsules via Podhaler twice daily, alternating 28 days on and 28 days off

Dispense # 224 Refill ____ times

☐ TOBI® (tobramycin solution for inhalation) 300 mg/5 ml ampules

Administer via nebulizer twice daily, alternating 28 days on and 28 days off

Dispense # 56 Refill ____ times

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

ENBREL® (etanercept) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access ENBREL® (etanercept) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis ☐ Psoriatic Arthritis ☐ Juvenile Idiopathic Arthritis

☐ Ankylosing Spondylitis ☐ Plaque Psoriasis

If requesting prescriber is not a Rheumatologist or Dermatologist, has one of these specialties been consulted on this case? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral, injectable, topical, phototherapy etc.)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

_____

4 PRESCRIPTION

Dosage Form and Quantity:

☐ Enbrel 25 mg prefilled syringe Dispense Quantity: _____

or

☐ Enbrel 25 mg multi-use vial Dispense Quantity: _____

or

☐ Enbrel 50 mg prefilled syringe Dispense Quantity: _____

or

☐ Enbrel 50 mg SureClick autoinjector Dispense Quantity: _____

Sig: Dose/Route/Frequency:_____

Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ GENERAL ~

Prior Authorization Request Form

In order for beneficiaries to receive Medicaid coverage for medications that require prior authorization, the prescriber must telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Contact Person at Office:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ **Sex:**_____

Will this medication be billed through the: ☐ **pharmacy benefit** or ☐ **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name):_____NPI #:_____

Pharmacy (if known):_____ Phone:_____ &/or FAX:_____

1. **Drug Requested:**_____ **Strength, Route & Frequency:**_____ **Length of therapy:**_____
   ☐ **Brand Name** ☐ **Generic Equivalent**

2. **Patient's diagnosis for use of this medication:**_____

3. **Previous history of a medical condition, allergies or other pertinent medical information, that necessitates the use of this medication:** _____
   Was patient seen by any other provider for this condition? YES / NO What specialty? _____

4. **Please list preferred medications previously tried and failed for this condition:**

Name of medication	Reason for failure	Date

5. **Please list pertinent laboratory test(s) or procedure(s) if applicable:**

Procedure	Findings	Date

6. **Other Information/ comments:**

Prescriber Signature:_____ **Date of this request:**_____

VERMONT

"GENERAL" SPECIALTY - Prior Authorization and Patient Enrollment Form

USE WHEN NO DRUG SPECIFIC FORM EXISTS - Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3

Department of Vermont Health Access

"GENERAL" SPECIALTY MEDICATIONS (Not drug specific)

PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

Drug Requested:_____

Strength, Route & Frequency:_____

Length of therapy:_____

Previous history of a medical condition, allergies or other pertinent medical information, that necessitates the use of this particular medication:

_____

Was patient seen by any other provider for this condition? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

Medications previously tried and failed for this condition:

Name of medication	Type of failure	Date

Please list pertinent laboratory test(s) or procedure(s) if applicable:

Procedure/Test	Findings	Date

Other Information/ comments:

_____

_____

4

PRESCRIPTION

Drug Name/Strength:_____

Sig: Dose: _____ Route: _____ Frequency: _____

Qty: _____ Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

GROWTH STIMULATING AGENTS - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access GROWTH STIMULATING AGENTS PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

Requested DVHA **PREFERRED** Growth Stimulating Agent

☐ Norditropin®

Growth Hormone Stimulation Test # 1	Test:	result:
Growth Hormone Stimulation Test # 2	Test:	result:
Patient's Height:		
Patient's Bone Age:		
Patient's Chronological Age:		
Growth Velocity:		
IGF-1 results:		

Please explain the medical necessity for a **'NON-PREFERRED'** product:

☐ Genotropin® ☐ Humatrope® ☐ Nutropin® ☐ Omnitrope® ☐ Saizen® ☐ Tev-Tropin®

Medical justification: _____

_____

Request is for a **'SPECIALIZED INDICATION'** product: (Criteria in Clinical Criteria Manual)

☐ Increlex® ☐ Serostim® ☐ Zorbtive®

Other information/ Prescriber comments:

4 PRESCRIPTION

☐ Norditropin® FlexPro 5 mg/1.5 ml ☐ Norditropin® FlexPro 10 mg/1.5 ml

☐ Norditropin® FlexPro 15 mg/1.5 ml ☐ Norditropin® NordiFlex 30 mg/3 ml

☐ Other Product: (Please Specify) _____

Dosage Form / Strength: _____

Dose/Route & Frequency (Sig):_____

Dispense Quantity: ☐ One month supply or _____ Refill X _____

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

HEMOPHILIA FACTORS - Patient Enrollment and Prescription Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221 🖷

Phone Number: 866-843-3604 ☎

3 Department of Vermont Health Access PRESCRIPTION HEMOPHILIA FACTORS

Patient Diagnosis:

☐ Hemophilia A – Factor VIII Disease

☐ Hemophilia B – Factor IX Disease

☐ von Willebrand Disease

Patient Weight (kg):	Native Factor Level:

Product Name:

Dose / Frequency Instructions:

# of doses ordered: _____ Refills: _____

If doses of different units are ordered, specific number of doses of each

Reason(s) for Use:

☐ Prophylaxis only ☐ Episodic only ☐ Prophylaxis and PRN

☐ Acute Bleeding Episode ☐ Surgical Prophylaxis ☐ Dental Procedure

Recent bleed while on Prophylaxis:

Date of bleed: _____/_____/_____

Location of bleed:_____ Severity of bleed:_____

# of Doses already administered prior to this order:_____ IU/Dose:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

☐ Needles/syringes: quantity sufficient for factor supply

Prescriber's Signature: _____ **Date:** _____

VERMONT

HEPATITIS C MEDICATIONS

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access HEPATITIS C MEDICATIONS/PRIOR AUTHORIZATION REQUEST

Patient Diagnosis: Hepatitis C YES ☐ NO ☐

If YES, Hepatitis C Supplemental Clinical Form must be completed and submitted for PA request to be considered.

Requested DVHA **PREFERRED** Ribavirin Hepatitis C Product?

☐ Ribavirin 200 mg Tablet (compare to Copegus®) **or**

Product: _____ Medical justification: _____

Requested DVHA **PREFERRED** Injectable Pegylated Interferon Hepatitis C Product?

☐ Pegasys® Prefilled Syringe ☐ Pegasys® Single Dose Vial ☐ Pegasys® Proclick **or**

Product: _____ Medical justification: _____

Polymerase Inhibitor	Protease Inhibitor
☐ Sovaldi® (sofosbuvir) 400 mg Tablet	☐ Olysio® (simeprevir) 150 mg Capsule **or** Product: _____ Medical justification: _____

4 PRESCRIPTION

Oral Ribavirin:

☐ Ribavirin 200 mg Tablet Refill for total:_____ weeks

Sig: Dose/Frequency: _____ Quantity:28 days' supply

Injectable Pegylated Interferon:

☐ Pegasys® Prefilled Syringe 180 mcg/0.5 ml "Convenience Kit" (4 syringes/box)

☐ Pegasys® 180 mcg/1 ml Single Dose Vial

☐ Pegasys® ProClick ☐ 180 mcg/0.5 ml or ☐ 135 mcg/0.5 ml

Sig: Dose/Route/Frequency:_____

Quantity: 28 days' supply Refill for total: _____ weeks

Oral Polymerase Inhibitor:

☐ Sovaldi® (sofosbuvir) 400 mg Tab Sig: Take one tablet (400 mg) by mouth once daily.

Dispense Quantity: 28 (4 weeks) Refill for total: _____ weeks

Oral Protease Inhibitor:

☐ Olysio® (simeprevir) 150 mg Sig: Take one cap (150 mg) by mouth once daily with food.

Dispense Quantity: 28 (4 weeks) Refill for total: _____ weeks

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

HEPATITIS C – SUPPLEMENTAL CLINICAL FORM

THIS FORM UST BE SUBMITTED WITH ALL REQUESTS FOR HEPATITIS C MEDICATION THERAPY

1 PATIENT IDENTIFICATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Does patient have other health insurance providing a pharmacy benefit? YES ☐ NO ☐

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Contact Person at Office

Telephone Number

Fax Number

Prescriber Specialty
☐ Board Certified Gastroenterology
☐ Board Certified Infectious Disease
☐ Other:_____
If therapy recommended by Specialist, please attach consult note. Attached: YES ☐ NO ☐

3 PATIENT CLINICAL INFORMATION (PART 1)

Diagnosis: **Hepatitis C** YES ☐ NO ☐ **Date of Initial Diagnosis**: ____/____/_____

Genotype: 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐

If Genotype 1: **Genotype 1a** YES ☐ NO ☐

If Yes and Prescribing Olysio®: **Q80K Polymorphism** YES ☐ NO ☐ N/A ☐

Fibrosis Score: 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ Unknown ☐

Decompensated Liver Disease: YES ☐ NO ☐

Hepatocellular carcinoma & awaiting liver transplant YES ☐ NO ☐

Status post-liver transplant YES ☐ NO ☐

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

4 PATIENT CLINICAL INFORMATION (PART 2)

Patient is: **Treatment Naïve** ☐ **Has received Prior Therapy** ☐

If Prior Therapy: Relapser ☐ Partial Responder ☐ Null Responder ☐ New Infection ☐

Prior regimen:_____

Dates of Prior Therapy/Duration: _____

Did Patient **Complete Planned Therapy**: YES ☐ NO ☐

If No, **Reason for Non-Completion:** Adverse Reaction ☐ Did Not Meet RGT Criteria ☐
Lost to Follow-Up ☐ Other ☐ Please explain: _____

HIV+ YES ☐ NO ☐

Is Patient **IFN ineligible:** YES ☐ NO ☐
If YES, reason: _____

Does patient have a history of **alcohol abuse:** YES ☐ NO ☐
If YES, date of last alcoholic drink: ___/___/_____

If YES, is patient currently enrolled in an **alcohol support program**: YES ☐ NO ☐
If YES, how is this independently **verified**:_____

Does patient have a history of **substance abuse**: YES ☐ NO ☐
If YES, clean date: ___/___/_____

If YES, is patient currently enrolled in a **substance use program:** YES ☐ NO ☐
If YES, how is this independently **verified**:_____

Has the patient been **educated to the possible side effects of therapy**: YES ☐ NO ☐

Proposed Therapy (complete Hepatitis Medication Order Form)
Attached: YES ☐ NO ☐

Rate the **Likelihood of Patient Completing the Proposed Therapy**:
High ☐ Moderate ☐ Indeterminate ☐

Pertinent Extenuating Circumstances (explain):_____
_____

NB: Recent Clinical Note Must be Attached for PA Consideration

5

Prescriber's Signature: _____ **Date:** _____

VERMONT

HUMIRA® (adalimumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access HUMIRA® (adalimumab) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis ☐ Psoriatic Arthritis ☐ Juvenile Idiopathic Arthritis

☐ Ankylosing Spondylitis ☐ Plaque Psoriasis ☐ Crohn's Disease ☐ Ulcerative Colitis

If requesting prescriber is not a Rheumatologist, Dermatologist or Gastroenterologist, has one of these specialties been consulted on this case? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral, injectable, topical, phototherapy etc.)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

4 PRESCRIPTION

Dosage Form and Quantity:

☐ Humira 40 mg/0.8 ml (Crohn/UC Starter kit-6) Dispense Quantity: 6 (1 kit)

Inject 4 pens (160 mg) subcutaneously on day 1 followed by 2 pens (80 mg) on day 15, then one pen (40 mg) every other week.

☐ Humira 40 mg/0.8 ml (Psoriasis Starter kit-4) Dispense Quantity: 4 (1 kit)

Inject 2 pens (80 mg) subcutaneously on day 1, one (1) pen (40 mg) on day 8, then one pen (40 mg) every other week.

☐ Humira 40 mg/0.8 ml prefilled syringe Dispense Quantity: 2 or 4

Inject 1 syringe (40 mg) subcutaneously ☐every other week ☐every week (select RA ONLY)

☐ Humira PEN 40 mg/0.8 ml Dispense Quantity: 2 or 4

Inject 1 pen (40 mg) subcutaneously ☐every other week ☐every week (select RA ONLY)

☐ Humira PED 20 mg/0.4 ml prefilled syringe Dispense Quantity: 2

Inject 1 syringe (20 mg) subcutaneously every other week

Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

KINERET® (anakinra) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access KINERET® (anakinra) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis

If requesting prescriber is not a Rheumatologist, has one been consulted on this case? ☐

Yes ☐ **No**

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral and injec etc.)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

_____

4 PRESCRIPTION

Dosage Form and Quantity:

☐ Kineret 100 mg/0.67 ml prefilled syringe

Dispense Quantity:

☐ 28 syringes

Sig: Dose/Route/Frequency:_____

Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ LONG ACTING OPIOIDS ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of long acting narcotics. These limits and criteria are based on concerns about safety and the potential for abuse and diversion. In order for beneficiaries to receive coverage for this drug, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office:_____

Drug Requested:

Please indicate: Brand Name ☐ or Generic Equivalent ☐

Dose /Frequency and Length of Therapy:

Diagnosis or Indication for Use::

Has the member previously tried any of the following preferred medications?

Check all that apply:	***Response, check all that apply:***
☐ Fentanyl Patches	☐ side-effect ☐ non-response ☐ allergy☐
☐ Morphine Sulfate CR 12 hr Tablet ☐	☐ side-effect ☐ non-response ☐ allerg☐

For tramadol products, has the member previously tried the following preferred medication?

Check if applicable:	***Response, check all that apply:***
☐ Tramadol immediate release	☐ side-effect ☐ non-response ☐ allergy

Is this an initial request or a subsequent request? ☐ Initial ☐ Subsequent

Prescriber comments:

Prescriber Signature:_____ **Date of this request:**_____

VERMONT

MULTIPLE SCLEROSIS Oral Medication

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221 🖷

Phone Number: 866-843-3604 ☎

3 Department of Vermont Health Access MULTIPLE SCLEROSIS Oral Medication PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Multiple Sclerosis

Complete for Aubagio (teriflunomide):

☐ Patient does not have any of the following contraindications to teriflunomide:

- Severe hepatic impairment
- Current treatment with leflunomide (Arava®)
- Patients who are pregnant or women of childbearing potential not using reliable contraception

Complete for Gilenya (fingolimod):

☐ Initial Request (please complete remainder of section)

☐ Patient has tolerated first dose under observation for a minimum of 6 hours with hourly pulse and blood pressure measurement and pre and post electrocardiogram.

Date of observed first dose: _____/_____/_____

☐ Subsequent Request (PA Renewal)

Prescriber Additional Comments:

4 PRESCRIPTION

☐ Aubagio 7 mg tablet or ☐ Aubagio 14 mg tablet Dispense Quantity: 28
Sig: Take one tablet once daily. Refill X:_____

☐ Gilenya 0.5 mg capsule Dispense Quantity: 28
Sig: Take one capsule once daily. Refill X:_____

☐ Tecfidera Capsules
Month 1 - Titration Starter Pack
Sig: 120 mg PO BID x 7 days # 14 capsules
240 mg PO BID x 23 days # 46 capsules
No refills

Maintenance Rx
Sig: 240 mg PO BID x 30 days Dispense Quantity: 60 Refill X:_____

Prescriber's Signature: _____ **Date:** _____

VERMONT

MULTIPLE SCLEROSIS SELF INJECTABLES - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access
PRESCRIPTION
MULTIPLE SCLEROSIS SELF INJECTABLES

Patient Diagnosis:

Product:

☐ Avonex 30 mcg/0.5 ml Prefilled Syringe (4 per box)

☐ Avonex 30 mcg Kit (Single Dose Vials) (4 per box)

☐ Betaseron 0.3 mg Prefilled Syringe

☐ Copaxone 20 mg Prefilled Syringe (30 per kit)

☐ Rebif Titration Pack X 1 **(Therapy initiation ONLY-No Refills)**
(contains 6 - 8.8 mcg and 6 – 22 mcg Prefilled Syringes)

☐ Rebif 22 mcg/0.5 ml Prefilled Syringes

☐ Rebif 44 mcg/0.5 ml Prefilled Syringes

(Please Note: This form not to be used for Tysabri PA request or ordering)

Quantity:	**Refills:**

Dose / Route/ Frequency Instructions (Sig):

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

☐ Needles/syringes: quantity sufficient for drug supply with refills as above

Prescriber's Signature: _____ **Date:** _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~NUTRITIONALS ~

Prior Authorization Request Form

Effective February 2002, Vermont Medicaid established coverage limits and criteria for prior authorization of Nutritional supplements. These limits and criteria are based on concerns about appropriate use and medical necessity. In order for beneficiaries to receive coverage for nutritionals, it will be necessary for the prescriber to telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address: _____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

Nutritional supplement will be administered via Tube Feeding? ☐ Yes ☐ No **(Proceed to diagnosis question)**

Patient Diagnosis/Condition:

☐ AIDS ☐ Chronic Diarrhea ☐ Dementia (includes Alzheimer's) ☐ Inflammatory Bowel Disease
☐ Cancer ☐ Cognitive Impairment ☐ Developmental Delays ☐ Parkinson's
☐ Celiac Disease ☐ Cystic Fibrosis ☐ Difficulty with chewing/swallowing food ☐ Short Gut
☐ Cerebral Palsy ☐ Request is for weight loss/low weight or low serum protein **(complete appropriate section below)**
☐ Other: _____

Unplanned Weight Loss/Extremely Low Weight:

Baseline: Date: ___/___/____ Height: _____ Weight: _____ BMI: _____

Current: Date: ___/___/____ Height: _____ Weight: _____ BMI: _____

Children: Mid-Upper Arm Circumference: _____ Head Circumference: _____

Laboratory Values: Date: ___/___/____ Albumin: _____ Pre-Albumin:_____

Additional clinical information to support PA request:

Requested Supplement: _____

Strength & Frequency: _____

Anticipated duration of supplementation: _____

Prescriber Signature: _____**Date of this request**: _____

VERMONT

ORAL ONCOLOGY/SELECT ADJUNCT - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access PRESCRIPTION ORAL ONCOLOGY/SELECT ADJUNCT

Patient Diagnosis:

BSA(m2) _____ Patient height (cm) _____ Patient weight(kg)_____

☐Maintenance Therapy # of Refills _____

☐Cycle Specific Therapy NO REFILLS Cycle # _____

☐Treatment / Dosage Change Reason : ☐Toxicity ☐Progression of Disease

☐Change in BSA ☐Other: _____

MEDICATION	Normalized Dose	Strength/ Frequency/ Route of Administration	QTY
☐GLEEVEC			
☐HEXALEN			
☐LUPRON DEPOT*			
☐MERCAPTOPURINE*			
☐MESNEX			
☐NEULASTA*			
☐NEUPOGEN*			
☐REVLIMID*			
Authorization # _____		New RX Required every 28 days	
☐SPRYCEL			
☐SUTENT			
☐TARCEVA			
☐TEMODAR			
☐XELODA			
Other:			
Additional RX Instructions:			

Prescriber's Signature: _____ **Date:** _____

* Not required to use Briova

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~QUETIAPINE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of quetiapine when used in doses of 50 mg/day or less. These criteria are based on concerns about safety and cost. The prescriber must telephone or complete and fax this form to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Diagnosis:_____

Contact Person at Office: _____

Request is for: Quetiapine _____ mg (strength) _____ (frequency/directions for use)

Patient Clinical Information to Support Quetiapine Prior Authorization Request

☐ **Indication for use is schizophrenia.** ☐ **Indication for use is bipolar disorder.**

☐ **Indication for use is adjunct treatment of Major Depressive Disorder (MDD).**

Patient initiated therapy with quetiapine for this indication on ___/___/____

Patient has responded inadequately to the antidepressants listed below (at least 3 from 2 different classes):

Medication Name and Dose	Dates

☐ **Indication for use is an anxiety disorder.**

Patient initiated therapy with quetiapine for this indication on ___/___/____

Patient has responded inadequately to the antidepressants listed below (at least 3 from 2 different classes):

Medication Name and Dose	Dates

Or two antidepressants above and ☐ buspirone (dates:_____)

☐ **Indication for use is another mental health disorder (not approved for insomnia).**

Please specify: _____

Patient initiated therapy with quetiapine for this indication on ___/___/____

Prescriber's Signature: _____ Date: _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ REMICADE ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Remicade. In order for beneficiaries to receive Medicaid coverage for Remicade, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Use this form for Remicade prior authorization requests only.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address: _____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Contact Person at Office: _____

Will this medication be billed through the: ☐ **pharmacy benefit** or ☐ **medical benefit** (J1745)? **(Please check one)**

Administering Provider/Facility if other than Prescriber (name):_____NPI #:_____

Pharmacy (if known):_____ Phone:_____ &/or FAX:_____

Remicade Infusion: Pt weight: _____ (kg) Dose: ____ (mg/kg) Total Dose: _____ (mg)

Frequency:_____Length of therapy:_____

Indication:

☐ Crohn's Disease ☐ Ulcerative Colitis ☐ Rheumatoid Arthritis

☐ Ankylosing Spondylitis ☐ Psoriasis (Plaque) ☐ Psoriatic Arthritis

List previous medications tried and failed for this condition:

Name of medication	Reason for failure	Date(s) attempted

Please explain why self-injectables (if indicated but not trialed) can not be trialed?

_____

Prescriber comments:

Prescriber Signature:_____**Date of this request:**_____

VERMONT

SIMPONI® (golimumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access
SIMPONI® (golimumab)
PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis ☐ Psoriatic Arthritis ☐ Ankylosing Spondylitis ☐ Ulcerative Colitis

If requesting prescriber is not a Rheumatologist, Dermatologist or Gastroenterologist, has one of these specialties been consulted on this case? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

☐ Initial Request (please complete remainder of section below)

☐ Subsequent Request: Explain response/tolerability to Simponi: _____

_____

Please explain outcomes of therapy with Enbrel and/or Humira (DVHA preferred products):

Therapy (and dates)	Reason for discontinuation

List previous medications/therapies tried and failed for this condition:

(include NSAIDs, DMARDs,TNF Blockers: oral and injectable)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

4 PRESCRIPTION

Dosage Form and Quantity:

☐ Simponi 50 mg/0.5 ml ☐ prefilled syringe or ☐ prefilled autoinjector Dispense Qty: 1

Sig: Administer 50 mg (1 syringe/autoinjector) subcutaneously once monthly.

Refill X:_____ (50 mg dose for RA,PsA or AS)

☐ Simponi 100 mg/1 ml ☐ prefilled syringe or ☐ prefilled autoinjector Dispense Qty: 3 **or** 1

☐ Sig: Loading Dose: Administer 200 mg (2 syringe/autoinjector) subcutaneously at Week 0 and then 100 mg (1 syringe/autoinjector) subcutaneously at Week 2.

☐ Sig: Administer 100 mg (1 syringe/autoinjector) subcutaneously once monthly.

Refill X:_____

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:**_____

VERMONT

STELARA® (ustekinumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access STELARA® (ustekinumab) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Plaque Psoriasis ☐ Psoriatic Arthritis

Patient Weight: _____ (kg)

If requesting prescriber is not a Dermatologist or Rheumatologist, has one been consulted on this case? ☐ **Yes** ☐ **No**

Specialist name: _____ Specialist Type: _____

☐ Initial Request (please complete remainder of section below)

☐ Subsequent Request: Explain response/tolerability to Stelara_____

Please explain outcomes of therapy with Enbrel and/or Humira (DVHA preferred products):

Therapy (and dates)	Reason for discontinuation

List previous medications/therapies tried and failed for this condition:

(include oral, injectable, topical, phototherapy etc.)

Therapy (and dates)	Reason for discontinuation

Prescriber Additional Comments:

4 PRESCRIPTION

Dosage Form and Quantity: (90 mg dose only permitted for patients > 100 kg)

☐ Stelara 45 mg/0.5 ml prefilled syringe Dispense Quantity: 0.5 ml

or

☐ Stelara 90 mg/1 ml prefilled syringe Dispense Quantity: 1 ml

Sig: Dose/Route/Frequency:_____

Refill X:_____

Note: Dosed as initial dose, then 4 weeks later, then every 12 weeks.

Deliver product to: ☐ Patient's home ☐ MD office ☐ Clinic

Prescriber's Signature: _____ **Date:** _____

SYNAGIS® PALIVIZUMAB

VERMONT RSV Season 2013-2014

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

Supervising Physician's Name (If Required for Mid-Level Practitioner)	NPI Number

WILCOX MEDICAL

Wilcox Home Infusion
250 Stratton Road
Rutland, Vermont 05701
A subsidiary of bioscrip

Form Last Updated 09/2013

Fax Completed Form to:

Fax Number: 855-775-7824

Phone Number: 800-639-1210

3 Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST SYNAGIS® (PALIVIZUMAB)

Gestational Age: weeks: days:	Current Weight: (kg)	Dose: 15mg / kg (weight verified monthly)

Diagnosis:

☐ Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under 12 months of age at the start of the RSV season (maximum 5 doses)

☐ Infants born at 29 - 32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses)

☐ Infants born at 32 - 35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)

☐ Infant attends child care ☐ One or more older siblings (or other child permanently in house) < 5 years of age (multiple births younger than 1 year of age do not qualify)

☐ Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses)

☐ Treatment: ☐ Dates of Use:

☐ Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease(CHD)

☐ Receiving medication to control congestive heart failure

☐ Moderate to severe pulmonary hypertension (maximum 5 doses)

☐ Have cyanotic heart disease

☐ Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old – maximum 5 doses)

☐ Congenital abnormalities of the airways

☐ Neuromuscular condition compromising handling of respiratory tract secretions

☐ Other:

NICU HISTORY

Did the patient spend time in the NICU?
☐ Yes ☐ No (If yes, please attach the NICU summary)

Was RSV prophylaxis recommended by the NICU/Hospital physician for this patient?
☐ Yes ☐ No

Was a NICU/Hospital /Clinic dose administered?
☐ Yes, Date(s): ☐ No

4 PRESCRIPTION

Synagis (palivizumab) 50 and/or 100 mg vials and supplies for administration.

Sig: Inject 15 mg/kg IM once every 4 weeks; expected date of first home injection:_____

Dispense Quantity: Quantity sufficient for prophylaxis thru 03/2014

Deliver product to: ☐ MD office ☐ Patient's home ☐ Clinic

☐ Home health nurse to administer injection Home Health Agency:_____

If delivery is to clinic, please give location:_____

Pediatric Anaphylaxis: Administer 0.01 ml/kg (max 0.3ml) of 1:1000 epinephrine solution subcutaneously or intramuscularly, and contact EMS or physician, as appropriate.

Other:_____

Sig: _____

Physician will monitor patient's response to therapy. Any complications in therapy will be reported to the physician either by the patient's caregiver, or the skilled nursing service (If other than physician's office or Wilcox Home Infusion)

Prescriber's Signature: _____ **Date:** _____

Supervising Physician's Signature: _____

This order is valid for the entire upcoming season if signed prior to the November dose, or for the remainder of the present season if signed after November.

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~VIVITROL~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of Vivitrol (naltrexone for IM extended release suspension). These criteria are based on concerns about safety. In order for beneficiaries to receive coverage for Vivitrol, it will be necessary for the prescriber to complete and fax this prior authorization request to Catamaran. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via Fax: 1-866-767-2649

Prescribing physician:

Name:_____

Phone #:_____

Fax #:_____

Address:_____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____Sex:_____

Diagnosis:_____

Contact Person at Office: _____

Administering physician:

Name: _____ Address: _____

Pharmacy (required)**:**_____ Phone:_____ &/or FAX:_____

QUALIFICATIONS

MDs	Prescribers must secure direct delivery of Vivitrol from the pharmacy to the physician's office. Pharmacies may not dispense Vivitrol directly to the patient. Vivitrol **may not** be billed through the Medical Benefit as a J-Code J2315.

PROCESS

► Please answer the following questions:

Patient diagnosis ?	□ Alcohol dependence □ Prevention of relapse to opioid dependency
Has the patient been opiate free for > 7 – 10 days	□ Yes □ No
For alcohol dependence: **(1)** Has the patient tried any of the following? Please document below. oral naltrexone: □ side-effect □ non-response □ allergy acamprosate: □ side-effect □ non-response □ allergy disulfiram: □ side-effect □ non-response □ allergy	□ Yes □ No
(2) Has patient had a recent hospital admission for alcohol detoxification?	□ Yes □ No If yes, date: ____/_____/____
For prevention of relapse to opioid dependency **(1)** Has the patient failed buprenorphine therapy? **(2)** Is the patient not a candidate for buprenorphine therapy? **(3)** Patient requires injectable therapy?	□ Yes □ No □ Yes □ No □ Yes □ No
Comments and additional patient history:	

Prescriber Signature: _____ **Date of request:** _____

VERMONT

XELJANZ® (tofacitinib) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name	First Name	Middle Initial

Date of Birth	Sex M ☐ F ☐	Medicaid ID #

Allergies: ☐ NKA or _____

Street Address	City

State	County	Zip Code

Home Phone	Cell Phone

Parent/Guardian	Day Telephone	Night Telephone

Emergency Contact	Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name	NPI Number	DEA Number

Telephone Number	Fax Number	Hospital/Clinic Name

Street Address	City

State	County	Zip Code

Contact Person at Office	Prescriber Specialty

briovaRx

catamaran
stay well ahead

Fax Completed Form to:

Fax Number: 800-218-3221

Phone Number: 866-843-3604

3 Department of Vermont Health Access XELJANZ® (tofacitinib) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

☐ Rheumatoid Arthritis

☐ Initial Request (please complete remainder of section below)

☐ Subsequent Request: Explain response/tolerability to Xeljanz_____

_____

Please explain outcomes of therapy with Enbrel and/or Humira (DVHA preferred products):

Therapy (and dates)	Reason for discontinuation

List previous medication tried and failed for this condition:

(include methotrexate, NSAIDs, DMARDs,TNF Blockers etc)

Medication (and dates)	Reason for discontinuation

Prescriber Additional Comments:

4 PRESCRIPTION

☐ Xeljanz® 5 mg tablet

Sig: ☐ Take one tablet TWICE daily. Dispense Quantity: 60

☐ Take one tablet ONCE daily. Dispense Quantity: 30

Refill X:_____

Prescriber's Signature: _____ **Date:** _____

VERMONT

Department of Vermont Health Access
312 Hurricane Lane, Suite 201
Williston, Vermont 05495

Agency of Human Services

~ XOLAIR ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Xolair. In order for beneficiaries to receive Medicaid coverage for Xolair, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to Catamaran. Please complete this form as directed and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing Physician:

Name:_____

Phone #:_____

Fax #:_____

Address: _____

Specialty: _____

Contact Person at Office: _____

Beneficiary:

Name:_____

Medicaid ID #:_____

Date of Birth:_____ Sex:_____

Patient Diagnosis:☐Moderate/Severe Persistent Asthma

☐Other: _____

If requesting prescriber is not a pulmonologist, allergist, or immunologist, date of last visit to one (required yearly):

Specialist name: _____ **Specialist Type**: _____ **Date:** _____

☐ **Initial Prior Authorization Request:** Please complete all portions of form below

☐ **Subsequent PA Request:** Has patient shown marked clinical improvement ☐ **Yes** ☐ **No**

List all previous therapies tried and failed for this condition:

Therapy	Specific Drug	Reason for Discontinuation
Inhaled Corticosteroid		
Chronic Oral Corticosteroid		
Leukotriene Receptor Antagonist		
Long-Acting Beta Agonist		

Has the member tested positive to at least one perennial aeroallergen by a skin or blood test (i.e. RAST, CAP, intracutaneous test)? ☐**Yes** ☐**No**
Please explain: _____

Is the member's IgE level ≥ 30 and ≤ 700 IU/ml? ☐**Yes** ☐ **No** Please provide IgE level: _____

Prescriber Signature:_____ **Date of this request:**_____